Market snapshot

Equities - India	Close	Chg .%	CYTD.%
Sensex	79,310	2.6	-6.9
Nifty-50	24,537	2.4	-6.1
Nifty-M 100	60,621	1.9	0.2
Equities-Global	**Close**	**Chg .%**	**CYTD.%**
S&P 500	7,354	-4.4	7.4
Nasdaq	24,315	-5.5	4.6
FTSE 100	10,783	-0.4	8.6
DAX	26,325	-0.4	7.5
Hang Seng	8,369	3.9	-6.1
Nikkei 225	61,078	-1.8	21.3
Commodities	**Close**	**Chg .%**	**CYTD.%**
Brent (US$/Bbl)	96	-0.1	54.2
Gold ($/OZ)	4,088	0.7	-5.4
Cu (US$/MT)	13,940	-1.3	11.9
Almn (US$/MT)	3,125	0.7	5.3
Currency	**Close**	**Chg .%**	**CYTD.%**
USD/INR	94.5	-0.2	5.1
USD/EUR	1.1	-0.1	-4.5
USD/JPY	157.7	-0.5	0.6
YIELD (%)	**Close**	**1MChg**	**CYTD chg**
10 Yrs G-Sec	7.2	-0.02	0.6
Flows (USD b)	**5-Nov**	**MTD**	**CYTD**
FIIs	1.59	3.51	-28.5
DIIs	-1.11	-3.03	72.2
Volumes (INRb)	**5-Nov**	**MTD***	**YTD***
Cash	1,853	1474	1336
F&O	1,35,437	2,89,510	2,53,269

Note: Flows, MTD includes provisional numbers.
Average

Today's top research idea

Titan Company: Festive delay weighs on jewelry; other segments performed well

- Titan Company (TTAN) has delivered consolidated revenue growth of 10% YoY (ex-bullion 23%). Standalone jewelry revenue (ex-bullion) rose 22% YoY. Jewelry demand was impacted by the festive season shifting to 3Q. Sales were strong during Navratri but slowed after Vijayadashami due to volatile gold prices. Customer footfalls started improving toward Oct'26 end.
- We remain constructive on growth in the jewelry industry, particularly among top players, and believe TTAN will remain well-positioned competitively, supported by initiatives such as its exchange program. Apart from industry formalization, stability in gold prices can further improve margin visibility for TTAN. We model a CAGR of 15% in sales, 23% in EBITDA, and 24% in APAT over FY26-28E. We reiterate our BUY rating on the stock with a TP of INR5,700, based on 55x Sep'28E EPS. TTAN remain one of our top picks.

Research covered

Cos/Sector	Key Highlights
Titan Company	Festive delay weighs on jewelry; other segments performed well
Other Updates	Redington IC| Reliance Inds. | Life Insurance | Adani Ports | M & M | Samvardh. Mothe. | Apollo Hospitals | Aurobindo Pharma | Bharat Forge | Uno Minda | Dabur | Ipca Labs. | Balkrishna Inds. | Premier Energies | Astral | Exide Inds. | Rubicon Research | P I Inds. | Apollo Tyres | Kirloskar Oil | The Ramco Cement | Tenneco Clean | Emami | Dr Agarwal's Health | Molbio Diagnostics | Century Plyboard | Blue Jet Health | Indo Count Inds. | Galaxy Surfact. | G R Infraproject | Cera Sanitary. | Campus Activeware | Safari Inds. | JK Lakshmi Cem. | VRL Logi. | Saatvik Green Energy | Ellenbarrie Inds. | TCI Express | Flash

Chart of the Day: Titan Company (Festive delay weighs on jewelry; other segments performed well)

Consolidated segmental snapshot

Consolidated (INR b)	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27
Total Sales	**166.3**	**188.4**	**255.7**	**271.0**	**215.0**	**207.6**
Watches sales (INR b)	12.7	14.8	13.0	12.2	15.4	18.8
YoY Growth (%)	24	13	14	8	21	27
Jewellery sales (INR b)	146.5	165.2	234.9	250.0	190.0	177.2
YoY Growth (%)	24	29	46	89	30	7
Jewellery (excluding gold ingots)	128.0	143.3	230.2	187.5	182.5	175.0
YoY Growth (%)	18	22	44	53	43	22
Eyewear sales (INR b)	2.4	2.2	2.3	2.3	2.9	2.8
YoY Growth (%)	13	9	18	18	21	28
Others	4.7	6.2	5.5	6.6	6.7	8.8
YoY Growth (%)	36	63	37	45	42	42
Total EBIT	**17.5**	**18.0**	**26.6**	**18.8**	**23.7**	**23.3**
Watches	2.9	2.4	1.6	1.4	3.0	4.1
YoY Growth (%)	159	21	44	8	3	73
EBIT Margin (%)	22.5	16.1	12.0	11.7	19.1	21.9
Jewellery EBIT (INR b)	14.1	15.1	24.8	18.2	19.5	18.7
YoY Growth (%)	28	19	42	37	39	24
EBIT Margin (%)	9.6	9.1	10.5	7.3	10.3	10.6
Eyewear EBIT (INR b)	0.2	0.1	0.2	0.2	0.2	0.2
YoY Growth (%)	5	-45	20	11	20	92
EBIT Margin (%)	8.4	5.5	10.4	9.3	8.3	8.2
Others EBIT (INR b)	0.4	0.4	0.0	(1.1)	1.0	0.3

Research Team

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

In the news today

Kindly click on textbox for the detailed news link

1

India's auto growth engine keeps humming, but the road ahead has a speed bump

The Indian automotive industry is expected to sustain growth momentum in the second half of the fiscal year.

2

MSME ministry, Samsung sign MoU to train 1,600 youth in electronics, appliance repair

The MSME ministry has partnered with Samsung India Electronics under a three-year MoU to train youth in electronics, mobile phones and home appliance servicing across 15 Technology Centres.

3

Adani CNG price crosses Rs 100 per kg mark in Ahmedabad for first time

Adani CNG prices in Ahmedabad have crossed Rs 100 per kg for the first time in history.

4

US tariff relief unlikely for Indian auto parts makers despite Democrats' Congress sweep

Indian auto component makers see little prospect of near-term relief from steep US tariffs despite Democrats gaining control of Congress.

5

Signature Global reports Rs 817.40 crore revenue in Q2FY27

Signature Global achieved a 148% increase in revenue to Rs 817.40 crore in Q2FY27 compared to the previous year.

6

Gold loan NPA rises in first five months while eases over a three-year horizon

India's gold loan market has experienced a rise in non-performing assets, reaching 0.78% by August 2023.

7

ONGC Q2 profit jumps 57% to Rs 15,489 crore on higher oil prices, rupee depreciation

ONGC has reported a significant 57% increase in quarterly profit, reaching Rs 15,489 crore.

Titan Company

Estimate changes	⇔
TP change	⇓
Rating change	⇔

Bloomberg	TTAN IN
Equity Shares (m)	888
M.Cap.(INRb)/(USDb)	4292.1 / 45.4
52-Week Range (INR)	5187 / 3734
1, 6, 12 Rel. Per (%)	-4/8/31
12M Avg Val (INR M)	4227

Financials &Valuations (INR b)

Y/E March	2026	2027E	2028E
Sales	875.8	987.7	1,152.2
Sales Gr. (%)	44.9	12.8	16.7
EBITDA	83.6	105.7	125.7
EBITDA Margin (%)	9.5	10.7	10.9
Adj. PAT	51.5	63.1	79.1
Adj. EPS (INR)	57.9	70.9	88.9
EPS Gr. (%)	36.9	22.5	25.4
BV/Sh.(INR)	176.4	226.1	288.3
Ratios			
RoE (%)	37.7	35.2	34.6
RoCE (%)	15.4	15.2	15.8
Payout (%)	19.3	30.0	30.0
Valuation			
P/E (x)	83.5	68.2	54.4
P/BV (x)	27.4	21.4	16.8
EV/EBITDA (x)	52.2	41.2	34.4
Div. Yield (%)	0.2	0.4	0.6

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	52.9	52.9	52.9
DII	14.4	15.3	14.2
FII	16.5	15.4	16.2
Others	16.2	16.3	16.8

FII Includes depository receipts

CMP: INR4,835 TP: INR5,700 (+18%) Buy

Festive delay weighs on jewelry; other segments performed well

- Titan Company (TTAN) has delivered consolidated revenue growth of 10% YoY (ex-bullion 23%). Standalone jewelry revenue (ex-bullion) rose 22% YoY. Jewelry demand was impacted by the festive season shifting to 3Q. Sales were strong during Navratri but slowed after Vijayadashami due to volatile gold prices. Customer footfalls started improving toward Oct'26 end.
- Domestic jewelry posted 15% LFL growth, and studded jewelry revenue grew 32% YoY. Studded share stood at 35% in 2Q. Buyer growth was flat YoY, while higher average ticket size supported value growth.
- TTAN reported an INR5.4b inventory gain following the increase in customs duty from 6% to 15%. Adjusting for the INR4.9bn gain in Tanishq, Mia and Zoya, standalone jewelry EBIT grew 22% YoY to INR16.9b, with EBIT margin flat YoY at 10.9% (est. 10.9%). Management maintained EBIT margin guidance at 11%. We model EBIT margin at ~11% for FY27/FY28.
- CaratLane's EBIT margin contracted 360bp YoY to 6.5% after adjusting for the INR460m inventory gain. It was impacted by high promotional expenses. DAMAS business reported a loss due to the ongoing geopolitical situation.
- Watch division reported revenue growth of 27% YoY (above) and EBIT growth of 73% YoY (21.9% margin). Eye care revenue rose 28% YoY and EBIT increased 92% (8.2% margin).
- We remain constructive on growth in the jewelry industry, particularly among top players, and believe TTAN will remain well-positioned competitively, supported by initiatives such as its exchange program. Apart from industry formalization, stability in gold prices can further improve margin visibility for TTAN. We model a CAGR of 15% in sales, 23% in EBITDA, and 24% in APAT over FY26-28E. We reiterate our BUY rating on the stock with a TP of INR5,700, based on 55x Sep'28E EPS. TTAN remain one of our top picks in the space.

Steady quarter; eyes on festive demand

- **Steady revenue growth:** TTAN's consolidated revenue grew by 10% YoY to INR206.1b (est. INR222.4b). Consolidated jewelry sales grew 7% YoY to INR177b (est. 198b); ex-bullion sales grew by 22% to INR175b. Watches sales grew 27% YoY to INR18.8b (est. INR16.2b). Eye care sales grew 28% YoY to INR2.8b (est. INR2.5b).
- **Domestic jewelry LFL growth at ~15%**: Standalone sales (ex-bullion) grew by 22% to INR155.5b (est. 28%). Bullion sales was nil as compared to INR19.6b YoY. Domestic jewelry (Tanishq, Mia and Zoya) posted 15% LFL growth, and all brands, including CaratLane, reported 15% growth. CaratLane's revenue grew 31%, primarily led by healthy double-digit buyers growth. Total jewelry store additions stood at 43, totaling 1,304 stores. In 2Q, Tanishq added eight stores, CaratLane added 13 stores, BeYon added four stores, and Mia added 18 stores.

- **Expansion on reported consol. margins:** There was a one-time inventory gain of INR5,360m (INR4,900m on Tanishq, Mia, and Zoya and INR460m on CaratLane) due to an increase in customs duty from 6% to 15%. Adjusting for this gain, gross margin expanded 310bp YoY to 24.5%. Ad spends increased by 15% YoY, other expense increased by 24% YoY and employee cost was up 22% YoY. Consolidated EBITDA, adjusted to gain, grew 31% YoY to INR24.5b (INR23.2b).
- **Standalone jewelry EBIT (ex-bullion) growth at 22%:** Adjusted for an inventory gain of INR4,900m, Standalone EBIT (ex-bullion) was up 22% YoY (est. 28%) at INR16.9b and EBIT margin was flat YoY at 10.9% (est. 10.9%). Adjusted for an inventory gain of INR460m, CaratLane's EBIT margin contracted 360bp YoY to 6.5%, impacted by higher discounts and A&P. Watches EBIT margin expanded 580bp YoY to 21.9% (est. 16.1%). Eye Care's margin expanded 270bp YoY to 8.2% (est. 7.0%).
- **Steady profitability:** Consolidated EBITDA grew 31% YoY to INR24.5b (INR23.2b). PBT was up 18% YoY to INR17.9b (est. INR18.9b). Adj. PAT was up 18% YoY to INR13.2b (est. INR14.2b). There is a decrease of INR6,710m in liability on fair value change of Damas business. We recorded the same as an exceptional item. Reported PAT rose 114% YoY to INR23.9b.

Highlights from the management commentary

- Jewelry demand remained healthy during the festive season, with a strong start during Navratri, some softness after Vijayadashami due to gold price volatility, and a recovery in customer footfalls towards Oct'26 end.
- Plain gold jewelry witnessed some softness in Sep'26 as consumers postponed purchases in anticipation of better gold prices. Management clarified that the slowdown was industry-wide and not due to competitive pressure.
- Management maintains jewelry margin guidance of 11% in FY27, as it continues to prioritize growth and customer acquisition over margin expansion.
- Management clarified that the INR6.7b adjustment in change in liability of Damas business is an accounting requirement related to the future put/call option payment and should be considered separately from operating performance. The adjustment may fluctuate depending on the recovery outlook.

Valuation and view

- We largely maintain our EPS estimates for FY27 and FY28.
- TTAN, with its superior competitive positioning (in sourcing, studded ratio, youth-centric focus, and reinvestment strategy), continues to outperform other branded players. Its brand recall and business moat are not easily replicable; therefore, Tanishq's competitive edge will remain strong in the category.
- The store count reached 3,751 as of Sep'26, and the expansion story remains intact. The non-jewelry business is also scaling up well and will contribute to growth in the medium term.
- Apart from industry formalization, stability in gold prices can further improve margin visibility for TTAN. Overall, we remain constructive on growth in the jewelry industry, particularly among top players, with TTAN as the bellwether and, given its superior historical execution track record, best positioned to benefit. We model a CAGR of 15% in sales, 23% in EBITDA, and 24% in APAT over FY26-28E. We reiterate our BUY rating on the stock with a TP of INR5,700, based on 55x Sep'28E EPS.

Consolidated Quarterly Performance (INR b)

Y/E March	FY26				FY27				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net Sales	**165.2**	**187.3**	**254.2**	**269.2**	**213.6**	**206.1**	**305.4**	**262.6**	**875.8**	**987.7**	**222.4**	-7.3
YoY change (%)	24.6	28.8	43.3	80.5	29.3	10.1	20.2	-2.4	44.9	12.8	18.8	
Gross Profit	**37.1**	**40.2**	**50.3**	**45.2**	**50.0**	**50.6**	**61.7**	**53.1**	**172.8**	**215.3**	**50.7**	
Margin (%)	22.5	21.4	19.8	16.8	23.4	24.5	20.2	20.2	19.7	21.8	22.8	
EBITDA	**18.3**	**18.8**	**27.1**	**19.4**	**24.8**	**24.5**	**33.0**	**23.4**	**83.6**	**105.7**	**23.2**	5.3
EBITDA growth %	46.8	22.9	40.8	26.0	35.7	30.6	21.5	20.9	34.0	26.5	24.0	
Margin (%)	11.1	10.0	10.7	7.2	11.6	11.9	10.8	8.9	9.5	10.7	10.5	
Depreciation	1.8	1.9	2.1	2.5	2.6	2.6	2.6	2.7	8.3	10.5	2.5	
Interest	2.7	2.8	2.8	3.5	3.5	5.4	3.5	4.1	11.8	16.5	3.3	
Other Income	1.1	1.1	1.5	1.8	1.5	1.5	1.8	1.1	5.5	5.8	1.5	
PBT	**14.8**	**15.2**	**23.8**	**15.3**	**20.2**	**17.9**	**28.6**	**17.8**	**69.0**	**84.5**	**18.9**	-5.2
Tax	3.9	4.0	5.8	3.9	5.5	4.7	6.9	4.3	17.5	21.4	4.7	
Rate (%)	26.3	26.4	24.3	25.3	27.2	26.4	24.0	24.4	25.4	25.4	25.0	
Adjusted PAT	**10.9**	**11.2**	**18.0**	**11.4**	**14.7**	**13.2**	**21.7**	**13.5**	**51.5**	**63.1**	**14.2**	-6.9
YoY change (%)	52.6	20.2	44.3	30.9	34.7	18.1	20.9	18.0	36.9	22.5	26.8	
Extraordinary	0.0	0.0	1.1	-0.4	-3.1	-10.7	0.0	0.0	0.8	-13.8	0.0	
Reported PAT	**10.9**	**11.2**	**16.8**	**11.8**	**17.8**	**23.9**	**21.7**	**13.5**	**50.8**	**76.9**	**14.2**	

E: MOSL Estimates *1QFY27 and 2QFY27 and margins and profits are adjusted to custom duty gain

Redington

BSE Sensex	S&P CNX
79,310	24,537

Bloomberg	REDI IN
Equity Shares (m)	782
M.Cap.(INRb)/(USDb)	286.9 / 3
52-Week Range (INR)	420 / 191
1, 6, 12 Rel. Per (%)	-15/66/53
12M Avg Val (INR M)	1824

Financials & Valuations (INR b)


Y/E MARCH	FY26	FY27E	FY28E
Sales	1,192	1,594	1,895
Sales Gr. (%)	20.0	33.8	18.9
EBITDA	22.4	31.3	40.3
EBITDA Margin (%)	1.9	2.0	2.1
PAT	12.8	19.5	25.2
EPS (Rs)	19.1	28.8	33.8
EPS Gr. (%)	-7.2	51.1	17.4
BV/Share	34.1	39.5	45.5
Ratios			
RoE	15.2	20.8	20.3
RoCE	16.3	20.8	23.9
RoIC	11.8	14.4	16.7
Valuations			
EV/Sales	0.3	0.2	0.2
EV/EBITDA	13.5	9.9	7.6
P/E (X)	19.9	14.0	10.7
P/BV (X)	10.8	9.3	8.1

Shareholding Pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	0.0	0.0	0.0
DII	16.1	16.4	17.0
FII	63.4	62.0	61.8
Others	20.5	21.6	21.2

FII includes depository receipts

Stock's performance (one-year)



CMP: INR367 **TP: INR500 (+36%)** **Buy**

Proxy play on AI-led Tech Upgrade Cycle

- Redington is the eighth-largest technology distribution provider operating in 32 countries with 440+ brands and 70K+ channel partners. The company is transitioning from being a traditional hardware reseller to an integrated solutions provider across mobility, computing, networking, software, cloud and cybersecurity. Redington's established OEM relationships and extensive geographic presence position it to capitalize on rising technology spending and enterprise digitization.
- Its competitive advantage lies in its scaled distribution network, extensive partner ecosystem, long-standing OEM relationships and ability to manage inventory and receivable risks. Redington's reach across geographies and customer segments enables it to offer integrated technology solutions while creating opportunities to cross-sell higher-value offerings.
- Redington's software solutions group (SSG) is emerging as a key growth driver, having delivered a 27% revenue CAGR over FY23-26, with 74% recurring revenue and gross margins of 5.5-6.0% compared with 4.9% for the overall business in FY26. Low cloud adoption among Indian SMEs, strong vendor partnerships and cross-selling opportunities should support sustainable growth and improve revenue visibility.
- The company is well positioned to benefit from rising enterprise technology spending, large data center deals, cybersecurity and AI spend, increasing localization and premiumization in India, and continued market share gains by Apple. Its established distribution infrastructure and OEM relationships provide a strong foundation for capturing these opportunities across the non-SSG business.
- Redington's transition toward high-margin software and cloud solutions, coupled with increasing cross-selling opportunities and operating leverage, should improve profitability. The growing SSG contribution is expected to partly offset margin pressure from low-margin data center deals, a higher mobility mix and macroeconomic challenges in Turkey.
- We expect Redington to deliver strong growth over FY26-29, supported by the scale-up of SSG and continued momentum in its core distribution business. EBITDA margin is expected to improve by 30bp to 2.2% by FY29E from 1.9% in FY26. Over FY26-29E, we expect a CAGR of ~23%/28%/27% in revenue/EBITDA/PAT. We initiate coverage on Redington with a **BUY** rating and a target price of INR500, valuing the company at 13x P/E on FY29E EPS.

Strong distribution network and established OEM relationships

- Its value proposition extends beyond distribution to credit support, inventory management, technical expertise and last-mile execution, creating a competitive advantage over smaller distributors.
- Long-standing relationships with leading OEMs, including HP, Apple, Lenovo and Microsoft, reinforce its credibility and provide access to fragmented reseller networks. Decades of expertise in managing inventory, receivables, payables and foreign-exchange exposure, supported by price-protection clauses, further strengthens its competitive positioning.

Redington's ESG/TSG/MSG/SSG segments contributed ~31%/16%/35%/17% to FY26 revenue, we expect segment wise revenue CAGR of ~14%/32%/19%/33%, respectively between FY26-29.

Diversified portfolio with rising contribution from high-growth segments

- Redington operates across endpoint solutions (ESG), technology solutions (TSG), mobility solutions (MSG) and software solutions (SSG), alongside other businesses. Its portfolio spans PCs, smartphones, enterprise hardware, cloud, SaaS and cybersecurity, positioning it to benefit from premiumization, AI adoption, data-center investments and increasing cloud and cybersecurity spending.
- **ESG:** Contributing ~31% of FY26 revenue (INR368b), ESG distributes PCs, laptops, printers and accessories. Device refresh cycles, AI-enabled PCs, rising digitalization and low PC penetration in India provide structural growth opportunities. We expect ~14% CAGR in revenue over FY26-29E.
- **TSG:** Contributing ~16% of FY26 revenue (INR193b), TSG provides networking, servers, storage and other enterprise technology solutions. Accelerating AI workloads, hyperscaler investments and data center expansion are key growth drivers. India's data center capacity is expected to increase to ~7.1GW from ~1.3GW, supporting our expectation of ~32% revenue CAGR over FY26-29E.
- **MSG:** Contributing ~35% of FY26 revenue (INR423b), MSG distributes smartphones through established relationships with Apple, Samsung and Motorola. Premiumization, replacement cycles and rising smartphone adoption should drive growth. Apple contributes over 30% of Redington's revenue, while the company handles ~50% of Apple's offline distribution in India. We expect MSG revenue to clock ~19% CAGR over FY26-29E.
- **SSG:** Contributing ~17% of FY26 revenue (INR198b), SSG offers cloud, software licensing, SaaS, professional services and cybersecurity solutions. Partnerships with AWS, Microsoft Azure and Google Cloud, alongside increasing AI adoption and the shift toward recurring software subscriptions, provide significant growth opportunities. With recurring revenue contributing 74% of sales during FY23-26, we expect SSG to deliver ~33% CAGR over FY26-29E, supporting improved revenue visibility and profitability.

We initiate coverage on Redington with a BUY rating and a TP of INR500, based on 13x P/E on FY29E EPS.

Valuation and view: Initiate coverage with BUY rating


- We believe Redington is well positioned to capitalize on structural growth in technology distribution, supported by established OEM relationships, an extensive channel network and a diversified geographic presence. Its expansion into cloud, SaaS and cybersecurity provides an opportunity to improve growth, revenue visibility and profitability.
- The growing contribution from SSG, supported by hyperscaler partnerships, recurring revenue and cross-selling opportunities, should drive operating leverage and partially offset margin pressure from low-margin hardware distribution. Meanwhile, data center investments, smartphone premiumization and AI-led device refresh cycles should support the core business.
- We expect Redington to deliver revenue/EBITDA/PAT CAGRs of ~23%/28%/27% over FY26-29E, with EBITDA margin estimated to improve by ~30bp to 2.2%. We initiate coverage on Redington with a BUY rating and a TP of INR500, valuing the company at 13x P/E on FY29E EPS.

Key risk and concern

- Low-margin nature of hardware distribution, working capital intensity, dependence on key OEMs, currency volatility and macroeconomic challenges.


STORY IN CHARTS

ICT distribution model




Source: Company, MOFSL

Enabling technology adoption




Source: Company, MOFSL

Redington AI practice




Source: Company, MOFSL

Redington customer lifecycle at glance




Source: Company, MOFSL


ICT Global Market Size (USD t)




ICT India Market Size (USD b)




We expect Redington to deliver a revenue CAGR of ~23% over FY26-29E (INR b)




We expect Redington to deliver EBITDA CAGR of ~28% over FY26-29E (INR b)




We project a strong recurring PAT CAGR of 27% for Redington over FY26-29E (INR b)



Return ratios likely to improve




We expect double digit revenue growth across segments and within it SSG segment expected to be outlier (INR b)



Source: Company, MOFSL

Redington is the 8th Largest Technology distributor globally (USD b)



Source: Company, MOFSL

Comparative valuations

Company Name	MCap (b)	Sales (b)			EBITDA (b)			PAT (b)			EPS			EPS CAGR (FY26-29E) (%)
		FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	
Redington	**286.6**	**1,594.0**	**1,894.6**	**2,190.5**	**31.3**	**40.3**	**47.4**	**23.3**	**26.4**	**30.6**	**28.8**	**33.8**	**39.1**	**27.1**
Rashi Peripherals	56	208.6	229.9	259.9	6.4	6.9	8.2	4.1	4.5	5.6	62.5	68.1	85.0	25.7
Ivalue Infosolution	10.5	11.7	13.6	15.8	1.7	2.1	2.3	1.2	1.5	1.9	23.1	28.6	35.0	24.6
GNG Electronics	83.2	26.2	35	45.4	3.3	4.7	6.2	2.2	3.1	4.4	19.2	27.4	38.7	49.4

Company Name	M Cap (b)	P/E				EV/Sales				ROE (%)			
		FY26	FY27E	FY28E	FY29E	FY26	FY27E	FY28E	FY29E	FY26	FY27E	FY28E	FY29E
Redington	**286.6**	**19.9**	**14.0**	**10.7**	**9.1**	**0.3**	**0.2**	**0.2**	**0.1**	**15.2**	**20.8**	**20.3**	**20.4**
Rashi Peripherals	56.0	19.8	13.6	12.5	10.0	0.4	0.3	0.3	0.3	14.9	17.4	15.5	16.5
Ivalue Infosolution	10.5	10.6	8.4	6.8	5.5	0.9	0.8	0.7	0.6	19.1	19.8	20.1	20.1
GNG Electronics	83.2	63.0	38.0	26.6	18.9	4.6	3.4	2.5	1.9	26.8	25.2	27.5	29.2

Reliance Industries

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR1,313 TP: INR1,520 (+16%) Buy

Diesel tightness remains key catalyst in coming quarters

- **Crude exports recover, diesel continues to lag:** Gulf crude exports have recovered to ~14mb/d in Sep'26 (75% of pre-war levels), but Middle East refined product exports are still down ~50%. Diesel tightness is accentuated by: 1) ~30% YoY decline in Russian refinery throughput, 2) tight jet fuel markets pulling yields away from gasoil, and 3) restricted access of Asian refiners to preferred crudes limiting gasoil yields. ***While higher refinery output could create a surplus in 1QCY27 (per IEA), it is unlikely to offset the deficit accumulated in CY26, keeping diesel cracks elevated till 2HCY27. In this note, we highlight that strong O2C performance in 2QFY27 was not a one-quarter phenomenon but could continue till 2HCY27.***

- **Twin benefits of access to cheap crude; high diesel yields work for RIL:** Complex refiners such as RIL with access to discounted crude grades and high diesel yields are best placed to take advantage of high diesel GRMs in next few months. RIL has access to both Russian and Venezuelan crude (Merey: USD16/bbl discount vs. Urals: USD10/bbl premium). ***Replacing Russian crude with Venezuelan crude, even partly, adds up to USD2/bbl to RIL's GRM, which is not reflected in our estimates currently and can be a key upside risk in FY28.*** Following a strong 2Q standalone performance and continued strength in product cracks/petchem prices, we recently raised our FY27/FY28 standalone EBITDA estimates by 13%/7%, primarily driven by an upgrade to our refining and upstream assumptions.

- **At CMP, stock factoring in 30% holdco discount; reiterate BUY:** RIL's stock price is down 10% over the last six months and at CMP, it is factoring in a 30% holdco discount, based on 20x Sep'28E EV/EBITDA for Retail (vs. our ascribed ~28x). While investors who invested in RIL for its digital services will now have an option to gain direct exposure through Jio Platforms (JPL), RIL will remain a play on India's largest retailer, largest integrated energy company, and several other growth optionality (such as New Energy, data center, AI, and FMCG). Further earnings upgrade on the back of stronger refining/petchem cycle, recovery in retail revenue growth and profitability remains the key medium-term trigger for the stock.

Reliance Industries Limited

Stock Info

Bloomberg	RELIANCE IN
Equity Shares (m)	13533
M.Cap.(INRb)/(USDb)	17774.2 / 188.1
52-Week Range (INR)	1612 / 1152
1, 6, 12 Rel. Per (%)	2/-12/-7
12M Avg Val (INR M)	20536
Free float (%)	50.4

Consol. Financials & Valuations (INR b)


Y/E Mar	FY26	FY27E	FY28E
Sales	10,572	12,718	12,807
EBITDA	1,789	2,129	2,202
Adj PAT	719	919	901
EPS (INR)	53.1	67.9	66.6
EPS Gr. (%)	3.2	27.9	-1.9
BV/Sh. (INR)	668	729	789
Ratios			
Net D/E	0.4	0.3	0.2
RoE (%)	8.2	9.7	8.8
RoCE (%)	8.0	9.1	8.9
Valuations			
P/E (x)	24.7	19.3	19.7
P/BV (x)	2.0	1.8	1.7
EV/EBITDA (x)	11.9	9.7	9.2
Div Yield (%)	0.5	0.5	0.5

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	49.6	49.6	49.1
DII	21.5	20.9	20.1
FII	18.0	18.6	20.1
Others	10.9	10.9	10.7

FII Includes depository receipts

Stock's performance (one-year)



Life Insurance Corporation

Estimate change	↓
TP change	⇄
Rating change	⇄

Bloomberg	LICI IN
Equity Shares (m)	12650
M.Cap.(INRb)/(USDb)	5161.2 / 54.6
52-Week Range (INR)	468 / 361
1, 6, 12 Rel. Per (%)	-4/0/-6
12M Avg Val (INR M)	2353

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Net Premiums	5,360	5,857	6,310
Surplus / Deficit	468.3	657.5	754.5
Sh. PAT	574.2	676.7	770.5
VNB margin (%)	21.2	23.2	23.8
RoEV (%)	1.6	10.5	10.6
Total AUM (INRt)	57.3	63.8	68.9
APE (INRb)	669.6	707.8	772.2
VNB (INRb)	141.8	164.2	183.8
EV per share	624	689	762
Valuations			
P/EV (x)	0.7	0.6	0.5
P/EVOP (x)	5.6	5.6	5.1

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	90.0	96.5	96.5
DII	6.1	1.0	1.4
FII	1.6	0.4	0.1
Others	2.3	2.1	2.0

FII Includes depository receipts

CMP: INR408 TP: INR470 (+15%) Buy

Miss across APE and VNB; EV up 1% from Mar'26

- In 2QFY27, LIC's new business APE grew 4% YoY to INR170b (8% miss). Individual APE declined 4% YoY to INR96.9b, while group APE rose 17% YoY to INR73.1b. For 1HFY27, APE grew 6% YoY.
- Absolute VNB grew 17% YoY to INR37b (14% miss), resulting in 250bp YoY VNB margin expansion to 21.8% (vs MOFSLe of 23.2%). For 1HFY27, VNB grew 34% YoY, with VNB margin of 22.3% (17.6% in 1HFY26).
- EV at INR8b grew 1% compared to Mar'26 EV of INR7.9b, with favorable contribution from core operations, while MTM movements were negative. LIC reported 20% YoY growth in shareholder PAT to INR121b (18% beat). For 1HFY27, PAT grew 21% YoY.
- Savings and protection businesses are expected to sustain healthy growth, with ULIPs recovering alongside equity markets. LIC is working to improve product expense ratios, which should support margin expansion and help narrow the gap with private-sector peers.
- We have cut our VNB margin estimates by 20bp for FY27/28 considering the performance in 2QFY27. We expect operating RoEV in the range of 11.5-12%. **Reiterate BUY with a TP of INR470 (premised on 0.6x FY28E EV).**

Non-par contribution falls YoY due to subdued quarter for ULIP

- LIC reported net premium income of INR1.5t (in line), which grew 16% YoY. Renewal premium grew 5% YoY to INR684b and single premium grew 35% YoY to INR684b. First year premium declined 4% YoY to INR104b.
- Individual APE declined 4% YoY due to a 17% YoY decline in non-par APE to INR34.1b, largely due to volatile equity market, which subdued ULIP demand. Par growth was subdued at 4% YoY, with APE at INR62.8b.
- The decline in ULIP contribution resulted in non-par APE contribution falling to 20.1% from 25.0% in 2QFY26, resulting in a sequential dip in VNB margin.
- In 1HFY27, in the non-par segment, LIC witnessed 35% YoY growth in individual savings APE and 59% YoY growth in protection APE. On the other hand, ULIP APE declined 40% YoY and annuity APE grew 5% YoY. Strong growth in savings and protection APE resulted in a benefit of 3.3% with respect to VNB margin in 1HFY27.
- Commission expenses rose 5% YoY to INR60.6b, while operating expenses declined 5% YoY to INR90.1b. Expense ratio declined to 10.2% from 12.0% in 2QFY26.
- Income from investments in policyholders' accounts grew 3% YoY to INR1.1t, while it increased 38% YoY to INR28.4b in shareholders' accounts. Total AUM grew 4% YoY to INR60t. Yield on investment for policyholders' accounts was flat YoY at 8.7% in 1HFY27 vs. 8.9% in 1HFY26.
- On the distribution front, contribution from the agency channel was 90.8% (92.0% in 2QFY26), with individual NBP from the channel growing 14% YoY. Individual NBP from bancassurance grew 9% YoY, with contribution stable YoY at 4.6%. The direct channel rose 13% YoY, while broker channel witnessed strong growth of 64% YoY.

- LIC maintains the highest agency force in the country with ~1.45m agents, of which 56% have a vintage of more than five years. This constitutes 43.7% of the industry's agency force. The company now has tie-ups with 88 bancassurance partners, 304 brokers, and 176 corporate agents, reflecting a massive distribution network spread across the country.
- The 13M/37M/61M persistency stood at 67.7%/58.8%/55.5% in 2QFY27. 37M persistency declined 250bp YoY.
- Solvency ratio stood at 235% (213% in 2QFY26).
- Apart from the benefit of favorable product mix shift, impact of assumptions contributed 2.8% to 1HFY27 VNB margin expansion, offset by a 1.4% impact of expenses.

Highlights from the management commentary

- Regulatory changes are expected to create better engagement opportunities with existing partners.
- LIC is stepping up agent training and awareness initiatives to improve annuity sales and reach customers seeking retirement income solutions.
- Banca channel picked up in 2Q after a subdued 1Q, with the momentum expected to continue through 3Q and the remainder of the year.

Valuation and view

- LIC reported a sequential dip in VNB margin and subdued quarter with respect to growth owing to weak ULIP demand. However, margin continues to expand YoY, led by increasing contribution of the non-par business and improving product-level margins. The growth trajectory is expected to improve as ULIP regains momentum, along with higher ticket sizes, improving agency channel productivity and continued growth in alternate channels. A shift toward higher-margin non-par products, cost optimization, and improvement in persistency will boost VNB margin going forward.
- We have cut our VNB margin estimates by 20bp for FY27/28 considering the performance in 2QFY27. We expect operating RoEV in the range of 11.5-12%. **Reiterate BUY with a TP of INR470 (premised on 0.6x FY28E EV).**

Quarterly performance

Policy holder's A/c	FY26				FY27				FY26	FY27E	2Q FY27E	Actual vs est
(INRb)	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
First year premium	75	108	106	130	92	104	116	150	419	462	115.6	-10%
Growth (%)	*1%*	*-3%*	*46%*	*17%*	*22%*	*-4%*	*9%*	*16%*	*13%*	*10%*	*6.7%*	
Renewal premium	599	650	693	819	618	684	713	884	2,761	2,899	678.5	1%
Growth (%)	*6%*	*5%*	*7%*	*4%*	*3%*	*5%*	*3%*	*8%*	*5%*	*5%*	*4.4%*	
Single premium	519	508	459	701	564	684	501	755	2,187	2,503	716.6	-5%
Growth (%)	*4%*	*8%*	*31%*	*21%*	*9%*	*35%*	*9%*	*8%*	*15%*	*14%*	*41.1%*	
Net premium income	**1,192**	**1,265**	**1,256**	**1,647**	**1,273**	**1,470**	**1,373**	**1,741**	**5,360**	**5,857**	1,410.9	4%
Growth (%)	*5%*	*5%*	*18%*	*12%*	*7%*	*16%*	*9%*	*6%*	*10%*	*9%*	*11.6%*	
PAT	**110**	**101**	**130**	**234**	**135**	**121**	**152**	**269**	**574**	**677**	102.7	18%
Growth (%)	*5%*	*32%*	*17%*	*23%*	*23%*	*20%*	*17%*	*15%*	*19%*	*18%*	*2.1%*	
Key metrics (INRb)												
New business APE	127	164	150	230	137	170	154	247	670	708	185.4	-8%
Growth (%)	*9%*	*-1%*	*50%*	*22%*	*8%*	*4%*	*3%*	*8%*	*18%*	*6%*	*13.2%*	
VNB	19	32	32	59	31	37	34	62	142	164	43.0	-14%
Growth (%)	*21%*	*8%*	*65%*	*67%*	*61%*	*17%*	*8%*	*4%*	*42%*	*16%*	*35.8%*	
AUM (INRt)	57	57	59	57	59	60	62	64	57	64	61.2	-3%
Growth (%)	*6%*	*3%*	*8%*	*5%*	*4%*	*4%*	*5%*	*11%*	*5%*	*11%*	*6.9%*	
Key Ratios (%)												bps
VNB Margins (%)	15.4	19.3	21.2	25.7	22.9	21.8	22.2	24.9	21.2	23.2	23.2	-138
Solvency ratio (%)	217.0	213.0	219.0	235.0	242.0	235.0			235.0	248.4		

Adani Ports & SEZ

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR1,885 **TP: INR2,170 (+15%)** **Buy**

Expanding global presence by acquiring Evos in Europe

- Adani Ports and Special Economic Zone (APSEZ) has agreed to acquire 100% stake in Netherlands-headquartered Evos B.V. (Evos) from Igneo Infrastructure Partners. The proposed transaction is an all-cash deal at an enterprise value of EUR2.56b. The transaction values Evos at an equity value of EUR1.18b, implying an acquisition multiple of 11.7x CY25 EV/EBITDA.
- For CY25, Evos delivered revenue and EBITDA of EUR392m and EUR219m, respectively (56% EBITDA margin). The transaction will be funded via debt and is subject to regulatory and other approvals, as well as works council consultation. Pro forma net debt-to-EBITDA for the combined entity stands at 2.76x (based on APSEZ FY26 and Evos CY25 financials) and is expected to be around 2.5x by FY27. As of 2QFY27, APSEZ had a cash balance of INR125b. Evos has 6.3 m cubic meters of storage capacity and handled 37 MMT of throughput during CY25.
- Evos' operations comprise eight port-based terminals across seven strategic ports in five countries - Netherlands, Germany, Spain, Belgium, and Malta. The company adds a high-margin, cash-generative liquids business to APSEZ's portfolio with average commercial occupancy at 99% and substantial part of revenue under take-or-pay contracts and CPI-linked contract base.
- The current margin of 56% is expected to improve as APSEZ deploys its resources, improves utilization, and brings in efficiency. The acquired assets are currently generating RoCE of ~7%, compared with ~14% for APSEZ's international portfolio in 1HFY27. However, management expects the RoCE to improve to double digits over the next 2-3 years as the assets ramp up.
- Similar to APSEZ's recent NQXT acquisition, Evos is also backed by a similar take-or-pay arrangement with most of the customers. While NQXT was acquired at ~17x EV/EBITDA, the current acquisition at ~11.7x EV/EBITDA appears relatively attractive, offering scope for value creation as the assets scale up.
- With strong cash flows, a healthy cash balance of INR125b, and a net debt-to-EBITDA ratio of 1.8x pre-acquisition, APSEZ is well-positioned for expansion. Capacity enhancements at key ports, ongoing infrastructure projects, and global port acquisitions provide visibility for stable growth in FY27 and beyond.
- **We have retained our estimates for now and would update our growth forecasts once the acquisition is completed.** We anticipate APSEZ to report 14% growth in cargo volumes over FY26-28. This growth is likely to drive a CAGR of 17%/18%/21% in revenue/EBITDA/PAT over FY26-28E. **We reiterate our BUY rating on the stock with a TP of INR2,170 (premised on 17x FY28E EV/EBITDA).**

Stock Info

Bloomberg	ADSEZ IN
Equity Shares (m)	2304
M.Cap.(INRb)/(USDb)	4342 / 46
52-Week Range (INR)	1949 / 1292
1, 6, 12 Rel. Per (%)	-3/7/35
12M Avg Val (INR M)	4712
Free float (%)	34.0

Financials Snapshot (INR b)


Y/E March	2026	2027E	2028E
Net Sales	387	454	526
EBITDA	229	265	317
Adj. PAT	136	150	199
EBITDA Margin (%)	59.0	58.3	60.3
Adj. EPS (INR)	59	65	86
EPS Gr. (%)	17.9	9.8	32.7
BV/Sh. (INR)	417	472	545
Ratios			
Net D/E (x)	0.5	0.4	0.3
RoE (%)	17.2	14.6	16.9
RoCE (%)	12.4	11.3	13.1
Payout (%)	11.8	10.8	8.1
Valuations			
P/E (x)	31.9	29.0	21.9
P/BV (x)	4.5	4.0	3.5
EV/EBITDA (x)	21.0	18.0	14.8
Div. Yield (%)	0.4	0.4	0.4
FCF Yield (%)	1.2	2.2	2.3

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	66.0	66.0	65.9
DII	13.2	13.6	15.0
FII	16.0	15.6	13.6
Others	4.8	4.8	5.5

FII includes depository receipts

Stock Performance (1-year)



Mahindra & Mahindra

Estimate change	↑
TP change	↔
Rating change	↔

Bloomberg	MM IN
Equity Shares (m)	1244
M.Cap.(INRb)/(USDb)	3889.1 / 41.2
52-Week Range (INR)	3840 / 2743
1, 6, 12 Rel. Per (%)	0/-5/-9
12M Avg Val (INR M)	9009

Financials & Valuations (INR b)

Y/E MARCH	2026	2027E	2028E
Sales	1,456	1,718	1,966
EBITDA	209.8	217.8	268.4
Adj. PAT	157.1	163.4	202.7
Adj. EPS (INR)	130.7	135.9	168.6
EPS Gr. (%)	32.4	4.0	24.1
BV/Sh. (INR)	618	716	843
Ratios			
RoE (%)	23.1	20.4	21.6
RoCE (%)	22.4	19.8	21.1
Payout (%)	25.2	27.8	24.8
Valuations			
P/E (x)	20.7	19.9	16.0
P/BV (x)	4.4	3.8	3.2
Div. Yield (%)	1.2	1.4	1.6
FCF Yield (%)	4.2	3.7	5.0

Shareholding pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	18.1	18.1	18.1
DII	33.7	32.2	29.6
FII	37.9	39.4	42.5
Others	10.3	10.3	9.8

FII includes depository receipts

CMP: INR3,128 **TP: INR3,850 (+23%)** **Buy**

Auto margins recover; growth remains strong

Tractor industry guidance for FY27E cut from mid-single digit to flat

- Mahindra & Mahindra's (MM) 2QFY27 PAT at INR51b was ahead of our estimates, led by higher-than-expected other income and beat on both segmental margins.
- On account of better-than-expected segmental margins and higher other income, we increase our earnings estimate for FY27/FY28 by 7.5% each. On the back of its healthy launch pipeline and positive consumer sentiment, management provided a strong outlook for FY27E across segments: MM UV at mid-to-high teens, and the LCV industry at double digits. While MM did cut tractor guidance from mid-single digits to flat for FY27, we were already factoring the same into our nos. We estimate MM to post a CAGR of ~20%/13%/14% in revenue/EBITDA/PAT over FY26-28. **Reiterate BUY with a TP of INR3,850 (based on FY28E SoTP).**

PAT beat, fueled by higher other income

- MM's 2Q standalone revenue grew 27% YoY to ~INR425b, broadly in line with our estimates, driven primarily by a strong ~15% growth in blended ASPs and a 11% YoY growth in volumes.
- RM costs came in higher than expectations, resulting in gross margins dipping 360bp YoY to 20.8% (estimated 21.5%).
- EBITDA margins came in line with our estimates at 11.7% (estimated 11.5%). EBITDA grew by 1.8% YoY to INR49.5b (in line).
- Auto segment's revenue grew 36% YoY to INR339b (in line), while PBIT margins at 7.7% beat our expectations of 7.1%.
- Farm revenue was flat YoY at INR85.9b, while farm PBIT margin beat our expectations at 16.8% (vs. est. of 16%).
- Other income was above our est. at INR28.3b due to a higher-than-expected dividends received from subsidiaries.
- Consequently, PAT exceeded our estimate, up 13% YoY to INR51b (estimated INR45b).

Key highlights from the management commentary

- Standalone auto PBIT margin improved QoQ to 9.8% from 8.9%, supported by ~5% price hikes, mix improvement, hedging and cost actions despite sharp steel, copper and rubber inflation.
- M&M retained mid-to-high teens FY27 SUV growth guidance, with Scorpio at full capacity and waiting periods across the portfolio. SUV capacity is set to rise from ~64.5k/month to ~82k by FY27-end and ~92k in FY28.
- EV penetration reached ~12% of SUV volumes in 1HFY27. Management sees adoption becoming increasingly self-sustaining, while scale, localization and supplier negotiations should gradually improve EV profitability.
- FY27 tractor industry growth guidance was reduced from +5% to flat, implying a double-digit decline in 2HFY27. Weakness is concentrated in Maharashtra and Karnataka, while northern markets remain relatively resilient.

Valuation and view

- On account of better-than-expected segmental margins and higher other income, we increase our earnings estimates for FY27/FY28 by 7.5% each. On the back of its healthy launch pipeline and positive consumer sentiment, management provided a strong outlook for FY27E across segments: MM UV at mid-to-high teens, and the LCV industry at double digits. MM cut tractor guidance from mid-single digits to flat for FY27, which we have already factored in into our estimates. We estimate MM to post a CAGR of ~20%/ 13%/14% in revenue/EBITDA/PAT over FY26-28. **Reiterate BUY with a TP of INR3,850 (based on FY28E SoTP).**

Quarterly Performance

Y/E March	FY26				FY27E				FY26	FY27E		Var.
INR b	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Total Volumes ('000 units)	361	350	423	397	410	387	442	412	1,530	1,651	387	
Growth YoY (%)	14.4	16.0	23.1	24.2	13.7	10.6	4.4	3.8	19.6	7.9	10.6	
Net Realization (INR '000/unit)	945	955	911	997	1,022	1,098	1,101	1,126	951	1,087	1,086	1.1
Growth YoY (%)	10.2	4.5	2.5	1.6	8.1	14.9	20.9	13.0	4.5	14.2	13.7	
Net Op. Income	**340.8**	**334.2**	**385.2**	**395.5**	**419.2**	**424.8**	**486.4**	**463.8**	**1,456**	**1,794**	**420**	1.1
Growth YoY (%)	26.1	21.3	26.1	26.2	23.0	27.1	26.3	17.3	25.0	23.3	25.7	
RM Cost (% of sales)	74.5	75.6	76.2	76.4	78.0	79.2	78.0	76.9	76.1	78.0	78.5	70bp
Staff (% of sales)	3.8	3.9	3.6	3.3	3.4	3.3	3.5	3.4	3.6	3.4	3.4	-10bp
Oth. Exp. (% of Sales)	5.8	5.9	5.5	6.2	6.5	5.8	6.2	7.7	5.9	6.6	6.6	-80bp
EBITDA	**48.8**	**48.6**	**56.7**	**55.6**	**51.1**	**49.5**	**59.8**	**55.6**	**210**	**216**	**48**	2.4
EBITDA Margins (%)	14.3	14.5	14.7	14.1	12.2	11.7	12.3	12.0	14.4	12.0	11.5	20bp
Change (%)	21.4	23.1	26.8	18.8	4.6	1.8	5.6	0.0	22.5	3.0	-0.6	
Other income	6.4	23.1	7.5	5.9	8.2	28.3	8.2	4.1	42.9	48.7	23.1	
Interest	0.6	0.6	0.6	0.7	1.0	0.7	0.6	0.3	2.5	2.5	0.5	
Depreciation	10.0	10.4	10.5	12.0	10.5	10.7	11.8	12.2	42.9	45.2	11.3	
PBT after EO	**44.7**	**60.7**	**52.0**	**48.8**	**47.8**	**66.4**	**55.7**	**47.2**	**206.2**	217.0	59.6	11.4
Tax	10.2	15.5	12.7	11.4	10.9	15.4	13.6	12.6	49.9	52.5	14.6	
Effective Tax Rate (%)	22.8	25.5	24.4	23.4	22.8	23.1	24.5	26.7	24.2	24.2	24.5	
Reported PAT	**34.5**	**45.2**	**39.3**	**37.4**	**36.8**	**51.0**	**42.0**	**34.6**	**156.4**	164.5	45.0	
Adj PAT	**34.5**	**45.2**	**40.1**	**37.4**	**36.8**	**51.0**	**42.0**	**34.6**	**157.1**	164.5	45.0	13.4
Change (%)	32.0	17.7	35.1	53.3	6.8	12.9	4.9	-7.4	32.5	4.7	-0.4	

E: MOFSL Estimates

Y/E March	FY26				FY27E				FY26	FY27E		Var.
Segmental (M&M + MVML)	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	
Realizations (INR '000/unit)												
Auto	1,101	1,099	1,037	1,124	1,230	1,253	1,261	1,264	1,089	1253	1,253	0.0
Farm Equipment	685	695	682	708	693	741	742	740	692	726	702	5.6
Blended	**945**	**955**	**911**	**997**	**1,022**	**1,098**	**1,101**	**1,126**	**951**	**1,087**	**1,086**	
Segment PBIT Margins (%)												
Auto	8.9	9.2	9.5	9.5	7.1	7.7	8.0	8.2	9.3	7.8	7.1	
Farm Equipment	19.8	19.7	20.2	19.4	18.5	16.8	17.5	18.3	19.8	17.8	16.0	

Key Performance Indicators	FY26				FY27E				FY26	FY27E	
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE
Tractors ('000 units)	134.1	122.9	149.6	119.8	158.0	116.0	134.6	107.2	526.4	515.9	116.0
Change (%)	10.4	31.6	22.8	36.1	17.9	-5.6	-10.0	-10.5	24.0	-2.0	-5.6
Total UV ('000 units)	223.2	223.6	270.0	271.9	248.3	266.4	302.4	300.0	988.7	1072.1	266.4
Change (%)	21.7	17.3	28.8	21.4	11.3	19.2	12.0	10.3	17.4	8.4	19.2
Cost Break-up											
RM Cost (% of sales)	74.5	75.6	76.2	76.4	78.0	79.2	78.0	76.9	76.1	78.0	78.5
Staff Cost (% of sales)	3.8	3.9	3.6	3.3	3.4	3.3	3.5	3.4	3.6	3.4	3.4
Other Cost (% of sales)	5.8	5.9	5.5	6.2	6.5	5.8	6.2	7.7	5.9	6.6	6.6
Gross Margins (%)	25.5	24.4	23.8	23.6	22.0	20.8	22.0	23.1	23.9	22.0	21.5
EBITDA Margins (%)	14.3	14.5	14.7	14.1	12.2	11.7	12.3	12.0	14.4	12.0	11.5
EBIT Margins (%)	11.4	11.4	12.0	11.0	9.7	9.1	9.9	9.4	11.5	9.5	8.8

E:MOSL Estimates

Samvardhana Motherson

Estimate changes	↑
TP change	↑
Rating change	↔

CMP: INR168 TP: INR200 (+19%) Buy

Bloomberg	MOTHERSO IN
Equity Shares (m)	10554
M.Cap.(INRb)/(USDb)	1790.4 / 19
52-Week Range (INR)	173 / 101
1, 6, 12 Rel. Per (%)	-2/38/65
12M Avg Val (INR M)	2681

Financials & Valuations

INR Billion	2026	2027E	2028E
Sales	1,261	1,565	1,817
EBITDA	119.0	151.0	186.5
Adj. PAT	41.5	62.7	86.4
EPS (Rs)	3.9	5.9	8.2
EPS Growth (%)	9.1	51.2	37.8
BV/Share (Rs)	38.8	43.6	50.0
Ratios			
Net D:E	0.0	-0.1	-0.2
RoE (%)	10.9	14.4	17.5
RoCE (%)	9.3	12.1	14.7
Payout (%)	16.4	20.0	22.0
Valuations			
P/E (x)	42.7	28.3	20.5
P/BV (x)	4.3	3.9	3.4
Div. Yield (%)	0.4	0.7	1.1
FCF Yield (%)	3.0	4.8	5.6

Shareholding pattern (%)

As Of	Sep-26	Jun-26	Sep-25
Promoter	48.6	48.6	48.6
DII	20.8	20.6	21.0
FII	13.3	13.1	12.0
Others	17.3	17.7	18.4

FII includes depository receipts

Margins resilient despite headwinds

Emerging business segment set to scale up rapidly from hereon

- Samvardhana Motherson's (SAMIL) 2QFY27 adjusted PAT at INR11.8b was above our estimate of INR11.1b, up ~38% YoY. EBITDA margin expanded 10bp YoY to 8.8% and was ahead of our estimate of 8.5%. Margin beat was driven by better-than-expected margin performance in the wiring business and MPP segment.
- We expect SAMIL to continue outperforming global automotive production, supported by increasing premiumization and EV penetration, a strong order backlog across automotive and non-automotive businesses, and the successful integration of recent acquisitions. Given the strong revenue growth and resilient margins, we have raised our earnings estimates by 8%/10% for FY27E/FY28E. Given the long-term growth opportunities, **we reiterate our BUY rating on the stock** with a revised TP of INR200, based on 24x FY28E EPS.

Better-than-expected margin performance leads to earnings beat

- SAMIL's consolidated revenue grew ~27% YoY to ~INR383b (in line with our estimate of INR372b), driven by acquisitions and healthy performance across businesses, especially wiring harness.
- EBITDA margin remained stable at 8.8%, above our estimate of 8.5%. This was primarily due to operational efficiencies and cost optimization efforts offsetting input cost inflation and asset integration impact.
- **Wiring harness** revenue grew 68% YoY to INR144b (above our estimate of INR118b), with margins declining 50bp YoY to 10% despite a 6% sequential rise in copper prices and Autoelectric integration (est. 9.4% margins).
- **Modules and polymer product** revenue grew ~4% YoY to INR160b (in line), with margin improving 90bp YoY to 8.3% (above our est. of 7.2%). Ongoing transformation and cost-efficiency initiatives in Europe supported margin improvement.
- **Integrated assemblies** revenue grew 2.7% YoY to INR26.5b (in line with our estimate of INR27.4b), while margins remained stable YoY at 12.3%, below our est. of 12.8%, primarily due to seasonality.
- **Emerging business** revenue grew 61% YoY to ~INR64.5b (below our est. of INR71.8b), while margins fell 110bp YoY to 8.4%, below our est. of 9%.
- **Vision systems** revenue came in line at INR54.1b, up 6.6% YoY. Margin was stable YoY at 9.2% despite seasonal softness (above estimated 9%).
- Overall, EBITDA grew 29% YoY to INR33.6b, ahead of our est. of INR31.5b. Additionally, other income was also higher than expected at INR801m.
- As a result, adj. PAT beat our expectations, growing by a strong ~38% YoY to INR11.8b (vs. our estimate of INR11.1b).
- INR19.7b of capex was undertaken in the quarter. Effective net debt as of 2Q end stood at INR112.9b, with the D/E ratio standing at 0.8x.

Key highlights from the management commentary

- The company has concluded the acquisitions of Nexans Autoelectric and Yutaka Giken in Jul'26. Collectively, these two acquisitions are expected to contribute nearly USD2b of annualized revenue.
- It has also announced the acquisition of Shenzhen Autocruis (China), a manufacturer of advanced digital vision and monitoring systems for PVs and CVs. Their product portfolio includes Camera Monitoring Systems (CMS), Full Display Mirrors (FDM), 360-degree Around View Monitoring (AVM), Driver Monitoring Systems (DMS), and Dashcam Video Recording (DVR) solutions.
- FY27 capex guidance has been maintained at INR60b (+/-10%), reflecting the company's continued investment-led growth strategy.
- Total planned investment in the consumer electronics business stands at around INR75b. Of this, INR65b would be invested in the mother plant, to be deployed over the next three years, which would have a capacity of 42m units p.a. One-third of this capex is done, while the balance capex will be incurred over the next two to three years.
- In 1QFY27, three new manufacturing plants were commissioned. Management expects a total of 10 new facilities to become operational during FY27, further supporting future growth and capacity expansion.
- Effective net debt fell to ~INR97.5b (vs. INR112b YoY). The leverage ratio remained stable QoQ at a multi-quarter low of 0.8x.

Valuation and view

We expect SAMIL to continue outperforming global automotive production, supported by increasing premiumization and EV penetration, a strong order backlog across automotive and non-automotive businesses, and the successful integration of recent acquisitions. Given the strong revenue growth and resilient margins, we have raised our earnings estimates by 8%/10% for FY27E/FY28E. Given the long-term growth opportunities, **we reiterate our BUY rating on the stock** with a revised TP of INR200, based on 24x FY28E EPS.

Quarterly performance (Consol.) (INR M)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net Sales	**302,120**	**301,730**	**314,094**	**343,093**	**352,438**	**382,799**	**410,488**	**419,104**	**1,261,037**	**1,564,828**	**372,449**	2.8
YoY Change (%)	4.7	8.5	13.5	17.0	16.7	26.9	30.7	22.2	10.9	24.1	23.4	
EBITDA	**24,583**	**26,107**	**30,431**	**37,908**	**30,962**	**33,572**	**40,356**	**46,097**	**119,029**	**150,987**	**31,493**	6.6
Margins (%)	8.1	8.7	9.7	11.0	8.8	8.8	9.8	11.0	9.4	9.6	8.5	
YoY Change (%)	-11.4	6.6	13.3	43.4	25.9	28.6	32.6	21.6	12.8	26.8	20.6	
Depreciation	12,297	12,179	13,208	13,654	13,582	13,991	14,500	15,265	51,339	57,339	14,200	
Interest	4,250	3,865	3,411	4,718	4,590	5,248	3,900	2,647	16,244	16,384	4,100	
Other income	805	1,212	514	575	816	801	930	745	3,105	3,292	750	
PBT before EO expense	**8,841**	**11,275**	**14,325**	**20,111**	**13,606**	**15,134**	**22,886**	**28,930**	**54,552**	**80,556**	**13,943**	8.5
Extra-Ord expense	1,365	362	465	1,944	0	0	0	0	4,135	0	0	
PBT after EO Expense	**7,476**	**10,914**	**13,861**	**18,167**	**13,606**	**15,134**	**22,886**	**28,930**	**50,417**	**80,556**	**13,943**	
Tax Rate (%)	30.1	34.7	31.7	21.3	33.6	32.2	27.0	21.2	28.2	27.0	27.0	
Min. Int & Share of profit	-300	-1,270	-920	-1,084	-1,287	-1,495	-1,129	-20	-3,573	-3,931	-928	
Reported PAT	**5,118**	**8,270**	**10,237**	**14,971**	**10,321**	**11,753**	**17,836**	**22,827**	**38,597**	**62,737**	**11,106**	
Adj PAT	**6,067**	**8,521**	**10,560**	**16,322**	**10,321**	**11,753**	**17,836**	**22,827**	**41,470**	**62,737**	**11,106**	5.8
YoY Change (%)	-39.0	14.1	20.1	55.4	70.1	37.9	68.9	39.9	9.0	51.3	30.3	

E: MOSL Estimates

Apollo Hospitals

Estimate change	↑
TP change	↓
Rating change	↔

Bloomberg	APHS IN
Equity Shares (m)	144
M.Cap.(INRb)/(USDb)	1235.8 / 12.9
52-Week Range (INR)	9327 / 6680
1, 6, 12 Rel. Per (%)	-3/18/11
12M Avg Val (INR M)	3106

Financials & Valuations (INRb)

Y/E March	FY26	FY27E	FY28E
Sales	251.1	299.0	342.3
EBITDA	37.5	46.7	53.8
Adj. PAT	19.6	25.1	30.3
EBITDA Margin (%)	14.9	15.6	15.7
Cons. Adj. EPS (INR)	136.0	174.5	210.7
EPS Gr. (%)	35.3	28.3	20.7
BV/Sh. (INR)	681.4	855.8	1,067.4
Ratios			
Net D:E	0.2	0.0	-0.1
RoE (%)	22.1	23.5	22.6
RoCE (%)	16.1	18.0	18.3
Payout (%)	4.3	3.4	2.8
Valuations			
P/E (x)	61.4	47.9	39.7
EV/EBITDA (x)	33.2	26.3	22.3
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	0.8	2.0	2.4
EV/Sales (x)	5.0	4.1	3.5

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	28.0	28.0	28.0
DII	22.3	23.9	21.4
FII	43.2	41.5	44.2
Others	6.5	6.5	6.4

FII includes depository receipts

CMP: INR8,371 TP: INR10,400 (+24%) Buy

Profit beat led by hospitals and HealthCo

Volume-led hospital growth and leaner digital spending sustain the earnings upcycle

- Apollo Hospitals and Enterprises (APHS) reported revenue in line with our estimate. The company delivered better-than-expected EBITDA/PAT, with a 6%/5% beat on our estimate for the quarter. The improved performance was driven largely by the Healthcare Services (hospital) segment and Healthco segment. Apollo Health and Lifestyle's (AHLL) revenue was lower compared to estimates. However, profitability was better-than-expected for the quarter.
- The Hospital segment continued to surprise us on volume growth, backed by higher occupancy at existing facilities and the addition of patient volumes from hospitals opened over the past 6M. This was also supported by a superior case mix/payor mix driving better realization on a YoY basis.
- The offline pharmacy segment remained resilient in terms of addition of stores as well as profitability. The online pharmacy also exhibited increased revenue, thereby reducing operating loss further in 2QFY27.
- We increase our earnings estimate by 2%/6% for FY27/FY28, factoring in: a) increased number of patients being treated, b) higher realization per patient, and c) scale-up of offline as well as online pharmacy business. We value APHS on an SOTP basis (27x EV/EBITDA for hospital business, 25x EV/EBITDA for offline pharmacy, 24x EV/EBITDA for AHLL and 2x EV/sales for online pharmacy business) to arrive at a TP of INR10,400.
- We remain positive on APHS on the back of: a) sustained improvement in the hospital segment, backed by higher volume growth/bed additions, and b) lower customer acquisition costs and improving GMV, driving profitable growth. Reiterate BUY.

EBITDA outgrows revenue even as new hospitals drag

- 2QFY27 revenue grew 23% YoY to INR76.1b (in line).
- EBITDA margin expanded 70bp YoY to 15.6%.
- EBITDA grew 29% YoY to INR11.9b (5% beat).
- Adj. PAT grew 32% YoY to INR6.3b (5% beat).
- For 1HFY27, revenue/EBITDA/PAT grew 21%/28%/33% YoY to INR145.5b/INR22.7b/INR12.1b.

Broad-based YoY growth across all segments

- Healthcare services revenue grew 23% YoY to INR39b.
- Hospital EBITDA grew 20% YoY to INR9.4b for 2QFY27.
- IP volumes rose 14% YoY; ARPP increased 8% YoY.
- 2Q occupancy was 73% vs. 69% in 2QFY26.
- Healthco's revenue grew 23.5% YoY to INR32.8b.
- Healthco achieved EBITDA of INR1.9b vs. INR1.1b YoY. EBITDA margin stood at 6%.
- Platform GMV grew 20% YoY to INR6.1b, while core segment GMV grew 27% YoY to INR5.7b (excluding GST impact).

- 222 new stores were opened in 2QFY27, taking total to 7,440 stores.
- Average run rate increased 15% YoY to 77k/day order across pharmacy, diagnostics, and consultations, including IP/OP referrals, in 2QFY27.
- AHLL revenue grew 20% YoY to INR4.3b.
- EBITDA grew 14% YoY in 2QFY27 to INR610m.
- Diagnostic/Spectra revenue stood at INR2.3b/INR840m for the quarter.

Highlights from the management commentary

- APHS plans to add 1,395 census beds across FY26-27, of which 520 beds are operational. All seven hospitals are expected to be launched by the coming quarter, with full capacity to be operationalized over the next 12M.
- New hospitals reported an EBITDA loss of INR350m in 2QFY27. The Hyderabad hospital achieved breakeven, while the remaining three hospitals are expected to break-even by FY27-end.
- APHS plans to add ~320 beds in FY28-29 through expansions at Jubilee Hills, Hyderabad, Raipur, Bengaluru, Mysuru, and Indore, taking planned additions to ~1,800 beds over the next two years.
- 24/7 achieved digital cash profitability of INR10m in 2QFY27 vs loss of INR399m in 2QFY26.
- APHS targets 20-30% increase in daily orders over the next 6M, with improving pharma unit economics, private-label and generics mix, and offline pharmacy synergies driving profitability. HealthCo margins are expected to improve over the next 2Q.
- HealthCo's near-term EBITDA margin has been moderated to ~6% due to manpower investments, employee bonuses, and one-time integration and scheme-related expenses. Management expects margins to reach higher single digits over the next 3-4 years.

Consolidated - Quarterly Earning Model INR(m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	vs Est
(INRm)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2QE	(%)
Gross Sales	**58,421**	**61,888**	**64,774**	**66,055**	**69,319**	**76,149**	**76,356**	**77,184**	**251,138**	**299,008**	**75,229**	**1.2%**
YoY Change (%)	14.9	10.7	17.2	18.1	18.7	23.0	17.9	16.8	15.2	19.1	19.3	
Total Expenditure	49,902	52,644	55,121	55,945	58,549	64,241	64,368	65,143	213,612	252,302	63,945	
EBITDA	**8,519**	**9,244**	**9,653**	**10,110**	**10,770**	**11,908**	**11,988**	**12,041**	**37,526**	**46,707**	**11,284**	**5.5%**
YoY Change (%)	26.2	13.4	26.8	31.3	26.4	28.8	24.2	19.1	24.2	24.5	19.9	
Margins (%)	14.6	14.9	14.9	15.3	15.5	15.6	15.7	15.6	14.9	15.6	15.0	
Depreciation	2,147	2,053	2,192	2,244	2,224	2,303	2,360	2,386	8,636	9,273	2,358	
Interest	1,083	986	1,126	1,191	1,081	1,140	1,201	1,213	4,386	4,635	1,213	
Other Income	402	545	528	439	479	448	493	457	1,914	1,878	452	
PBT before EO expense	**5,691**	**6,750**	**6,863**	**7,114**	**7,944**	**8,913**	**8,920**	**8,899**	**26,418**	**34,676**	**8,165**	
Extra-Ord expense/(Income)	0	0	192	0	0	0	0	0	192	0	0	
PBT	**5,691**	**6,750**	**6,671**	**7,114**	**7,944**	**8,913**	**8,920**	**8,899**	**26,226**	**34,676**	**8,165**	
Tax	1,417	1,807	1,657	1,702	1,884	2,449	2,275	2,278	6,583	8,886	1,992	
Rate (%)	24.9	26.8	24.8	23.9	23.7	27.5	25.5	25.6	25.1	25.6	24.4	
Minority Interest & P /L of Asso. Cos.	-54	171	-9	119	253	166	140	135	227	694	155	
Reported PAT	**4,328**	**4,772**	**5,023**	**5,293**	**5,807**	**6,298**	**6,505**	**6,486**	**19,416**	**25,096**	**6,018**	
Adj PAT	**4,328**	**4,772**	**5,167**	**5,293**	**5,807**	**6,298**	**6,505**	**6,486**	**19,560**	**25,096**	**6,018**	**4.7%**
YoY Change (%)	41.8	26.0	38.8	35.9	34.2	32.0	25.9	22.5	35.3	28.3	26.1	
Margins (%)	7.4	7.7	8.0	8.0	8.4	8.3	8.5	8.4	7.8	8.4	8.0	

Aurobindo Pharma

Estimate change	⟷
TP change	↑
Rating change	⟷

Bloomberg	ARBP IN
Equity Shares (m)	575
M.Cap.(INRb)/(USDb)	1027 / 10.9
52-Week Range (INR)	1797 / 1106
1, 6, 12 Rel. Per (%)	-2/23/59
12M Avg Val (INR M)	1805

Financials & Valuations (INR b)

Y/E MARCH	2026	2027E	2028E
Sales	336.5	400.9	447.4
EBITDA	68.6	83.5	93.5
Adj. PAT	35.6	44.7	51.1
EBIT Margin (%)	15.1	15.7	16.1
Cons. Adj. EPS (INR)	61.3	77.0	88.0
EPS Gr. (%)	0.4	25.6	14.4
BV/Sh. (INR)	652.4	725.0	807.1
Ratios			
Net D:E	-0.1	0.0	-0.1
RoE (%)	10.1	11.2	11.5
RoCE (%)	8.9	10.1	10.7
Payout (%)	6.6	5.2	6.8
Valuations			
P/E (x)	29.2	23.2	20.3
EV/EBITDA (x)	14.0	11.6	9.8
Div. Yield (%)	2.9	2.4	2.1
FCF Yield (%)	0.2	0.2	0.3
EV/Sales (x)	2.9	-0.7	4.8

Shareholding Pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	51.9	51.9	51.8
DII	24.4	25.1	27.6
FII	17.4	16.4	14.2
Others	6.3	6.6	6.4

FII includes depository receipts

CMP: INR1,785 TP: INR2,110 (+18%) Buy

Operational beat led by broad-based formulation growth

Growth levers in place: EU, Lannett, and PenG to drive a 20% earnings CAGR

- Aurobindo Pharma (ARBP) delivered better-than-expected revenue/ EBITDA with 7% beat for the quarter. However, earnings came in line due to higher depreciation and a higher tax rate for the quarter.
- The formulation segment grew at a higher-than-expected rate during the quarter, backed by superior execution across key geographies.
- ARBP sustained growth momentum in EU segment through continued portfolio expansion, deeper customer engagement, improving market penetration and reliable supply execution reaching EUR288m in quarterly sales in 2QFY27. Management remains confident of further growth despite an annualized revenue base of over EUR1b from this geography.
- The addition of Lannett, differentiated product launches, higher volume gains, as well as injectables led to improved performance in US segment for the quarter.
- We largely maintain our estimates for FY27/FY28. We value ARBP at 21x 12M forward earnings to arrive at our TP of INR2,110.
- We expect a 20% earnings CAGR over FY26-28, led by an improved outlook in the EU, differentiated product launches in the US, integration benefits from the Lannett acquisition, production scale-up of the China facility and higher margins from the PenG project. **Maintain BUY.**

Segment mix benefits partly offset by higher opex YoY

- Aurobindo's (ARBP) 2QFY27 sales grew 24% YoY to INR102.6b (a **7% beat**), driven by strong performance across all business areas
- Gross margin (GM) was up 150bp YoY to 61.2%, due to better business mix.
- EBITDA margin expanded 75bp YoY to 21%. This was due to decrease in R&D cost (down 130bps as % of sales) offset by increases in other costs and staff costs (up 130bps/75bps as a % of sales)
- EBITDA grew 28.5% YoY to INR21.6b (a beat of 7%)
- Adj. PAT grew 33% at INR11.2b (in line).
- For 1HFY27, its revenue/EBITDA/PAT grew 20%/24%/30% YoY at INR194b/ INR40.8b/INR21.8b.

Broad-based growth across all segments

- Overall formulation sales grew 24.2% YoY to INR91b.
- US formulations revenue grew 25.2% YoY to INR45.6b (CC: 14.4% YoY to USD477m; ~44% of sales).
- Europe formulation sales grew ~27% YoY to INR32b (18.5% YoY in CC terms ; ~31% of sales).
- Growth Markets sales grew 16% YoY to INR10.3b (~10% of sales).
- ARV revenue grew 10.2% YoY to INR3.6b (~3% of sales).
- API sales grew ~21% YoY basis to INR11.6b (~11% of sales).

Highlights from the management commentary

- ARBP reiterated guidance of double-digit revenue YoY growth, EBITDA margin of 21%+ with absolute EBITDA of INR80b+ for FY27.
- ARBP guided that FY28 financial performance is expected to be significantly stronger than FY27 due to full-year consolidation benefits from Lannett, positive operating leverage in China, and expanding biosimilar commercialization.
- Raw material procurement costs faced inflation due to geopolitical disruptions in the Gulf, with management noting that the cost escalation has not yet fully flowed into consumption and will partly impact upcoming quarters.
- Raleigh manufacturing facility received a Voluntary Action Indicated (VAI) classification from the US FDA, clearing the pathway for transdermal, dermal, and respiratory filings and commercial launches.
- Penicillin G fermentation facility attained capability to manufacture 15K TPA, with current production operating at approximately 10K TPA against total domestic Indian market demand of roughly 9K TPA, targeting an output expansion to 12K TPA in FY28.
- Penicillin G plant is operating at a modest positive EBITDA level prior to the receipt of PLI scheme benefits, supported by manufacturing yield gains and recent benchmark price increases in 6-APA.
- Advanced the complex respiratory franchise through the mid-quarter launch of generic Advair (G-Adware) and approval of generic Qvar (GQR); pipeline includes 1 approved MDI asset, 4 in-house inhalation candidates in development, a co-development partnership with a global pharma major, and ongoing global in-licensing discussions targeting multi-billion dollar market categories with scale-up expected around mid-FY29.

Quarterly Performance (Consolidated) (INRm)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	
INRm	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			2QE	vs Est
Net Sales	**78,681**	**82,857**	**86,459**	**88,533**	**91,504**	**102,633**	**101,408**	**105,344**	**336,531**	**400,888**	**96,195**	**6.7%**
YoY Change (%)	4.0	6.3	8.4	5.6	16.3	23.9	17.3	19.0	6.1	19.1	16.1	
EBITDA	**16,034**	**16,781**	**17,733**	**18,009**	**19,243**	**21,558**	**21,296**	**21,385**	**68,558**	**83,481**	**20,201**	**6.7%**
YoY Change (%)	-5.4	7.1	8.9	-3.3	20.0	28.5	20.1	18.7	1.6	21.8	20.4	
Margins (%)	20.4	20.3	20.5	20.3	21.0	21.0	21.0	20.3	20.4	20.8	21.0	
Depreciation	4,057	4,292	4,647	4,786	4,868	5,312	5,114	5,313	17,782	20,607	4,856	
Interest	978	952	928	982	1,017	1,022	964	935	3,840	3,938	973	
Other Income	1,053	1,156	1,541	1,170	2,116	1,654	1,550	1,450	4,921	6,770	1,650	
PBT before EO expense	**12,053**	**12,693**	**13,700**	**13,412**	**15,475**	**16,878**	**16,768**	**16,586**	**51,857**	**65,706**	**16,022**	
Forex loss/(gain)	4	-50	-335	482	-526	-29	0	0	101	-555	0	
Exceptional (expenses)/income	0	0	(653)	0	(834)	0	0	0	-653	-834	0	
PBT	**12,049**	**12,743**	**13,382**	**12,931**	**15,166**	**16,906**	**16,768**	**16,586**	**51,103**	**65,427**	**16,022**	
Tax	3,826	4,278	4,287	3,698	4,831	5,638	5,198	5,175	16,089	20,842	4,807	
Rate (%)	31.8	33.6	32.0	28.6	31.9	33.4	31.0	31.2	31.5	31.9	30.0	
Minority Interest	-25	-20	-9	20	10	7	30	30	-33	77	30	
Reported PAT	**8,248**	**8,485**	**9,103**	**9,213**	**10,326**	**11,261**	**11,540**	**11,381**	**35,048**	**44,508**	**11,185**	
Adj PAT	**8,250**	**8,451**	**9,319**	**9,557**	**10,536**	**11,242**	**11,540**	**11,381**	**35,577**	**44,699**	**11,185**	**0.5%**
YoY Change (%)	-8.5	3.4	5.8	1.3	27.7	33.0	23.8	19.1	0.4	25.6	32.4	
Margins (%)	10.5	10.2	10.8	10.8	11.5	11.0	11.4	10.8	10.6	11.1	11.6	

Bharat Forge

Estimate changes	↓
TP change	↓
Rating change	↔

Bloomberg	BHFC IN
Equity Shares (m)	489
M.Cap.(INRb)/(USDb)	856.6 / 9.1
52-Week Range (INR)	2295 / 1299
1, 6, 12 Rel. Per (%)	-13/-8/36
12M Avg Val (INR M)	2308

Consol. Financials & Valuations (INR b)

Y/E Mar	2026	2027E	2028E
Sales	168.1	196.3	226.3
EBITDA (%)	17.4	17.0	19.2
Adj. PAT	11.9	14.8	21.9
EPS (INR)	25.0	30.3	44.8
EPS Gr. (%)	17.0	21.1	47.9
BV/Sh. (INR)	200	256	286
Ratios			
Net D:E	0.7	0.3	0.3
RoE (%)	12.6	13.4	16.6
RoCE (%)	8.6	9.5	12.2
Payout (%)	34.8	36.4	33.3
Valuations			
P/E (x)	69.9	57.7	39.0
P/BV (x)	8.7	6.8	6.1
EV/EBITDA (x)	30.2	26.3	20.0
Div. Yield (%)	0.5	0.6	0.9

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	43.1	44.1	44.1
DII	33.0	32.3	32.3
FII	15.2	15.0	13.6
Others	8.6	8.6	10.1

FII Includes depository receipts

CMP: INR1,753 **TP: INR1,800 (+3%)** **Neutral**

Auto growth benefits offset by defense delays

Defense order execution remains the key monitorable

- Bharat Forge (BHFC)'s 2QFY27 standalone adjusted PAT at INR3.8b came in line. Higher commodity and energy costs weighed on standalone margins. Consolidated PAT declined 7% YoY due to losses in the US subsidiaries and lower standalone margins.
- Due to the margin pressure witnessed in 2Q, continued losses in the US operations, and delays in ATAGS revenue recognition (higher margin business), we cut our FY27/FY28 earnings estimate by 6%/5% respectively. The GST rate cut has helped revive the domestic auto business, which augurs well for BHFC. Conversely, the US Class8 cycle momentum seems to have peaked, with weak Oct net orders. Defense, aerospace, and JSA are likely to remain the key growth drivers for BHFC in the coming years, while delays in revenue recognition from defense orders will hurt near-term earnings.
- We now expect BHFC to post a CAGR of 16%/22%/36% in revenue/ EBITDA/PAT over FY26-28E. However, at current valuations of 58x FY27E and 39x FY28E earnings, most positives seem to be factored in. **Reiterate Neutral with a TP of INR1,800 per share (valued at 40x FY28E EPS).**

In-line performance

- 2Q standalone revenue grew 30% YoY to INR25.2b (in-line). Volumes grew 25% YoY to 70,703MT, while realizations grew 3.6% YoY to INR357/kg.
- Auto revenue grew 51% YoY to INR13.5b (18% above estimate), whereas non-auto revenue grew 11% YoY to INR11.7b (missing our estimate of INR13.3b).
- Export revenue at INR13b grew ~39% YoY on account of double-digit growth in CV and PV business. 2Q export performance was driven by a combination of inventory restocking, a rebound in NA truck production volumes, as well as modest volume and market share gains in Europe. On the other hand, domestic CV revenue grew 44% YoY on account of higher production. Overall domestic revenue grew 21% YoY to INR12.2b.
- Standalone EBITDA margins declined 250bp YoY to 25.8% (vs est of 25.4%) due to higher energy and input costs. EBITDA grew 18% YoY at INR6.5b (in-line).
- There was an exceptional expense of INR206m due to incidental expenses pertaining to the restructuring of Bharat Forge CDP (German subsidiary).
- Adjusted for this expense, PAT grew 23% YoY to INR3.8b(in line).
- Consolidated revenue rose 21% YoY to INR48.7b, while consolidated margins were down ~220bp YoY at 15.8%. It reported PAT of INR2.8b.
- Overseas subsidiaries' margins contracted 220bp YoY to 1.6% in 2Q from 3.8% YoY due to losses in the US business. Europe subsidiaries' margin declined 50bp YoY at 3.1%, and US subsidiaries' margin fell from 4.2% in 2QFY26 to -1.4% in 2QFY27.

Highlights from the management interaction

- India manufacturing revenue is expected to increase from the current ~INR30–34b per quarter to ~INR50b by the end of FY28, while EBITDA margin could expand by at least 200–250bp as aerospace, defense, semiconductor and other non-auto businesses scale up
- Unexecuted defense order book stood at ~INR 109.5b; 2HFY27 revenue should improve as recent programs enter execution, while ATAGS deliveries are expected to begin in 1QFY28 with an expected EBITDA margin of ~20–22%.
- Management expects H2FY27 to be stronger than H1FY27, driven by price recoveries and program ramp-ups across aerospace, industrial exports, semiconductors, CVs, passenger vehicles, marine and domestic subsidiaries.
- Bharat Forge is investing ~INR 13b in Baramati to add ~100,000 tonnes of forging capacity, supporting growth in aerospace, semiconductor and industrial businesses over the next 2–3 years.

Valuation and view

Due to the margin pressure witnessed in 2Q, continued losses in US operations, and delays in ATAGS revenue (a higher-margin business), we cut our FY27/FY28 earnings estimate by 6%/5% respectively. The GST rate cut has helped revive the domestic auto business, which augurs well for BHFC. On the other hand, the US Class 8 cycle momentum seems to have peaked, with weak Oct net orders. Defense, aerospace, and JSA are likely to remain the key growth drivers for BHFC in the coming years, while delays in revenue recognition in defense orders will impact near-term earnings. We now expect BHFC to post a CAGR of 16%/22%/36% in revenue/ EBITDA/PAT over FY26-28E. However, at current valuations of 58x FY27E and 39x FY28E earnings, most positives seem to be factored in. **Reiterate Neutral with a TP of INR1,800 per share (valued at 40x FY28E EPS).**

S/A Quarterly **(INR M)**

	FY26				FY27E				FY26	FY27E		Variance
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net operating income	**21,047**	**19,469**	**20,837**	**22,604**	**23,474**	**25,264**	**25,181**	**26,024**	**83,957**	**99,942**	**24,842**	**1.7**
Change (%)	-10.0	-13.3	-0.6	4.5	11.5	29.8	20.9	15.1	-5.1	19.0	27.6	
EBITDA	**5,718**	**5,511**	**5,664**	**6,173**	**5,857**	**6,525**	**6,774**	**7,154**	**23,066**	**26,309**	**6,298**	**3.6**
EBITDA Margins (%)	27.2	28.3	27.2	27.3	25.0	25.8	26.9	27.5	27.5	26.3	25.4	50bp
Change (%)	-12.2	-11.9	-7.1	0.1	2.4	18.4	19.6	15.9	-7.9	14.1	14.3	
Non-Operating Income	422	465	273	285	343	309	420	518	1,445	1,589	390	-20.8
Interest	522	483	414	402	432	485	380	303	1,822	1,600	420	15.4
Depreciation	1125	1112	1120	1124	1150	1170	1190	1215	4,480	4,725	1180	-0.8
EO Exp / (Inc)	0	79	487	4,930	245	206	0	0	5,496	245	0	
PBT after EO items	**4,493**	**4,380**	**4,403**	**4,932**	**4,618**	**5,179**	**5,624**	**6,154**	**12,712**	**21,328**	**5,088**	**1.8**
Tax	1108	1202	1035	1180	1159	1264	1417	1596	4,525	5,436	1282	
Eff. Tax Rate (%)	24.7	27.9	26.4	23.9	25.1	24.4	25.2	25.9	35.6	25.5	25.2	
Rep. PAT	**3,385**	**3,099**	**2,880**	**-1,178**	**3,214**	**3,709**	**4,207**	**4,558**	**8,187**	**15,892**	**3,806**	
Adj. PAT	**3,385**	**3,150**	**3,194**	**3,752**	**3,396**	**3,864**	**4,207**	**4,558**	**11,727**	**16,074**	**3,806**	**1.5**
Change (%)	-10.6	-10.3	-7.9	4.0	0.3	22.7	31.7	21.5	-18.4	37.1	20.8	

E: MOFSL Estimates

Uno Minda

Estimate changes	↑
TP change	↑
Rating change	↔

Bloomberg	UNOMINDA IN
Equity Shares (m)	577
M.Cap.(INRb)/(USDb)	770.9 / 8.2
52-Week Range (INR)	1355 / 994
1, 6, 12 Rel. Per (%)	13/21/11
12M Avg Val (INR M)	1031

Consol. Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	196.6	257.7	302.1
EBITDA	22.5	28.2	34.9
Adj. PAT	12.2	15.5	20.0
EPS (INR)	20.7	26.9	34.7
EPS growth %	27.0	29.6	29.2
BV/Sh. (INR)	125.7	151.5	184.3
Ratios			
RoE (%)	19.1	20.6	22.0
RoCE (%)	19.0	21.1	22.7
Payout (%)	12.5	11.2	11.5
Valuations			
P/E (x)	64.4	49.7	38.5
P/BV (x)	10.6	8.8	7.2
Div. Yield (%)	0.2	0.2	0.3
FCF Yield (%)	0.2	0.2	1.0

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	68.4	68.4	68.5
DII	17.1	17.5	15.8
FII	8.8	8.2	10.0
Others	5.8	6.0	5.8

CMP: INR1,335 TP: INR1,560 (+17%) Buy

Strong 2Q performance despite commodity inflation

Capacity ramp-up, stable industry growth to drive outperformance

- Uno Minda's (UML) 2QFY27 earnings at INR4.2b beat our estimates. EBITDA margin contracted 50bp YoY to 11% (vs est. of 10.6%), primarily due to commodity cost inflation and wage revision impact. Revenue grew ~38% YoY to INR66.6b and beat our estimates, driven by broad-based growth across segments.
- Due to stronger-than-expected 2Q performance and stable growth momentum for the underlying industry in 2H, we increase our earnings estimates by 13%/10% for FY27/FY28. Management expects FY27 to be a key growth year, with several new projects entering commercialization or ramp-up, supplementing the two plants commissioned in 4QFY26. The company has a strong pipeline of technology-led opportunities and recent business wins across key verticals, including: 1) entry into the 4W PV seating business, with INR3.2b investment in a new facility, 2) incremental sunroof orders, leading to an additional INR850m capacity expansion at Bawal, 3) additional orders for advanced pixel-based headlamps and tail lamps from a global PV OEM, and 4) new customer additions in seating, including an incumbent Japanese OEM and a bus seating customer. Further, the ramp-up of recently commissioned alloy wheel capacities is expected to support growth momentum.
- Overall, we expect UML to post a healthy CAGR of 24%/25%/30% in revenue/EBITDA/PAT over FY26-28. Returns are expected to rise in FY28 following the ramp up of new capacities. Overall, we value UML at 45x FY28E EPS to arrive at a TP of INR1,560. Maintain BUY

Strong operating performance

- Consol 2QFY27 revenue beat our estimates, growing 38.3% YoY to INR66.6b (vs. estimate of INR59.1b).
- RM costs came in higher than expectations, resulting in gross margins dipping 340bp YoY to 32.4% (estimated 34%).
- EBITDA was up ~33% YoY to INR7.3b (17% above est). EBITDA margin contracted ~40bp YoY (70bp QoQ) to 11% (above our estimate of 10.6%).
- As a result, adj. PAT beat our estimates and grew 38% YoY to INR4.2b (est. of INR3.3b).

Segmental updates:

- **Switches** posted strong 36.8% YoY growth in revenue to INR16.1b (beating expectations), with revenue share stable YoY at 24%.
- **Lighting** recorded ~25% YoY growth to INR13.8b (beating expectations), with the revenue mix declining to 21%.
- **Casting** beat our expectations with strong 57.1% YoY growth to INR14.4b, with the revenue mix improving to 22%.
- **Seatings** witnessed 34.5% YoY growth to INR4.8b (ahead of expectations), with the revenue mix remaining stable at 7%.

- **Green Mobility** now makes up 10% of UML's consolidated revenue.
- **Others**, which includes **Acoustics**, witnessed 16.9% YoY growth to ~INR11b, broadly in line with our estimates. The revenue mix declined YoY to 17% in 2Q.

Key highlights from the management commentary

- Management remains constructive on the Indian automotive industry and expects growth momentum to sustain in 2HFY27, supported by the festive and wedding seasons, new product launches and improving demand.
- UML continues to secure technology-led orders across key segments, including advanced pixel-based lighting, sunroofs, ambient lighting, seating and EV chargers, strengthening its medium-term growth pipeline.
- Strategic investments include INR3.2b greenfield facility for 4W PV seating and an additional INR850m capex at Bawal for sunroof capacity expansion, alongside ongoing alloy wheel and die-casting capacity additions.
- The INR52-53b capex pipeline provides significant growth headroom, with new projects targeting 18-20% pre-tax ROCE by the third full year of production. Blended EBITDA margins from these projects are expected to be within the range of the company's current profitability.
- FY27 EBITDA margin guidance was retained at 11% (+/- 50bp). While commodity pass-throughs may cause near-term dilution, management expects operating leverage and improved gross contribution to support margin expansion.
- Net debt increased to INR24.2b as investments continued; however, 1H operating cash flow remained healthy at INR7.1b.

Valuation and view

Due to stronger-than-expected 2Q performance and growth momentum sustaining for the underlying industry in 2H, we increase our earnings estimates by 13%/10% for FY27/FY28. Management expects FY27 to be a key growth year, with several new projects entering commercialization or ramp-up, supplementing the two plants commissioned in 4QFY26. The company has a strong pipeline of technology-led opportunities and recent business wins across key verticals, including: 1) entry into the 4W PV seating business, with a INR3.2b investment in a new facility, 2) incremental sunroof orders, leading to an additional INR850m capacity expansion at Bawal, 3) additional orders for advanced pixel-based headlamps and tail lamps from a global PV OEM, and 4) new customer additions in seating, including an incumbent Japanese OEM and a bus seating customer. Further, the ramp-up of recently commissioned alloy wheel capacities is expected to support growth momentum. Overall, we expect UML to post a healthy CAGR of 24%/25%/30% in revenue/ EBITDA/PAT over FY26-28. Returns are expected to rise in FY28 following the ramp up of new capacities. Overall, we value UML at 45x FY28E EPS to arrive at a TP of INR1,560 per share and maintain our BUY rating on the stock.

Quarterly Performance (S/A)

(INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net Op Revenues	**44,891**	**48,140**	**50,181**	**53,364**	**55,569**	**66,554**	**67,260**	**68,315**	**1,96,576**	**2,57,695**	**59,123**	**12.6**
Growth YoY (%)	17.6	13.4	19.9	17.8	23.8	38.3	34.0	28.0	17.2	31.1	22.8	
Total Cost	**39,460**	**42,623**	**44,645**	**47,336**	**49,852**	**59,222**	**59,794**	**60,676**	**1,74,064**	**2,29,544**	**52,856**	**12.0**
RM Cost (% sales)	63.2	64.2	64.1	65.2	66.7	67.6	67.0	65.9	64.2	66.8	66.0	
Staff Cost (% sales)	13.9	13.2	13.1	12.4	12.9	11.3	11.5	11.8	13.1	11.8	12.8	
Other Exp (% sales)	10.8	11.1	11.7	11.0	10.1	10.1	10.4	11.2	11.2	10.4	10.6	
EBITDA	**5,431**	**5,518**	**5,535**	**6,028**	**5,717**	**7,333**	**7,466**	**7,638**	**22,512**	**28,151**	**6,267**	**17.0**
EBITDA Margins (%)	12.1	11.5	11.0	11.3	10.3	11.0	11.1	11.2	11.5	10.9	10.6	
Change (%)	33.2	14.4	21.1	14.5	5.3	32.9	34.9	26.7	20.1	25.0	13.6	
Other Income	120	129	37	57	63	45	100	181	344	389	146	
Depreciation	1,593	1,734	1,790	1,918	1,766	1,781	2,354	1,953	7,036	7,854	2,040	
EBIT	**3,958**	**3,913**	**3,782**	**4,168**	**4,014**	**5,597**	**5,212**	**5,866**	**15,821**	**20,686**	**4,374**	
Finance Cost	440	454	528	449	461	487	485	492	1,870	1,925	480	
PBT before JV, associates & tax	**3,518**	**3,459**	**3,255**	**3,719**	**3,553**	**5,110**	**4,727**	**5,374**	**13,951**	**18,761**	**3,894**	**31.2**
Share of Profit of associates/ JVs	473	634	740	642	476	598	770	807	2,489	2,650	660	
Tax	901	865	714	844	873	1,300	1,237	1,408	3,323	4,818	1,002	**29.7**
Effective Tax Rate (%)	25.6	25.0	21.9	22.7	24.6	25.4	26.2	26.2	23.8	25.7	25.7	
PAT after Share of profit of JVs	**3,090**	**3,228**	**3,281**	**3,518**	**3,155**	**4,408**	**4,260**	**4,773**	**13,116**	**16,594**	**3,552**	
Non-controlling interests	183	188	239	260	197	211	336	338	869	1,082	236	
Adj. PAT	**2,907**	**3,040**	**3,042**	**3,258**	**2,958**	**4,197**	**3,924**	**4,435**	**12,247**	**15,511**	**3,315**	**26.6**
Growth (%)	46.0	28.5	30.8	22.4	1.8	38.1	29.0	36.1	31.1	26.7	9.1	

Key Performance Indicators

Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FY26	FY27E	2QE	(%)
Net Op Revenues	44,891	48,140	50,181	53,364	55,569	66,554	67,260	68,315	1,96,576	2,57,695	59,123	
Growth YoY (%)	17.6	13.4	19.9	17.8	23.8	38.3	34.0	28.0	17.2	31.1	22.8	
Cost Break-up												
RM Cost (% of sales)	63.2	64.2	64.1	65.2	66.7	67.6	67.0	65.9	64.2	66.8	66.0	160bp
Staff Cost (% of sales)	13.9	13.2	13.1	12.4	12.9	11.3	11.5	11.8	13.1	11.8	12.8	-150bp
Other Cost (% of sales)	10.8	11.1	11.7	11.0	10.1	10.1	10.4	11.2	11.2	10.4	10.6	-50bp
Gross Margins (%)	36.8	35.8	35.9	34.8	33.3	32.4	33.0	34.1	35.8	33.2	34.0	-160bp
EBITDA Margins (%)	12.1	11.5	11.0	11.3	10.3	11.0	11.1	11.2	11.5	10.9	10.6	40bp
EBIT Margins (%)	8.8	8.1	7.5	7.8	7.2	8.4	7.7	8.6	8.0	8.0	7.4	100bp

Segmental Revenues

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Switches Segment	11,110	11,760	12,410	13,430	13,350	16,090	16,257	16,602	48,710	62,300	14,347	**12.1**
YoY Change %	16.0	11.3	18.8	17.4	20.2	36.8	31.0	23.6	15.9	27.9	22.0	
Lighting Segment	10,130	11,060	11,290	11,540	11,530	13,810	14,113	14,370	44,020	53,823	12,277	**12.5**
YoY Change %	13.3	14.0	15.0	13.5	13.8	24.9	25.0	24.5	14.0	22.3	11.0	
Castings Segment	8,240	9,170	9,710	9,820	10,900	14,410	14,565	14,609	36,940	54,484	11,921	**20.9**
YoY Change %	9.9	8.9	26.4	14.2	32.3	57.1	50.0	48.8	14.7	47.5	30.0	
Seatings Segment	3,200	3,540	3,610	3,810	4,080	4,760	4,404	4,456	14,160	17,700	4,425	**7.6**
YoY Change %	18.1	23.8	32.2	17.2	27.5	34.5	22.0	17.0	22.6	25.0	25.0	
Green Mobility Segment	3,050	3,210	3,560	4,230	5,420	6,490	6,693	6,835	14,050	25,438	5,585	**16.2**
YoY Change %					77.7	102.2	88.0	61.6	NM	81.1	74.0	
Others	9,161	9,400	9,601	10,534	10,290	10,990	11,229	11,442	38,696	43,951	10,568	**4.0**
YoY Change %	-3.1	-13.9	-14.0	892.0	12.3	16.9	17.0	8.6	28.1	13.6	12.4	

E:MOSL Estimates

Dabur

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR385 TP: INR425 (+10%) Neutral

Strategy remains intact, aiming for better outcome

- At Dabur's analyst meet, newly appointed CEO Mr. Herjit S. Bhalla outlined "IGNITE" as the roadmap for the second half of Vision VII (FY25-28). The emphasis was on sharper execution of existing initiatives rather than new announcements, and a refreshed strategy is expected in six months. Dabur has 27 brands with turnover above INR1b, seven category-leading brands contributing ~50% of revenue, reach across ~8.5mn outlets and penetration in eight out of 10 Indian households.
- The first half of Vision VII has largely been about strengthening the base. Dabur exited six non-core brands, rationalized 350+ SKUs and consolidated its distributor network by 43% under Project Saksham, shifting from category-wise distributors to a unified model without exiting any geography. These changes have doubled distributor throughput and are now driving a recovery in General Trade. Cost programs delivered INR1.15b of savings over 18 months, while the premium portfolio has scaled up to ~20% of revenue. With the base in place, the focus now shifts to brand investment, which was held back over the past year by input-cost inflation.
- IGNITE builds on this through four levers. The core will be energized with a 150bp step-up in A&P. High-growth platforms in OTC & digestives, skin care, home care and foods will be scaled. The quality of urban and rural reach will be improved. Premium contribution is targeted to rise to 23% by FY28. Efficiency programs will fund the reinvestment, with savings in the second half of the Vision targeted at 1.5x the first half. M&A will stay within existing or closely adjacent categories, complemented by minority stakes in D2C brands through Dabur Ventures.
- Dabur's 2QFY27 consolidated revenue grew 12% YoY to INR35.6b (in line), led by 10.7% growth in India business and 20% growth in International. India volume growth stood at 5.5% (below est.). Home & Personal Care grew 11% YoY, Healthcare grew 6.9%, and Food & Beverages grew 17.4% YoY. GM contracted 60bp YoY to 48.8%. EBITDA margin declined 70bp YoY to 17.7%, with EBITDA growing 8% to INR6.3b (both in line). We expect margins to recover gradually through calibrated pricing, premiumization and productivity gains, and we build in EBITDA growth of 11% for FY27E and 14% for FY28E.
- After delivering muted sales growth over the past two years (1.3% in FY25 and 5% in FY26), Dabur expects to return to double-digit consolidated revenue growth in FY27. We see the shift toward volume-led growth, funded by internal savings and reinvested behind brands, as the right direction. Moreover, the early signs of GT recovery, premium mix and volume recovery are encouraging. However, the sustainability of demand momentum and commodity inflation remain key monitorables in FY27. The strategy refresh in six months should provide better visibility on the next leg of growth. We reiterate our Neutral rating on the stock with a TP of INR425 (30x Sep'28E EPS).

Stock Info

Bloomberg	DABUR IN
Equity Shares (m)	1774
M.Cap.(INRb)/(USDb)	683 / 7.2
52-Week Range (INR)	534 / 354
1, 6, 12 Rel. Per (%)	-7/-19/-21
12M Avg Val (INR M)	973
Free float (%)	33.7

Financials Snapshot (INR b)

Y/E Mar	2027E	2028E	2029E
Sales	148.0	159.2	170.6
Sales Gr. (%)	12.2	7.6	7.1
EBITDA	27.2	31.0	33.5
Margins (%)	18.4	19.5	19.7
Adj. PAT	21.3	24.3	25.6
Adj. EPS (INR)	12.0	13.7	14.4
EPS Gr. (%)	10.0	14.0	5.2
BV/Sh.(INR)	66.0	67.8	69.1
Ratios			
RoE (%)	18.4	20.5	21.1
RoCE (%)	16.6	18.4	19.2
Payout (%)	91.5	91.1	97.0
Valuations			
P/E (x)	32.8	28.7	27.3
P/BV (x)	6.0	5.8	5.7
EV/EBITDA (x)	22.4	19.5	17.9
Div. Yield (%)	2.8	3.2	3.6

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	66.3	66.2	66.2
DII	18.3	18.7	17.4
FII	9.6	9.7	10.9
Others	5.8	5.4	5.5

FII Includes depository receipts

Quarterly Performance (Consolidated)

(INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Domestic FMCG vol. growth (%)	**-1.0**	**2.0**	**3.0**	**6.0**	**5.0**	**5.5**	**5.0**	**8.5**	**2.5**	**6.0**	**8.0**	
Net sales	**34,046**	**31,913**	**35,587**	**30,380**	**37,644**	**35,631**	**40,184**	**34,504**	**1,31,926**	**1,47,962**	**35,973**	-1.0%
YoY change (%)	1.7	5.4	6.1	7.3	10.6	11.6	12.9	13.6	5.0	12.2	12.7	
Gross profit	**16,013**	**15,778**	**17,218**	**14,679**	**17,824**	**17,404**	**19,087**	**16,262**	**63,688**	**70,578**	**17,447**	-0.2%
Margin (%)	47.0	49.4	48.4	48.3	47.3	48.8	47.5	47.1	48.3	47.7	48.5	
EBITDA	**6,678**	**5,881**	**7,341**	**4,618**	**7,414**	**6,324**	**8,221**	**5,192**	**24,518**	**27,151**	**6,512**	-2.9%
Margins (%)	19.6	18.4	20.6	15.2	19.7	17.7	20.5	15.0	18.6	18.4	18.1	
YoY growth (%)	2.0	6.4	7.7	8.2	11.0	7.5	12.0	12.4	5.8	10.7	10.7	
Depreciation	1,141	1,154	1,172	1,222	1,212	1,189	1,270	1,338	4,689	5,009	1,269	
Interest	346	397	311	400	366	396	300	338	1,454	1,400	350	
Other income	1,440	1,401	1,406	1,750	1,726	1,719	1,700	1,787	5,998	6,931	1,513	
PBT	**6,630**	**5,731**	**7,265**	**4,747**	**7,562**	**6,458**	**8,351**	**5,303**	**24,373**	**27,673**	**6,406**	0.8%
Tax	1,543	1,282	1,575	1,117	1,695	1,470	2,088	1,665	5,517	6,917	1,601	
Rate (%)	23.3	22.4	21.7	23.5	22.4	22.8	25.0	31.4	22.6	25.0	25.0	
Adjusted PAT	**5,222**	**4,608**	**5,795**	**3,769**	**5,991**	**5,138**	**6,435**	**3,888**	**19,393**	**21,452**	**4,977**	3.2%
YoY change (%)	2.7	6.4	9.2	14.8	14.7	11.5	11.0	3.2	7.7	10.6	8.0	

E: MOSL Estimates

Ipca Laboratories

Estimate change	↑
TP change	↔
Rating change	↔

Bloomberg	IPCA IN
Equity Shares (m)	254
M.Cap.(INRb)/(USDb)	494.5 / 5.2
52-Week Range (INR)	2039 / 1276
1, 6, 12 Rel. Per (%)	-9/24/55
12M Avg Val (INR M)	565

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	96.5	111.8	124.1
EBITDA	19.8	25.9	29.9
Adjusted PAT	11.6	15.2	17.6
EBIT Margin (%)	16.2	19.2	20.4
Cons. Adj EPS (INR)	45.6	60.1	69.6
EPS Gr. (%)	26.9	31.7	15.7
BV/Sh. (INR)	317.8	368.4	427.5
Ratios			
Net D-E	0.0	0.0	-0.1
RoE (%)	15.4	17.5	17.5
RoCE (%)	14.9	17.2	17.0
Payout (%)	11.1	13.4	11.6
Valuation			
P/E (x)	42.7	32.4	28.0
EV/EBITDA (x)	25.1	19.2	16.6
Div. Yield (%)	0.3	0.4	0.4
FCF Yield (%)	1.7	1.7	3.0
EV/Sales (x)	5.1	4.4	4.0

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	44.7	44.7	44.7
DII	36.6	37.4	36.8
FII	11.5	10.7	10.4
Others	7.2	7.2	8.1

FII Includes depository receipts

CMP: INR1,950 **TP: INR2,250 (15+%)** **Buy**

Largely in-line show; formulation drive earnings

Generics, branded exports and chronic therapies keep growth on track

- Ipca Lab (IPCA) exhibited better-than-expected revenue (4% beat) in 2QFY27, led by improved performance in export formulation business. API sales also remained resilient for the second consecutive quarter.
- However, EBITDA/PAT came in largely in line with our estimate for the quarter due to higher other expenses for the quarter.
- The generics segment supported growth in export formulation segment. The growth was broad-based across geographies. The branded export segment also witnessed three consecutive quarters of high-teen YoY growth.
- The chronic segment performed better than industry, driving overall growth in domestic formulation segment. The acute therapies largely grew in line with the industry.
- We raise our earnings estimates for FY28 by 6%, factoring in a) sustainable growth in export formulation segment, b) increasing market share gain in domestic formulation segment, and c) better margins. We value IPCA at 30x 12-month forward earnings to arrive at our TP of INR2,250.
- We expect a 13%/23%/23% CAGR in revenue/EBITDA/PAT to reach INR124b/INR30b/INR17.6b by FY28. This would be driven by superior execution across domestic and export formulation and currency tailwinds. Maintain BUY

Strong revenue growth and margin expansion

- 1QFY27 sales grew 13.8% YoY to INR29.1b (beat by 4%).
- Gross margin (GM) expanded 260bp YoY to 72%.
- EBITDA margin also expanded 180bp YoY to 23.1% (miss by 50bp).
- EBITDA grew 23.6% YoY to INR6.7b (in line).
- Adjusted for exceptional item related to provision for claims, PAT grew 21% YoY to INR3.9b (in line).
- Revenue/EBITDA/PAT were in line with BBG estimates for 2QFY27.
- For 1HFY27, revenue/EBITDA/PAT grew by 17.1%/39.7%/42.4% to INR56b/INR13.4b/INR7.9b.

Exports drive formulation growth, while API remains subdued

- Formulation's sales grew 19.7% YoY to INR18.1b (62% of sales).
- Export formulation sales grew 32.5% YoY to INR6.5b (22% of total sales).
- Domestic formulation sales grew 13.6% YoY to INR11.6b (39% of total sales).
- Exports (generics formulation) grew 36% YoY to INR3.6b (56% of export sales). Exports (branded formulation) grew 18.9% YoY to INR1.7b (26% of export sales). Exports (institutional sales) grew 45.3% YoY to INR1.2b (18% of export sales).
- API sales grew 6.5% to INR4.3b (15% of sales). Export API sales declined 6.9% YoY to INR3b (69% of API sales). Domestic API sales grew 56.1% YoY to INR1.4b (31% of API sales).
- Revenue from subsidiaries grew 4% YoY to INR6.5b (23% of sales).

Highlights from the management commentary

- Management retained its FY27 revenue growth guidance of 14-16%.
- Management expects consolidated EBITDA margin to improve by 100-125bp annually, with standalone IPCA EBITDA margin expected to expand by ~150bp annually.
- Domestic formulation sales are guided to sustain full-year revenue growth of 15-16% YoY.
- Institutional generic sales for full-year FY27 are projected to exceed the earlier guidance of INR3b to reach INR3.3b to INR3.4b in FY27.
- Unichem Laboratories EBITDA margin was diluted by INR310m of incremental freight costs as air shipment share surged from 5-6% to 25% due to shipping line transit delays, reducing quarterly EBITDA by ~INR300m.

Consolidated - Quarterly Earning Model

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	% Chg
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2QE	
Net Revenues (Core)	**23,089**	**25,565**	**23,925**	**23,885**	**27,881**	**29,099**	**27,965**	**26,851**	**96,463**	**1,11,796**	**27,947**	**4.1**
YoY Change (%)	10.3	8.6	6.6	6.3	20.8	13.8	16.9	12.4	7.9	15.9	9.3	
EBITDA	**4,164**	**5,449**	**5,334**	**4,839**	**6,695**	**6,735**	**6,488**	**5,961**	**19,786**	**25,879**	**6,595**	**2.1**
YoY Change (%)	6	23.2	15.2	12.8	60.8	23.6	21.6	23.2	14.6	30.8	21	
Margins (%)	18	21.3	22.3	20.3	24	23.1	23.2	22.2	20.5	23.1	23.6	
Depreciation	1,001	1,033	1,076	1,071	1,108	1,145	1,122	1,077	4,181	4,453	1,142	
EBIT	**3,164**	**4,416**	**4,258**	**3,767**	**5,587**	**5,590**	**5,366**	**4,884**	**15,604**	**21,426**	**5,453**	
YoY Change (%)	7.7	29.1	16.8	14.6	76.6	26.6	26	29.6	17.4	37.3	23.5	
Margins (%)	13.7	17.3	17.8	15.8	20	19.2	19.2	18.2	16.2	19.2	19.5	
Interest	185	196	176	202	119	126	115	134	759	494	140	
Other Income	327	279	202	337	253	250	255	260	1,144	1,018	260	
PBT before EO Expense	**3,305**	**4,498**	**4,283**	**3,902**	**5,721**	**5,714**	**5,506**	**5,009**	**15,989**	**21,950**	**5,573**	
One-off (gain)/ Expense	0	583	-177	-142	0	243	0	0	264	243	0	
PBT after EO Expense	**3,305**	**3,916**	**4,460**	**4,045**	**5,721**	**5,472**	**5,506**	**5,009**	**15,725**	**21,708**	**5,573**	
Tax	961	1,081	819	951	1,493	1,556	1,569	1,443	3,812	6,061	1,533	
Rate (%)	29.1	27.6	18.4	23.5	26.1	28.4	28.5	28.8	23.8	27.6	27.5	
Reported PAT	**2,344**	**2,835**	**3,641**	**3,094**	**4,228**	**3,915**	**3,937**	**3,567**	**11,914**	**15,647**	**4,041**	
Minority Interest	-12	-9	-378	-103	-209	-164	-100	-100	-503	-573	-100	
Adj PAT after Minority Int	**2,332**	**3,247**	**3,119**	**2,882**	**4,019**	**3,925**	**3,837**	**3,467**	**11,580**	**15,247**	**3,941**	**-0.4**
YoY Change (%)	21.3	40.9	25.7	19.2	72.3	20.9	23	20.3	26.9	31.7	21.3	
Margins (%)	10.1	12.7	13	12.1	14.4	13.5	13.7	12.9	12	13.6	14.1	

Balkrishna Industries

Estimate change	⟷
TP change	↑
Rating change	⟷

Bloomberg	BIL IN
Equity Shares (m)	193
M.Cap.(INRb)/(USDb)	464.3 / 4.9
52-Week Range (INR)	2775 / 1965
1, 6, 12 Rel. Per (%)	7/8/6
12M Avg Val (INR M)	698

Financials & valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	106.6	135.1	153.5
EBITDA	24.6	26.3	33.2
Adj. PAT	12.4	14.0	18.0
EPS (Rs)	64.3	72.6	92.9
EPS Growth (%)	-24.9	12.8	28.1
BV/Share (INR)	566.8	619.3	688.3
Ratios			
RoE (%)	11.6	12.2	14.2
RoCE (%)	10.1	9.4	11.2
Payout (%)	24.9	27.6	25.8
Valuations			
P/E (x)	37.4	33.1	25.9
P/BV (x)	4.2	3.9	3.5
Div. yield (%)	0.7	0.8	1.0
FCF yield (%)	-1.6	-0.3	1.2

Shareholding pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter (%)	58.3	58.3	58.3
DII (%)	25.4	24.6	24.7
FII (%)	9.1	10.3	10.7
Others (%)	7.2	6.8	6.3

FII includes depository receipts

CMP: INR2,404 **TP: INR2,350 (-2%)** **Neutral**

India demand strong; margin recovery likely in FY28

Margin recovery likely in FY28E amid falling crude

- Balkrishna Industries' (BKT) 2Q earnings at INR2.9b were ahead of our estimate of INR2.6b, primarily due to a better-than-expected operating performance.
- BKT is now experiencing a gradual pick-up in demand across its key regions, with India likely to remain its key growth driver and huge potential expected from the Americas. However, its foray into the PCR/TBR segments is likely to be closely monitored for: 1) the pace at which it gains material traction, and 2) whether margins and returns will be materially dilutive in the long run. The stock has underperformed in the recent past and valuations at 33x FY27E and 26x FY28E are not too demanding. However, its future target multiple is likely to depend on its ability to succeed in these new segments—not only by capturing market share, but by doing so without materially hurting core returns, which, in our view, is likely to be a challenge. **Reiterate Neutral with a TP of INR2,350, valued at 25x FY28E EPS.**

Earnings beat due to a strong operating performance

- 2Q revenue of INR34.5b was above our estimate of INR31.1b, up 49% YoY, due to strong volume and realization growth.
- Volumes grew 30% YoY to 91,397 MT (-3% QoQ), ahead of our estimate of 85,707 MT.
- Blended ASPs were also up 14.3% YoY at ~INR377k per ton and broadly in line with our estimate of INR363k per ton.
- EBITDA was up ~26% YoY at INR6.3b (15% above our est). EBITDA margin contracted ~330bp YoY and 233bp QoQ to 18.2% (above our estimate of 17.5%).
- MTM gain of INR80m in 2QFY27 boosted profitability.
- As a result, adj. PAT grew 10% YoY to ~INR3b, ahead of our estimate of INR2.7b.
- The board declared an INR4/share interim dividend.
- CFO for 1HFY27 stood at outflow of INR10m due to adverse working capital impact of INR12.2b, while FCF outflow was INR19.5b.

Key highlights from the management commentary

- BKT delivered strong 2Q volume growth across geographies, with India continuing to outperform and now contributing ~40% of overall volumes. Management aims to sustain the run rate achieved over the past two quarters.
- Higher raw material and freight costs weighed on profitability, while ~2-3% price hikes, largely in India, were insufficient to fully offset inflation. Freight remained elevated at ~6.5% of sales, with further cost pressure expected over the next few quarters.

- Existing capacity is fully utilized and new capacity is ramping up, primarily for third-party customers. BKT is also moving toward specialty carbon blacks to improve mix and margins.
- TBR and two-wheeler tyres are seeing strong acceptance, while PCR launches are scheduled for Jan'27. Under Vision 2030, BKT targets 20% of turnover from on-road tyres, supported by the Pirelli partnership.
- 1HFY27 capex stood at ~INR18.5b vs. FY27 guidance of INR30b. Net debt increased to ~INR28.9b as project execution accelerated, but management expects future earnings to support debt servicing.

Valuation and view

BKT is now experiencing a gradual pick-up in demand across its key regions, with India likely to remain its key growth driver and huge potential expected from the Americas. However, its foray into the PCR/TBR segments is likely to be closely monitored for: 1) the pace at which it gains material traction, and 2) whether margins and returns will be materially dilutive in the long run. The stock has underperformed in the recent past and valuations at 33x FY27E and 26x FY28E are not too demanding. However, its future target multiple is likely to depend on its ability to succeed in these new segments—not only by capturing market share but by doing so without materially hurting core returns, which, in our view, is likely to be a challenge. **Reiterate Neutral with a TP of INR2,350, valued at 25x FY28E EPS.**

Quarterly Earning Model (Standalone) **(INR M)**

Y/E March	FY26				FY27E				FY26	FY27E	FY27	VAR
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Volumes (Ton)	**80,664**	**70,252**	**80,620**	**85,820**	**93,770**	**91,397**	**87,070**	**88,762**	**3,17,356**	**3,60,999**	**85,707**	**6.6**
YoY Change (%)	-3.5	-4.2	5.6	4.6	16.2	30.1	8.0	3.4	0.7	13.8	22.0	
Realizations (INR '000/ton)	**342.1**	**330.3**	**332.8**	**337.2**	**363.5**	**377.4**	**379.3**	**377.2**	**335.8**	**374.2**	**363.4**	**3.9**
YoY Change (%)	4.3	-1.8	-1.2	-2.5	6.3	14.3	14.0	11.8	-0.3	11.4	10.0	
Net Revenues	**27,594**	**23,207**	**26,827**	**28,942**	**34,087**	**34,495**	**33,029**	**33,480**	**1,06,560**	**1,35,092**	**31,143**	**10.8**
YoY Change (%)	0.7	-5.8	4.3	2.0	23.5	48.6	23.1	15.7	0.4	26.8	34.2	
EBITDA	**6,560**	**4,999**	**6,134**	**6,632**	**7,016**	**6,295**	**6,116**	**6,534**	**24,232**	**25,960**	**5,463**	**15.2**
Margins (%)	23.8	21.5	22.9	22.9	20.6	18.2	18.5	19.5	22.7	19.2	17.5	**70bp**
YoY Change (%)	-8.1	-19.2	-4.0	-5.7	6.9	25.9	-0.3	-1.5	-9.6	295.7	9.3	
Depreciation	1,862	1,901	1,921	1,955	2,033	2,164	2,210	2,363	7,640	8,770	2,150	
Interest	290	319	420	440	420	700	415	323	1,470	1,858	410	
Forex loss/(gain)	1,540	10	-360	250	-570	-80	0	0	1,440	-570	0	
Other Income	1,040	710	768	-36	680	380	650	867	-36	2,480	600	
PBT before EI	**3,908**	**3,478**	**4,920**	**3,950**	**5,813**	**3,891**	**4,141**	**4,714**	**16,162**	**18,479**	**3,503**	**11.1**
Extra-Ord expense	0	0	83	0	0	0	0	0	83	0	0	
PBT	**3,908**	**3,478**	**4,837**	**3,950**	**5,813**	**3,891**	**4,141**	**4,714**	**16,079**	**18,479**	**3,503**	**11.1**
Rate (%)	26.6	23.7	22.4	25.3	25.8	24.8	25.0	20.2	24.4	25.2	23.4	
Adj PAT	**2,867**	**2,653**	**3,817**	**2,951**	**4,314**	**2,926**	**3,106**	**3,762**	**12,412**	**14,028**	**2,683**	**9.1**
YoY Change (%)	-39.9	-24.1	-13.2	-18.5	50.5	10.3	-18.6	27.5	-23.8	13.0	1.2	

E: MOFSL Estimates

Premier Energies

Estimate change	⟷
TP change	↓
Rating change	⟷

CMP: INR883 **TP: INR1,150 (+30%)** **Buy**

Capacity ramp-up remains the key earnings driver

- **Premier Energies (PEL)'s 2Q in line:** PEL reported an in-line consolidated revenue/EBITDA at INR26.3b/INR7.4b, with an EBITDA margin of 28%. APAT was also in line at INR4.6b. Module/cell production for the quarter was 1.2GW/0.92GW with a CUF of 55%/99%.
- **Key things we liked about the result:** 1) strong order inflows, with new orders of ~INR40b taking the total order book to INR163b, with deliveries over 12–14months, providing strong revenue visibility, 2) commissioning of the 7GW cell plant remains on track, with ALMM-II inspection expected in the third week of November'26 and commercial production expected to begin in Nov'26, 3) The company continues to maintain industry-leading cell utilization, with cell CUF at 99%, and 4) BESS Phase 1 (6GWh) targeted for 2QFY28, with 40% localization comfortably achievable.
- **Key monitorables:** 1) Timely ramp-up of the upcoming 7GW cell manufacturing capacity, with the earlier CUF target of ~50–60% by Nov'26 revised to 25–30% by Dec'26, while the ~70% CUF target by Mar'27 remains unchanged, and 2) Progress on US cell manufacturing plans, with PEL at an advanced stage of finalizing the factory location with its JV partner and expects finalization over the next 12–18 months.
- **Valuation and view:** We value the domestic module business at 13x FY28E EBITDA and the new business segment at 10x FY28E EBITDA. The sum of these segment valuations (adjusting for net debt) results in a TP of INR1,150/share. **Reiterate BUY.**

In-line 2Q

Financial Performance

- Consolidated revenue came in line with our est. at INR26.3b (+43% YoY, +7% QoQ).
- EBITDA came in at INR7.4b (+31% YoY, +3% QoQ), 2% below our estimate, with an EBITDA margin of 28% (vs. our est. of 28.7%).
- Adjusted PAT was also in line with our est. at INR4.6b (+30% YoY, -1% QoQ).
- Module/cell production stood at 1.2GW/0.92GW in 2QFY27 with a CUF of 55%/99%.

Other Highlights

- Module/cell manufacturing capacity stands at 11.1GW/10.6GW.
- The order book stood at 10.7GW, valued at ~INR166b in 2QFY27 (compared with INR150b in 1QFY27), comprising 48% modules, 48% cells, 2% transformers, and 1% EPC.
- 2Q revenue breakup: 77% from modules sales, 18% from cell sales, and 4% from Transcon.

Bloomberg	PREMIERE IN
Equity Shares (m)	454
M.Cap.(INRb)/(USDb)	400.6 / 4.2
52-Week Range (INR)	1134 / 660
1, 6, 12 Rel. Per (%)	-9/-17/-20
12M Avg Val (INR M)	1647

Financial Snapshot (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	78.2	129.1	185.1
Sales Gr. %	20.0	65.0	43.4
EBITDA	23.8	34.8	44.9
EBITDA margin %	30.4	26.9	24.2
Adj. PAT	15.1	19.4	22.1
EPS (INR)	33.3	42.7	48.9
EPS Gr. (%)	61.1	28.2	14.3
BV/Sh. (INR)	95.1	137.1	185.2
Ratios			
ND/Equity	0.4	0.7	0.7
ND/EBITDA	0.6	1.3	1.3
RoE (%)	42.4	36.8	30.3
RoIC (%)	63.4	44.7	31.4
Valuations			
P/E (x)	27.5	21.5	18.8
EV/EBITDA (x)	18.1	13.2	10.5

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	58.5	58.5	63.9
DII	18.9	18.0	13.3
FII	7.6	8.5	5.1
Others	15.0	15.1	17.7

- The Board approved INR59.5b for setting up 10GW ingot and wafer facility in Andhra Pradesh. Phase I (5GW) is targeted for completion by Dec'27.
- The Board declared an interim dividend of INR0.50/share

Highlights of 2QFY27 performance

- Solar manufacturing reported an EBITDA/PAT margin of 29.3%/17.9%.
- The 7GW TOPCon cell plant at Naidupeta was commissioned, with commercial production commencing in Nov'26. CUF is guided at 25–30% by Dec'26 and ~70% by Mar'27.
- Total solar order book stood at INR162.6b (~10GW), following fresh 2Q orders of INR40.0b, with execution scheduled over 12–14 months. Retail accounts for ~35–40% of the order book.
- Blended DCR module realizations stood at INR21.5–22/Wp, with retail at INR23–24/Wp, C&I at INR21–21.5/Wp and IPP at INR20–20.5/Wp.
- Non-DCR module realizations stood at INR12.75–13/Wp, generating single-digit EBITDA margins.
- The Transcon transformer business reported a 2Q revenue of INR1.22b, PAT of INR180m and an order book of INR3.3b; revenues are expected to more than treble over the next three years.
- The Ingot-wafer facility is progressing as planned, with Phase 1 (5GW) targeted for Dec'27 and Phase 2 (5GW) by Jun'28. The project has secured 169 acres of land along with power and water approvals.
- FY27 capex is guided at INR24b, with H2 capex of ~INR7b.

Valuation and view

- The valuation of PEL has been derived through a sum-of-the-parts (SoTP) methodology: the domestic module business is valued at 13x FY28E EBITDA. The new business segment, is valued at 10x FY28E EBITDA, consistent with domestic peer valuations. The sum of these segment valuations (adjusting for net debt) results in a TP of INR1,150/share.

Consolidated performance INRm

Y/E March	FY26				FY27E				FY26	FY27E	FY27 2QE	Var. (%)	YoY (%)	QoQ (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE						
Net Sales	**18,207**	**18,369**	**19,365**	**22,303**	**24,626**	**26,319**	**34,436**	**43,735**	**78,244**	**1,29,115**	**26,071**	**1**	**43**	**7**
YoY Change (%)	*9.9*	*20.3*	*13.0*	*37.6*	*35.3*	*43.3*	*77.8*	*96.1*	*20.0*	*65.0*	*41.9*			
Total Expenditure	12,725	12,760	13,432	15,555	17,482	18,961	25,254	32,666	54,471	94,363	18,599	**2**	**49**	**8**
EBITDA	**5,483**	**5,609**	**5,932**	**6,748**	**7,144**	**7,358**	**9,182**	**11,069**	**23,772**	**34,752**	**7,472**	**-2**	**31**	**3**
YoY Change (%)	*53.0*	*47.4*	*15.5*	*27.7*	*30.3*	*31.2*	*54.8*	*64.0*	*33.5*	*46.2*	**33**			
Margin (%)	*30*	*31*	*31*	*30*	*29*	*28*	*27*	*25*	*30.4*	*26.9*	*28.7*			
Depreciation	1,575	1,457	702	791	956	1,166	2,064	2,472	4,525	6,659	1,125	4	-20	22
Interest	368	325	474	415	439	422	1,391	1,721	1,582	3,973	636	-34	30	-4
Other Income	488	845	297	386	450	242	396	461	2,015	1,549	477	-49	-71	-46
PBT before EO expense	**4,027**	**4,672**	**5,053**	**5,928**	**6,198**	**6,011**	**6,123**	**7,336**	**19,681**	**25,668**	**6,188**			
Extra-Ord income/(exp.)	0	0	0	0	0	0	0	0	0	0	0			
PBT	**4,027**	**4,672**	**5,053**	**5,928**	**6,198**	**6,011**	**6,123**	**7,336**	**19,681**	**25,668**	**6,188**	**-3**	**29**	**-3**
Tax	952	1,138	1,136	1,410	1,485	1,389	1,433	1,701	4,635	6,008	1,423			
Rate (%)	*23.6*	*24.3*	*22.5*	*23.8*	*24.0*	*23.1*	*23.4*	*23.2*	*23.6*	*23.4*	*23.0*			
Minority Interest	0	0	-1	0	89	44	76	97	-1	306	76			
Share of JV & associates	2	0	-1	50	5	1	2	-2	51	7	1			
Reported PAT	**3,078**	**3,534**	**3,917**	**4,568**	**4,631**	**4,580**	**4,615**	**5,536**	**15,098**	**19,362**	**4,689**	**-2**	**30**	**-1**
Adj PAT	**3,078**	**3,534**	**3,917**	**4,568**	**4,631**	**4,580**	**4,615**	**5,536**	**15,098**	**19,362**	**4,689**	**-2**	**30**	**-1**
YoY Change (%)	*39.5*	*47.9*	*38.6*	*45.7*	*34.0*	*22.6*	*15.2*	*21.0*	*161.1*	*128.2*	*24.9*			
Margin (%)	*17*	*19*	*20*	*20*	*19*	*17*	*13*	*13*	*19.3*	*15.0*	*18.0*			

Astral

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	ASTRA IN
Equity Shares (m)	269
M.Cap.(INRb)/(USDb)	372.9 / 3.9
52-Week Range (INR)	1769 / 1312
1, 6, 12 Rel. Per (%)	-7/-11/-1
12M Avg Val (INR M)	1183

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	65.7	80.9	92.4
EBITDA	10.6	11.6	15.6
Adj. PAT	5.4	6.2	9.6
Adj. EPS (INR)	16.2	14.3	16.9
EPS Gr. (%)	20.8	23.5	35.7
BV/Sh. (INR)	6.8	13.1	52.0
Ratios			
Net D:E	-0.2	-0.2	-0.3
RoE (%)	13.8	14.0	18.2
RoCE (%)	20.5	20.1	26.0
Valuations			
P/E (x)	66.8	59.0	38.9
P/BV (x)	9.2	8.3	7.1
EV/EBITDA (x)	34.4	31.5	23.1
Div. Yield (%)	0.3	0.5	0.5

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	54.2	54.2	54.2
DII	24.1	21.3	17.8
FII	11.1	13.9	16.6
Others	10.6	10.6	11.4

CMP: INR1,388 TP: INR1,608 (+16%) Buy

Demand momentum stays strong; margins to gradually recover

Healthy volume/revenue; moderation in margins in 2QFY27

- Astral (ASTRA) reported a weak operating performance in 2QFY27.
- Consolidated revenue grew 26% YoY, EBITDA was flat, and PAT declined 6% YoY.
- Gross and EBITDA margins contracted by 300-400bp YoY as the company could not fully pass on input cost inflation.
- Plumbing: pipe volume/revenue up 19%/25% YoY, EBITDA margin 16.3% vs. 18-23% range in last five quarters.
- Adhesives: revenue up 29% YoY, EBITDA margin 7.6% vs. 8.7-12.1% range in last five quarters.
- Bathware revenue grew by 26.8% YoY.
- Cash balance stood at ~INR4.6b.

Key highlights from the management commentary

- 2Q strong pipe volume was aided by restocking after a below normal inventory at 1Q-end.
- Pipe demand momentum has sustained in Oct'26.
- ASTRA expects to continue to gain market share in all product categories.
- Pipe margin to recover with full pass-on of input cost inflation.
- Adhesives margins to gradually improve to ~10%, driven by improvement in both domestic and UK/US markets.
- Management expects consolidated EBIDTA margin to gradually recover from 3Q onward and reach 15% (from 13.1% in 2Q).
- Took 5% price rise in CPVC pipe from Oct'26.
- All cost inflation already passed in PVC pipes.
- Capex: 1H at INR2.6b, FY27E ay INR4b.
- GEM Paints – all legacy issues like collection cycle and dealer network are behind.

Valuation and view

- After a miss in earnings in 2Q, we cut our estimates by 14%/2% in FY27/28 owing mainly to lowering of margin estimates.
- After a modest CAGR of 16%/11% /7% in revenue/EBITDA/APAT over FY21-26, we now estimate a CAGR of 19%/21%/31% over FY26-28 with RoE/RoCE (pre-tax) estimated to reach ~18%/26% in FY28.
- **After a recent correction in stock price, we reiterate our BUY rating on ASTRA with a revised TP of INR1,608, based on 45x FY28E EPS.**
- **While we build in meaningful improvement in margins, any miss can lead to a de-rating in ASTRA's scrip.**

Quarterly performance

(INR m)

	FY26				FY27E				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Net Sales	**13,612**	**15,774**	**15,415**	**20,885**	**15,780**	**19,883**	**19,900**	**25,355**	**65,686**	**80,918**	**18,887**	**5**
YoY Change (%)	-2	15	10	24	16	26	29	21	12.6	23.2	19.7	
Total Expenditure	11,763	13,206	13,042	17,056	13,468	17,278	17,086	21,535	55,067	69,367	15,975	
EBITDA	**1,849**	**2,568**	**2,373**	**3,829**	**2,312**	**2,605**	**2,815**	**3,820**	**10,619**	**11,551**	**2,912**	**-11**
Margins (%)	13.6	16.3	15.4	18.3	14.7	13.1	14.1	15.1	16.2	14.3	15.4	
Depreciation	719	723	734	740	754	787	797	807	2,916	3,145	764	
Interest	123	160	126	235	58	122	110	110	644	400	103	
Other Income	91	114	95	173	128	118	128	138	473	512	138	
PBT before EO expense	**1,098**	**1,799**	**1,608**	**3,027**	**1,628**	**1,814**	**2,036**	**3,041**	**7,532**	**8,518**	**2,183**	
Extra-Ord expense	0	0	-165	-61	0	-95	0	0	-226	-95	0	
PBT	**1,098**	**1,799**	**1,443**	**2,966**	**1,628**	**1,719**	**2,036**	**3,041**	**7,306**	**8,423**	**2,183**	**-21**
Tax	306	451	366	836	426	446	529	791	1,959	2,192	568	
Rate (%)	27.9	25.1	25.4	28.2	26.2	25.9	26.0	26.0	26.8	26.0	26.0	
Minority Interest	-19	0	0	0	2	1	0	0	-19	3	0	
Profit/(Loss) - Associates	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	**811**	**1,348**	**1,077**	**2,130**	**1,200**	**1,272**	**1,506**	**2,250**	**5,366**	**6,229**	**1,616**	**-21**
Adj PAT	**811**	**1,348**	**1,242**	**2,191**	**1,200**	**1,367**	**1,506**	**2,250**	**5,592**	**6,324**	**1,616**	**-15**
YoY Change (%)	-32.6	22.5	8.9	22.2	48.0	1.4	21.3	2.7	6.8	13	19.9	
Margins (%)	6.0	8.5	8.1	10.5	7.6	6.9	7.6	8.9	8.5	7.8	8.6	

E: MOSL Estimates

Exide

Estimate changes	↑
TP change	↓
Rating change	↔

CMP: INR363 **TP: INR381 (+5%)** **Neutral**

Bloomberg	EXID IN
Equity Shares (m)	850
M.Cap.(INRb)/(USDb)	308.1 / 3.3
52-Week Range (INR)	496 / 287
1, 6, 12 Rel. Per (%)	-19/-2/0
12M Avg Val (INR M)	1185

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Net Sales	172.7	198.5	213.3
EBITDA	19.4	24.1	26.1
Adj. PAT	11.2	14.5	16.2
Adj. EPS (INR)	13.2	17.0	19.0
EPS Gr. (%)	3.8	29.6	11.5
BV/Sh. (INR)	172.6	187.5	204.1
Ratio			
RoE (%)	7.6	9.1	9.3
RoCE (%)	7.7	9.4	9.7
Payout (%)	15.2	12.6	12.6
Valuations			
P/E (x)	27.6	21.3	19.1
P/BV (x)	2.1	1.9	1.8
Div Yield (%)	0.6	0.6	0.7
FCF Yield (%)	5.9	4.4	5.1

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	46.0	46.0	46.0
DII	17.6	19.3	18.5
FII	13.2	10.6	10.9
Others	23.2	24.1	24.7

FII Includes depository receipts

Earnings beat led by strong growth across segments

Pricing action to support margins in the near term

- Exide's (EXID) 2QFY27 PAT of INR3.9b came in above our est. of INR2.9b. Strong double-digit YoY growth was observed across key segments, which led to 20.3% YoY growth in revenues, beating our expectations.
- The outlook for the lead-acid business remains positive across the auto and industrial segments (excluding telecom). However, we remain cautious about the long-term returns from the lithium-ion business. Moreover, the stock, trading at ~21.3x/19.1x FY27E/28E EPS, appears fairly valued.
- **We reiterate our Neutral rating with an SoTP-based TP of INR381. We value the core (lead acid) business at 14x FY28E EPS. We add a value of INR71 per share for the EV business (based on book value) and INR45 per share for its stake in HDFC Life.**

Strong double-digit growth across segments

- EXID's 2Q revenue was 6% above our estimates, up 20% YoY to INR50.3b, supported by healthy demand, continued benefits of GST 2.0 reforms, a lower base, and stronger execution of the 'One Exide' operating model.
- Automotive OEM business delivered over 25% YoY growth for the fourth consecutive quarter.
- The 2W/4W replacement business delivered double-digit growth for the fourth consecutive quarter, driven by steady aftermarket demand.
- Home Inverters and Solar delivered 20%+ YoY growth for the second consecutive quarter, with favorable seasonal demand and govt. schemes continuing to support Home UPS and Rooftop solar adoption, respectively.
- Exports business grew 20%+ YoY for the 2nd consecutive quarter, on a low base. The company signed a long-term strategic cooperation agreement with ExCom Energy Solutions GmbH, Germany, to grow its industrial battery and energy storage business across the European Economic Area.
- Gross margin improved 100bp QoQ to 30.6%. On a YoY basis, input costs remained elevated due to prolonged geopolitical challenges. On a QoQ basis, the full benefit of softer lead LME and antimony prices could not be realized due to a weaker rupee.
- EBITDA margin came in at 12.1% (170bp higher than estimates), supported by cost optimization initiatives, along with calibrated price increases and volume growth. Absolute EBITDA stood at INR6b (up 53.6% YoY) and was 22% higher than our estimates.
- PAT came in 32% above estimates, at INR3.9b, up 75% YoY.
- CFO for 1HFY27 stood at ~INR7b, while FCF came in positive at ~INR5.8b.

Highlights from the management commentary

- Management remains constructive on lead-acid battery demand, supported by healthy growth across automotive OEM, replacement, solar, inverter, and industrial segments. Both OEM and aftermarket demand are growing concurrently, supporting capacity utilization.
- Automotive OEM growth is expected to moderate to low double digits in 2HFY27, although absolute volumes are expected to remain at elevated levels. Replacement business growth is expected to broadly sustain at H1FY27 levels.
- Management expects the 2W and 4W replacement businesses to sustain healthy growth, supported by an expanding vehicle parc and distribution network. Home inverter and solar businesses remain growth drivers, with solar also benefiting from government initiatives.
- Management expects to maintain EBITDA margins within the 12–12.5% range over the next two quarters, supported by calibrated price increases and cost optimization, subject to lead prices and currency movements.
- The company has undertaken cumulative price increases of over 10% between January and October 2026 to offset input-cost inflation. Further calibrated price hikes will be undertaken as required to protect margins.
- Management expects annual lead-acid capex to remain at INR4-5b, while further equity funding into the lithium-ion subsidiary is likely to continue over the next couple of years to support working capital and the business ramp-up.
- Commercial revenues from the LFP business commenced in Oct'26, while NMC revenues are expected to follow after completion of customer validation. Supplies to major OEMs are expected to commence around Q4FY27, potentially from Feb'27.

Valuation and view

The outlook for the lead-acid business remains positive across the auto and industrial segments (excluding telecom). However, we remain cautious about the long-term returns from the lithium-ion business. Moreover, the stock, trading at ~21.3x/19.1x FY27E/28E EPS, appears fairly valued. **We reiterate our Neutral rating with an SoTP-based TP of INR381. We value the core (lead acid) business at 14x FY28E EPS. We add a value of INR71 per share for the EV business (based on book value) and INR45 per share for its stake in HDFC Life.**

S/A Quarterly Performance (INR M)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Net Sales	**45,098**	**41,783**	**40,297**	**45,511**	**53,051**	**50,261**	**46,140**	**49,089**	**172,689**	**198,541**	**47,633**	**5.5**
Growth YoY (%)	4.6	-2.1	4.7	9.4	17.6	20.3	14.5	7.9	4.1	15.0	14.0	
RM cost (%)	69.2	70.2	68.4	69.9	70.5	69.4	69.5	68.9	69.4	69.6	70.5	
Employee cost (%)	6.1	6.4	6.5	6.0	5.7	6.3	5.8	5.8	6.3	5.9	6.1	
Other Exp(%)	12.6	14.0	13.4	12.4	11.5	12.2	12.7	13.2	13.1	12.4	13.0	
EBITDA	**5,482**	**3,947**	**4,696**	**5,304**	**6,552**	**6,063**	**5,537**	**5,910**	**19,429**	**24,062**	**4,954**	**22.4**
EBITDA Margin(%)	12.2	9.4	11.7	11.7	12.4	12.1	12.0	12.0	11.3	12.1	10.4	170bp
Change (%)	10.9	-18.4	4.7	13.7	19.5	53.6	17.9	11.4	4.3	340.4	26	
Non-Operating Income	182	424	183	142	140	424	185	136	931	886	430	
Interest	91	89	85	84	83	87	90	95	349	356	90	
Depreciation	1,276	1,306	1,270	1,158	1,176	1,177	1,380	1,407	5,010	5,140	1,280	
PBT after EO Exp	**4,297**	**2,976**	**3,434**	**4,204**	**5,433**	**5,223**	**4,252**	**4,544**	**14,911**	**19,452**	**4,014**	**30.1**
Effective Tax Rate (%)	25.4	25.8	25.0	25.7	25.0	26.0	25.5	25.5	25.5	25.5	27.0	
Adj. PAT	**3,205**	**2,207**	**2,644**	**3,124**	**4,073**	**3,865**	**3,168**	**3,387**	**11,181**	**14,492**	**2,930**	**31.9**
Change (%)	14.6	-25.9	7.9	22.7	27.1	75.1	19.8	8.4	3.8	29.6	32.7	

Key performance indicators

Cost Break-up												
RM(%)	69.2	70.2	68.4	69.9	70.5	69.4	69.5	68.9	69.4	69.6	70.0	-10bp
Employee cost (%)	6.1	6.4	6.5	6.0	5.7	6.3	5.8	5.8	6.3	5.9	6.0	0bp
Other Exp(%)	12.6	14.0	13.4	12.4	11.5	12.2	12.7	13.2	13.1	12.4	12.6	-20bp
Gross Margin (%)	30.8	29.8	31.6	30.1	29.5	30.6	30.5	31.1	30.6	30.4	30.0	10bp
EBITDA Margin(%)	12.2	9.4	11.7	11.7	12.4	12.1	12.0	12.0	11.3	12.1	11.4	30bp
EBIT Margin(%)	9.7	7.3	9.0	9.4	10.4	10.6	9.4	9.5	8.9	10.0	9.2	20bp

E: MOSL Estimates

Rubicon Research

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	RUBICON IN
Equity Shares (m)	166
M.Cap.(INRb)/(USDb)	288.1 / 3
52-Week Range (INR)	1899 / 609
1, 6, 12 Rel. Per (%)	-1/78/171
12M Avg Val (INR M)	531

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	17.5	23.0	27.6
EBITDA	4.0	5.6	6.9
Adjusted PAT	2.5	3.5	4.5
EBITDA Margin (%)	22.8	24.5	25.0
Cons. Adj EPS (INR)	14.9	21.5	27.5
EPS Growth (%)	83.6	43.7	28.1
BV/Share (INR)	78.1	97.2	121.4
Ratios			
Net D-E	-0.1	-0.1	-0.2
RoE (%)	27.0	24.5	25.2
RoCE (%)	26.6	28.0	30.0
Payout (%)	11.8	11.8	11.8
Valuations			
P/E (x)	116.4	81.0	63.3
EV/EBITDA (x)	71.7	50.7	41.2
Div. Yield (%)	0.1	0.1	0.2
FCF Yield (%)	-0.1	0.5	0.9
EV/Sales (x)	16.4	12.5	10.3

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	51.2	59.8	60.0
DII	15.7	9.4	10.5
FII	9.0	7.5	9.4
Others	24.0	23.3	20.1

FII includes depository receipts

CMP: INR1,741 TP: INR2,090 (+20%) Buy

Beat streak continues; margin guidance raised again

Compliance track-record/R&D productivity underpin long-term earnings visibility

- Rubicon Research (Rubicon) has beaten our estimates yet again, extending its consistent, long streak of beats since its IPO in Oct'25. Revenue, EBITDA, and PAT stood 5%, 11%, and 7% ahead of our estimates, respectively. Sequential revenue scale-up was also strong following the tactical measures taken in 1QFY27, with the consequent operating leverage further lifting profitability for the quarter.
- 2QFY27 revenue grew 40% YoY and 8% QoQ. This was particularly noteworthy as growth was driven by stronger traction in already commercialized products, even as the commercialization of three products approved in 2QFY27 were deferred by a quarter (since revised norms require export license applications to be made after receipt of product approval). This is expected to bode well for growth ahead as these recently approved products get commercialized.
- Rubicon has raised its FY27 EBITDA margin guidance for the second straight quarter: from 22–23% in 4QFY26 to 23%+ in 1QFY27, and now to 24%+ in 2QFY27. This also bears testimony of management's track record of guiding conservatively and delivering ahead of expectations. Notably, the latest upgrade comes despite further opex expected from the operationalization of the Pithampur facility and likely further growth-enabler costs related to the Arinna prescription business.
- All of Rubicon's facilities have now completed USFDA inspections, with each site either classified NAI/VAI or expected to receive VAI. Every inspection except one at an R&D site was unannounced. NJ site was inspected in May'26 and EIR was received with VAI status. Pithampur site (Form 483 -2 observations) was inspected in Jul'26 and received regulatory filing approval in 1QFY27. Satara site inspection (Oct'26) had form 483 with one observation. Ambernath site inspection (Oct'26) resulted in form 483 with three observations related to system improvements and two related to product application review. All the observations of all the facilities are procedural in nature with no data integrity issues and, hence, are expected to result in a VAI status. This provides a strong testament to a robust and consistent compliance culture across the network.
- Pre-tax annualized RoACE remains remarkably strong at 36%, despite nearly 25% of capital employed (INR4b out of INR15.5b) being deployed in assets that are either pre-revenue or yet to materially contribute to returns.
- R&D productivity stands at 5.8x, based on annualized 1HFY27 revenue (ex-Arinna), against R&D spend over the preceding nine quarters (FY23, FY24 and 1QFY25). Notably, this INR2.2b of lagged spend supporting FY27 revenue is the lowest of the last three R&D cycles. Subsequent financial years will see benefit of materially higher lagged R&D spend cycles (INR2.8b for FY28, INR3.8b for FY29, and INR5b for FY30), which, combined with a proven track record of over 5x R&D productivity, provide strong growth visibility well into FY30.

- We raise our FY27/FY28 earnings estimates by 4%/3%, factoring in faster scale-up of the existing portfolio and new launches. Rubicon brings together a rare combination of superior R&D productivity, strong execution, and a solid compliance culture. We reiterate our view that it offers the longest and strongest runway for earnings growth, not just within healthcare but across our coverage universe. We value Rubicon at 70x 12M forward earnings to arrive at a TP of INR2,090. Reiterate BUY.

Strong operating performance drives healthy earnings growth

- 2QFY27 revenue grew 40% YoY to INR5.8b (beat by 5%).
- Gross margins remained stable sequentially.
- EBITDA margin expanded 210bp YoY to 25% (beat by 140bp), supported by better operating leverage, with other expenses declining 310bp YoY as a percentage of sales.
- R&D expenses was 10.8% of sales (INR624m) for 2QFY27. R&D expenses are fully charged to the P&L.
- EBITDA increased 53% YoY to INR1.4b (beat by 11%).
- PAT surged 67.9% YoY to INR904m (beat by 7%).
- For 1HFY27, Revenue/EBITDA/PAT grew 45.3%/57.5%/80.3% to INR11.1b/INR2.7b/INR1.8b.

Highlights from the management commentary

- Rubicon received three product approvals in 2QFY27, with 90 active approved products as of Sep'26.
- In CC, revenue grew 23% YoY/5% QoQ to USD58m (Ex-Arinna) in 2QFY27.
- Specialty portfolio's contribution to gross profit for the quarter is 36%.
- Rubicon has raised its FY27 EBITDA margin guidance for the second straight quarter: from 22–23% in 4QFY26 to 23%+ in 1QFY27, and now to 24%+ in 2QFY27.
- Rubicon received three USFDA approval in 2QFY27. The commercialization was deferred by a quarter due to revised norms w.r.t export licenses. This makes the strong sequential revenue performance in 2QFY27 even more commendable.
- The company delivered strong profitability performance despite operative expense associated with three facilities (Pithampur, CSN and New Jersey), which are yet to contribute to revenue.
- Pithampur is expected to generate revenue from FY28 onwards. New Jersey commercialization is also expected in FY28 and is function of product filings, regulatory inspection and subsequent launches.

Quarterly Result Snapshot (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27	
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			2Q	vs Est.
Gross Sales	**3,525**	**4,120**	**4,755**	**5,139**	**5,343**	**5,764**	**5,921**	**5,961**	**17,540**	**22,989**	**5,515**	**5%**
YoY Change (%)	11.3	39.2	51.7	43.5	51.6	39.9	24.5	16.0	36.6	31.1	33.8	
EBITDA	**791**	**943**	**1,081**	**1,187**	**1,291**	**1,441**	**1,451**	**1,460**	**4,002**	**5,643**	**1,301**	**11%**
YoY Change (%)	31.4	52.9	54.7	63.8	63.2	52.8	34.2	23.0	**51.5**	41.0	**38**	
Margins (%)	22.4	22.9	22.7	23.1	24.2	25.0	24.5	24.5	22.8	24.5	23.6	
Depreciation	96	119	116	123	151	180	182	183	453	698	159	
Interest	106	114	98	104	93	114	112	113	422	432	91	
Other Income	6	7	38	26	21	23	22	21	77	87	55	
PBT	**596**	**717**	**906**	**987**	**1,104**	**1,169**	**1,179**	**1,185**	**3,205**	**4,637**	**1,106**	
Tax	163	179	178	219	256	265	271	273	738	1,064	259	
Rate (%)	27.3	24.9	19.6	22.2	23.2	22.7	23.0	23.0	23.0	23.0	23.4	
Reported PAT	**433**	**539**	**728**	**768**	**848**	**904**	**908**	**912**	**2,467**	**3,572**	**848**	
Adj PAT	**433**	**539**	**728**	**768**	**820**	**904**	**908**	**912**	**2,467**	**3,544**	**848**	**7%**
YoY Change (%)	69.4	56.2	91.2	111.8	89.4	67.9	24.7	18.8	83.6	43.7	57.4	
Margins (%)	12.3	13.1	15.3	14.9	15.4	15.7	15.3	15.3	14.1	15.4	15.4	
EPS (INR)	**2.6**	**3.3**	**4.4**	**4.7**	**5.0**	**5.5**	**5.5**	**5.5**	**14.9**	**21.5**	**5.1**	**7%**

PI Industries

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	PI IN
Equity Shares (m)	152
M.Cap.(INRb)/(USDb)	268.5 / 2.8
52-Week Range (INR)	3833 / 1749
1, 6, 12 Rel. Per (%)	-29/-43/-48
12M Avg Val (INR M)	863

Financials & Valuations (INR b)

Y/E Mar	2026	2027E	2028E
Sales	67.1	64.8	74.3
EBITDA	17.0	10.7	14.5
PAT	12.4	6.6	9.8
EBITDA (%)	25.3	16.5	19.5
EPS (INR)	81.8	43.3	64.4
EPS Gr. (%)	(25.1)	(47.0)	48.8
BV/Sh. (INR)	739	766	815
Ratios			
Net D/E	(0.3)	(0.3)	(0.3)
RoE (%)	11.6	5.8	8.2
RoCE (%)	11.5	5.7	8.1
Payout (%)	18.4	36.9	24.8
Valuations			
P/E (x)	21.7	41.0	27.5
EV/EBITDA (x)	14.7	23.2	16.7
Div Yield (%)	0.9	0.9	0.9
FCF Yield (%)	(1.9)	2.5	3.4

Shareholding Pattern (%)

As on	Sep-26	Jun-26	Sep-25
Promoter	46.1	46.1	46.1
DII	31.5	31.6	30.4
FII	14.8	14.8	16.4
Others	7.6	7.4	7.1

Note: FII includes depository receipts

CMP: INR1,770 **TP: INR2,060 (+16%)** **Buy**

Weak Agchem export volume weighs on performance

Operating performance below our estimate

- PI Industries (PI) reported a weak quarter as revenue declined 9% YoY, primarily due to an 18% YoY dip in Custom Synthesis and Manufacturing (CSM; 68% of the business). This dip was attributed to muted global agrochemical demand and continued pricing pressure. Domestic Agri/Pharma (28%/4%) business reported a revenue growth of 19%/20% YoY. Gross margin contracted 780bp YoY, while lower volumes led to adverse operating leverage, resulting in an overall EBITDA margin contraction of 15pp YoY.
- Going forward, we remain cautiously optimistic, supported by a stable ~USD1.25b order book and expectations of a gradual recovery in global agrochemical demand, an increasing contribution from new CSM molecules, growth in domestic agri and biologicals, and the scaling up of newer platforms across pharma CRDMO and electronic specialty chemicals.
- We cut our FY27/FY28 earnings estimates by 38%/27% due to declining realizations and margin pressure on key molecules in CSM. We expect revenue/ EBITDA/Adj PAT to dip 4%/37%/47% YoY in FY27. However, revenue/ EBITDA/Adj PAT are likely to grow 15%/36%/49% YoY in FY28. **Reiterate BUY with a TP of INR2,060 at 32x FY28 EPS (10% discount to the 10-year 1Y forward EPS).**

Lower gross margin and adverse operating leverage weighs on margins

- Revenue stood at INR17.0b (est. INR18.2b), down 9% YoY. Agrochemicals business revenue dipped 10% YoY to INR16.3b and pharma business revenue increased 20% YoY to INR759m.
- Agchem exports declined-18% due to soft demand and pricing pressure from genericization in global agrochemical industry
- EBITDA stood at INR2.3b (est. INR4.3b) down 57% YoY. EBITDA margins contracted 15pp YoY to 13.7% (est. 23.6%); gross margins: 50% (down 780bp YoY); employee expenses rose 330bp YoY to 15.1% and other expenses were up 420bp YoY to 20.7% of sales.
- EBIT margin for the Agrochemical business stood at 15.2% (down 17.5pp) and Pharma reported an operating loss of INR601mm vs operating loss of INR819m in 2QFY26. Adj. PAT was down 70% YoY to INR1.2b (est. INR3.0b)
- For 1HFY27, the revenue/EBITDA/Adj PAT declined 10%/43%/55% to INR34.0b/INR6.0b/INR3.7b.
- Gross debt stood at INR2.1b vs INR2.4b as of Mar'26. CFO stood at INR8.9b vs INR2.5b as of Sept'25.
- NWC increased by 18 days to 139 vs 121 days in 2QFY26, led by an increase of 9 days in DSO and decrease of 9 days in DPO.

Highlights from the management commentary

- **CSM:** Agchem exports declined 18% YoY, driven by a 13–14% decline in realizations and 3–4% lower volumes, reflecting genericization, competitive pricing, and weak farmer economics. PI is prioritizing volume and market-share retention over full RM cost pass-through. Gross margins are expected to be 48–49%, with management targeting gradual improvement over the next 2–3 quarters. Any easing in RM costs could support recovery, although the impact would be visible with a lag of around a couple of quarters.
- **Electronic Specialty chemicals:** Management indicated that the business is expected to witness a meaningful ramp-up from next year, with a targeted revenue opportunity of USD100m over the next 3–4 years in niche application areas. The company is selectively leveraging its process chemistry capabilities and building infrastructure, including kilo labs at Udaipur, to support commercialization.
- **Domestic Agri:** Domestic Agri business grew 19% YoY in Q2FY27, driven by an expanding product portfolio and a wider crop reach. Domestic biologicals remained a key growth driver, registering 45% YoY growth and increasing their contribution to 18% of the domestic Agri portfolio. The company continues to expand its biologicals portfolio and strengthen market penetration, leveraging its distribution network and farmer engagement.

Valuation and view

- While near-term demand and margins remain subdued in CSM, margin recovery is expected as RM prices ease over the coming quarters.
- Going forward, we believe growth recovery will be led by: 1) new molecules in CSM (commercialization of 20+ molecules over the last few years with ~16-18 share), and a strong pipeline of 60+ projects (with over 60% in advanced stages of development); 2) a robust pipeline of biological products across various development stages; and 3) the ramp-up of its pharma business, with a focus on profitable growth.
- We cut our FY27/FY28 earnings estimates by 38%/27% due to declining realizations and margin pressure on key molecules in CSM. We expect revenue/ EBITDA/Adj PAT to decline 4%/37%/47% YoY in FY27. However, revenue/ EBITDA/Adj PAT are likely to grow 15%/36%/49% YoY in FY28. **Reiterate BUY with a TP of INR2,060 at 32x FY28 EPS (10% discount to the 10-year 1Y forward EPS).**

Quarterly Earning Model

(INRm)

Y/E March	FY26				FY27				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2Q	(%)
Net Sales	**19,005**	**18,723**	**13,757**	**15,652**	**17,023**	**17,018**	**14,331**	**16,388**	**67,137**	**64,760**	**18,151**	**-6**
YoY Change (%)	-8.1	-15.7	-27.6	-12.4	-10.4	-9.1	4.2	4.7	-15.8	-3.5	-3.1	
Total Expenditure	13,814	13,310	10,734	12,283	13,349	14,691	12,310	13,744	50,141	54,094	13,873	
EBITDA	**5,191**	**5,413**	**3,023**	**3,369**	**3,674**	**2,327**	**2,021**	**2,644**	**16,996**	**10,666**	**4,277**	**-46**
Margins (%)	27.3	28.9	22.0	21.5	21.6	13.7	14.1	16.1	25.3	16.5	23.6	
Depreciation	965	980	1,054	1,067	1,037	1,049	1,090	1,100	4,066	4,276	1,150	
Interest	39	26	62	37	79	84	60	55	164	278	60	
Other Income	859	825	667	756	641	611	700	750	3,107	2,702	807	
PBT before EO expense	**5,046**	**5,232**	**2,574**	**3,021**	**3,199**	**1,805**	**1,571**	**2,239**	**15,873**	**8,814**	**3,875**	
Extra-Ord expense	0	0	-1,051	20	0	0	0	0	-1,031	0	0	
PBT	**5,046**	**5,232**	**3,625**	**3,001**	**3,199**	**1,805**	**1,571**	**2,239**	**16,904**	**8,814**	**3,875**	
Tax	1,074	1,160	516	1,003	776	618	395	564	3,753	2,353	876	
Rate (%)	21.3	22.2	14.2	33.4	24.3	34.2	25.2	25.2	22.2	26.7	22.6	
MI & Profit/Loss of Asso. Cos.	-28	-21	-4	-4	-19	-35	-35	-35	-57	-124	-14	
Reported PAT	**4,000**	**4,093**	**3,113**	**2,002**	**2,442**	**1,222**	**1,210**	**1,711**	**13,208**	**6,585**	**3,012**	
Adj PAT	**4,000**	**4,093**	**2,325**	**2,017**	**2,442**	**1,222**	**1,210**	**1,711**	**12,435**	**6,585**	**3,012**	**-59**
YoY Change (%)	-10.9	-19.5	-37.6	-39.0	-39.0	-70.1	-47.9	-15.2	-25.1	-47.0	-26.4	
Margins (%)	21.0	21.9	16.9	12.9	14.3	7.2	8.4	10.4	18.5	10.2	16.6	

Key Performance Indicators

Y/E March	FY26				FY27				FY26	FY27E
Particulars	**1Q**	**2Q**	**3Q**	**4Q**	**1Q**	**2Q**	**3QE**	**4QE**		
CSM Revenue (INRm)	14,897	14,105	10,574	11,537	13,000	11,518	10,680	11,652	**51,113**	**46,850**
% Change	-13.6	-18.0	-32.1	-15.4	-12.7	-18.3	1.0	1.0	**-19.7**	**-8.3**
Domestic Formulation (INRm)	3,385	3,984	2,584	3,067	3,481	4,741	2,842	3,374	**13,020**	**14,438**
% Change	5.9	-13.4	-7.9	-9.3	2.8	19.0	10.0	10.0	**-6.9**	**10.9**
Pharma	723	634	599	1,048	542	759	809	1,362	**3,004**	**3,472**
% Change	185.8	54.3	-6.0	23.3	-25.0	19.7	35.0	30.0	**39.7**	**15.6**
Cost Break-up										
RM Cost (% of sales)	42.6	42.7	41.0	42.2	43.3	50.5	49.0	48.0	**42.2**	**47.6**
Staff Cost (% of sales)	12.2	11.8	16.6	14.5	15.3	15.1	17.9	15.9	**13.5**	**16.0**
Other Cost (% of sales)	17.9	16.6	20.5	21.8	19.8	20.7	19.0	20.0	**19.0**	**19.9**
Gross Margins (%)	57.4	57.3	59.0	57.8	56.7	49.5	51.0	52.0	**57.8**	**52.4**
EBITDA Margins (%)	27.3	28.9	22.0	21.5	21.6	13.7	14.1	16.1	**25.3**	**16.5**
EBIT Margins (%)	22.2	23.7	14.3	14.7	15.5	7.5	6.5	9.4	**19.3**	**9.9**

Apollo Tyres

Estimate change	⟷
TP change	⟷
Rating change	⟷

Bloomberg	APTY IN
Equity Shares (m)	635
M.Cap.(INRb)/(USDb)	266 / 2.8
52-Week Range (INR)	541 / 365
1, 6, 12 Rel. Per (%)	-4/2/-16
12M Avg Val (INR M)	488

Financials & valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	284.7	324.3	343.9
EBITDA	41.4	38.8	47.9
Adj. PAT	17.0	14.9	19.4
EPS (INR)	26.7	23.4	30.5
EPS Growth (%)	36.6	-12.4	30.4
BV/Share (INR)	328.4	350.1	379.5
Ratios			
RoE (%)	10.8	8.6	10.4
RoCE (%)	13.8	11.3	13.6
Payout (%)	27.8	25.6	22.9
P/E (x)	15.7	17.9	13.7
P/BV (x)	1.3	1.2	1.1
Div. Yield (%)	1.4	1.4	1.7
FCF Yield (%)	8.7	-1.8	1.5

Shareholding Pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	36.9	36.9	37.0
DII	34.9	30.6	29.5
FII	10.5	10.5	12.2
Others	17.7	22.0	21.4

FII includes depository receipts

CMP: INR419 **TP: INR490 (+17%)** **Buy**

Earnings hit by commodity inflation

Pricing action to support margins in the near term

- Apollo Tyres (APTY)'s 2QFY27 earnings came in below our estimates at INR3.1b (-24% YoY) because of weakness in the Europe business coupled with a 420bp YoY contraction in EBITDA margin due to severe commodity headwinds. Despite subdued market conditions, the PCR business continued to gain share in Europe while calibrated pricing actions have been taken across segments to partially offset the raw material inflation.
- We factor in a steady 10% revenue CAGR on a consolidated basis over FY25-28E. While margins are likely to be under pressure in FY27, we expect them to recover in FY28, led by the normalization of cost pressure and restructuring benefits. The stock's valuations at 17.9x/ 13.7x FY27E/FY28E EPS appear attractive, especially when compared with those of peers. **We reiterate our BUY rating on APTY** with a TP of INR490 (valued at 16x FY28E consol. EPS).

Margin compression leads to earnings miss

- APTY's consolidated revenue grew ~17% YoY to INR79.7b (in line) in 2QFY27, while standalone revenue rose ~26% YoY to INR59.2b (in line).
- Consolidated EBITDA margin contracted ~420bp YoY to 10.7% (est. 11.8%), as EBITDA declined 16.2% YoY to ~INR8.6b (below our expectation of INR9.2b).
- APTY posted an exceptional expense of INR269m as part of the payments made to employees who opted for a reorganization within the company.
- Other income was higher than expected at INR424m (expected INR210m).
- However, adj PAT came in below our expectations, declining 24% YoY to INR3.1b.
- Consolidated CFO for 1HFY27 stood at INR2.6b, with FCF coming in negative at INR11.9b.

Segmental performance:

- Standalone revenue grew ~26% YoY to INR59.2b. Standalone EBITDA margin contracted 420bp YoY to 11.1% (below our expectation of 11.5%), while PAT declined marginally YoY to INR2.8b (ahead of estimates).
- The EU revenue (in INR terms) dipped 1.6% YoY to INR21.6b and EBIT margin contracted significantly (by 200bp) to 2.4%.

Highlights from the management commentary

- India operations revenue grew 26%, supported by broad-based growth across OEM and replacement channels. OEM volumes led the growth, registering over 25% YoY growth, followed by low double-digit growth in the replacement segment, while exports remained largely flat.
- European operations remained under pressure, with revenue declining 12% YoY, primarily due to weakness in the truck and agricultural segments, a subdued regional demand environment, and temporary supply disruptions arising from the manufacturing transition following the Enschede plant closure.

- Raw material costs increased by ~25% since Apr'26, representing one of the steepest and fastest inflation cycles experienced by the company in recent years. Management expects the overall raw material basket to increase by a further mid-to-high single-digit percentage between 2Q and 3QFY27, indicating that the commodity inflation cycle is yet to fully stabilize.
- The company has implemented cumulative price hikes of 13-15% across categories by the end of Oct'26, against an estimated 16-17% increase required to offset raw material inflation, with the full impact expected to flow through in 3QFY27. Further hikes may be considered depending on commodity trends and competitive conditions.
- Consolidated net capex stood at ~INR15b during 1HFY27, broadly in line with the company's full-year capex plan. Investments are directed towards capacity expansion, technology, product development, and digital transformation.

Valuation and view

We factor in a steady 10% revenue CAGR on a consolidated basis over FY25-28E. While margins are likely to be under pressure in FY27, we expect them to recover in FY28, led by the normalization of cost pressure and restructuring benefits. The stock's valuations at 17.9x/ 13.7x FY27E/FY28E EPS appear attractive, especially when compared with those of peers. **We reiterate our BUY rating on APTY** with a TP of INR490 (valued at 16x FY28E consol. EPS).

Consolidated - Quarterly Earnings Model (INR M)

Y/E March	FY26				FY27E				FY26	FY27		VAR
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	
Net Revenues	**65,608**	**68,311**	**77,431**	**73,357**	**73,978**	**79,682**	**88,154**	**82,493**	**284,706**	**324,306**	**78,125**	**2**
YoY Change (%)	3.6	6.1	11.8	14.2	12.8	16.6	13.8	12.5	12.2	24.1	14.4	
EBITDA	**8,677**	**10,207**	**11,859**	**10,688**	**8,680**	**8,554**	**10,578**	**11,008**	**41,432**	**38,820**	**9,221**	**-7**
Margins (%)	13.2	14.9	15.3	14.6	11.7	10.7	12.0	13.3	14.6	12.0	11.8	
YoY Change (%)	-4.6	16.3	25.2	27.6	0.0	-16.2	-10.8	3.0	16.0	-6.3	-9.7	
Depreciation	3,776	3,834	3,853	3,967	3,907	3,806	4,100	4,336	15,430	16,150	4,010	
Interest	1,006	1,010	1,001	898	915	942	1,100	1,390	3,915	4,348	1,080	
Other Income	189	297	496	352	583	424	225	14	1,334	1,246	210	
PBT before EO expense	**4,085**	**5,660**	**7,501**	**6,175**	**4,441**	**4,229**	**5,603**	**5,295**	**23,421**	**19,568**	**4,341**	**-3**
Extra-Ord expense	3,702	1,800	271	4,561	-235	269	0	0	10,335	0	0	
PBT	**383**	**3,860**	**7,229**	**1,614**	**4,676**	**3,960**	**5,603**	**5,295**	**13,086**	**19,568**	**4,341**	
Tax Rate (%)	66.5	33.2	34.9	-290.8	25.4	26.2	20.6	24.9	-4.8	24.0	20.6	
MI & Profit/Loss of Asso. Cos.	-1	-1	-2	-3	-1	-2	-1	3	0	0	-1	
Reported PAT	**129**	**2,580**	**4,705**	**6,310**	**3,489**	**2,923**	**4,450**	**3,976**	**13,718**	**14,871**	**3,448**	
Adj PAT	**2,961**	**4,103**	**5,437**	**4,476**	**3,318**	**3,118**	**4,450**	**3,976**	**16,978**	**14,871**	**3,448**	**-10**
YoY Change (%)	-10.6	36.2	59.8	65.3	12.1	-24.0	-18.2	-11.2	36.5	-12.4	-16.0	
Margins (%)	4.5	6.0	7.0	6.1	4.5	3.9	5.0	4.8	6.0	4.6	4.4	
Standalone (India)												
Net Revenues	**47,254**	**47,149**	**51,390**	**52,370**	**54,619**	**59,217**	**61,668**	**61,959**	**198,162**	**237,462**	**55,164**	**7**
YoY Change (%)	2.9	5.7	13.2	14.3	15.6	25.6	20.0	18.3	9.0	19.8	17.0	
EBITDA	**6,447**	**7,206**	**7,466**	**7,640**	**6,549**	**6,546**	**7,523**	**8,789**	**28,759**	**29,408**	**6,344**	**3**
Margins (%)	13.6	15.3	14.5	14.6	12.0	11.1	12.2	14.2	14.5	12.4	11.5	
Adj PAT	**2,233**	**2,795**	**4,668**	**3,197**	**2,888**	**2,762**	**3,153**	**3,855**	**18,845**	**12,565**	**2,433**	**14**
YoY Change (%)	-1.4	66.9	273.1	122.3	29.3	-1.2	-32.5	20.6	183.1	-33.3	-13.0	
Europe (EUR m)												
Net Revenues	**146**	**177**	**180**	**170**	**147**	**157**	**171**	**150**	**678**	**625**	**177**	**-11**
YoY Change (%)	0.0	3.5	-1.6	-3.4	0.7	-11.3	-5.0	-12.0	1.0	-7.6	0.0	
Margins (%)	10.8	12.7	17.9	14.6	8.9	10.3	14.0	11.4	14.0	11.2	11.2	

Source: MOSL Estimates

Kirloskar Oil Engines

Estimate changes	↓
TP change	↓
Rating change	↔

Bloomberg	KOEL IN
Equity Shares (m)	145
M.Cap.(INRb)/(USDb)	231.8 / 2.5
52-Week Range (INR)	2720 / 933
1, 6, 12 Rel. Per (%)	-38/-10/61
12M Avg Val (INR M)	1232

Financials Snapshot (INR b)

Y/E MARCH	FY27E	FY28E	FY29E
Net Sales	68.8	90.1	116.1
EBITDA	8.3	12.2	16.3
PAT	5.1	8.0	11.0
EPS (INR)	35.3	54.9	75.4
GR. (%)	10.6	55.5	37.5
BV/Sh (INR)	259.0	302.7	363.0
Ratios			
ROE (%)	14.4	19.5	22.7
RoCE (%)	14.2	19.3	22.5
Valuations			
P/E (X)	45.2	29.0	21.1
P/BV (X)	6.2	5.3	4.4
EV/EBITDA (X)	27.6	18.6	13.4
Div Yield (%)	0.4	0.7	1.0

Shareholding pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	41.0	41.1	41.1
DII	27.0	26.0	28.0
FII	11.1	11.3	8.3
Others	20.9	21.6	22.6

FII includes depository receipts

CMP: INR1,592 TP: INR2,600 (+63%) Buy

Inflationary pressure continued in 2QFY27

Kirloskar Oil Engines (KOEL)'s 2QFY27 result came in below our estimate due to a miss on EBITDA margin. Revenue growth came in better than our estimates on sharp scale-up seen in distribution and exports. Lower gross margin and lack of operating leverage benefits resulted in a miss in EBITDA margin. KOEL has gained market share in MHP and select segments of HHP in powergen and plans to grow HHP segment at a faster pace. We cut our estimates by 13%/8%/8% for FY27/28/29 to factor in lower margin and expect revenue/EBITDA/PAT CAGR of 27%/30%/33% over FY26-29. The stock has corrected sharply in the recent past, but we believe that underlying thesis remains strong and inflationary pressure is hitting performance over the last few quarters. We expect price hikes and plateauing of RM prices to aid margin recovery going forward. We maintain BUY with a revised TP of INR2,600 (INR2,800 earlier), valuing the core business at 35x two-year forward earnings.

Beat on revenue; margin and PAT miss our estimates

KOEL's 2QFY27 revenue increased 19% YoY to INR17.4b (vs. our est. of INR16.6b), driven by better-than-expected growth in exports and distribution segments. Gross margin contracted 150bp YoY to 33.9%. Other expenses as % of sales increased 100bp YoY to 16.3%. These factors led to EBITDA margin contraction of 300bp YoY to 11% (vs. est. of 13%), while absolute EBITDA declined 6% YoY to INR1.9b. Led by lower-than-expected margin, higher-than-expected non-operating expenses and lower other income, PAT of INR1.2b (-14% YoY) came in below estimates. For 1HFY27, revenue increased 18% YoY, while EBITDA/PAT declined 5%/12% YoY, and margin contracted 270bp YoY to 11.1%. For 1HFY27, OCF declined 83% YoY to INR398m, mainly due to lower profitability and higher working capital requirements, while it reported a free cash outflow of INR1.6b (vs. an inflow of INR966m last year).

Powergen segment growth remained healthy

Powergen segment registered a growth of 17% YoY, led by volume growth, price increase and ramp-up across HHP segment. Demand for powergen has remained strong from data centre, hospitality, realty, etc., and the company has gained market share in MHP segment and has crossed more than 30% market share in 1,010kVA category in HHP. KOEL is taking calculated price increases due to inflationary pressure and we expect further price hikes if current inflationary trends worsen. Going ahead, we expect powergen segment to continue to benefit from 1) demand and pricing growth, 2) further ramp-up in HHP segment, and 3) scale-up in execution of Hypernext DC order from FY28. First phase of ongoing capex for powergen will be commissioned by next fiscal and second phase by FY29, which will also aid powergen segment growth. We expect powergen segment revenue to clock 33% CAGR over FY26-29.

Operating leverage benefits to commence from 2HFY27/FY28

During 2QFY27, gross margin for KOEL was down by 150bp YoY due to higher commodity prices, lag in price increases and execution of certain contracts taken at older RM prices. KOEL has done relatively better than KKC on gross margin. However, other expenses have surged due to higher marketing related spend and impact of higher crude prices on indirect expenses. Going ahead, as per management, operating leverage gains should start getting reflected in margin from 2HFY27/FY28 as volumes improve. In our estimates, we bake in 100-130bp reduction in EBITDA margin for FY27-29.

Industrial segment's performance impacted by execution delays

Industrial revenue grew by a muted 2% YoY to INR3.8b in 2QFY27 due to execution-related challenges during the quarter. It is working with its key OEM partners on targeted price hikes, and KASL completed its first commercial billing in defense and aerospace systems. We expect a sequential recovery in the segment as the price hikes start reflecting and execution normalizes. We trim our FY27 estimates to factor in the slower execution in 2QFY27, and expect segment revenue to clock a 25% CAGR over FY26-29.

Distribution and aftermarket emerging as a steady growth driver

Distribution & aftermarket revenue grew 29% YoY to INR2.9b and growth is driven by the strategic initiatives taken by KOEL over the years, including: 1) diversification beyond traditional engine spares into whole goods, 2) the scale-up of New Life, KOEL's repowering and reconditioning business, 3) groundwork on channel setup and product placement, which is now largely complete, and 4) costs for scaling the business already being incurred, so incremental revenue should flow at better margins. We raise our estimates for the segment to factor in strong momentum in 1HFY27. We expect segment revenue to clock a 20% CAGR over FY26-29.

Exports recovery led by higher powergen contribution

Export revenue grew 50% YoY to INR2.6b (vs. our est. of INR1.4b), after a 12% decline in 1QFY27. Growth was broad-based across Africa, the UAE and East Asia. Powergen now contributes over 45% of international revenue, overtaking industrial engines, and demand is spread across Africa, the UAE and East Asia, which helped offsets the impact from the on-going Middle East disruption, which had impacted 1Q revenue. The Deutz agreement to distribute KOEL's 1.6-litre engine platform globally, starting with the Americas, adds a new growth avenue in advanced-emission markets. We raise our estimates to factor in 2Q outperformance, stronger order intake and a more diversified customer base. We expect export revenue to clock a 17% CAGR over FY26-29.

Arka's profitability held back by planned investments

Arka Fincap's revenue stood at INR2.1b in 2QFY27, while segment PBT was lower at INR61m. FY27 is a planned year of investment in distribution and technology as Arka moves from prime loans against property (LAP) to higher-yielding small-ticket LAP and used-vehicle finance. AUM stood at INR77.8b, and the network has expanded to 146 branches and over 2,000 employees across seven states. Asset quality remained healthy, with GNPA at ~1% and net NPA improving to 0.5%, and the balance sheet is well capitalized with Tier-1 capital above 21% and leverage below 3.8x.

Management expects the investment phase to run until Dec'26, with higher-margin business and better ROA from 1QFY28.

Financial outlook

We cut our estimates by 13%/8%/8% for FY27/28/29 to factor in lower margin. We thus expect a revenue CAGR of 27% over FY26-29, driven by 33%/25%/20%/17% CAGR in powergen/industrial/ distribution/exports. We expect an EBITDA/PAT CAGR of 30%/33% over the same period.

Valuation and recommendation

The stock is currently trading at 45x/29x/21x P/E on FY27/28/29E earnings. Adjusted for subsidiary valuation, KOEL is trading at 40x/26x/19x P/E on FY27/FY28/29E earnings, which is still at a significant discount to the market leader. **We reiterate our BUY rating with a revised SoTP-based TP of INR2,600** (vs. INR2,800), valuing the core business at 35x on two-year forward earnings.

Standalone - Quarterly Earning (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Net Sales	**12,720**	**14,595**	**13,806**	**15,347**	**14,713**	**17,390**	**17,369**	**19,352**	**56,468**	**68,824**	**16,629**	**5**
YoY Change (%)	(5.3)	22.2	18.6	8.7	15.7	19.1	25.8	26.1	24.9	34.6	13.9	
Total Expenditure	11,004	12,555	12,118	13,419	13,058	15,479	15,198	16,830	49,096	60,565	14,468	
EBITDA	**1,716**	**2,040**	**1,688**	**1,928**	**1,655**	**1,911**	**2,171**	**2,522**	**7,373**	**8,259**	**2,162**	**(12)**
YoY Change (%)	(13.2)	23.7	44.3	10.8	(3.6)	(6.3)	28.6	30.8	24.2	26.3	6.0	
Margins (%)	13.5	14.0	12.2	12.6	11.2	11.0	12.5	13.0	13.1	12.0	13.0	
Depreciation	332	348	361	392	404	429	421	431	1,433	1,685	383	12
Interest	31	28	22	31	21	35	22	11	110	90	18	89
Other Income	121	116	80	89	108	98	103	104	407	413	120	(19)
PBT before EO expense	**1,476**	**1,780**	**1,385**	**1,595**	**1,337**	**1,545**	**1,831**	**2,184**	**6,236**	**6,897**	**1,881**	**(18)**
Extra-Ord expense	-	-	201	96	-	-	-	-	297	-	-	
PBT	**1,476**	**1,780**	**1,184**	**1,499**	**1,337**	**1,545**	**1,831**	**2,184**	**5,939**	**6,897**	**1,881**	**(18)**
Tax	380	445	311	388	344	393	470	562	1,524	1,770	483	
Rate (%)	25.8	25.0	26.2	25.9	25.7	25.5	25.7	25.8	25.7	25.7	25.7	
Reported PAT	**1,095**	**1,335**	**874**	**1,111**	**993**	**1,152**	**1,361**	**1,621**	**4,415**	**5,127**	**1,398**	**(18)**
Adj PAT	**1,095**	**1,335**	**1,022**	**1,183**	**993**	**1,152**	**1,361**	**1,621**	**4,636**	**5,127**	**1,398**	**(18)**
YoY Change (%)	(18.7)	20.2	57.1	12.1	(9.3)	(13.7)	33.2	37.0	23.9	23.1	4.7	
Margins (%)	8.6	9.1	7.4	7.7	6.7	6.6	7.8	8.4	8.2	7.4	8.4	

	FY26				FY27E				FY26	FY27E	FY27E	Est
INR m	**1Q**	**2Q**	**3Q**	**4Q**	**1Q**	**2Q**	**3QE**	**4QE**			**2QE**	**Var (%)**
Segmental revenue												
Powergen	6,090	6,780	6,030	7,080	7,200	7,920	7,839	9,516	25,980	32,475	8,136	(3)
Industrial	3,100	3,730	3,900	3,710	3,680	3,810	4,875	5,252	14,440	17,617	4,401	(13)
Distribution & After Market	2,230	2,270	2,380	2,810	2,680	2,930	2,975	3,031	9,690	11,616	2,724	8
Exports	1,200	1,710	1,400	1,620	1,060	2,570	1,680	1,806	5,930	7,116	1,368	88
Total revenue (B2B+B2C)	**12,620**	**14,490**	**13,710**	**15,220**	**14,620**	**17,230**	**17,369**	**19,605**	**56,040**	**68,824**	**16,629**	**4**

The Ramco Cements

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	TRCL IN
Equity Shares (m)	236
M.Cap.(INRb)/(USDb)	191.8 / 2
52-Week Range (INR)	1215 / 711
1, 6, 12 Rel. Per (%)	-12/-13/-17
12M Avg Val (INR M)	266

Financial Snapshot (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	90.1	102.0	110.2
EBITDA	14.4	14.2	17.5
Adj. PAT	2.5	2.3	4.7
EBITDA Margin (%)	16.0	13.9	15.9
Adj. EPS (INR)	10.6	9.7	19.8
EPS Gr. (%)	170.8	-8.5	103.9
BV/Sh. (INR)	345	352	369
Ratios			
Net D:E	0.4	0.4	0.3
RoE (%)	3.2	2.8	5.5
RoCE (%)	4.9	4.2	6.0
Payout (%)	8.5	0.0	0.0
Valuations			
P/E (x)	76.5	83.6	41.0
P/BV (x)	2.4	2.3	2.2
EV/EBITDA(x)	15.2	15.5	12.5
EV/ton (USD)	87	74	74
Div. Yield (%)	0.3	0.0	0.0
FCF Yield (%)	3.2	3.3	4.9

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	42.6	42.6	42.6
DII	33.4	32.9	31.9
FII	7.2	7.5	8.2
Others	16.8	17.0	17.4

FII Includes depository receipts

CMP: INR812 TP: INR850 (+5%) Neutral

Beat estimates; higher realization/volume drive performance

Strong volume growth; non-core asset monetization on track

- The Ramco Cements' (TRCL) 2QFY27 performance was above estimates, led by higher-than-estimated volume/realization. EBITDA declined ~17% YoY to INR3.2b (38% beat). EBITDA/t declined ~23% YoY to INR653 (est. INR488). OPM dipped 4.2pp YoY to ~13% (vs. estimated ~10%). Adj. PAT was down 53% YoY at INR347m (vs. our estimated net loss of INR279m).
- Management indicated that sales volumes were significantly higher in the south region vs. east, which supported higher blended realization. Cement prices have increased across south and east regions in Oct'26. Fuel prices are significantly higher; hence, it is maintaining lower fuel inventory and awaiting correction in fuel prices before replenishing fuel inventory. Capacity is targeted to reach 31mtpa by Mar'27, with Kolimigundala Line-2 and clinker unit expected by Dec'26.
- We increase our EBITDA estimates by ~13%/10% for FY27/FY28E, considering improvement in profitability. We value the stock at 13x FY28E EV/EBITDA to arrive at a TP of INR850. **Reiterate Neutral.**

Volume up ~9% YoY; realization/t up ~1% YoY (+3% vs. est.)

- Revenue/EBITDA/adj. PAT stood at INR24.6b/INR3.2b (+10%/-17% YoY and +6%/+38%) in 2QFY27. Adj. PAT declined ~53% YoY to INR347m (vs. est. net loss of INR279m). Sales volume grew ~9% YoY to 4.94mt (+3% vs. est.). Realization/t was up ~1% YoY/QoQ (each) at INR4,972/t (+3% vs. est.).
- Opex/t was up 6% YoY (~1% below estimates), led by 10%/7%/2% increase in variable cost/other/freight expenses per ton. Employee expenses/t declined ~3% YoY. OPM dipped 4.2pp YoY to ~13%, and EBITDA/t declined ~23% YoY to INR653. Depreciation increased ~4% YoY, while interest costs declined ~17% YoY. Other income was up ~7% YoY.
- In 1HFY27, revenue/EBITDA/PAT stood at INR47.3b/INR6.3b/INR568m (+10%/-20%/-65% YoY). OPM contracted 4.9pp YoY to ~13%. EBITDA/t declined ~27% YoY to INR659. OCF stood at INR2.7b vs. INR6.5b in 1HFY26. Capex stood at INR3.7b vs. INR6.0b in 1HFY26. Net cash outflow stood at INR1.0b vs. FCF at INR451m in 1HFY26.

Highlights from the management commentary

- Cement capacity utilization stood at 72% vs. 71%/70% in 2QFY26/1QFY27. Volume share from south stood at ~83% and from east at ~17%.
- Blended fuel consumption cost was USD140/t (INR1.99/kcal) vs. USD122/USD127 (INR1.49/INR1.85 per kcal) in 2QFY26/1QFY27.
- Capex during 2QFY27/1HFY27 stood at INR2.0b/INR3.7b. FY27 capex guided at INR8b.

View and valuation

- TRCL's operating performance was supported by higher cement volumes and improved realizations, alongside strong construction chemicals growth. Near-term profitability is likely to remain impacted by high coal costs. Capacity expansion to 31mtpa by Mar'27, Kolimigundala commissioning and further non-core asset monetization remain key monitorables.
- We estimate a CAGR of ~11%/10%/37% in revenue/EBITDA/PAT over FY26-28. We estimate a volume CAGR of ~7% over FY26-28. Further, we estimate EBITDA/t of INR700/INR804 in FY27/FY28 vs. INR765 in FY26. Net debt is likely to decline to INR29.1b by FY28E from INR39.2b as of Sep'26, backed by disciplined capex and monetization of non-core assets. The net debt-to-EBITDA ratio is estimated to be 1.7x in FY28E vs. 3.1x as of Sep'26 (TTM).
- The stock is trading fairly at 15x/13x FY27E/FY28E EV/EBITDA. We value the stock at 13x FY28E EV/EBITDA to arrive at our TP of INR850. **Reiterate Neutral.**

Quarterly Performance **(INR b)**

Y/E March	FY26				FY27E				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Sales volume (m ton)	4.12	4.55	4.59	5.55	4.62	4.94	4.85	5.91	18.81	20.31	4.80	3
YoY Change (%)	(5.5)	1.3	5.0	5.0	12.1	8.7	5.6	6.4	1.7	8.0	5.5	
Realization (INR/ton)	5,027	4,914	4,581	4,693	4,917	4,972	5,072	5,106	4,792	5,022	4,847	3
YoY Change (%)	4.9	8.2	1.3	3.8	(2.2)	1.2	10.7	8.8	4.4	4.8	(1.4)	
QoQ Change (%)	11.2	(2.3)	(6.8)	2.4	4.8	1.1	2.0	0.7			(1.4)	
Net Sales	**20.7**	**22.3**	**21.0**	**26.1**	**22.7**	**24.6**	**24.6**	**30.2**	**90.1**	**102.0**	**23.3**	6
YoY Change (%)	(0.9)	9.6	6.3	9.0	9.6	10.0	16.9	15.7	6.1	13.2	4.1	
Total Expenditure	16.7	18.5	18.2	22.3	19.6	21.4	21.2	25.6	75.7	87.8	20.9	2
EBITDA	**4.0**	**3.9**	**2.8**	**3.7**	**3.1**	**3.2**	**3.3**	**4.6**	**14.4**	**14.2**	**2.3**	38
YoY Change (%)	24.5	24.0	0.5	16.2	(22.8)	(16.5)	19.2	22.4	16.8	(1.2)	(39.5)	
Margins (%)	19.2	17.3	13.4	14.3	13.5	13.1	13.6	15.1	16.0	13.9	10.1	307
Depreciation	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	7.4	7.7	1.9	(0)
Interest	1.0	1.1	1.1	1.0	1.0	0.9	0.9	0.9	4.2	3.8	0.9	3
Other Income	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.4	0.3	0.1	(37)
PBT before EO expense	**1.2**	**1.0**	**0.1**	**1.0**	**0.3**	**0.5**	**0.6**	**1.7**	**3.3**	**3.1**	**(0.4)**	NA
Extra-Ord expense/(Income)	-	-	(4.8)	(0.7)	(0.1)	(0.0)	-	-	(5.5)	(0.2)	-	-
PBT	**1.2**	**1.0**	**4.9**	**1.8**	**0.4**	**0.5**	**0.6**	**1.7**	**8.8**	**3.3**	**(0.4)**	NA
Tax	0.3	0.3	1.0	0.3	0.1	0.1	0.1	0.4	1.9	0.8	(0.1)	
Prior year tax	-	-	-	-	-	-	-	-	-	-	-	
Rate (%)	26.2	25.9	20.3	17.2	23.3	26.8	25.5	25.6	21.1	25.5	21.0	
Reported PAT	**0.9**	**0.7**	**3.9**	**1.5**	**0.3**	**0.4**	**0.4**	**1.3**	**6.9**	**2.4**	**(0.3)**	NA
Adj PAT	**0.9**	**0.7**	**0.1**	**0.9**	**0.2**	**0.3**	**0.4**	**1.3**	**2.5**	**2.3**	**(0.3)**	NA
YoY Change (%)	142.3	190.5	64.8	201.0	(74.2)	(53.4)	731.4	51.5	170.8	(8.5)	(137.5)	
Margins (%)	4.2	3.3	0.2	3.3	1.0	1.4	1.8	4.3	2.8	2.2	(1.2)	

Tenneco Clean Air

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	TENNIND IN
Equity Shares (m)	404
M.Cap.(INRb)/(USDb)	188.7 / 2
52-Week Range (INR)	657 / 419
1, 6, 12 Rel. Per (%)	-13/-29/-
12M Avg Val (INR M)	1171

Financials & valuations (INR m)

Y/E March	FY26	FY27E	FY28E
Sales	64,277	73,013	85,344
EBITDA	10,397	12,041	14,644
Adj. PAT	6,823	7,872	9,758
EPS (INR)	16.9	19.5	24.2
EPS Growth (%)	8.2	15.4	24.0
BV/Share (INR)	34.7	40.2	48.4
Ratios			
RoE (%)	52.5	52.1	54.6
RoCE (%)	54.6	54.5	56.6
Payout (%)	71.0	71.8	66.2
Valuations			
P/E (x)	27.7	24.0	19.4
P/BV (x)	13.5	11.6	9.7
EV / EBITDA (x)	17.7	15.3	12.4
Div. Yield (%)	2.6	3.0	3.4

Shareholding pattern (%)

As On	Sep-26	Jun-26
Promoter	59.8	74.8
DII	22.7	11.4
FII	11.9	9.7
Others	5.6	4.1

FII includes depository receipts

CMP: INR468 **TP: INR655 (+40%)** **BUY**

Domestic visibility intact; export order halves

- Tenneco Clean Air (TENNIND) reported a value-added revenue of INR15.2b, up 32% YoY (11% above our est.). Revenue growth was led by strong order execution across both segments, with Clean Air & Powertrain growing 27% YoY and Suspension growing 38% YoY.
- EBITDA stood at INR2.6b (up 21% YoY), 6% above our estimates. EBITDA margin stood at 15.2% vs. 16.9% in 2QFY26 due to elevated commodity costs and the incremental cost of operating as a listed entity.
- PAT stood at INR1.7b (up 15% YoY), beating our estimates by 10% due to better-than-expected operational profits.
- The total order book stood at ~INR165b (up 33% vs. the FY26 order book), representing ~35% of Clean Air & Powertrain orders and 65% of Suspension orders. Overall booked business included INR8.7b from export programs, strengthening multi-year revenue visibility. Overall booked business now covers more than 100% of the company's FY30 revenue plan.
- CFO for 1HFY27 stood at INR4.6b, and net cash stood at INR8.7b.
- Although the current order book provides more than 100% coverage of the FY2030 revenue target, the export outlook has weakened. The export order book has fallen ~50% YoY, hit by Western market contraction, Chinese competition and US tariff uncertainty. In addition, the implementation of BS VII has been delayed, pushing out the expected content-per-vehicle uplift in the domestic business. Factoring in the slower export recovery and the later BS VII timeline, we have cut our FY29E revenue estimate by 5%. The domestic order book, however, remains strong and has limited the impact of the export shortfall on earnings. As exports carried higher margins than the domestic business, we cut our margin estimates by 20-60 bp for FY27-FY29. At CMP, the stock is trading at 24.0x FY28E and 19.4x FY29E. **We reiterate our BUY rating with a revised TP of INR655 (based on 30x Sep'28 EPS of INR22).**

Valuation and view

- TENNIND enters its next phase of growth from a position of strength, commanding ~59% share in CV Clean Air, ~68% in off-highway Clean Air (ex-tractors), ~18% in PV Clean Air, and ~55% in PV shock absorbers and struts. These leadership positions, backed by deep OEM relationships and Tenneco's global technology and R&D, create strong entry barriers. We see multiple growth levers ahead as premiumization raises suspension content, while BS-VII, CAFE III, and TREM-V drive higher Clean Air content across PVs, CVs, and off-highway applications. Localization of advanced technologies, new customer programs, and India's emergence as an export hub should further support market- and wallet-share gains. We estimate a 17% earnings CAGR for the consolidated business (FY26-FY29E).

- With a capital-efficient model and strong balance sheet, TENNIND is well placed to pursue growth while sustaining healthy returns. Its net cash position, negative working capital cycle, 90%+ core RoCE, and strong cash conversion (70%+ CFO/EBITDA; 80%+ FCF/PAT) provide resilience and support expansion into new segments. At the CMP of INR468, the stock trades at 24.0x/19.4x FY28E/29E EPS. We have a BUY rating on the stock with a revised Target Price of INR655 (based on 30x Sep'28E earnings).
- **Key risks:** 1) Faster EV adoption, 2) termination of the technology license or PE exit overhang, 3) intensifying competition, 4) commodity fluctuations, and 5) loss of key customers.

Consolidated - Quarterly Earnings

	FY26				FY27E				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net operating income	**12,856**	**12,806**	**12,853**	**15,524**	**15,448**	**17,183**	**15,210**	**16,437**	**54,040**	**64,277**	**14,967**	**15**
Change (%)	3.5	2.9	5.4	9.9	9.6	26.6	13.0	6.8	10.5	18.9	10.0	
Value added Revenue	**11,665**	**11,515**	**11,941**	**14,058**	**13,816**	**15,229**	**13,934**	**15,778**	**49,180**	**58,756**	**13,713**	**11**
Total Revenue (%)	90.7%	89.9%	92.9%	90.6%	89.4%	88.6%	91.6%	96.0%	91.0%	91.4%	91.6%	
RM/Sales (%)	66.97	65.34	66.10	65.21	64.20	66.03	64.56	65.01	65.70	65.82	66.03	0 bps
Staff Cost (%)	7.1	6.5	6.3	7.3	7.0	6.1	6.4	6.5	6.8	6.5	7.0	(90) bps
Other Exp. (%)	12.7	12.4	13.2	13.0	13.5	13.3	13.1	12.9	12.8	13.2	13.4	(10) bps
EBITDA	**2,289**	**2,168**	**2,225**	**2,573**	**2,469**	**2,616**	**2,438**	**2,875**	**9,255**	**10,397**	**2,468**	**6**
EBITDA Margins (%)	17.8	16.9	17.3	16.6	16.0	15.2	16.0	17.5	17.1	16.2	16.5	(130) bps
Change (%)	7.5	5.7	24.8	17.6	7.9	20.7	9.6	11.8	18.8	17.7	13.9	
Non-Operating Income	308	121	47	114	87	92	80	96	590	354	80	14
Interest	71	106	71	88	84	99	95	82	336	360	100	-1
Depreciation	254	258	283	287	278	280	382	370	1082	1310	349	-20
Exceptional Items	0	0	-272	0	0	0	0	0	-272	0	0	
PBT after EI items	**2,272**	**1,924**	**1,646**	**2,313**	**2,194**	**2,328**	**2,041**	**2,519**	**8,155**	**9,081**	**2,100**	**11**
Tax	591	417	458	645	542	594	514	629	2112	2279	529	
Eff. Tax Rate (%)	26.0	21.7	23.9	27.9	24.7	25.5	25.2	25.0	25.1	25.1	25.2	
Rep. PAT	**1,681**	**1,507**	**1,188**	**1,668**	**1,652**	**1,734**	**1,527**	**1,890**	**6,043**	**6,801**	**1,569**	**10**
Change (%)	12.0	10.0	-5.2	18.9	-1.7	15.0	28.5	13.3	9.3	12.5	4.2	
Adj. PAT	**1,678**	**1,505**	**1,459**	**1,666**	**1,650**	**1,731**	**1,526**	**1,887**	**6,307**	**6,793**	**1,569**	**10**
Change (%)	12.0	10.0	16.5	18.9	-1.7	15.0	4.6	13.3	14.2	7.7	4.2	

Emami

Estimate change	⟷
TP change	↓
Rating change	⟷

Bloomberg	HMN IN
Equity Shares (m)	437
M.Cap.(INRb)/(USDb)	169.4 / 1.8
52-Week Range (INR)	551 / 357
1, 6, 12 Rel. Per (%)	-5/-17/-23
12M Avg Val (INR M)	386

Financials & Valuations (INR b)

Y/E March	2027E	2028E	2029E
Sales	45.5	50.5	55.8
Sales Gr. (%)	20.4	10.9	10.6
EBITDA	10.8	12.4	14.6
EBITDA Margin (%)	23.8	24.7	26.1
Adj. PAT	8.3	9.2	10.7
Adj. EPS (INR)	18.9	21.0	24.5
EPS Gr. (%)	-3.5	10.8	17.0
BV/Sh.(INR)	72.9	79.4	87.9
Ratios			
RoE (%)	27.1	27.5	29.3
RoCE (%)	30.8	30.7	32.6
Payout (%)	60.7	62.0	59.1
Valuation			
P/E (x)	20.5	18.5	15.8
P/BV (x)	10.0	9.2	8.3
EV/EBITDA (x)	28.1	24.3	20.5
Div. Yield (%)	3.0	3.4	3.7

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	54.8	54.8	54.8
DII	23.6	27.0	25.0
FII	9.0	7.9	10.9
Others	12.6	10.3	9.2

FII Includes depository receipts

CMP: INR388 TP: INR475 (+22%) Buy

Positive growth delivery; cost pressure persists

- Emami's consolidated revenue grew 36% YoY to INR10.8b (24% LFL; beat) in 2QFY27, aided by the consolidation of Axiom Ayurveda and IncNut Digital. Domestic business delivered 49% revenue growth, with LFL revenue/volume growth of 32%/26%, on a weak base of -15%/-16% in 2QFY26 (GST transition). The strong recovery in underlying volumes is encouraging, although the low base aided growth. Management expects total business growth of 18-20% in 2HFY27, supported by sustained momentum across core brands and strategic investments.
- Hair Care and Skin Care delivered strong growth of 30% and 31%, respectively, while Healthcare grew 11%. The strategic investment portfolio recorded 73% LFL growth, with its contribution to domestic revenue rising to ~26% from ~18% in 1Q. International business declined 2% YoY, but management gave positive guidance for FY27. Management expects the international business recovery to strengthen over the coming quarters.
- Gross margin contracted sharply by 520bp YoY to 65.8%, with raw material inflation accounting for ~400bp of the decline and the balance attributable to the changing business mix following acquisitions. Consequently, EBITDA margin contracted 190bp YoY to 20.4%. EBITDA grew 25% YoY to INR2.2b (beat), supported by robust topline growth. Emami has implemented ~5.5% price increases to fully offset input cost inflation. The company expects elevated inventory costs to sustain margin pressure through 2HFY27, with meaningful RM cost relief expected only in FY28. We expect EBITDA growth to be 13-15% in FY27/FY28.
- Domestic demand momentum strengthened, with 26% underlying volume growth, albeit on a weak base. The strategic investment portfolio continues to scale rapidly, providing an increasingly meaningful growth lever. We believe elevated input costs and higher brand investments are likely to keep margins under pressure through 2HFY27. Emami's calibrated pricing actions and productivity initiatives should aid gradual margin recovery going ahead. **Given its reasonable valuations of 19x/16x FY28/FY29 EPS, we reiterate our BUY rating with a TP of INR475 (based on 20x on Sep'28 EPS).**

Strong print; organic volume up 26%

- **Strong organic growth:** Consolidated net sales grew 36% YoY to INR10.8b (24% LFL; est. INR9.6b), aided by the acquisition of Axiom Ayurveda and IncNut Digital. Domestic revenue grew 49% YoY, with LFL revenue/volume growth of 32%/26%, on a weak base of -15%/-16% in 2QFY26, indicating a healthy recovery in underlying demand. International business declined 2% YoY, although it grew 6% excluding Nepal and Iraq, reflecting improving momentum across key markets.

- **Strategic portfolio continues with its strong momentum:** The strategic investments portfolio grew 73% on an LFL basis and now contributes 26% of domestic revenue (~18% in 1QFY27). Hair Care and Skin Care grew 30%/31%, while Healthcare grew 11%. Within the core portfolio, Cool Oils grew in the thirties, Kesh King in the high teens and BoroPlus in the twenties. Talc and Prickly Heat powder sales more than doubled, while Pain Management grew in the teens. Emami is also boosting its innovation pipeline, with the launch of the FromMaa baby care range and increased focus on sunscreen and shower gel.
- **EBITDA grow 25% YoY in 2Q:** Gross margin contracted 520bp YoY to 65.8% (est. 66.5%), remaining the key drag on operating profitability. Employee expenses, advertising spend, and other expenses increased 16%/38%/24%, respectively, reflecting higher brand investments and operating costs. Consequently, EBITDA margin contracted 190bp YoY to 20.4% (in line). Nevertheless, strong revenue growth aided 25% YoY EBITDA growth to INR2.2b (est. INR2b), despite RM pressure.
- **Higher tax limits PAT growth:** PBT (before exceptional items) grew 28% YoY to INR2b (est. INR1.7b), supported by strong operating performance. However, the effective tax rate stood at 25% versus our expectation of 18%, largely due to the normalization of tax rates following the phase-out of fiscal benefits. Consequently, APAT declined 6% YoY to INR1.6b (est. INR1.5b).

Key highlights from the management commentary

- Rural demand was mixed. South, West and parts of UP lagged due to deficient rainfall, while districts with good rainfall did well. Demand should pick up post-Diwali as winter, the portfolio's peak season, sets in.
- **The company has implemented price increases of ~5.5% for FY27 and has fully passed through input cost inflation.**
- **The company guided for total business growth is guided at 18-20% for 2HFY27, as momentum across core brands and strategic investments continues.**
- Organized channels contributed 37% of domestic business (32% in 1QFY27), with MT and e-commerce maintaining strong momentum.
- Quick commerce accounted for ~15% of total digital sales.
- Emami's effective tax rate normalized to ~25% (compared with the previous year's MAT credit utilization/entitlement).

Valuation and view

- We trim our EPS estimated by 1-2% for FY27 and FY28.
- Emami's sharp recovery in domestic volumes, sustained momentum across core brands and rapid scaling of its strategic investment portfolio strengthen its medium-term growth outlook. The increasing salience of the strategic portfolio contribution to domestic revenue reinforces confidence in its emerging growth engines. Moreover, Emami continues to strengthen its distribution reach predominantly through alternate channels (MT, e-com, and QC).
- While elevated input costs and higher brand investments are likely to defer margin recovery to FY28, we believe the improving growth trajectory is adequately captured in the stock's valuation of 19x/16x FY28/FY29 EPS. **We reiterate our BUY rating with a TP of INR475 (based on 20x Sep'28E EPS).**

Consol. Quarterly performance (INR m)

Y/E MARCH	FY26				FY27E				FY26	FY27E	FY27E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Domestic volume gr. (%)	-3.0	-16.0	9.0	-7.0	16.0	43.0	12.0	12.0	-4.3	20.8	16.0	
Net Sales	**9,041**	**7,985**	**11,518**	**9,251**	**10,392**	**10,877**	**13,514**	**10,740**	**37,795**	**45,522**	**9,577**	13.6%
YoY change (%)	-0.2	-10.3	9.8	-3.9	14.9	36.2	17.3	16.1	-0.8	20.4	19.9	
Gross Profit	**6,276**	**5,671**	**8,136**	**6,332**	**6,840**	**7,159**	**9,054**	**7,219**	**26,415**	**30,272**	**6,369**	12.4%
Gross margin (%)	69.4	71.0	70.6	68.4	65.8	65.8	67.0	67.2	69.9	66.5	66.5	
EBITDA	**2,142**	**1,785**	**3,842**	**1,867**	**2,262**	**2,223**	**4,225**	**2,137**	**9,637**	**10,847**	**1,955**	13.7%
Margins (%)	23.7	22.4	33.4	20.2	21.8	20.4	31.3	19.9	25.5	23.8	20.4	
YoY change	-1.1	-28.7	13.4	-14.9	5.6	24.5	10.0	14.4	-6.0	12.6	9.5	
Depreciation	445	453	453	423	428	453	460	498	1,773	1,839	466	
Interest	24	26	29	32	56	61	55	53	111	180	25	
Other Income	216	214	190	232	185	230	210	246	851	870	218	
PBT	**1,889**	**1,520**	**3,549**	**1,645**	**1,963**	**1,939**	**3,920**	**1,831**	**8,603**	**9,699**	**1,683**	15.2%
Tax	225	18	256	209	558	481	706	283	708	2,027	303	
Rate (%)	11.9	1.2	7.2	12.7	28.4	24.8	18.0	15.4	8.2	20.9	18.0	
Adj. PAT	**1,843**	**1,711**	**3,408**	**1,603**	**1,524**	**1,611**	**3,374**	**1,710**	**8,565**	**8,265**	**1,556**	3.6%
YoY change (%)	8.3	-26.7	13.4	-11.6	-17.3	-5.8	-1.0	6.7	-3.3	-3.5	-9.1	
Reported PAT	**1,643**	**1,484**	**3,195**	**1,432**	**1,389**	**1,455**	**3,202**	**1,529**	**7,753**	**7,620**	**1,367**	6.4%
YoY change (%)	9.1	-29.7	14.5	-11.7	-15.4	-1.9	0.2	6.8	-3.4	-1.7	-7.9	

E: MOFSL Estimates

Dr. Agarwal's Health Care

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	AGARWALE IN
Equity Shares (m)	317
M.Cap.(INRb)/(USDb)	162.3 / 1.7
52-Week Range (INR)	568 / 401
1, 6, 12 Rel. Per (%)	-3/11/4
12M Avg Val (INR M)	202

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	20.8	26.1	31.8
EBITDA	5.7	7.0	8.7
Adjusted PAT	1.3	1.9	2.8
EBIT Margin (%)	14.1	14.2	15.4
Cons. Adj EPS (INR)	4.0	5.8	8.5
EPS Growth (%)	59.0	46.0	46.5
BV/Share (INR)	64.6	70.9	79.9
Ratios			
Net D-E	-0.1	-0.2	-0.2
RoE (%)	6.8	9.1	12.0
RoCE (%)	8.9	10.4	12.9
Payout (%)	0.0	0.0	1.0
Valuations			
P/E (x)	128.3	87.9	60.0
EV/EBITDA (x)	28.2	24.0	19.1
Div. Yield (%)	0.0	0.0	0.0
FCF Yield (%)	-6.4	4.2	3.3
EV/Sales (x)	7.7	6.5	5.3

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	32.3	32.3	32.4
DII	30.8	27.8	28.0
FII	34.6	37.9	38.0
Others	2.2	2.0	1.5

FII includes depository receipts

CMP: INR511 **TP: INR635 (+24%)** **Buy**

Beat on estimates; increased surgeries drive earnings

SSSG/facility addition provide impetus for stable growth outlook

- Dr. Agarwal Healthcare (DAHL) delivered better-than-expected financial performance, with a 6%/5% beat on revenue/EBITDA. The PAT beat was much higher (35%) due to lower interest/tax rate and higher other income.
- There was superior YoY growth across centers, both mature (3+ years into operations) and emerging facilities. DAHL reported 17% same-store-sales growth (SSSG) for all facilities set-up/acquired up to 1HFY24. Facilities that commenced operations in FY24/FY25 witnessed 21%/68% YoY revenue growth in 1HFY27.
- Growth was backed by sustained momentum in the number of surgeries performed, supported by healthy improvement in realization.
- Region-wise, North continued to lead with 60% YoY revenue growth, followed by West/East ~30% YoY each and South ~24.6% YoY in 1HFY27. South region remained the largest contributor.
- Further, DAHL has revised its expansion plan to operationalize 65 facilities in FY27 vs. 60 guided in 1QFY27.
- We raise our estimates by 6%/7% for FY27/FY28, factoring in an increased share of higher-end surgeries, a faster pace of opening new facilities, and revised guidance on number of facilities.
- We value DAHL at 25x EV/EBITDA for the surgery business, 15x EV/EBITDA for the opticals business, and 10x EV/EBITDA for the pharmacy business, adjusted for its stake Thind hospital, and arrive at a TP of INR635. Maintain BUY.

Operational leverage supports earnings growth

- DAHL's 2QFY27 revenue grew 31.4% YoY to INR6.6b (**beat 6%**).
- EBITDA margin contracted 50bp YoY to 26.8% (our estimate: 27.1%) due to an increase in employee costs (up 40bps % of sales).
- Consequently, EBITDA grew 29.1% YoY to INR1.7b (**beat 5%**).
- PAT came in at INR547m in 2QFY27, up 84.4% YoY from INR297m in 2QFY27.

Broad-based growth across all segments

- Surgeries revenue grew 28% YoY to INR4.3b (66% of overall revenue).
- Number of surgeries increased 22.2% YoY to 95,841 in 2QFY27, while average revenue per surgery rose 5% YoY to INR45,069.
- Diagnosis, Consultations, & Others grew 50.8% YoY to INR799m (12% of overall revenue).
- Opticals, contact lens and accessories grew 36.2% YoY to INR917m (14% of overall revenue).
- Eye care-related pharma products grew ~24% YoY to INR519m (8% of overall revenue).

Highlights from the management commentary

- SSSG remained strong at 18.8%/17.7% YoY in 2QFY27/1HFY27, driven by ~8% YoY volume growth (7.5%/0.5% footfall/conversion), 9.5% YoY value growth, (including 8%/1.5% from premiumization/pricing).
- DAHL added 39 facilities in 1HFY27, comprising 34 surgical and five primary centers. These included 19 greenfield additions and two acquired facilities in 2QFY27. The total network expanded to 324 facilities, including 305 in India across 172 cities.
- DAHL raised the expansion guidance to 65 new facilities, including 55/10 surgical/primary centers for FY27, vs. earlier target of 60 facilities, including 40 surgical centers. 26 facilities, including 21 surgical centers, are planned for addition in 2HFY27.
- DAHL raised capex guidance from INR4b to INR5b for FY27.
- Surgical centers generate average monthly realization of INR7.5-8.0m; offering better throughput than primary centers.
- DAHL acquired two facilities in Delhi NCR (Greater Kailash/Loni, Ghaziabad) for INR550m through a business transfer agreement. The acquired centers generated ~INR135m/INR71.6m of revenue /EBITDA over the last 12 months. The acquisition cost ~INR330m will be paid upfront, with the balance linked to milestones over four years.
- DAHL expects growth from deeper penetration in existing markets, particularly South and expansion in micro markets of Mumbai/Delhi NCR.

Quarterly Earning Model

Y/E March	FY26				FY27E				FY26	FY27E	FY27	
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			2QE	vs Est
Net Sales	**4,874**	**4,987**	**5,299**	**5,641**	**6,140**	**6,555**	**6,629**	**6,794**	**20,801**	**26,118**	**6,200**	**5.7%**
YoY Change (%)	20.8	19.7	23.0	22.6	26.0	31.4	25.1	20.4	21.6	25.6	24.3	
Total Expenditure	3,596	3,626	3,858	4,026	4,436	4,797	4,872	4,980	15,105	19,085	4,520	
EBITDA	**1,279**	**1,361**	**1,441**	**1,615**	**1,704**	**1,758**	**1,757**	**1,814**	**5,696**	**7,033**	**1,680**	**4.6%**
YoY Change (%)	23.3	27.3	31.5	21.4	33.3	29.1	21.9	12.3	25.7	23.5	23.4	
Margins (%)	26.2	27.3	27.2	28.6	27.8	26.8	26.5	26.7	27.4	26.9	27.1	
Depreciation	630	679	688	767	783	827	846	867	2,762	3,323	774	
EBIT	**649**	**683**	**754**	**848**	**921**	**931**	**911**	**947**	**2,933**	**3,710**	**906**	
YoY Change (%)	34.7	37.2	46.6	16.8	41.9	36.4	20.9	11.7	32.1	26.5	32.8	
Margins (%)	13.3	13.7	14.2	15.0	15.0	14.2	13.7	13.9	14.1	14.2	14.6	
Interest	247	226	211	221	234	230	247	241	905	952	254	
Other Income	134	79	105	126	64	98	72	69	444	302	69	
PBT before EO expense	**536**	**537**	**648**	**753**	**751**	**799**	**736**	**775**	**2,473**	**3,061**	**722**	
Extra-Ord expense	0	0	0	-13	0	0	0	0	13	0	0	
PBT	**536**	**537**	**648**	**766**	**751**	**799**	**736**	**775**	**2,486**	**3,061**	**722**	
Tax	155	172	211	267	201	230	225	225	805	881	216	
Rate (%)	29.0	32.0	32.6	34.8	26.8	28.8	30.5	29.0	32.4	28.8	30.0	
MI & P/L of Asso. Cos.	80	68	99	103	98	21	60	70	350	249	100	
Reported PAT	**301**	**297**	**337**	**397**	**452**	**547**	**452**	**480**	**1,332**	**1,931**	**405**	
Adj PAT	**301**	**297**	**337**	**388**	**452**	**547**	**452**	**480**	**1,323**	**1,931**	**405**	**35.3%**
YoY Change (%)	148.3	79.5	80.3	8.4	50.5	84.4	33.9	23.6	59.0	46.0	36.3	
Margins (%)	6.2	6.0	6.4	6.9	7.4	8.4	6.8	7.1	6.4	7.4	6.5	
EPS	**1.0**	**0.9**	**1.1**	**1.2**	**1.4**	**1.7**	**1.4**	**1.5**	**4.2**		**1.3**	**35.3%**

Molbio Diagnostics

Estimate change	⟷
TP change	⟷
Rating change	⟷

Bloomberg	MOLBIO IN
Equity Shares (m)	115
M.Cap.(INRb)/(USDb)	161.7 / 1.7
52-Week Range (INR)	1687 / 926
1, 6, 12 Rel. Per (%)	-15/-/-
12M Avg Val (INR M)	4646

Financials & Valuations (INRb)

Y/E March	FY26	FY27E	FY28E
Sales	14.5	17.9	22.1
EBITDA	3.2	4.5	6.5
Adjusted PAT	1.7	2.6	4.3
EBITDA Margin (%)	22.2	25.3	29.5
Cons. Adj EPS (INR)	14.9	23.0	38.4
EPS Gr. (%)	10.2	54.1	66.8
BV/Sh. (INR)	103.7	126.7	165.1
Ratios			
Net D-E	0.1	0.0	-0.1
RoE (%)	15.8	20.0	26.3
RoCE (%)	13.9	15.3	22.9
Payout (%)	0.0	0.0	0.0
Valuation			
P/E (x)	94.0	61.0	36.6
EV/EBITDA (x)	49.5	35.0	24.0
Div. Yield (%)	0	0	0
FCF Yield (%)	0.1	4.3	21.3
EV/Sales (x)	11.0	8.9	7.1

Shareholding Pattern (%)

As On	Sep-26
Promoter	41.3
DII	19.1
FII	1.6
Others	38.0

FII includes depository receipts

CMP: INR1,404 **TP: INR1,800 (+28%)** **Buy**

Weak quarter; FY27 outlook remains intact

Geographic/product expansion and wider application underway

- Molbio's 2QFY27 revenue decreased 55.4% YoY to INR2.6b.
- Truenat test-kit sales decreased 62% YoY to INR1.9b (76% of sales). Truenat devices sales decreased 38.5% YoY to INR311m (12% of sales). Services revenue grew 2.6x YoY to INR180m (7% of sales). Prognosys revenue grew 50% YoY to INR90m (3% of sales). OptraScan revenue at INR50m (2% of sales) jumped 4x QoQ.
- Gross margin (GM) was broadly stable YoY at 61.6%.
- EBITDA margin contracted 1,200bp YoY to 17%, due to lower operating leverage (employee/other cost increased 880bp/320bp as % of sales).
- As a result, EBITDA decreased 74% YoY to INR4.4b.
- Adj. PAT fell 86.2% YoY to INR151m, lagging EBITDA growth due to higher depreciation and effective tax rate.

Innovation to add new growth levers beyond TB

- The subdued performance was due to a delay in rate negotiation with government. ~INR1b revenue shifted to next quarter.
- Truenat devices/test kit contributed~ 12%/76% revenue in 2QFY27. MOLBIO is planning to expand beyond TB testing into newer molecular applications such as Hepatitis/HPV with launch of new platforms.
- Notably, three new platforms are nearing launch, with CDSCO approvals expected over 4-5 months, expanding presence across molecular screening, multiplex diagnostics.
- The three new platforms are (1) TruePOC, a swab-based molecular screening solution targeting underserved markets; (2) TrueAMP, a multiplexing platform for syndromic testing across respiratory, STI, sepsis and antimicrobial resistance panels; (3) TrueSight, AI-enabled solution providing CBC, five-part differential count, haemoglobin and cell morphology analysis.
- In addition to human use, Molbio is gearing up for use of its X-ray products for veterinary.

Valuation and view

- We maintain our FY27/FY28 earnings estimates, factoring in a) increasing utilization of test-kits beyond TB with stronger international adoption, and b) veterinary imaging, which offers a longer-term growth opportunity for Prognosys.
- Considering the differentiated R&D-driven business model and strong earnings CAGR of 60% over FY26-28, we value MOLBIO at 45x 12-month forward earnings to arrive at a TP of INR1,800. **Maintain BUY.**

Highlights from the management commentary

- Reiterated revenue growth guidance at ~25% YoY and EBITDA margin at 24-25% for FY27.
- The new government rate-contract pricing remains broadly unchanged from the previous contract, with no significant pricing pressure.
- MOLBIO expects growth over the next 2-3 years to be driven by continued expansion in TB testing, new molecular applications such as Hepatitis/HPV and the launch of new platforms.
- Following approval for Hepatitis B and C testing, MOLBIO has been included in national testing algorithm. State-level procurement is underway, while CG procurement has been initiated with first order expected shortly.

Consolidated - Quarterly Earnings Model

Y/E March	FY26			FY27E				FY26	FY27
	1Q	2Q	4Q	1Q	2Q	3QE	4QE		
Gross Sales	**997**	**5,803**	**5,606**	**4,084**	**2,590**	**5,132**	**6,134**	**14,457**	**17,939**
YoY Change (%)				309.6	-55.4	NA	9.4	41.7	24.1
Total Expenditure	1,150	4,121	4,019	3,078	2,151	3,736	4,443	11,242	13,408
EBITDA	**-153**	**1,682**	**1,587**	**1,006**	**439**	**1,396**	**1,690**	**3,214**	**4,532**
Margins (%)	-15.3	29.0	28.3	24.6	17.0	27.2	27.6	22.2	25.3
Depreciation	123	70	121	107	89	97	86	636	942
Interest	36	138	196	171	234	257	281	335	378
Other Income	8	11	48	31	58	49	67	95	205
PBT before EO expense	**-304**	**1,485**	**1,318**	**759**	**175**	**1,092**	**1,391**	**2,338**	**3,424**
Extra-Ord expense	0	0	0	0	0	0	0	-27	0
PBT after EO exp	**-304**	**1485**	**1318**	**759**	**175**	**1092**	**1391**	**2,311**	**3,424**
Tax	-73	409	360	232	98	322	410	670	1,062
Rate (%)	24.10	27.54	27.31	30.52	56	29.50	29.50	29	29
Minority Interest & P/L of Asso. Cos.	6	-22	50	-60	-74	-45	-55	-25	-234
Reported PAT	**-237**	**1,098**	**908**	**587**	**151**	**815**	**1,035**	**1,666**	**2,596**
Adj PAT	**-237**	**1,098**	**908**	**587**	**151**	**815**	**1,035**	**1,669**	**2,589**
YoY Change (%)	NA	NA	NA	-347.7	-86.2	NA	14.0		55.1

Century Plyboards

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	CPBI IN
Equity Shares (m)	222
M.Cap.(INRb)/(USDb)	144.4 / 1.5
52-Week Range (INR)	859 / 618
1, 6, 12 Rel. Per (%)	-13/-20/-10
12M Avg Val (INR M)	79
Free float (%)	28.2

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	54.0	68.6	77.4
EBITDA	6.5	9.0	11.0
Adj. PAT	2.7	3.8	5.6
Adj. EPS (INR)	12.2	17.1	25.0
EPS Gr. (%)	36.1	40.9	45.9
BV/Sh. (INR)	117.3	132.9	155.9
Ratios			
RoE (%)	10.4	12.9	16.0
RoCE (%)	11.5	14.7	16.6
Payout (%)	8.5	8.8	8.0
Valuations			
P/E (x)	53.7	38.1	26.1
P/BV (x)	5.6	4.9	4.2
EV/EBITDA (x)	24.9	18.0	14.7
Div. Yield (%)	0.2	0.2	0.3

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	71.8	71.8	72.6
DII	19.5	19.4	18.1
FII	3.6	3.9	4.3
Others	5.1	4.9	5.0

CMP: INR650 TP: INR750 (+15%) Buy

Plywood margin may moderate in 2H

In-line 2QFY27; revenue/EBITDA/PAT grew 28%/32%/46% YoY

- Century Plyboards (CPBI) reported an in-line result in 2QFY27.
- Revenue/EBITDA/PAT grew 28%/32%/46% YoY, while EBITDA margin stood at 12.9%, up ~30bp YoY and QoQ.
- Plywood segment continued to report strong results, with revenue growth of 29% YoY and EBITDA margin of 15.8%.
- MDF and Particle Board continued to drag down overall margins.

Key highlights from the management commentary

- Plywood margin may moderate in 2H owing to increased spending on marketing.
- Plywood capacity is fully utilized; recently commissioned a 60k cbm greenfield plant at Hoshiarpur, which is planned to scale up to 100k cbm within six months.
- MDF: Margin may remain under pressure till capacity addition continues in the industry; expects to achieve 20% EBITDA margin in FY29.
- Laminate segment is expected to revive strongly, aided by the launch pipeline of refreshed products and realignment of distribution channel.
- Took 2-3% price hike in plywood w.e.f. Nov'26.
- Current debt is at its peak; expects reduction in coming years using internal cash flows
- Land is acquired in Uttar Pradesh for plywood manufacturing, and MDF is still in process.
- Major capex programs beyond FY28 are not finalized yet. The plans to set up a facility in Odisha for Plywood and Particle Board are still in early stages and will start after two years.

Valuation and view

- After an in-line result in 2Q, we cut our earnings estimates by 5-8% owing to lower other income and a higher effective tax rate, while we kept revenue and EBITDA broadly unchanged.
- Over FY26-28E, we now expect CPBI to clock a CAGR of 20%/30%/43% in revenue/EBITDA/APAT.
- RoE/RoCE (pre-tax) is expected to remain muted at ~16% each in FY28 due to the ongoing heavy capex programs.
- Given CPBI's leadership position in its key building product segments and high earnings growth expectations, we reiterate our BUY rating on CPBI with a TP of INR750, based on 30x FY28E EPS.
- Any weakness in the Plywood business poses downside risk to our call.

Quarterly performance

(INR m)

	FY26				FY27				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Net Sales	**11,694**	**13,855**	**13,501**	**14,922**	**15,614**	**17,800**	**16,791**	**18,667**	**53,972**	**68,592**	**17,229**	**3**
YoY Change (%)	16.3	17.1	18.4	24.5	33.5	28.5	24.4	25.1	19.2	27.1	24.3	
Total Expenditure	10,412	12,109	11,798	13,148	13,636	15,503	14,473	16,023	47,468	59,635	14,993	
EBITDA	**1,282**	**1,746**	**1,702**	**1,774**	**1,978**	**2,297**	**2,318**	**2,645**	**6,504**	**8,957**	**2,236**	**3**
Margins (%)	11.0	12.6	12.6	11.9	12.7	12.9	13.8	14.2	12.1	13.1	13.0	
Depreciation	367	476	483	495	541	567	577	587	1,821	2,272	**551**	
Interest	222	311	313	290	296	339	334	329	1,135	1,299	**291**	
Other Income	19	19	17	47	22	21	23	25	102	91	24	
PBT before EO expense	**712**	**979**	**924**	**1,037**	**1,163**	**1,412**	**1,430**	**1,753**	**3,651**	**5,477**	**1,418**	
Extra-Ord expense	0	0	-76	-1	0	0	0	0	-77	0	0	
PBT	**712**	**979**	**848**	**1,036**	**1,163**	**1,412**	**1,430**	**1,753**	**3,574**	**5,477**	**1,418**	**0**
Tax	182	269	197	242	330	376	379	465	890	1,549	**369**	
Rate (%)	25.6	27.5	23.3	23.3	28.4	26.6	26.5	26.5	24.9	28.3	26.0	
Minority Interest	-11	-20	-12	-13	-30	-29	-30	-30	-56	-119	-12	
Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	**519**	**689**	**639**	**781**	**803**	**1,008**	**1,021**	**1,259**	**2,627**	**3,809**	**1,037**	**-3**
Adj PAT	**519**	**689**	**715**	**781**	**803**	**1,008**	**1,021**	**1,259**	**2,704**	**3,809**	**1,037**	**-3**
YoY Change (%)	8.6	72.4	22.3	48.9	54.9	46.2	42.8	61.1	36.1	40.9	50.6	
Margins (%)	4.4	5.0	5.3	5.2	5.1	5.7	6.1	6.7	5.0	5.6	6.0	

E: MOSL Estimates

Blue Jet Healthcare

Estimate changes	⟷
TP change	⟷
Rating change	⟷

Bloomberg	BLUEJET IN
Equity Shares (m)	189
M.Cap.(INRb)/(USDb)	109.1 / 1.2
52-Week Range (INR)	648 / 325
1, 6, 12 Rel. Per (%)	-1/15/-1
12M Avg Val (INR M)	355

Financial Snapshot			(INR b)
Y/E March	FY26	FY27E	FY28E
Sales	9.5	12.6	14.2
EBITDA	2.9	4.0	4.8
PAT	2.5	3.3	3.8
EPS (INR)	13.1	17.7	20.3
EPS Gr. (%)	-18.8	35.0	15.0
BV/Sh.(INR)	78.4	130.3	148.9
Ratios			
Net D:E	-0.1	-0.3	-0.4
RoE (%)	19.9	17.5	14.6
RoCE (%)	20.1	17.3	14.4
Payout (%)	8.4	8.4	8.4
Valuations			
P/E (x)	44.0	32.6	28.3
P/BV (x)	7.3	4.4	3.9
EV/EBITDA (x)	33.5	25.0	20.6
Div. Yield (%)	0.2	0.3	0.3
FCF Yield (%)	1.1	-1.9	1.5

Shareholding pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	73.2	73.2	79.8
DII	7.5	9.1	3.6
FII	0.8	0.6	1.8
Others	18.6	17.1	14.7

FII includes depository receipts

CMP: INR576 TP: INR710 (+23%) Buy

Healthy order visibility supports growth; input costs weigh on margins

Operating performance above our estimate

- Blue Jet Healthcare (BLUEJET) reported revenue growth of 2.3x YoY and 28% QoQ, driven by strong growth in pharma intermediates (PI) and contrast media intermediates. PI revenue (~49% of sales) rose 4.2x YoY, while contrast media intermediates revenue (~39% of sales) grew 80% YoY. This was partially offset by a 19% YoY decline in high-intensity sweeteners (7% of sales).
- Going ahead, we expect BLUEJET's growth to be supported by a strong PI order book, the ramp-up of commercial central nervous system (CNS) and oncology products, and steady demand in contrast media. Price increases with select customers from 3QFY27 should aid margin recovery, while Mahad's commissioning in 2HFY27 should strengthen backward integration and cost competitiveness.
- We largely retain our FY27E/FY28E earnings despite the significant beat in 2Q, as we tone down our 2HFY27 gross margin assumption (from +350bp YoY to flat), reflecting higher crude prices than last year. **We value the stock at 35x FY28E EPS to arrive at a TP of INR710. Reiterate BUY**.

Strong revenue growth; price hikes ease cost pressures

- BLUEJET reported revenue of INR3.8b in 2QFY27, up 2.3x/28% YoY/QoQ (est. INR2.4b). Pharma intermediates (PI)/contrast media intermediates revenue grew 4.2x/80% YoY to INR1.8b/INR1.5b, while high-intensity sweeteners' revenue declined 19% YoY to INR277b.
- On a QoQ basis, PI/ Contrast Media Intermediates revenue grew 51%/25%, while high-intensity sweeteners' revenue declined 30%.
- Gross margin stood at 48.5% (-16.5pp YoY, -470bp QoQ).
- As a percentage of sales, employee costs stood at ~5% (vs. ~11% in 2QFY26), while other expenses stood at ~12% (vs. ~21% in 2QFY26).
- EBITDA stood at INR1.2b (est. INR805m), up 2.2x/21% YoY/QoQ. EBITDA margin was 31.6% (-160bp YoY, -190bp QoQ).
- Adj. PAT stood at INR1b (up 97% YoY, up 31% QoQ), in line with our estimate of INR628m.
- In 1HFY27 Revenue/EBITDA/Adj. PAT grew 29%/23%/26% YoY to INR6.7b/INR2.2b/INR1.8b
- Cash outflow from operations stood at INR256m in 1HFY27 vs CFO of INR2.1b in 1HFY26.

Highlights from the management commentary

- **Guidance and margin outlook:** Healthy order visibility across contrast media and PI supports the 2HFY27 outlook, although shipment timing and product mix may drive quarterly fluctuations. Price increases with select customers from 3QFY27 should partly offset higher raw-material, reagent, and solvent costs. Sequential margin recovery will depend on input-price stability and the extent of cost pass-through.

- **Contrast media and forward integration:** Existing production volumes remain steady, while forward integration into iodinated intermediates should meaningfully improve realizations and margins. Mahad's key starting material (KSM) facility remains on track for commissioning in 2H, strengthening backward integration and supply security. A new contrast media intermediate was delivered and validated for an innovator, although the underlying molecule remains in late-stage clinical development.
- **Peptides and R&D:** BLUEJET is entering the peptides business through building blocks and fragments, with further integration dependent on customer requirements. Supplies for the new innovator program remain at the trial/validation stage. The Hyderabad R&D center is operational with ~50 scientists and plans to install ~100 fume hoods across two phases, expanding capabilities across complex chemistry platforms.

Valuation and view

- We believe BLUEJET is well placed to sustain growth as its PI portfolio expands and integration in the contrast media segment deepens. Profitability should gradually improve as revised customer pricing offsets part of the input-cost pressure and commissioning at Mahad strengthens cost competitiveness.
- We expect a CAGR of 22%/28%/25% in revenue/EBITDA/PAT over FY26-28. **We value the stock at 35x FY28E EPS to arrive at a TP of INR710. Reiterate BUY.**

Standalone - Quarterly Snapshot (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27 2QE	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Gross Sales	**3,548**	**1,655**	**1,924**	**2,347**	**2,931**	**3,757**	**2,586**	**3,327**	**9,473**	**12,601**	**2,439**	**54%**
YoY Change (%)	*117.8*	*-20.5*	*-39.4*	*-31.1*	*-17.4*	*127.1*	*34.4*	*41.8*	*-7.9*	*33.0*	*47.4*	
Total Expenditure	2,338	1,105	1,455	1,634	1,950	2,570	1,878	2,160	6,532	8,558	1,635	
Gross Margin (%)	*48.4%*	*65.0%*	*51.7%*	*56.4%*	*53.2%*	*48.5%*	*52.0%*	*56.0%*	*54.0%*	*52.3%*	*56.1%*	
EBITDA	**1,210**	**549**	**469**	**713**	**981**	**1,188**	**707**	**1,167**	**2,941**	**4,043**	**805**	**48%**
Margin (%)	*34.1*	*33.2*	*24.4*	*30.4*	*33.5*	*31.6*	*27.4*	*35.1*	*31.0*	*32.1*	*33.0*	
Depreciation	57	59	60	65	67	69	75	80	240	291	70	
Interest	7	46	3	6	7	6	15	15	62	43	15	
Other Income	83	243	132	229	152	262	138	224	687	777	120	
PBT before EO expense	**1,229**	**687**	**538**	**871**	**1,059**	**1,374**	**755**	**1,296**	**3,325**	**4,485**	**840**	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	**1,229**	**687**	**538**	**871**	**1,059**	**1,374**	**755**	**1,296**	**3,325**	**4,485**	**840**	
Tax	317	166	136	228	277	349	189	325	847	1,140	211	
Rate (%)	*25.8*	*24.1*	*25.3*	*26.2*	*26.1*	*25.4*	*25.0*	*25.0*	*25.5*	*25.4*	*25.2*	
MI & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	**912**	**521**	**402**	**643**	**783**	**1,025**	**566**	**972**	**2,478**	**3,346**	**628**	
Adj. PAT	**912**	**521**	**402**	**643**	**783**	**1,025**	**566**	**972**	**2,478**	**3,346**	**628**	**63%**
YoY Change (%)	*141.3*	*-10.6*	*-59.0*	*-41.6*	*-14.2*	*96.6*	*41.0*	*51.0*	*-18.5*	*35.0*	*20.5*	
Margin (%)	*25.7*	*31.5*	*20.9*	*27.4*	*26.7*	*27.3*	*21.9*	*29.2*	*26.2*	*26.6*	*25.8*	

Indo Count

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	ICNT IN
Equity Shares (m)	198
M.Cap.(INRb)/(USDb)	99.2 / 1.1
52-Week Range (INR)	537 / 217
1, 6, 12 Rel. Per (%)	3/70/83
12M Avg Val (INR M)	311
Free float (%)	41.2

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	41.4	56.7	66.7
EBITDA	3.9	7.4	9.1
EBITDA (%)	9.5	13.0	13.6
Adj. PAT	1.3	3.9	5.1
EPS (INR)	6.4	19.5	25.7
EPS Gr.%	(49.3)	205.6	31.4
BV/Sh. (INR)	118.9	134.6	155.1
Ratios			
Net D/E	0.6	0.4	0.3
RoE (%)	5.5	15.4	17.7
RoCE (%)	5.0	10.7	12.6
Payout (%)	31.3	20.0	20.0
Valuations			
P/E (x)	78.3	25.6	19.5
P/B (x)	4.2	3.7	3.2
EV/EBITDA (x)	28.7	15.1	12.0
Div. yield (%)	0.4	0.8	1.0

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	58.8	58.8	58.8
DII	6.1	5.8	5.3
FII	10.7	10.1	10.0
Others	24.5	25.3	26.0

CMP: INR501 TP: INR635 (+27%) Buy

Strong growth; momentum to sustain in 2HFY27

Indo Count (ICNT)'s revenue grew 57% YoY to INR16.7b in 2QFY27, led by 33% growth in the core business and 177% growth in the new business. Bed linen volumes rose 12% YoY, partly aided by the execution of orders delayed in 1Q. EBITDA grew 125% YoY, with margins expanding to 13.9%, driven by revenue growth and operating leverage despite higher RM costs. Management retained its FY27 revenue targets of INR40b for the core and INR15b for the new businesses. The Bhilad facility was hit by flooding, with INR450m inventory loss and a corresponding insurance claim recognized as exceptional items; insurers have approved an interim payment of INR150m.

Strong growth across core and new businesses

ICNT's revenue jumped 57% YoY to INR16.7b in 2QFY27, with the new business surging 177% YoY to INR5b, while the core business grew 33% YoY. Bed linen had strong volumes growth at 12% YoY reaching 28m mtrs of sales, partly driven by the fulfillment of orders delayed in 1Q because of container unavailability. Bed linen realizations grew 19% YoY and 17% QoQ to INR426 per mtr, led by market share gains, increased wallet share and an improvement in the product mix in the core business which had deteriorated in 1Q. Utilization for the quarter was 73% for the core business. Utilization at all three utility bedding facilities in the US combined stood at 65%. ICNT has also expanded Wamsutta's presence beyond D2C into the broader US retail market. 1H revenue growth stood at 42%, with the core business growing 17% YoY, while the new business surged 186% YoY. Bed linen volumes grew 5% YoY, while realizations grew 12% YoY. Management expects momentum to sustain in 2H, and remains confident of achieving INR40b revenue in the core business and INR15b revenue in the new business, with bed linen volumes of 105-110m mtrs.

Higher RM costs impacts gross margins, EBITDA Margin improved 420bp

In 1Q, gross margin contracted 260bp YoY and 500bp QoQ, hit by higher cotton and cotton yarn prices. Gross margins are expected to improve as cotton and cotton yarn prices ease. EBITDA grew 125% YoY to INR2.3b, with EBITDA margin at 13.9% (+420bp YoY), despite employee expenses and other expenses growing 55% and 25% YoY, respectively. The strong growth was primarily driven by robust topline growth and partly supported by operating leverage from the scale-up of the new business. We expect gross and EBITDA margins to reach 53.6% and 13.6%, respectively, by FY28, driven by new business ramp-up.

Valuation and view: Reiterate Buy

We expect ICNT's growth to be driven by new business, followed by the core business with the latter expected to post a 15% CAGR over FY26-28, while the new business is well positioned to deliver ~67% growth. We expect a CAGR of 27%/52%/100% in revenue, EBITDA, and PAT, respectively, over FY26-28. We have raised our earnings estimates and reiterate our BUY rating with a revised TP of INR635, valuing the stock at 15x FY28E EV/EBITDA. Key risks: customer and geographic concentration and commodity price movements. (refer to our IC note dated Jun'26).

Consolidated - Quarterly performance (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	2Q FY27E	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Net Sales	**9,587**	**10,621**	**10,628**	**10,577**	**12,070**	**16,727**	**14,348**	**13,544**	**41,413**	**56,688**	12,958	29.1
YoY Change (%)	1.8	2.5	-7.7	3.4	25.9	57.5	35.0	28.0	-0.2	36.9	22.0	
Gross Profit	**5,142**	**5,625**	**5,675**	**6,054**	**6,678**	**8,425**	**7,461**	**7,027**	**22,495**	**29,591**	7,114	18.4
Total Expenditure	8,477	9,585	9,718	9,714	10,636	14,396	12,485	11,801	37,494	49,318	11,423	26.0
EBITDA	**1,110**	**1,037**	**910**	**863**	**1,434**	**2,330**	**1,863**	**1,742**	**3,920**	**7,369**	1,535	51.8
Margin (%)	11.6	9.8	8.6	8.2	11.9	13.9	13.0	12.9	9.5	13.0	11.8	
Depreciation	380	392	394	426	453	464	465	445	1,592	1,827	460	0.8
Interest	311	318	295	436	316	366	315	306	1,360	1,302	318	15.1
Other Income	86	194	114	300	170	262	250	239	695	922	194	35.0
PBT before EO items	**505**	**521**	**335**	**302**	**835**	**1,763**	**1,333**	**1,231**	**1,663**	**5,162**	951	85.4
Extraordinary Loss	0	0	0	0	0	0	0	0	0	0	0	
PBT	**505**	**521**	**335**	**302**	**835**	**1,763**	**1,333**	**1,231**	**1,663**	**5,162**	951	85.4
Tax	115	130	91	60	203	444	333	310	396	1,291	228	94.5
Rate (%)	22.8	25.0	27.1	19.8	24.3	25.2	25.0	25.2	23.8	25.0	24.0	
JV and Associates												
Reported PAT	**390**	**390**	**244**	**242**	**632**	**1,319**	**1,000**	**920**	**1,267**	**3,872**	723	82.5
Adj PAT	**390**	**390**	**244**	**242**	**632**	**1,319**	**1,000**	**920**	**1,267**	**3,872**	723	82.5
YoY Change (%)	-49.8	-51.4	-67.6	116.5	62.0	237.7	309.4	280.3	-49.3	205.6	85.1	
Margin (%)	4.1	3.7	2.3	2.3	5.2	7.9	7.0	6.8	3.1	6.8	5.6	

Galaxy Surfactants

Estimate changes	↓
TP change	↓
Rating change	↔

Bloomberg	GALSURF IN
Equity Shares (m)	35
M.Cap.(INRb)/(USDb)	76.7 / 0.8
52-Week Range (INR)	2697 / 1510
1, 6, 12 Rel. Per (%)	-16/13/0
12M Avg Val (INR M)	64

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	52.5	67.8	66.2
EBITDA	4.8	7.3	6.5
PAT	2.8	4.5	3.8
EPS (INR)	78	126	106
EPS Gr. (%)	-9.1	61.2	-15.6
BV/Sh. (INR)	774	868	947
Ratios			
Net D:E	-0.0	-0.1	-0.2
RoE (%)	10.8	15.3	11.7
RoCE (%)	11.0	15.6	12.0
Payout (%)	25.6	25.6	25.6
Valuations			
P/E (x)	27.9	17.3	20.5
P/BV (x)	2.8	2.5	2.3
EV/EBITDA (x)	16.0	10.3	11.1
Div. Yield (%)	0.9	1.5	1.2
FCF Yield (%)	2.6	3.3	5.8

Shareholding pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	70.9	70.9	70.9
DII	13.2	13.5	12.9
FII	3.9	3.8	4.2
Others	12.0	11.8	12.0

FII includes depository receipts

CMP: INR2,163 TP: INR2,660 (+23%) Buy

Strong operating performance, driven by volume growth and premium mix

Strong beat on our estimates

- Galaxy Surfactants (GALSURF) delivered a strong 2QFY27 performance, with EBITDA surging 72%, while EBITDA/kg jumped 56% YoY to ~INR26, driven by operating leverage, an improved Specialty Care mix, and sustained demand for premium offerings across domestic and international markets.
- Backed by a strong 1H performance and an upward revision in FY27 EBITDA/KG guidance from INR24-25 to INR26-27, we raise our FY27 earnings estimates by 11%. However, we cut our FY28 estimates by 17%, as synthetic surfactants are expected to become more economically attractive than palm-kernel-oil-derived surfactants amid the expected normalization of crude oil prices. **Reiterate BUY with a TP of INR2,660 (based on 25x FY28E EPS).**

Healthy volume growth supports topline momentum

- Consol. revenue grew 37% YoY to INR18.1b (est. INR15.8b), primarily led by consolidated volumes registering high-single-digit YoY growth, driven by strong mid-teens growth in India and the AMET regions.
- Revenue from India/Rest of World (ROW)/AMET grew 31%/47%/30% YoY to ~INR7.8b/INR4b/INR5.8b. Revenue from local and niche/MNC/regional players grew 37%/37%/37% YoY to INR1.4b/INR8.7b/INR8b.
- The revenue contribution of Performance Surfactants now stands at 65% compared with 63% in 2QFY26.
- EBITDA margin stood at 10.5% vs. 8.3% in 2QFY26, led by a 300bp expansion in gross margin to 27.5%. Employee costs as a % of sales stood at 5.8% (vs. 6.1% in 2QFY26), while other expenses stood at 11.3% (vs. 10.1% in 2QFY26).
- EBITDA stood at INR1.9b (est. INR1.5b), up 72% YoY and Adj. PAT stood at INR1.2b (est. INR868m), up 80% YoY.
- In 1HFY27, revenue/EBITDA/Adj. PAT grew 38%/87%/96% YoY to INR35.9b/INR4.4b/INR2.9b.
- Gross debt stood at INR2.3b as of Sep'26 vs. INR1.6b as of Sep'25.

Key highlights from the management commentary

- **Guidance:** Management anticipates exiting the year on a stronger footing, and achieving the higher end of its 6-8% volume growth guidance while raising full-year EBITDA/KG guidance to INR26-27 from INR24-25, supported by a favorable mix and operating leverage.
- **India**: India delivered strong volume growth of 16% across both Performance Surfactants and Specialty Care segments, driven by healthy demand across Tier-1, non-Tier-1 and D2C customers. Demand momentum remains encouraging, supported by sustained premiumization, with consumers increasingly shifting toward higher-performance and differentiated products, driving growth across the company's portfolio.

- **International:** AMET delivered strong mid-teens volume growth on both YoY and QoQ bases, supported by healthy demand across Tier-1 and non-Tier-1 customers, with improving demand conditions and stronger customer engagement despite geopolitical uncertainties in West Asia and inflationary pressures. In contrast, ROW volumes declined ~9%, primarily due to supply-chain disruptions in APAC and Europe, while premium and masstige Specialty Care volumes in the Americas remained resilient.

Valuation and view

- While the macro environment remained challenging in 2Q, marked by significant feedstock volatility, the company's disciplined execution, supply chain agility, and diversified portfolio enabled it to navigate external headwinds effectively and emerge stronger.
- Going forward, we expect GALSURF's growth to be driven by 1) the company's consistent focus on R&D and innovation, 2) growing domestic demand led by the recovery in Tier 1 customers, 3) likely growth recovery in AMET, 4) expanding global operations, and 5) a strong pipeline of new products.
- We expect a CAGR of 12%/17%/17% in revenue/EBITDA/adj. PAT, along with a volume CAGR of 6% over FY26-28. Backed by a strong 1H performance and the upward revision in FY27 EBITDA/KG guidance from INR24-25 to INR26–27, we raise our FY27 earnings estimates by 11%. However, we cut our FY28 estimates by 17%, as synthetic surfactants are expected to become more economically attractive than palm-kernel-oil-derived surfactants due to the expected normalization of crude oil prices. **Reiterate BUY with a TP of INR2,660 (based on 25x FY28E EPS).**

Consolidated - Quarterly Snapshot **(INR m)**

Y/E March	FY26				FY27				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Gross Sales	**12,779**	**13,262**	**13,295**	**13,147**	**17,819**	**18,104**	**15,941**	**15,903**	**52,483**	**67,766**	**15,755**	**15%**
YoY Change (%)	31.2	24.8	27.6	14.8	39.4	36.5	19.9	21.0	24.3	29.1	18.8	
Total Expenditure	11,541	12,157	12,101	11,931	15,327	16,209	14,417	14,483	47,730	60,437	14,253	
Gross Margin (%)	26.2%	24.5%	24.9%	25.8%	29.3%	27.5%	26.3%	26.0%	25.4%	27.3%	25.8%	
EBITDA	**1,239**	**1,105**	**1,194**	**1,216**	**2,492**	**1,895**	**1,523**	**1,419**	**4,753**	**7,330**	**1,502**	**26%**
Margin (%)	9.7	8.3	9.0	9.3	14.0	10.5	9.6	8.9	9.1	10.8	9.5	
Depreciation	293	298	307	332	360	347	400	450	1,230	1,557	380	
Interest	66	73	85	85	93	100	110	115	309	417	90	
Other Income	112	58	48	3	33	64	75	80	221	251	60	
PBT before EO expense	**992**	**792**	**849**	**802**	**2,072**	**1,512**	**1,088**	**934**	**3,435**	**5,607**	**1,092**	
Extra-Ord expense	0	0	119	0	0	0	0	0	119	0	0	
PBT	**992**	**792**	**730**	**802**	**2,072**	**1,512**	**1,088**	**934**	**3,316**	**5,607**	**1,092**	
Tax	197	127	141	178	413	315	223	192	643	1,142	224	
Rate (%)	19.9	16.0	19.3	22.1	19.9	20.8	20.5	20.5	19.4	20.4	20.5	
Reported PAT	**795**	**665**	**590**	**624**	**1,659**	**1,198**	**865**	**743**	**2,674**	**4,465**	**868**	
Adj PAT	**795**	**665**	**686**	**624**	**1,659**	**1,198**	**865**	**743**	**2,770**	**4,465**	**868**	**38%**
YoY Change (%)	-0.3	-21.5	6.1	-17.7	108.7	80.1	26.2	19.0	-9.2	61.2	30.6	
Margin (%)	6.2	5.0	5.2	4.7	9.3	6.6	5.4	4.7	5.3	6.6	5.5	

G R Infraprojects

Estimate change	⟷
TP change	⟷
Rating change	⟷

Bloomberg	GRINFRA IN
Equity Shares (m)	97
M.Cap.(INRb)/(USDb)	76.2 / 0.8
52-Week Range (INR)	1175 / 730
1, 6, 12 Rel. Per (%)	-9/-19/-27
12M Avg Val (INR M)	71

Financials & Valuations (INR b)

Y/E Mar	2026	2027E	2028E
Sales	76.2	92.4	106.9
EBITDA	8.3	10.2	13.9
APAT	8.1	8.0	11.5
EBITDA (%)	10.9	11.0	13.0
EPS (INR)	83.3	82.7	119.0
EPS Gr. (%)	11.6	-0.7	43.8
BV/Sh. (INR)	916.6	999.3	1118.3
Ratios			
Net D/E	0.0	-0.1	-0.1
RoE (%)	9.6	8.6	11.2
RoCE (%)	9.5	8.8	11.3
Payout (%)	4.0	0.0	0.0
Valuations			
P/E (x)	9.4	9.5	6.6
P/BV (x)	0.9	0.8	0.7
EV/EBITDA (x)	8.6	6.2	4.6
Div Yield (%)	0.0	0.0	0.0
FCF Yield (%)	-1.4	19.4	5.2

Shareholding pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	74.7	74.7	74.7
DII	19.6	19.5	19.4
FII	2.3	2.5	2.9
Others	3.5	3.4	3.1

FII includes depository receipts

CMP: INR788 TP: INR980 (+24%) Buy

Strong execution drives earning; order pipeline remains strong

- Revenue rose ~64% YoY to ~INR20.1b during 2QFY27 (33% above our estimate).
- EBITDA grew 59% YoY to INR1.91b (26% above our estimate). EBITDA margin stood at 9.5% in 2QFY27 (-30bp YoY). APAT rose ~23% YoY to INR1.61b (25% above our estimate).
- During 1HFY27, Revenue/EBITDA/APAT grew 45%/31%/5%.
- The order book currently stands at ~INR246b, with road projects accounting for 69% of the order book.
- GRINFRA reported strong execution in 2QFY27; however, margins remained under pressure. Nevertheless, the order book is robust, anchored by road projects and supported by increasing traction in new segments such as oil & gas, railways, power transmission, and tunneling. **We largely maintain our estimates for FY27/FY28 and expect GRINFRA to clock a revenue and EBITDA CAGR of 18% and 29%, respectively, over FY26-28. We reiterate our BUY rating with an SoTP-based TP of INR980.**

Robust order book, sector diversification, and strong financial discipline

- The order book stood at ~INR246b as of Sept'26. The road segment continues to dominate (69% of the order book), but the company is steadily diversifying into oil and gas, railways, metros, power transmission, hydro, tunneling, and telecom.
- The company expects FY27 order inflows of ~INR200b, comprising ~INR140-150b from roads and ~INR35-40b from power transmission.
- The company's standalone debt-equity stood at 0.04x, among the best in the sector. Consolidated net debt-equity stood at 0.53x.

Key takeaways from the management commentary

- In 2QFY27, the company delivered strong execution, driving robust revenue growth of 64% YoY.
- EBITDA margins remain under pressure due to higher construction costs arising from geopolitical disruptions and elevated crude-linked commodity prices. Management indicated a 1.5-2.0% impact on margins from higher input costs, including steel, cement, aggregates, and transportation.
- Working capital days increased to 152 (vs. 98 as of Sept'25), driven primarily by higher debtor days.
- Management indicated that investments in subsidiaries stood at INR31b as of Sept'26, with equity commitment of INR5b expected in 2HFY27, while the balance equity commitment of INR26-27b for HAM/BOT projects is expected to be invested over FY28 and FY29.
- Monetization of 5-6 completed HAM assets could unlock approximately INR12.5b of invested equity during FY27.

Valuation and view

- While the company has a healthy order book and provides strong order inflow guidance, an improving bidding environment (lower competition and tighter prequalification norms), coupled with a strong balance sheet, provides visibility for sustainable growth.
- We expect GRINFRA to clock a revenue and EBITDA CAGR of 18% and 29%, respectively, over FY26-28. **Reiterate our BUY rating with an SoTP-based TP of INR980.**

Quarterly Performance (Standalone) **(INR m)**

Y/E March (INR m)	FY26				FY27E				FY26	FY27E	FY27	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Variance
Net Sales	**18,261**	**12,337**	**20,395**	**25,209**	**24,234**	**20,191**	**21,440**	**26,550**	**76,202**	**92,415**	**15,206**	**33%**
YoY Change (%)	(3.7)	9.4	39.4	29.7	32.7	63.7	5.1	5.3	18.5	21.3	23.3	
EBITDA	**2,311**	**1,204**	**2,054**	**2,734**	**2,671**	**1,916**	**2,358**	**3,220**	**8,303**	**10,166**	**1,521**	**26%**
Margins (%)	12.7	9.8	10.1	10.8	11.0	9.5	11.0	12.1	10.9	11.0	10.0	
Depreciation	524	510	491	457	440	427	500	594	1,984	1,961	475	
Interest	119	113	101	100	133	56	110	116	432	415	130	
Other Income	1,163	1,184	1,276	988	641	728	750	817	4,610	2,936	800	
PBT before EO expense	**2,830**	**1,764**	**2,738**	**3,165**	**2,740**	**2,160**	**2,498**	**3,327**	**10,498**	**10,725**	**1,716**	
Extra-Ord expense	-	-	411	2,121	-	-	-	-	2,532	-	-	
PBT	**2,830**	**1,764**	**3,149**	**5,286**	**2,740**	**2,160**	**2,498**	**3,327**	**13,029**	**10,725**	**1,716**	
Tax	672	456	828	1,113	703	550	629	837	3,069	2,719	432	
Rate (%)	23.7	25.8	26.3	21.1	25.7	25.4	25.2	25.2	23.6	25.4	25.2	
Reported PAT	**2,158**	**1,308**	**2,322**	**4,173**	**2,036**	**1,610**	**1,870**	**2,490**	**9,961**	**8,007**	**1,284**	
Adj PAT	**2,158**	**1,308**	**2,013**	**2,582**	**2,036**	**1,610**	**1,870**	**2,490**	**8,062**	**8,007**	**1,284**	**25%**
YoY Change (%)	14.2	12.7	53.8	(9.8)	(5.6)	23.1	(7.1)	(3.6)	11.6	(0.7)	(1.9)	
Margins (%)	11.8	10.6	9.9	10.2	8.4	8.0	8.7	9.4	10.6	8.7	8.4	

Cera Sanitaryware

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	CRS IN
Equity Shares (m)	13
M.Cap.(INRb)/(USDb)	61.9 / 0.7
52-Week Range (INR)	6740 / 4398
1, 6, 12 Rel. Per (%)	-14/-12/-20
12M Avg Val (INR M)	104
Free float (%)	45.6

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	20.5	24.5	27.5
EBITDA	2.7	3.2	3.8
Adj. PAT	2.1	2.5	3.1
Adj. EPS (INR)	164.4	193.2	242.5
EPS Gr. (%)	-14.5	17.6	25.5
BV/Sh. (INR)	1,141.6	1,254.8	1,407.3
Ratios			
RoE (%)	14.4	15.4	17.2
RoCE (%)	19.0	20.8	23.8
Payout (%)	47.4	41.4	37.1
Valuations			
P/E (x)	29.2	24.9	19.8
P/BV (x)	4.2	3.8	3.4
EV/EBITDA (x)	20.1	17.0	13.7
Div. Yield (%)	1.6	1.7	1.9

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	54.4	54.4	54.4
DII	14.1	14.1	13.6
FII	15.7	15.5	15.8
Others	15.8	16.1	16.2

CMP: INR4,802 TP: INR6,304 (+31%) Buy

Volume-driven growth to sustain; margins to expand

A mixed-bag quarter: Healthy revenue but soft margins

- Cera Sanitaryware (CRS) reported a mixed operating performance in 2QFY27, with healthy revenue growth offset by soft margins.
- Revenue grew 24% YoY and was a 7% beat on our estimate. Revenue was volume-led and driven by strong growth in sanitary-ware (up 24% YoY, 45% mix) and faucet-ware (up 38% YoY, 43% mix) segments.
- Gross margin stood at 44%, contracting 528bp YoY and 189bp QoQ.
- EBITDA grew 9% YoY (in line). EBITDA margin stood at 12.2%, contracting 203bp YoY and expanding 202bp QoQ.
- Consequently, PAT declined 1% YoY and missed our estimate by 6%.
- The net WC cycle remained under tight control (58 days vs. ~75 days YoY).
- The company maintained a healthy cash balance of ~INR9b.

Key highlights from the management commentary

- **Guidance:** The company expects strong volume traction to sustain in 2H, alongside an improvement in margins (13-14%), aided by the full pass-through of RM cost inflation.
- 2Q revenue growth was led by strong volumes in newer markets (UP, Bihar, Jharkhand, etc.), offsetting some weakness in traditional markets.
- 2Q revenue growth (up 27% YoY) levers: volume 16.6%, pricing 9.1%, mix 1.7%.
- 2Q sanitary-ware revenue (up 24% YoY) levers: volume 14.3%, pricing 6.7%, mix 2.7%.
- 2Q faucet-ware revenue (up 38% YoY) levers: volume 24%, pricing 10.3%, mix 1.9%.
- Th company took an 8% price hike in faucet-ware from Sep, following a rise in brass cost.
- Cumulative price hike: Sanitary-ware 12%, faucet-ware 24%.
- New project business contracts are being secured at better pricing.
- Project revenue contribution stood at 39% and is expected to remain stable at ~40%.
- Sanitary-ware capacity utilization stood at 82%, while faucet-ware capacity was increased by 100k units to 500k.

Valuation and view

After a mixed-bag results in 2Q, we reduce our FY27/28 earnings estimate by 5%/1% owing to lower margin expectations. We now estimate a 16%/19%/21% CAGR in revenue/EBITDA/APAT over FY26-28, with an EBITDA margin of 13-14%, in line with CRS's guidance. However, a high cash surplus of ~INR9b and a strong annual FCF of ~INR1.5b will restrict RoE (~17%) and pre-tax RoCE (~24%). **On a reasonable valuation of ~20x FY28E P/E, we reiterate our BUY rating on CRS with a TP of INR6,304, based on 26x FY28E P/E. A slower-than-expected recovery in sales and margins poses key risks to our positive view on the stock.**

Quarterly performance

(INR m)

	FY26				FY27E				FY26	FY27E	FY27	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Net Sales	**4,339**	**4,734**	**4,990**	**6,438**	**4,860**	**6,030**	**6,231**	**7,404**	**20,501**	**24,525**	**5,654**	**7**
YoY Change (%)	8.3	-3.9	11.1	11.4	12.0	27.4	24.9	15.0	7.0	19.6	15.9	
Total Expenditure	3,808	4,063	4,479	5,459	4,368	5,297	5,409	6,275	17,809	21,348	4,903	
EBITDA	**531**	**671**	**511**	**979**	**492**	**733**	**822**	**1,129**	**2,692**	**3,177**	**751**	**-2**
Margins (%)	12.2	14.2	10.2	15.2	10.1	12.2	13.2	15.3	13.1	13.0	13.3	
Depreciation	91	98	98	99	94	98	101	104	387	396	97	
Interest	14	16	20	14	13	14	15	15	65	56	15	
Other Income	186	166	114	63	213	109	120	120	529	562	150	
PBT before EO expense	**612**	**722**	**507**	**929**	**598**	**730**	**827**	**1,130**	**2,769**	**3,286**	**789**	
Extra-Ord expense	0	0	-185	107	0	0	0	0	-78	0	0	
PBT	**612**	**722**	**322**	**1,035**	**598**	**730**	**827**	**1,130**	**2,691**	**3,286**	**789**	**-7**
Tax	146	156	86	262	145	169	203	277	649	793	193	
Rate (%)	23.9	21.6	26.6	25.3	24.2	23.1	24.5	24.5	24.1	24.1	24.5	
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	
Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	**466**	**566**	**237**	**773**	**453**	**561**	**624**	**853**	**2,042**	**2,492**	**595**	**-6**
Adj PAT	**466**	**566**	**421**	**667**	**453**	**561**	**624**	**853**	**2,120**	**2,492**	**595**	**-6**
YoY Change (%)	-1.0	-16.7	-8.1	-23.4	-2.7	-0.9	48.2	28.0	-14.5	17.6	5.1	
Margins (%)	10.7	12.0	8.4	10.4	9.3	9.3	10.0	11.5	10.3	10.2	10.5	

E: MOFSL Estimates

Campus Activewear

Estimate change	⟷
TP change	⟷
Rating change	⟷

Bloomberg	CAMPUS IN
Equity Shares (m)	306
M.Cap.(INRb)/(USDb)	61.2 / 0.6
52-Week Range (INR)	287 / 182
1, 6, 12 Rel. Per (%)	-10/-21/-23
12M Avg Val (INR M)	161

Financials & Valuations (INR b)

Y/E March	FY27E	FY28E	FY29E
Sales	20.5	23.6	27.1
EBITDA	3.3	4.0	4.9
Adj. PAT	1.8	2.2	2.8
EBITDA Margin (%)	16.0	17.0	18.0
Adj. EPS (INR)	5.7	7.3	9.2
EPS Gr. (%)	16.6	27.4	26.6
BV/Sh. (INR)	33.8	39.1	45.8
Ratios			
Net D:E	0.1	0.0	-0.1
RoE (%)	18.0	20.0	21.7
RoCE (%)	16.2	17.8	19.3
Payout (%)	35.0	34.3	27.1
Valuations			
P/E (x)	34.9	27.4	21.6
EV/EBITDA (x)	19.1	15.3	12.4
EV/Sales (X)	3.1	2.6	2.2
Div. Yield (%)	1.0	1.3	1.3

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	72.1	72.1	72.1
DII	10.8	11.4	11.8
FII	5.8	6.0	6.0
Others	11.3	10.5	10.1

FII includes depository receipts

CMP: INR200 **TP: INR290 (+45%)** **Buy**

Volume-led growth; premiumization supports ASP expansion

- Despite the festive shift, Campus' revenue grew 17% YoY (vs. our estimate of ~15%), led by ~10% YoY volume growth and ~6% YoY increase in ASP.
- Gross margin contracted 245bp YoY (~160bp miss) due to RM inflation flowing through ahead of price hikes. EBITDA margin contracted 35bp (~35bp beat), aided by lower A&P spends. The company implemented price hikes in Oct'26 to mitigate RM inflationary pressures.
- Management retained its mid-teen FY27 revenue growth guidance and expects to deliver ~17% EBITDA margin (including other income), which implies ~18-19% margins in 2H (similar to 2HFY26), with any RM deflation providing further upside.
- We fine-tune our FY27-28 estimates and model FY26-29 revenue/EBITDA/PAT CAGRs of ~15%/19%/23%, with EBITDA margin expanding ~155bp to ~18% by FY29.
- **Reiterate BUY with a revised TP of INR290, based on 33x Dec'28E EPS.**

Robust 2Q; operating leverage offsets RM pressures

- 2Q revenue grew 17% YoY to INR4.52b (in line), led by ~10% volume growth to 6.3m pairs and ~6% ASP growth to INR713.
  - Volume growth remained healthy despite the festive shift to 3Q, while ASP benefited from price hikes and premiumization.
  - D2C online/offline grew ~23%/~11% YoY, while trade distribution grew ~14%.
  - Within D2C online, own website (~6.4% contribution) and quick commerce (2.4%) doubled their share of revenue in 1HFY27.
  - Women's and Kids' volumes grew ~29% YoY in 1HFY27, increasing their contribution to 23% of total volumes.
- Gross profit grew 12% YoY to INR2.3b (~2% miss), as gross margin contracted ~245bp YoY to 50.9% (~160bp miss).
- EBITDA grew 14% YoY to INR568m (+5% beat), with margins contracting 35bp YoY to 12.6% (+35bp beat), as lower employee (12% YoY) and other expenses (10% YoY) and an 11% decline in A&P spends offset GM pressure.
- PAT grew ~21% YoY to INR243m (+7% beat), with PAT margin expanding ~20bp YoY to 5.4% (~30bp beat). Lower depreciation and finance costs supported earnings, partly offset by lower other income.
- 1H revenue grew ~15% YoY, led by ~11% volume growth and 3% YoY ASP hike.
- Gross profit rose ~12% YoY as GM contracted ~115bp YoY to 52.8%.
- Reported EBITDA grew 12% YoY as margin contracted ~25bp YoY to 13.3%, with ~3% YoY decline in A&P spends partly offsetting gross margin pressure.
- Adjusted pre-IND AS EBITDA rose ~18% YoY to INR0.86b, with margin expanding ~25bp YoY to 10.2%.

- 1H's reported PAT grew 19% YoY, with margin expanding ~25bp YoY to 6%.
- The implied ask-rate for 2HFY27 revenue/EBITDA/PAT growth stands at 16%/12%/16%.

Festive working capital build-up weighs on FCF generation in 1HFY27

- Campus' net working capital (NWC) days rose ~20 days YoY to 109 in 1HFY27, driven by higher inventory days (122 vs. 110 YoY) and lower payable days (49 vs. 58 YoY), with receivable days stable YoY at 37.
- Absolute NWC rose 40% YoY to INR5.6b in 1HFY27 (vs. 15% revenue growth). Inventory rose 26% YoY to INR6.3b.
- Adjusted OCF (post interest and leases) **outflow stood at INR1b in 1HFY27 (vs. INR545m outflow** YoY), due to a working capital build-up of INR1.65b (vs. INR1.07b YoY).
- **Capex moderated to INR229m in** 1HFY27 (vs. INR1b YoY, land purchase), leading to an FCF (post interest and leases) outflow of INR1.25b (vs. INR1.59b outflow YoY).

Key takeaways from the management commentary

- **Guidance:** Management reiterated the guidance of mid-teen revenue growth. It has guided for 17% EBITDA margin (including other income) for FY27, which implies ~18-19% EBITDA margin in 2H (similar to LY), driven by pricing, mix, and operating leverage, with any RM cost deflation providing a further upside.
- **Promoter stake:** The promoter family has no plans to sell its stake in the foreseeable future, addressing the recent stock overhang.
- **Women's and Kids':** Volumes grew 27%/34%, respectively, in 1HFY27, increasing their revenue contribution to 22.7% (up 100bp). Kids' category is expected to follow the growth trajectory witnessed in women's category, led by school shoes and expansion into younger age groups and sports footwear.

Valuation and view

- Campus is expanding beyond its core category of sports shoes into sneakers, performance footwear, women's, and kids' categories. Sharper segmentation, affordability-led positioning and ongoing operational initiatives are supporting stronger execution and improving product mix.
- We fine-tune our FY27-29 estimate and model FY26-29E revenue/EBITDA/PAT CAGRs of ~15%/19%/23%, with EBITDA margin expanding ~155bp to ~18% by FY29.
- Further, management indicated that there is no plan for a promoter stake sale over the medium term, seeking to assuage investors' concerns about a potential stake sale.
- **We reiterate our BUY rating with an unchanged TP of INR290, based on 33x Dec'28 EPS.**

Valuation based on Dec'28E P/E

Particulars	INR/Share
EPS	8.7
Target PE (x)	33
Equity value/share (INR)	**290**
CMP (INR)	200
Upside/(Downside) (%)	46%

Source: MOFSL, Company

Valuation summary

	CMP	M.Cap	FY26-29E CAGR (%)			P/E (X)			EV/EBITDA (x)			RoE (%)		
	(INR)	INR b	Sales	EBITDA	PAT	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
VMM	94	440	18.4	23.7	26.1	43.7	33.9	26.2	27.7	21.3	16.1	12.7	14.3	15.9
V2 Rel	153	56	34.7	31.8	38.8	28.3	20.0	13.9	16.2	11.0	8.1	17.9	20.2	22.5
V-Mart	772	61	18.6	27.9	35.8	38.8	26.3	19.7	20.4	15.3	12.0	15.4	19.0	20.8
Value Retailers			**21.3**	**25.7**	**29.1**	**40.9**	**30.8**	**23.3**	**24.7**	**18.5**	**14.1**	**15.3**	**17.9**	**19.8**
D-Mart	3,406	2,222	16.3	16.1	16.2	65.6	56.1	47.7	40.0	34.3	29.4	13.3	13.5	13.8
Trent	3,080	1,642	20.9	27.6	26.9	74.2	57.9	46.2	45.0	35.1	28.0	29.0	29.3	29.0
Lenskart	734	1,276	26.8	45.3	57.5	131.4	89.6	61.2	74.9	53.5	39.5	10.4	13.5	16.9
Vedant fashions	515	125	5.9	10.5	7.8	32.0	28.7	26.5	23.3	19.8	17.7	20.0	20.9	20.8
ABLBL	77	93	9.2	7.3	14.5	36.0	32.5	30.0	14.9	13.5	12.0	17.2	16.8	16.4
Arvind fas	361	48	11.6	17.7	25.4	30.5	21.6	16.7	13.2	10.6	8.9	15.7	19.1	20.9
Shoppers Stop	357	39	10.7	27.5	NA	96.5	39.1	28.7	16.9	13.2	11.3	10.9	13.5	13.9
Go Fashion	267	14	7.6	15.7	15.0	27.3	19.6	15.6	13.1	8.6	6.2	6.6	8.4	10.0
Traditional retailers			**13.3**	**19.6**	**24.0**	**52.5**	**40.0**	**31.8**	**28.9**	**22.5**	**18.1**	**14.4**	**15.8**	**16.7**
Metro	874	238	13.3	12.3	11.3	53.7	47.4	41.7	35.8	31.1	26.9	20.7	20.5	20.4
Relaxo	294	73	6.6	9.5	14.1	35.2	28.9	26.7	21.6	17.4	15.6	9.2	10.5	10.7
Bata	641	82	7.0	8.9	17.0	38.9	32.4	25.0	18.0	14.9	14.5	13.0	15.0	18.4
Campus	207	63	15.2	22.8	23.4	36.1	28.3	22.4	20.7	16.4	12.6	18.0	20.0	21.7
Footwear			**10.5**	**13.4**	**16.5**	**41.0**	**34.3**	**28.9**	**24.0**	**20.0**	**17.4**	**15.2**	**16.5**	**17.8**

Consolidated Quarterly Earnings

(INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Revenue	**3,433**	**3,866**	**5,886**	**4,556**	**3,852**	**4,521**	**6,918**	**5,187**	**17,741**	**20,478**	**4,455**	**1.5**
YoY Change (%)	1.2	16.0	14.3	12.3	12.2	16.9	17.5	13.8	11.4	15.4		
Gross Profit	**1,875**	**2,062**	**3,097**	**2,345**	**2,118**	**2,300**	**3,535**	**2,634**	**9,378**	**10,587**	**2,339**	-1.7
Gross margin	54.6	53.3	52.6	51.5	55.0	50.9	51.1	50.8	52.9	51.7	52.5	-3
Total Expenditure	2,940	3,367	4,784	3,732	3,305	3,953	5,683	4,260	14,822	17,202	3,911	1.1
EBITDA	**493**	**499**	**1,103**	**825**	**547**	**568**	**1,235**	**927**	**2,919**	**3,277**	**543**	**4.6**
EBITDA margins (%)	14.4	12.9	18.7	18.1	14.2	12.6	17.9	17.9	16.5	16.0	12.2	
Depreciation	201	219	224	239	226	239	250	262	883	977	249	-4.1
Interest	49	62	73	59	48	51	57	71	243	227	58	-12.0
Other Income	61	52	55	61	80	51	90	45	228	266	67	-23.5
PBT	**304**	**270**	**861**	**588**	**353**	**330**	**1,017**	**639**	**2,022**	**2,339**	**304**	**8.6**
Tax	82	69	224	146	92	87	256	155	521	589	76	13.3
Rate (%)	26.9	25.5	26.0	24.9	25.9	26.2	25.2	24.2	25.8	25.2	25.2	
Reported PAT	**222**	**201**	**637**	**441**	**261**	**243**	**761**	**484**	**1,501**	**1,751**	**227**	**7.0**
Adj PAT	**222**	**201**	**637**	**441**	**261**	**243**	**761**	**484**	**1,501**	**1,751**	**227**	**7.0**
YoY Change (%)	-13	40	37	26	18	21	20	10	23.9	16.6		

E: MOFSL Estimates

Safari Industries

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	SII IN
Equity Shares (m)	49
M.Cap.(INRb)/(USDb)	61.3 / 0.6
52-Week Range (INR)	2507 / 1155
1, 6, 12 Rel. Per (%)	-13/-11/-36
12M Avg Val (INR M)	118
Free float (%)	55.3

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	20.5	22.9	26.3
EBITDA	2.7	2.6	3.3
Adj. PAT	1.7	1.6	2.1
EPS (INR)	34.2	31.7	42.1
EPS Gr.%	17.2	-7.4	32.7
BV/Sh. (INR)	227.5	256.0	293.7
Ratios			
Net D:E	-0.1	-0.2	-0.3
RoE (%)	16.2	13.1	15.3
RoCE (%)	13.2	10.3	12.1
Payout (%)	11.7	10.3	10.3
Valuations			
P/E (x)	36.5	39.4	29.7
P/B (x)	5.5	4.9	4.3
EV/EBITDA (x)	22.0	22.9	17.1
Div. yield (%)	0.3	0.3	0.3

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	44.7	44.7	44.9
DII	28.5	28.3	26.1
FII	11.0	10.6	12.3
Others	15.8	16.5	16.7

CMP: INR1,251 **TP: INR1,800 (+44%)** **Buy**

Revenue in line; margins hit by raw material inflation

Safari Industries (SII) reported revenue in line with expectations in 2QFY27. Consolidated revenue grew 9.1% YoY to INR5.8b (-1.1% QoQ). Raw material inflation hurt profitability. Gross margin contracted ~280bp YoY to 44.3%. EBITDA declined 19.3% YoY to INR597m, and EBITDA margin contracted ~360bp YoY (~255bp QoQ) to 10.3%. PAT fell 21.3% YoY to INR369m. For 1HFY27, revenue grew 10.3% YoY to INR11.7b, while EBITDA fell 11.9% to INR1.35b (margin of 11.5%, -290bp YoY) and PAT fell 13.1% to INR847m. The Board approved capex of up to INR1.7b for SII and up to INR0.6b for its subsidiary Safari Manufacturing (SML). The SML investment will increase monthly capacity from 1.0m to 1.6m pieces by Jun'28 and will be funded through internal accruals. We estimate a revenue CAGR of ~13% over FY26-28, with EBITDA margin recovering from ~11.2% in FY27 to ~12.8% in FY28 as price hikes catch up with input costs. The Board declared an interim dividend of INR2/share.

Higher volumes driving growth

Growth remains intact, though at a moderated pace. Revenue grew 9.1% YoY in 2Q, slightly slower than 1Q (+10.3%), with growth mainly volume-led. The 5-6% price hike in April has not fully offset the sharp rise in PP/PC prices amid the West Asia crisis. SML is operating at 100% utilization of its existing 1m pieces/month, constraining further volume until additional capacity comes onstream. The approved addition of 0.6m pieces/month (+60%) is expected to ease this constraint from FY29 onwards. The INR1.7b standalone capex toward infrastructure and land for a new warehouse is expected to support distribution and growth of the premium and Urban Jungle portfolios.

Margins under pressure

Gross margin contracted ~280bp YoY and ~30bp QoQ to 44.3%, as PP/PC inflation outpaced pricing actions. Staff costs increased 17.3% YoY to 7.1% of sales, partly due to higher ESOP expenses of INR71m in 1H vs INR19m in 1HFY26, while other expenses rose 10.4%. Consequently, EBIT declined 27.6% YoY to INR409m, with higher depreciation and interest costs contributing to a 24% decline in PBT despite a 25.7% increase in other income. Operating cash flow declined sharply to INR16m in 1H from INR616m in 1HFY26, primarily due to an INR1.5b increase in receivables since Mar'26, alongside INR372m of short-term debt. However, net cash remains healthy at ~INR 2.4b, providing adequate headroom to fund planned capex through internal accruals.

Valuation and view: Reiterate BUY

We expect SII to deliver industry-leading growth and gain market share by focusing on: 1) strengthening the Urban Jungle brand along with SI-Select (premium positioning), 2) expanding SML capacity and warehousing infrastructure, 3) introducing new SKUs, and 4) steadily expanding its exclusive brand outlet (EBO) network. While we remain confident about SII's growth prospects, rising competitive intensity from VIP, Samsonite, and D2C players, along with input-cost volatility, could weigh on near-term performance. We factor in FY27E EBITDA margin of ~11.2% and FY28E margin of ~12.8%, and reiterate our BUY rating with a DCF-based TP of INR 1,800. Key risks: Prolonged raw-material inflation and aggressive discounting by regional competitors.

Consol. Qtrly performance (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	2QFY27E	v/s Est (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Net Sales	**5,278**	**5,336**	**5,124**	**4,733**	**5,886**	**5,822**	**5,841**	**5,392**	**20,470**	**22,942**	**6,189**	**-5.9**
YoY Change (%)	17.3	16.5	15.7	12.4	11.5	9.1	14.0	13.9	15.5	12.1	16.0	
Gross Profit	**2,416**	**2,511**	**2,382**	**2,335**	**2,623**	**2,577**	**2,599**	**2,410**	**9,643**	**10,209**	**2,754**	**-6.4**
Total Expenditure	4,486	4,595	4,567	4,115	5,132	5,225	5,210	4,809	17,762	20,376	5,434	-3.8
EBITDA	**793**	**740**	**557**	**618**	**754**	**597**	**631**	**584**	**2,708**	**2,566**	**755**	**-20.9**
Margin (%)	15.0	13.9	10.9	13.1	12.8	10.3	10.8	10.8	13.2	11.2	12.2	
Depreciation	174	176	177	179	190	188	195	218	706	792	193	-2.4
Interest	22	21	23	20	25	24	23	20	86	93	20	22.0
Other Income	58	58	61	71	72	72	70	71	248	285	75	-3.6
PBT before EO items	**654**	**601**	**417**	**491**	**611**	**457**	**483**	**416**	**2,163**	**1,966**	**617**	**-26.0**
Extraordinary Inc / (Exp)	0	0	0	0	0	0	0	0	0	0	0	
PBT	**654**	**601**	**417**	**491**	**611**	**457**	**483**	**416**	**2,163**	**1,966**	**617**	**-26.0**
Tax	150	133	89	116	133	87	97	96	486	413	148	-41.0
Rate (%)	22.8	22.1	21.2	23.6	21.8	19.1	20.0	23.1	22.4	21.0	24.0	
JV and Associates	0	0	0	0	0	0	0	0			0	
Reported PAT	**505**	**469**	**329**	**375**	**478**	**369**	**386**	**320**	**1,678**	**1,553**	**469**	**-21.2**
Adj PAT	**505**	**469**	**329**	**375**	**478**	**369**	**386**	**320**	**1,678**	**1,553**	**469**	**-21.2**
YoY Change (%)	13.7	58.0	5.6	-0.3	-5.4	-21.2	17.4	-14.5	17.5	-7.4	0.1	
Margin (%)	9.6	8.8	6.4	7.9	8.1	6.3	6.6	5.9	8.2	6.8	7.6	

Exhibit 1: Changes to our estimates (INR m)

INR m	Old		New		Change (%)	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Revenue	23,460	26,850	22,942	26,253	-2.2	-2.2
EBITDA	3,138	3,663	2,566	3,349	-18.2	-8.6
EBITDA margin %	13.4	13.6	11.2	12.8		
PAT	1,933	2,273	1,553	2,062	-19.6	-9.3
EPS	39.4	46.4	31.7	42.1	-19.6	-9.3

Source: MOFSL, Company

JK Lakshmi Cement

Estimate change	↓
TP change	⟷
Rating change	⟷

Bloomberg	JKLC IN
Equity Shares (m)	124
M.Cap.(INRb)/(USDb)	58.7 / 0.6
52-Week Range (INR)	883 / 452
1, 6, 12 Rel. Per (%)	-7/-29/-40
12M Avg Val (INR M)	124

Financial Snapshot (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	67.6	76.2	81.9
EBITDA	10.1	9.3	11.6
Adj. PAT	4.3	3.2	4.1
EBITDA Margin (%)	14.9	12.2	14.2
Adj. EPS (INR)	34.3	25.9	33.3
EPS Gr. (%)	34.4	-24.5	28.5
BV/Sh. (INR)	313	332	358
Ratios			
Net D:E	0.3	0.5	0.7
RoE (%)	11.5	8.0	9.7
RoCE (%)	9.7	7.1	7.9
Payout (%)	19.1	27.4	20.7
Valuations			
P/E (x)	13.8	18.3	14.2
P/BV (x)	1.5	1.4	1.3
EV/EBITDA(x)	7.3	8.2	7.6
EV/ton (USD)	43	41	41
Div. Yield (%)	1.4	1.5	1.5
FCF Yield (%)	6.9	-7.6	-11.3

Shareholding pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	45.1	45.1	45.1
DII	25.3	26.6	22.8
FII	8.7	8.6	12.6
Others	20.8	19.7	19.5

FII Includes depository receipts

CMP: INR473 TP: INR640 (+35%) Buy

In-line EBITDA; target 2H volume growth in line with industry

Demand and pricing improves; scales back expansion plans

- JK Lakshmi Cement's (JKLC) 2QFY27 operating performance was in line with our estimate. EBITDA declined ~26% YoY to INR1.5b. EBITDA/t declined ~29% YoY to INR517 (est. of INR490). OPM contracted 4.1pp YoY 9.5%. Adj. profit declined 75% YoY to INR205m (-24% vs. our estimate, led by lower-than-estimated other income and higher-than-estimated ETR).
- Management highlighted that demand improved in Oct'26 and anticipates volume growth at ~7%-8% YoY in 2H, in line with the industry. Cement prices (both trade/non-trade) also improved in Oct'26, with a further hike expected post festive season alongside a pickup in demand. Fuel costs are estimated to further increase during 2HFY27. It has revised its capacity expansion target to 25mtpa by FY30 from the earlier target of 30mtpa, prioritizing balance sheet discipline over aggressive expansion.
- We maintain our EBITDA estimate for FY27-FY28. However, we cut our EPS by ~12%/5% for FY27E/FY28 on account of lower other income. We value the stock at 9x FY28E EV/EBITDA to arrive at a TP of INR640. **Reiterate BUY.**

Sales volume rises 5% YoY; realization/t increases ~1% YoY

- Consolidated revenue/EBITDA/adj. PAT stood at INR16.2b/INR1.5b/INR205m (+6/-26%/-75% YoY and +4%/+4%/-24% vs. our estimates). Volume grew 5% YoY to 3.0mt (in line). Realization/t rose ~1%/2% YoY/QoQ to INR5,420/t.
- Opex/t rose ~5% YoY, led by an increase in variable cost/other expenses per ton by ~13%/10% YoY. Employee cost/Freight cost/t declined ~10%/7% YoY. OPM contracted 4.1pp YoY to ~9.5%, and EBITDA/t declined ~29% YoY to INR517 in 2QFY27. Depreciation/interest cost rose ~9%/1% YoY. Other income declined ~56% YoY.
- In 1HFY27, revenue/EBITDA/PAT stood at INR35.2b/INR4.1b/INR1.3b (+8%/-21%/-44% YoY). OPM contracted 4.2pp YoY to ~12%. EBITDA/t declined 26% YoY to INR627. Operating cash outflow stood at INR1.0b vs. operating cash inflow of INR3.5b in 1HFY26. Capex stood at INR5.1b vs. INR2.5b in 1HFY26. Net cash outflow stood at INR6.2b vs. FCF at INR991.4m in 1HFY26.

Highlights from the management commentary

- Management indicated that demand started improving toward the latter part of Sep'26 and remained encouraging in Oct'26. It expects to achieve industry-level volume growth of ~7-8% in 2HFY27.
- It indicated that fuel cost increased to INR1.82/kcal in 2QFY27 from INR1.54/kcal in 1QFY27. It expects fuel cost to rise further to INR2.00/kcal in 3QFY27 and INR2.15–2.20/kcal in 4QFY27, assuming the current cost environment persists.
- It has reconfigured its Eastern expansion plans. The revised Eastern expansion of 4.6mtpa comprises 1.6mtpa at Durg, 1.5mtpa at Madhubani (Bihar), and 1.5mtpa in West Bengal. Capex is pegged at INR15.0b for FY27 and INR20.0b over the subsequent two years.

Valuation and view

- JKLC's 2QFY27 operating performance was in line with estimates. However, PAT was below estimates due to lower other income. Profitability is likely to improve in 2H, driven by price action, positive operating leverage, and cost optimization measures. However, elevated fuel costs remains a key concern. Going forward, the progress on its expansions in the Eastern region and improvement in capacity utilization will be key monitorables.
- We estimate a CAGR of ~10%/7% in revenue/EBITDA over FY26-28. We estimate EBITDA/t at INR663/INR777 in FY27/FY28 vs. INR757 in FY26, and a volume CAGR of ~6% over FY26-28. We expect net debt to increase to INR30.5b by FY28 vs. INR20.3b as of Sep'26, with net debt-to-EBITDA ratio at 2.6x in FY28 vs. 2.3x as of Sep'26. The stock is trading at 8x FY27E/FY28E (each) EV/EBITDA. We value the stock at 9x FY28E EV/EBITDA to arrive at a TP of INR640. **Reiterate BUY.**

Quarterly performance (consolidated) **(INR b)**

Y/E March	FY26				FY27E				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Sales Volumes (mt)	3.33	2.84	3.28	3.90	3.60	2.98	3.40	4.03	13.35	14.01	3.02	(1)
YoY Change (%)	10.0	14.8	8.3	8.3	8.2	4.9	3.6	3.5	10.0	5.0	6.3	
Net Sales	**17.4**	**15.3**	**15.9**	**19.0**	**19.0**	**16.2**	**18.8**	**22.2**	**67.6**	**76.2**	**15.6**	4
YoY Change (%)	11.3	24.1	6.1	0.2	9.4	5.6	18.4	16.6	9.2	12.7	1.9	
EBITDA	**3.1**	**2.1**	**2.1**	**2.9**	**2.6**	**1.5**	**2.2**	**3.0**	**10.1**	**9.3**	**1.5**	4
YoY Change (%)	39.9	133.3	1.7	(18.5)	(16.9)	(26.0)	5.2	4.8	16.9	(8.1)	(26.0)	
Margin (%)	17.9	13.6	12.9	15.0	13.6	9.5	11.5	13.5	14.9	12.2	9.5	4
Depreciation	0.8	0.8	0.9	0.8	0.8	0.8	0.9	0.9	3.2	3.4	0.9	(1)
Interest	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	2.1	2.2	0.5	(2)
Other Income	0.2	0.2	0.3	0.4	0.2	0.1	0.2	0.2	1.1	0.6	0.2	(57)
PBT before EO expense	**2.0**	**1.0**	**0.9**	**1.9**	**1.4**	**0.3**	**0.9**	**1.7**	**5.9**	**4.3**	**0.3**	(17)
Extra-Ord. expense	-	-	0.2	-	-	-	-	-	0.2	-	-	
PBT	**2.0**	**1.0**	**0.8**	**1.9**	**1.4**	**0.3**	**0.9**	**1.7**	**5.7**	**4.3**	**0.3**	(17)
Tax	0.5	0.2	0.2	0.5	0.3	0.1	0.2	0.5	1.5	1.1	0.1	
Prior period tax adj.	-	-	-	-	-	-	-	-	-	-	-	
Rate (%)	26.5	21.5	24.2	27.6	23.6	28.6	26.0	26.5	25.7	25.6	26.0	
Reported PAT	**1.5**	**0.8**	**0.6**	**1.4**	**1.1**	**0.2**	**0.6**	**1.3**	**4.2**	**3.2**	**0.3**	(20)
Minority Interest	(0.0)	(0.0)	0.0	0.1	(0.0)	(0.0)	(0.0)	(0.0)	0.1	(0.0)	(0.0)	
Adj. PAT	**1.5**	**0.8**	**0.7**	**1.2**	**1.1**	**0.2**	**0.7**	**1.3**	**4.3**	**3.2**	**0.3**	(24)
YoY Change (%)	62.6	NM	(4.7)	(29.4)	(28.1)	(74.6)	(7.0)	2.4	36.6	(24.5)	(66.5)	
Per ton analysis (INR)												
Net realization	**5,234**	**5,388**	**4,841**	**4,881**	**5,294**	**5,420**	**5,529**	**5,500**	**5,067**	**5,437**	**5,167**	5
RM Cost	922	942	952	1,000	1,111	1,095	1,040	1,010	956	1,062	1,050	4
Employee Expenses	374	457	352	286	355	410	375	318	361	361	424	(3)
Power, Oil, and Fuel	1,137	1,295	1,131	1,077	1,190	1,444	1,564	1,515	1,152	1,428	1,290	12
Freight and Handling Outward	1,194	1,235	1,119	1,122	1,151	1,154	1,190	1,199	1,163	1,175	1,130	2
Other Expenses	672	725	662	661	769	800	725	715	678	749	783	2
Total Expenses	**4,299**	**4,655**	**4,216**	**4,146**	**4,575**	**4,904**	**4,894**	**4,756**	**4,310**	**4,774**	**4,676**	5
EBITDA	**936**	**733**	**625**	**734**	**719**	**517**	**635**	**744**	**757**	**663**	**490**	5

Source: Company, MOFSL

VRL Logistics

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	VRLL IN
Equity Shares (m)	175
M.Cap.(INRb)/(USDb)	54.7 / 0.6
52-Week Range (INR)	348 / 225
1, 6, 12 Rel. Per (%)	1/22/20
12M Avg Val (INR M)	69

Financial Snapshot (INR b)

Y/E MARCH	2026	2027E	2028E
Sales	32.2	38.3	41.8
EBITDA	6.5	8.3	8.5
Adj. PAT	2.4	3.7	3.8
EBITDA Margin (%)	20.2	21.6	20.4
Adj. EPS (INR)	13.5	22.3	22.7
EPS Gr. (%)	29.5	64.5	2.0
BV/Sh. (INR)	65.3	70.5	84.9
Ratios			
Net D:E	0.4	0.3	0.1
RoE (%)	21.3	31.2	28.6
RoCE (%)	18.7	24.8	22.8
Payout (%)	35.1	0.0	52.9
Valuations			
P/E (x)	23.1	14.1	13.8
P/BV (x)	4.8	4.4	3.7
EV/EBITDA(x)	8.7	6.7	6.3
Div. Yield (%)	1.6	0.0	3.8
FCF Yield (%)	6.9	8.1	8.5

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	60.2	60.2	60.2
DII	24.5	24.9	24.3
FII	3.7	2.7	4.0
Others	11.6	12.2	11.5

FII includes depository receipts

CMP: INR313 TP: INR400 (+28%) Buy

Strong 2Q performance; volume growth to drive earnings

- VRL's revenue grew 21% YoY to INR9.6b (7% above our estimate).
- EBITDA grew 46% YoY to INR2.2b in 2Q FY27 (17% above our estimate).
- EBITDA margin was 23% (+400bp YoY/+180bp QoQ) vs. our estimate of 21%.
- Driven by strong operating performance, APAT rose to INR 1.03b in 2Q FY27 v/s INR 499m in 2Q FY26 (32% above our estimate).
- During 1HFY27, Revenue/EBITDA/APAT grew by 19%/35%/84% YoY
- Volume grew 11% YoY to 1.08MT, driven by regaining customers lost during the earlier freight rate rationalization, adding new contractual customers, and exiting the low-margin business. Realization rose 9% YoY to INR8,840/ton.
- VRL delivered a strong performance in 2QFY27, driven by 9% higher realizations and 11% volume growth, with EBITDA margin reaching an all-time high of 23%. Going ahead, management remains focused on driving tonnage growth, while realizations are expected to remain broadly stable.
- We raise our FY27/FY28 APAT estimates by 14%/18%, factoring in healthy volume growth and sustained margins. We expect volume growth momentum to continue in FY27-28, supported by branch additions and higher tonnage from existing customers. **We expect VRL to clock a CAGR of 9% in volume and 14%/14%/26% in revenue/EBITDA/PAT over FY26-28. Reiterate BUY with a revised TP of INR400 (based on 18x FY28E EPS).**

Highlights from the management commentary

- Management expects to sustain the current realization level of around INR8,800/ton, with the next leg of revenue growth expected to be driven primarily by volume expansion.
- Fleet size stood at 5,941 vehicles in 2QFY27, up from 5,782 a year ago, with a net addition of 159 vehicles in line with volume growth. Of the total fleet, 11% is fully depreciated, while 76% is debt-free, reflecting a healthy asset profile.
- Management expects its expansion into untapped Eastern Indian markets, particularly West Bengal and Bihar, through new branch additions to gradually drive volume growth. An increase in average lead distance is also expected to support higher realizations over the medium term.
- For 2HFY27, management has guided for a total capex of ~INR1.5-1.6b vs INR1.6b in 1HFY27. This would be largely for vehicle procurement and expansion of owned logistics infrastructure.

Valuation and view

- Management expects to drive volume growth through higher volumes from existing customers and the addition of new clients while maintaining realizations at current levels and sustaining margins.
- We raise our FY27/FY28 APAT estimates by 14%/18%, factoring in healthy volume growth and sustained margins. We expect volume growth momentum to continue in FY27-28, supported by branch additions and higher tonnage from existing customers. **We expect VRL to clock a CAGR of 9% in volume and 14%/14%/26% in revenue/EBITDA/PAT over FY26-28. Reiterate BUY with a revised TP of INR400 (based on 18x FY28E EPS).**

Quarterly performance

Y/E March (INR m)	FY26				FY27E				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	vs Est
Net Sales	**7,443**	**7,970**	**8,270**	**8,529**	**8,788**	**9,619**	**9,782**	**10,141**	**32,211**	**38,331**	**9,028**	**7**
YoY Change (%)	2.4	-0.3	0.2	5.4	18.1	20.7	18.3	18.9	1.9	19.0	13.3	
EBITDA	**1,516**	**1,511**	**1,700**	**1,775**	**1,866**	**2,210**	**2,062**	**2,143**	**6,502**	**8,281**	**1,894**	**17**
Margins (%)	20.4	19.0	20.6	20.8	21.2	23.0	21.1	21.1	20.2	21.6	21.0	
YoY Change (%)	74.5	13.6	2.1	-4.9	23.1	46.2	21.3	20.8	13.5	27.4	25.3	
Depreciation	647	648	681	635	624	639	670	711	2,610	2,643	650	
Interest	262	242	219	227	227	239	240	240	950	946	260	
Other Income	65	70	38	64	60	47	65	84	237	256	60	
PBT before EO expense	**672**	**691**	**838**	**977**	**1,075**	**1,378**	**1,217**	**1,277**	**3,179**	**4,948**	**1,044**	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	**672**	**691**	**838**	**977**	**1,075**	**1,378**	**1,217**	**1,277**	**3,179**	**4,948**	**1,044**	
Tax	172	192	191	255	270	349	307	321	811	1,247	263	
Rate (%)	25.6	27.8	22.8	26.1	25.1	25.3	25.2	25.2	25.5	25.2	25.2	
Reported PAT	**500**	**499**	**648**	**721**	**805**	**1,030**	**910**	**956**	**2,368**	**3,701**	**781**	
Adj PAT	**500**	**499**	**648**	**721**	**805**	**1,030**	**910**	**956**	**2,368**	**3,701**	**781**	**32**
YoY Change (%)	272.4	39.2	9.0	-2.8	60.9	106.4	40.6	32.5	29.5	56.3	56.5	
Margins (%)	6.7	6.3	7.8	8.5	9.2	10.7	9.3	9.4	7.4	9.7	8.7	

Saatvik Green Energy

Estimate change	⟷
TP change	⟷
Rating change	⟷

Bloomberg	SAATVIK IN
Equity Shares (m)	127
M.Cap.(INRb)/(USDb)	45.6 / 0.5
52-Week Range (INR)	552 / 328
1, 6, 12 Rel. Per (%)	-20/-26/-
12M Avg Val (INR M)	94

Financial Snapshot (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	45.5	51.9	82.8
Sales Gr. %	110.7	14.1	59.5
EBITDA	5.4	3.8	11.7
EBITDA margin %	11.9	7.4	14.1
Adj. PAT	3.6	2.0	6.2
EPS (INR)	28.4	15.6	48.6
EPS Gr. (%)	46.3	(44.9)	210.7
BV/Sh. (INR)	107.1	122.7	171.3
Ratios			
ND/Equity	0.6	1.4	1.6
ND/EBITDA	1.5	5.5	2.9
RoE (%)	42.4	13.6	33.0
RoCE (%)	27.5	8.6	14.0
Valuations			
P/E (x)	12.6	22.9	7.4
EV/EBITDA (x)	9.9	17.4	6.8

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	76.0	76.0	76.0
DII	11.2	11.0	8.0
FII	0.1	0.2	0.5
Others	12.8	12.8	15.5

CMP: INR359 TP: INR470 (+31%) Buy

Margin improvement hinges on cell ramp-up

- Saatvik Green Energy (SGEL) reported a revenue of INR9b, 15% above our estimate, as module sales were 640MW (10% above our est. of 580MW). EBITDA came in 5% below our est. at INR443m due to a lower EBITDA margin of 4.9% vs our est. of 6%. APAT was 2x our est. at INR232m driven by substantially high other income (INR253m, +190% QoQ).
- **Key things we liked:** 1) the 2.4GW cell manufacturing capacity is scheduled for ALMM-II inspection in Sep'26, with production expected to commence in Dec'26 and full ramp-up by 4QFY27; 2) a strong order book of 6.7GW (INR88b), comprising 60% DCR and 40% non-DCR orders; and 3) management maintaining FY27 revenue guidance of INR60b and EBITDA margin guidance of 12%.
- **Key monitorables**: 1) ramp-up of the new 2.4GW cell manufacturing capacity and timely commissioning of the 3.6GW cell facility; 2) improvement in EBITDA margins as cell capacity ramps up; 3) revenue and EBITDA contribution from non-solar businesses, which management aims to increase to 15% of revenue by FY28 (currently 4–5%); and 4) new order momentum and pricing across both DCR and non-DCR segments.
- **Valuation:** We value SGEL at 8x FY28E EBITDA and, adjusting for net debt, we derive a TP of INR470, implying an upside of 31%.

Beat on revenue but margins contract

Financial Highlights

- Revenue stood at INR 9b (+18% YoY, +77% QoQ), 15% above our estimate as module sales stood at 640MW (10% above our est. of 580MW)
- EBITDA came in 5% below our est. at INR443m (-59% YoY, +31% QoQ) due to a lower EBITDA margin of 4.9% vs our est. of 6%.
- APAT was 2x our est. at INR232m (-72% YoY, +320% QoQ), driven by high other income (INR253m, +190% QoQ).
- An exceptional loss of INR26.3m due to a fire at its Ambala facility was recorded.

Operational Highlights

- Module production/sales stood at 658MW/640MW in 2QFY27, compared with 408MW/334MW in 1QFY27.
- Capacity utilization stood at 58.5% in 2QFY27 (vs. an implied 34% in 1QFY27)
- Order book stands at 6.7GW (INR88b) in 2QFY27, compared with 6.4GW (INR82b) in 1QFY27.
- Module capacity stands at 6.1GW at present. The 2.4GW cell facility's ALMM List-II inspection is expected in Nov'26.

Highlights of the 2QFY27 performance

- The Utility/C&I segments contributed ~55%/28% of 2Q revenue, while Retail contributed 12% and other businesses 4%, with the latter targeted to reach 15% of revenue over the next two years.
- Odisha Phase I operationalized 1.3GW of module capacity on 2nd Nov'26, with the remaining 2.7GW on track for commissioning in Dec'26 to reach a total module capacity of 8.8GW.
- The 2.4GW cell line at Odisha commenced trial runs, with ALMM List II inspection scheduled in Nov'26 and production ramp-up targeted by Dec'26.
- The FY27 annual guidance remained unchanged at ~INR60b revenue and 12% EBITDA margin, implying significant margin acceleration in H2FY27.
- The confirmed order book stood at 6.68GW (60% DCR / 40% non-DCR), bolstered by major wins from SECI (INR10.4b) and Vikram Engineering (INR4.7b).
- The next phases of backward integration are mapped out, with Phase 2 (3.6GW cell capacity, taking total capacity to 6GW) having broken ground, with commissioning targeted for FY28, and Phase 3 (6GW ingots/wafers) planned for FY29.
- Average realization was INR13.49/Wp in 2QFY27 and INR13.89/Wp in 1HFY27.

Valuation and view

- We value SGEL at 8x FY28E EBITDA and, adjusting for net debt, we derive a TP of INR470, implying an upside of 31%.

Consolidated performance (INRm)

Y/E March	FY26				FY27E				FY26	FY27E	FY27 2QE	Var. (%)	YoY (%)	QoQ (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE						
Net Sales	**9,157**	**7,680**	**12,570**	**16,077**	**5,110**	**9,026**	**13,284**	**24,474**	**45,484**	**51,895**	**7,820**	**15**	**18**	**77**
YoY Change (%)	272.3	61.6	142.6	74.9	-44.2	17.5	5.7	52.2	110.7	14.1	1.8			
Total Expenditure	7,387	6,597	11,086	15,000	4,772	8,583	12,393	22,318	40,069	48,066	7,353	17	30	80
EBITDA	**1,771**	**1,084**	**1,484**	**1,076**	**338**	**443**	**891**	**2,156**	**5,415**	**3,829**	**468**	**-5**	**-59**	**31**
Margin (%)	19.3	14.1	11.8	6.7	6.6	4.9	6.7	8.8	11.9	7.4	6.0			
Depreciation	125	137	147	233	134	149	225	346	642	855	164	-9	9	11
Interest	190	136	231	155	217	240	255	271	713	984	245	-2	76	11
Other Income	40	152	114	90	87	253	86	72	396	498	94	168	67	190
PBT before EO expense	**1,496**	**962**	**1,221**	**778**	**74**	**306**	**497**	**1,610**	**4,456**	**2,488**	**153**			
Extra-Ord income/(exp.)	0	0	0	-39	0	-26	0	0	-39	-26	0			
PBT	**1,496**	**962**	**1,221**	**738**	**74**	**280**	**497**	**1,610**	**4,417**	**2,462**	**153**	**83**	**-71**	**278**
Tax	307	130	274	134	20	78	90	319	845	507	37	108	-40	280
Rate (%)	21	13	22	18	28	28	18	20	19	21	24.4			
Minority Interest	0	0	0	-2	-1	-10	0	0	-2	-12	0.0			
Share of JV & associates	0	0	0	0	0	0	0	0	0	0	0			
Reported PAT	**1,188**	**832**	**946**	**606**	**55**	**213**	**408**	**1,291**	**3,573**	**1,966**	**116**	**83**	**-74**	**286**
Adj PAT	**1,188**	**832**	**946**	**638**	**55**	**232**	**408**	**1,291**	**3,605**	**1,987**	**116**	**100**	**-72**	**320**
YoY Change (%)	458.9	36.4	133.9	-32.6	-95.4	-72.2	-56.9	102.2	333.1	110.0	-86			
Margin (%)	13.0	10.8	7.5	4.0	1.1	2.6	3.1	5.3	7.9	3.8	1.5			

Ellenbarrie Industrial Gases

Estimate change	↓
TP change	↔
Rating change	↔

Bloomberg	ELLEN IN
Equity Shares (m)	141
M.Cap.(INRb)/(USDb)	44.1 / 0.5
52-Week Range (INR)	472 / 175
1, 6, 12 Rel. Per (%)	-15/15/-28
12M Avg Val (INR M)	167

Financials & Valuations (INR b)

Y/E Mar	FY27E	FY28E	FY29E
Sales	4.5	7.9	9.6
EBITDA	1.6	2.2	2.9
PAT	1.4	1.7	2.1
EPS (INR)	9.8	12.0	14.9
EPS Growth (%)	28.3	22.5	23.6
BV/Share (INR)	79.2	91.2	106.1
P/E (x)	31.8	26.0	21.0
P/BV (x)	4.0	3.4	2.9
EV/EBITDA (x)	28.4	21.2	15.8
EV/Sales (x)	10.3	6.0	4.7
RoE (%)	13.2	14.1	15.1
RoCE (%)	11.0	11.5	13.4

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	77.2	77.2	77.2
DII	8.8	11.6	14.4
FII	0.6	1.1	1.2
Others	13.5	10.2	7.3

Note: FII includes depository receipts

CMP: INR313 TP: INR400 (+28%) Buy

New capacity additions to support growth

EBITDA below estimate due to higher transport costs; Adj. PAT in line

- Ellenbarrie Industrial Gases (ELLEN) delivered a steady performance in 2QFY27, with EBITDA growing 20% YoY to INR402m on account of capacity ramp-up and increase in realizations marginally offset by a rise in power costs.
- We expect growth momentum to accelerate, driven by the ramp-up of the Uluberia-II facility and the East India on-site plant, alongside the upcoming North and Central India merchant plants, now expected to be operational by 2HFY28. Increasing contribution from argon is expected to provide an additional growth impetus.
- While we broadly maintain our FY27 earnings estimates, we lower our FY28 estimates by 7% to factor in delay in the commercialization of the North India plant (~220 TPD), which is now expected in 2HFY28. **We reiterate our BUY rating with a TP of INR400 (based on 30x Sep'28 EPS).**

Operating performance remains steady amid cost headwinds

- ELLEN reported a total revenue of INR1.1b (in line) in 2QFY27, up ~28% YoY.
- EBITDA margin stood at 35.2% (est. 39.3%) vs. 37.5% in 2QFY26. Margins contracted due to higher transport costs and salary hike arrears.
- EBITDA grew 20% YoY to INR402m (est. INR434m) for the quarter.
- Adj. PAT declined 3% YoY to INR356m (est. INR353m).
- In 1HFY27, Revenue/EBITDA/Adj. PAT grew 23%/21%/27% YoY to INR2.1b/INR779m/INR706m.
- Gross debt stood at INR1.4b as of Sep'26, compared to INR1.8b in Sep'26.
- CFO stood at INR436m in Sep'26 vs INR659m in Sep'25.
- **Gases and related products & services** grew 27% YoY to INR1.1b, while EBIT stood at INR433m, rising 20% YoY. EBIT margin stood at 39% (vs 41% in 2QFY26).
- **Revenue for Project Engineering** grew 80% YoY to INR14m, while operating loss stood at INR10m (vs EBIT of INR3.4m in 2QFY26).

Highlights from the management commentary

- **Expansion plans:** The ramp up of recently commissioned Uluberia 2 merchant plant (~220 TPD), along with the East India onsite plant (~320 TPD), is expected to drive near-term revenue growth. The next phase of expansion, comprising two merchant plants in North and Central India, is expected to become operational around mid-FY28, with revenue contribution commencing in 2HFY28.
- **Argon:** Argon's contribution to the overall gas mix increased to ~16% in 2QFY27 from ~10% in 1QFY27, driven equally by higher volumes and improved realizations, supported by the ramp-up of the Uluberia II facility. Management expects argon contribution to sustain at 14–16%, backed by favorable demand-supply dynamics, with demand outpacing supply.

- **Outlook:** Management reiterated its guidance of ~20% revenue growth in the core gases business, primarily driven by volumes, with higher argon contribution supporting realizations. The company is expanding its geographical presence to strengthen its pan-India footprint and emerge as a pan-India player, while targeting long-term EBITDA margins of ~40% in the gases segment, supported by a higher share of onsite operations and premium gases.
- **Project engineering :** ELLEN secured a major INR4.8b BHEL contract in Sept'26 for the design, **engineering**, supply, erection, and commissioning of a 1,200 TPD cryogenic air separation unit in Odisha for coal gasification. The project will be executed over eight quarters, with revenue recognition linked to execution progress. EBITDA margins are expected to remain in high-single-digit to low-double-digits.

Valuation and view

- ELLEN's growth story will be led by: 1) capacity expansion across India, 2) demand of argon outpacing supply, 3) increasing traction in inquiries for onsite plants, 4) stable demand from well-diversified core industries, 5) India's manufacturing expansion and accelerating industrial activity, and 6) increasing demand for oxygen from coal gasification.
- We expect ELLEN to clock a CAGR of 41%/34%/25% in revenue/EBITDA/PAT during FY26-29. While we broadly maintain our FY27 earnings estimates, we lower our FY28 estimates by 7% to factor in delay in the commercialization of the North India plant (~220 TPD), which is now expected in 2HFY28. **We reiterate our BUY rating with a TP of INR400 (based on 30x Sep'28 EPS).**

Consolidated - Quarterly Snapshot **(INR m)**

Y/E March	FY26				FY27				FY26	FY27E	FY27	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Gross Sales	**836**	**892**	**813**	**874**	**987**	**1,143**	**1,164**	**1,220**	**3,416**	**4,515**	**1,104**	**4%**
YoY Change (%)	24.3	-5.8	19.6	6.0	18.0	28.2	43.1	39.6	9.3	32.2	23.8	
Total Expenditure	529	557	565	577	611	741	746	777	2,228	2,874	670	
Gross Margin (%)	88.8%	90.6%	87.4%	86.7%	89.3%	88.3%	88.0%	88.0%	88.4%	88.4%	89.0%	
EBITDA	**307**	**335**	**249**	**298**	**376**	**402**	**419**	**443**	**1,188**	**1,641**	**434**	**-7%**
Margin (%)	36.7	37.5	30.6	34.1	38.1	35.2	36.0	36.3	34.8	36.3	39.3	
Depreciation	51	51	52	61	63	69	95	95	215	322	75	
Interest	46	11	15	23	20	25	30	35	95	109	37	
Other Income	68	126	161	165	171	171	150	155	520	643	150	
PBT before EO expense	**278**	**400**	**342**	**379**	**465**	**479**	**444**	**468**	**1,399**	**1,852**	**472**	
Extra-Ord. expense	0	0	0	-46	0	0	0	0	-46	0	0	
PBT	**278**	**400**	**342**	**333**	**465**	**479**	**444**	**468**	**1,353**	**1,852**	**472**	
Tax	91	32	81	104	115	123	112	118	309	466	119	
Rate (%)	32.8	8.1	23.8	31.2	24.7	25.6	25.2	25.2	22.8	25.2	25.2	
Reported PAT	**187**	**367**	**261**	**229**	**350**	**356**	**332**	**350**	**1,044**	**1,385**	**353**	**1%**
Adj. PAT	**187**	**367**	**261**	**260**	**350**	**356**	**332**	**350**	**1,079**	**1,385**	**353**	**1%**
YoY Change (%)	15.6	23.8	35.9	42.7	86.8	-2.9	27.3	34.5	29.6	28.3	-3.8	
Margin (%)	22.4	41.2	32.1	29.8	35.4	31.2	28.5	28.7	31.6	30.7	32.0	

TCI Express

Estimate change	⟷
TP change	⟷
Rating change	⟷

CMP: INR505 **TP: INR530 (+5%)** **Neutral**

In-line performance

- TCI Express's (TCIE) 2QFY27 revenue grew 9% YoY to INR3.3b (in line). EBITDA stood at INR396m (+12% YoY), 4% above our estimate. EBITDA margin came in at 11.8% in 2QFY27 vs. our estimate of 11.6%.
- APAT rose ~6% YoY to INR267m (in line). Volumes grew 6% YoY to 0.265m tons.
- TCIE reported a steady performance in 2QFY27, backed by healthy surface segment growth, which was driven by higher yields and increased business from large enterprises. Management targets volume growth of 11-12% in 2HFY27 as it expects further improvement in SME demand to drive a recovery in overall demand. **We broadly retain our FY27 and FY28 estimates and expect TCIE to deliver a CAGR of 6%/8%/11% in volume/revenue/EBITDA over FY26-28. We reiterate our Neutral rating with a TP of INR530, based on 18x FY28E EPS.**

Key highlights from the management commentary

- 2Q volumes stood at 0.265m tons (+6% YoY). Capacity utilization was steady at 84%.
- The company implemented its annual general price increase along with a fuel surcharge revision in Jun'26 to offset higher fuel costs.
- The company has been able to pass on higher fuel costs to customers and has taken 1.5% net price hikes. Management expects this pricing momentum to continue in 3Q and 4QFY27, supported by the seasonal increase in demand during the peak period.
- For 2HFY27, management has guided for volume growth of 11-12% and revenue growth of 14-15% YoY.
- Management expects 50-100bp improvement in EBITDA margin in FY27, driven by cost optimization, higher automation benefits, and price hikes.

Valuation and view

- TCIE's 2Q was broadly in line. We believe volume growth will gradually improve, supported by a recovery in demand from the SME segment, the rising contribution of the multimodal logistics segment, and ecommerce shipment volumes.
- We largely maintain our estimates for FY27 and FY28. We expect TCIE to clock a CAGR of 6%/8%/11% in volume/revenue/EBITDA over FY26-28**. We reiterate our Neutral rating with a revised TP of INR530 (based on 18x FY28E EPS).**

Stock Info

Bloomberg	TCIEXP IN
Equity Shares (m)	38
M.Cap.(INRb)/(USDb)	19.4 / 0.2
52-Week Range (INR)	687 / 447
1, 6, 12 Rel. Per (%)	-6/-7/-23
12M Avg Val (INR M)	60

Financials Snapshot (INR b)

Y/E March	2026	2027E	2028E
Net Sales	12.4	13.2	14.3
EBITDA	1.3	1.4	1.6
Adj. PAT	0.9	1.0	1.1
EBITDA Margin (%)	10.7	10.9	11.4
Adj. EPS (INR)	23.5	25.1	28.5
EPS Gr. (%)	4.7	7.1	13.4
BV/Sh. (INR)	216	233	254
Ratios			
Net D/E (x)	0.0	0.0	0.0
RoE (%)	11.3	11.2	11.7
RoCE (%)	11.2	11.1	11.6
Payout (%)	34.1	31.8	28.1
Valuations			
P/E (x)	21.4	19.9	17.6
P/BV (x)	2.3	2.1	2.0
EV/EBITDA (x)	14.2	12.9	11.4
Div. Yield (%)	1.6	1.6	1.6
FCF Yield (%)	1.3	1.3	0.7

Shareholding Pattern (%)

As of	Sep-26	Jun-26	Sep-25
Promoter	69.4	69.5	69.5
DII	8.7	8.9	9.4
FII	0.8	0.8	0.9
Others	21.1	20.9	20.3

FII includes depository receipts

Quarterly Performance

	FY26				FY27E				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	vs Est
Net Sales	**2,868**	**3,085**	**3,141**	**3,268**	**3,120**	**3,359**	**3,362**	**3,394**	**12,362**	**13,234**	**3,272**	**3**
YoY Change (%)	-2.1	-1.0	5.9	6.4	8.8	8.9	7.1	3.8	2.3	7.1	6.1	
EBITDA	**300**	**354**	**336**	**331**	**336**	**396**	**360**	**353**	**1,318**	**1,445**	**380**	**4**
Margins (%)	10.5	11.5	10.7	10.1	10.8	11.8	10.7	10.4	10.7	10.9	11.6	
YoY Change (%)	-8.4	-3.7	16.3	26.0	12.1	11.9	7.0	6.5	5.7	9.6	7.2	
Depreciation	53	53	60	91	68	69	72	75	254	284	70	
Interest	3	3	3	10	7	9	8	8	19	32	0	
Other Income	34	35	31	43	34	34	37	50	143	154	37	
PBT before EO expense	**278**	**332**	**305**	**273**	**295**	**352**	**317**	**320**	**1,188**	**1,283**	**347**	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	**278**	**332**	**305**	**273**	**295**	**352**	**317**	**320**	**1,188**	**1,283**	**347**	
Tax	68	80	76	65	72	85	80	85	289	321	87	
Rate (%)	24.5	24.2	24.9	23.8	24.2	24.2	25.2	26.5	24.4	25.0	25.2	
Reported PAT	**210**	**252**	**229**	**208**	**224**	**267**	**237**	**235**	**898**	**962**	**259**	**3**
Adj PAT	**210**	**252**	**229**	**208**	**224**	**267**	**237**	**235**	**898**	**962**	**259**	**3**
YoY Change (%)	-5.8	0.9	19.2	7.3	6.5	6.0	3.6	13.2	4.7	7.1	3.1	
Margins (%)	7.3	8.2	7.3	6.4	7.2	7.9	7.0	6.9	7.3	7.3	7.9	

Bharti Airtel

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th Nov 2026
Time: 12:00 PM IST

Financial Valuations (INR b)

INRb	FY27E	FY28E	FY29E
Net Sales	2,441	2,793	3,089
EBITDA	1,374	1,610	1,783
Adj. PAT	357	511	629
EBITDA Margin (%)	56.3	57.7	57.7
Adj. EPS (INR)	57.2	81.9	100.8
EPS Gr. (%)	30	43	23
BV/Sh. (INR)	303	358	420
Ratios			
Net D:E	0.7	0.2	-0.1
RoE (%)	22.4	27.6	28.9
RoCE (%)	16.7	20.3	22.5
Div. Payout (%)	55.8	54.9	54.5
Valuations			
EV/EBITDA (x)	10.3	8.4	7.2
P/E (x)	36.0	25.1	20.4
P/BV (x)	6.8	5.7	4.9

CMP: INR2,057 — Buy

Good 2Q, largely driven by strong show in Africa and robust wireless ARPU growth

Overall Bharti Airtel reported a robust 2QFY27, with higher-than-expected wireless ARPU growth and a strong show continuing in Africa. India wireless revenue/EBITDA grew ~3-4% QoQ (vs. 3-5% QoQ for RJio), driven by one additional day QoQ and part flow-through of recent tariff rationalization. India wireless ARPU rose ~2.7% QoQ (vs. ~1.5% QoQ for RJio), however consumer wireless net adds moderated to 0.7m (vs. QoQ acceleration to 5.4m for RJio). After muted net adds in 1Q, subscriber additions improved in Homes, though ARPU decline accelerated. Further, we note that Bharti continues to trail RJio on HBB net adds.. Airtel Africa continued strong double digit CC revenue and EBITDA growth, with further boost from cross-currency tailwinds. Reported capex rose ~10% YoY, due to front-ending of capex in Africa. Bharti's OCF generation remained healthy, however recommencement of deferred 5G spectrum payments (up ~INR44b YoY), led to moderation in FCF to INR97b (vs. INR146b QoQ). Dividend payments along with 5G spectrum repayments led to ~INR60b increase in net debt.

Healthy 2Q, driven by a strong show in Africa and robust ARPU growth in India wireless

- Bharti's consolidated revenue at INR609b (+17% YoY, our est. INR604b), was up 4% QoQ, driven primarily by robust growth in Africa (+7% QoQ, ~3% ahead) and India wireless (+3.4% QoQ, marginally ahead).
- India revenue (including Indus) grew ~3% QoQ to INR423b (+9% YoY) and was broadly in line with our estimate.
- Bharti's consolidated EBITDA at INR349b (+18% YoY, 2% ahead of our est. INR342b), rose ~5% QoQ, driven largely by robust performance in Airtel Africa (+8% QoQ, ~5% ahead). India wireless EBITDA grew ~3.8% QoQ (11% YoY, marginally higher than our est).
- India EBITDA (including Indus) at INR257b (+3.8% QoQ, +11% YoY) was largely in line with our estimate (INR255b).
- Reported EBITDA margin expanded ~50bp QoQ to 57.4% (+70bp YoY) and was ~80bp ahead of our estimate, driven by higher margin in Indus (+85bp QoQ, 140bp beat), Airtel Africa (+35bp QoQ, 90bp beat) .
- Bharti's consolidated EBITDAaL grew 5.5% QoQ to INR315b, with India EBITDAaL rising ~4.3% QoQ to INR238b (margins expanded ~70bp QoQ).
- Reported PBT (before share of JVs) at INR155b (+11% QoQ, +27% YoY) was ~3% above our est., due to higher EBITDA. Net finance cost declined ~4% QoQ (+17% YoY, ~6% above our est.) and D&A rose ~3% QoQ, (in line).
- Adjusted for exceptional items (IPO expense for Airtel Africa money), attributable PAT at INR90.2b grew 12% QoQ (+33% YoY), and was, marginally ahead of our estimate of INR88.8b.

FCF generation moderates to INR97b in 2Q due to commencement of 5G spectrum repayments; net debt inches up due to deferred spectrum and dividend payments

- Consolidated committed capex rose ~10% YoY to INR125b (though -7% QoQ), driven by higher capex in Africa (+49% YoY). India capex (ex-Indus) rose ~5% YoY (-7% QoQ) to INR74b as higher capex in Homes (+17% YoY), DTH (+56% YoY) and Enterprise (+53% YoY) was partly offset by lower wireless capex (-16% YoY).
- Cash capex in tangible assets rose ~28% YoY (flat QoQ) to INR138b, while intangible capex jumped to INR24b (from INR4b QoQ), largely due to recommencement of deferred 5G spectrum payments (partly reflected in finance costs).
- Bharti's consolidated OCF (after WC and leases) stood at INR321b (vs. INR314b QoQ, INR286b YoY). However, consolidated free cash flow (after leases and interest payments) moderated to INR97b (vs. ~INR146b YoY), largely due to commencement of spectrum repayments (INR44b higher YoY).
- Bharti's consolidated net debt (ex-leases) rose ~INR64b QoQ to INR883b (vs. INR818b QoQ), due to dividend and deferred spectrum payments. Including the impact of leases, Bharti's consolidated net debt rose ~INR93b QoQ to INR1.67t (vs. INR1.57t QoQ).
- India business net debt (ex-leases) inched up ~INR58b QoQ to INR751b (vs. INR693b QoQ).
- Bharti's consolidated net debt (including leases) to EBITDA (annualized) was stable at 1.18x (vs. 1.17x QoQ). India SA net debt to EBITDA stood at 1.07x (vs. 1.04x QoQ).
- Excluding lease impact, Bharti's net debt to EBITDAaL was broadly stable at 0.7x (vs. 0.69x QoQ) for consolidated business and 0.79x (vs. 0.76x QoQ) for India SA.

India wireless: Robust 2QFY27; tariff rationalization drives higher ARPU growth, but weighs on subscriber net adds

- Bharti's India wireless ARPU at INR271 (+6% YoY, above our est. INR269), grew ~2.7% QoQ (vs. +1.5%/3.5% QoQ/YoY for RJio), due to one additional day QoQ and rationalization of INR299 entry level plan.
- Bharti's subscriber net adds moderated to 0.7m paying net adds (vs. 3.3m net adds QoQ, vs. 5.4m consumer wireless net adds for RJio) and was below our estimate of ~3m net adds.
- Subscriber mix continues to improve as Bharti added ~1.23m postpaid net adds (+4% QoQ, 13.5% YoY). Bharti's 4G/5G net additions were muted at ~3m (vs. ~5m QoQ).
- Bharti's India wireless revenue grew 3.4% QoQ (vs. 3.2%/11% QoQ/YoY for RJio, including FTTH) to INR309b (+10% YoY, our est. INR308b).
- India wireless EBITDA rose 3.8% QoQ (vs. 5.2%/14% QoQ/YoY for RJio including FTTH) to INR189b (+11% YoY, vs. our est. INR188).
- Despite higher diesel costs, reported wireless EBITDA margin inched up ~23bp QoQ to 61% (+135bp YoY, vs. +100bp QoQ for RJio to 55.7%) and was in line with our estimate.
- Incremental margin came in at ~68% (vs. ~65% in 1QFY27, ~88% for RJio and our estimate of ~69%).

- India wireless capex moderated ~21% QoQ to INR36b (-16% YoY) and was ~19% below our estimate.

Homes: Subscriber net adds recover, ARPU decline accelerates

- After weakness in 1Q, Bharti's Homes BB net adds recovered to ~0.68m (vs. ~0.47m QoQ, though trail ~1.4m QoQ for RJio and marginally lower our estimate of ~0.75 net adds) to reach ~15.4m subs (+29% YoY).
- Reported ARPU declined sharp ~3.5% QoQ to INR509/month (-6% YoY, 3% below our est. INR521).
- Homes revenue inched up ~2% QoQ to INR23.4b (+25% YoY). Homes EBITDA at INR11.4b (+1.4% QoQ, 22% YoY) was in line with our estimate.
- EBITDA margin contracted ~35bp QoQ to 48.8% (-125bp YoY), but was ~105bp above our estimate.
- Capex in Homes Business remained elevated with ~15% QoQ uptick to INR22b (+17% YoY, 46% above our estimate).

Enterprise: Growth in line; margin slightly weaker QoQ

- Airtel Business (Enterprise) revenue grew ~4% QoQ to INR58.8b (+11% YoY, in line).
- EBITDA at INR25.3b rose ~1% QoQ (+15% YoY, 2% below our est. of INR25.8b) as EBITDA margin dipped ~100bp QoQ to 43% (vs. our est. of 44% and 41.6% YoY).
- Capex rose ~24% QoQ to INR11.7b (+53% YoY) and was ~14% above our est.

Other businesses: Better-than-expected growth and margins in Africa; DTH continues to face headwinds

- Airtel DTH's revenue at INR7.7b, was flat QoQ (+2% YoY) as ARPU grew ~1.6% QoQ (flat YoY) to INR163 (in line). Subscriber base declined by ~443k (vs. 6k net adds in 1QFY27 and higher than our estimate of ~150k decline QoQ). DTH EBITDA grew 0.6% QoQ to INR3.3b (-9% YoY, ~6% miss) as margins expanded ~40bp QoQ to 43.3% (-5.3pp YoY and ~220bp below our estimate).
- Airtel Africa (AAF) continued to report strong double-digit YoY constant currency growth. AAF's reported revenue (in INR) rose ~7% QoQ (+38% YoY, 3% ahead), while EBITDA jumped ~8% QoQ (42% YoY, ~5% ahead) driven by strong margin delivery in East Africa.

Other highlights: Customer engagement ahead of peers

- Data volume for India wireless business rose ~7% QoQ (vs. ~7% QoQ in 1QFY27, +3% QoQ for RJio including FTTH), while data usage per sub improved further to 36.5GB/month (vs. 34.4GB QoQ, 44.2GB/month reported by RJio, including FTTH).
- Voice usage on network in India wireless was stable QoQ (vs. flat QoQ in 1QFY27 and flat QoQ for RJio), with minute of usage (MoU) per subscriber moderating to 1,131mins (vs. 1,135min QoQ, but higher than 942mins for RJio).
- Bharti's tower additions further moderated to ~0.5k towers QoQ (vs. 1.6k in 4QFY26 and 2.9k macro towers added by Indus) bringing the total tower count to ~348k. while, revenue per site grew ~3% QoQ to INR294k/month (+8% YoY)

Consolidated results

	2QFY26	1QFY27	2QFY27	YoY	QoQ	2QFY27E	vs est
Revenue	**521.5**	**585.4**	**608.8**	**16.7**	**4.0**	**604.0**	**0.8**
Access charges	13.2	15.9	16.0	21.2	0.8	16.1	(0.6)
License and spectrum fee	38.2	41.7	43.2	13.0	3.6	43.8	(1.4)
Network operating costs	101.2	108.1	112.1	10.8	3.7	112.0	0.1
Employee costs	18.6	21.8	21.7	16.8	(0.4)	21.1	2.7
SG&A expenses	54.6	64.9	66.3	21.3	2.1	69.1	(4.1)
Total costs	225.8	252.4	259.3	14.8	2.8	262.1	(1.1)
EBITDA	**295.6**	**333.0**	**349.5**	**18.2**	**4.9**	**341.9**	**2.2**
EBITDA margin (%)	56.7	56.9	57.4	71.3	51.4	56.6	80.1
Depreciation and amortization	131.8	142.4	146.2	10.9	2.7	146.3	(0.1)
EBIT	**163.8**	**190.7**	**203.3**	**24.1**	**6.6**	**195.6**	**3.9**
EBIT margin (%)	31.4	32.6	33.4	198.2	82.0	32.4	100.9
Net finance cost	41.4	50.5	48.3	16.7	(4.3)	45.6	6.0
PBT	**122.4**	**140.2**	**155.0**	**26.6**	**10.6**	**150.0**	**3.3**
Tax provision	36.7	37.6	47.2	28.5	25.4	45.5	3.7
PAT before minority interest	85.7	102.6	107.8	25.8	5.1	104.5	3.1
Share of associates / JVs	0.8	1.1	1.1	35.6	1.5	1.0	9.8
Minority interest	18.6	18.4	18.2	-	(1.2)	16.7	9.2
Extraordinary items	-	3.5	1.8	-	-	-	-
Reported net income	**67.9**	**81.7**	**88.9**	**30.9**	**8.8**	**88.8**	**0.1**
Adjusted net income	**67.9**	**80.6**	**90.1**	**32.7**	**11.9**	**88.8**	**1.5**
Reported EPS (INR)	11.7	13.4	14.2	21.6	6.5	14.2	0.1
Adjusted EPS (INR)	11.7	13.2	14.5	23.3	9.5	14.2	1.5

Exhibit 2: Net debt trends

Debt and cash trends	Sep-23	Mar-24	Sep-24	Mar-25	Jun-25	Sep-25	Mar-26	Jun-26	Sep-26
Reported gross debt	**1,578**	**1,520**	**1,465**	**1,484**	**1,374**	**1,401**	**1,218**	**1,262**	**1,212**
LT debt	333	276	197	202	208	202	194	177	176
ST debt (inc. current maturities)	162	204	291	376	258	264	137	198	164
Deferred payment liabilities	1,084	1,040	977	906	908	935	887	887	872
Cash and Cash Equivalents	**103**	**110**	**54**	**99**	**119**	**134**	**307**	**443**	**330**
Net Debt excluding Lease Obligations	**1,475**	**1,410**	**1,410**	**1,385**	**1,255**	**1,267**	**910**	**819**	**883**
Lease Obligation	596	637	792	653	661	681	737	754	783
Net Debt including Lease Obligations	**2,070**	**2,046**	**2,202**	**2,038**	**1,916**	**1,947**	**1,648**	**1,572**	**1,666**
Net debt (including leases) to EBITDA	**2.63**	**2.61**	**2.50**	**1.86**	**1.70**	**1.63**	**1.29**	**1.17**	**1.18**
Net debt (excluding leases) to EBITDAaL		**1.85**	**1.60**	**1.42**	**1.26**	**1.19**	**0.79**	**0.69**	**0.70**

Exhibit 3: FCF (post-interest and leases) trend

	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27	FY26	FY25
CFO post-tax before WC changes	**194**	**214**	**236**	**255**	**267**	**283**	**293**	**308**	**306**	**309**	**1,150**	**900**
WC changes	24	35	21	3	40	19	34	(21)	30	29	72	84
Cashflow from operations	**218**	**249**	**257**	**259**	**307**	**302**	**327**	**286**	**336**	**338**	**1,222**	**983**
Lease payments	(18)	(20)	(16)	(17)	(17)	(16)	(16)	(18)	(22)	(17)	(67)	(72)
Capex in tangible assets	(99)	(96)	(84)	(98)	(111)	(108)	(108)	(113)	(138)	(138)	(440)	(376)
Capex in intangible assets	**(71)**	**(57)**	**(35)**	**(69)**	**(2)**	**(6)**	**(5)**	**(12)**	**(4)**	**(24)**	**(24)**	**(231)**
Paid finance cost	**(42)**	**(64)**	**(33)**	**(38)**	**(33)**	**(26)**	**(30)**	**(60)**	**(32)**	**(62)**	**(149)**	**(175)**
FCF, post lease and interest payment	**(12)**	**14**	**90**	**37**	**143**	**146**	**169**	**84**	**140**	**97**	**542**	**129**
Spectrum prepayments	79	85	36	60	-	-	-	-	-	-	-	260
Adjusted FCF post leases and interest	**68**	**98**	**126**	**97**	**143**	**146**	**169**	**84**	**140**	**97**	**542**	**389**

Exhibit 4: Segmental performance

	2QFY26	1QFY27	2QFY27	YoY	QoQ	2QFY27E	vs est
Segmental revenue (INR b)							
India (incl. Indus)	**387**	**412**	**423**	**9.4**	**2.7**	**424**	**(0.2)**
Wireless	**281**	**299**	**309**	**10.1**	**3.4**	**308**	**0.6**
Homes	18.6	22.9	23.4	25.3	2.1	23.7	(1.5)
DTH	7.5	7.7	7.7	2.4	(0.3)	7.8	(0.8)
Airtel Business	52.8	56.7	58.8	11.4	3.8	58.6	0.4
Passive infra	81.9	84.3	85.2	4.0	1.0	87.3	(2.5)
Africa	**137**	**176**	**188**	**37.6**	**7.1**	**183**	**3.0**
Consolidated	**521**	**585**	**609**	**16.7**	**4.0**	**604**	**0.8**
Eliminations	(57)	(61)	(64)			(64)	
Segmental EBITDA (INR b)							
India (incl. Indus)	**232**	**248**	**257**	**10.9**	**3.8**	**255**	**0.9**
Wireless	**170**	**182**	**189**	**11.3**	**3.8**	**188**	**0.6**
Homes	9.3	11.2	11.4	22.1	1.4	11.3	0.6
DTH	3.7	3.3	3.3	(8.8)	0.6	3.5	(5.7)
Airtel Business	21.9	24.9	25.3	15.1	1.3	26	(2.0)
Passive infra	47.0	46.2	47.4	0.9	2.5	47	0.0
Africa	**67**	**88**	**95**	**41.6**	**7.9**	**91**	**4.9**
Consolidated	**296**	**333**	**349**	**18.2**	**4.9**	**342**	**2.2**
Eliminations	(23)	(23)	(22)			(24)	
Segmental EBITDA margin (%)							
India (incl. Indus)	**60.0**	**60.1**	**60.8**	**84**	**69**	**60.1**	**71.0**
Wireless	**60.3**	**60.8**	**61.0**	**70**	**23**	**61.0**	**0.8**
Homes	50.1	49.1	48.8	(126)	(33)	47.8	103.8
DTH	48.6	42.9	43.3	(532)	38	45.5	(222.4)
Airtel Business	41.6	44.0	43.0	138	(102)	44.0	(105.6)
Passive infra	57.3	54.8	55.6	(169)	83	54.3	138.2
Africa	**49.1**	**50.2**	**50.5**	**145**	**34**	**49.6**	**91.7**
Consolidated	**56.7**	**56.9**	**57.4**	**71**	**51**	**56.6**	**80.1**
Segmental capex (INR b)							
India (incl. Indus)	**96**	**97**	**99**	**2.7**	**2.2**	**89**	**10.7**
Wireless	**43**	**46**	**36**	**(15.7)**	**(21.3)**	**45**	**(19.3)**
Homes	18.6	19.0	21.8	17.2	14.8	15.0	45.4
DTH	3.1	5.9	4.8	55.6	(19.0)	4.7	2.1
Airtel Business	8	9	12	52.9	24.1	10	14.3
Passive infra	26	17	25	(4.4)	44.1	15	65.0
Africa	**17**	**37**	**26**	**48.8**	**(30.6)**	**24**	**5.9**
Consolidated	**114**	**134**	**125**	**9.7**	**(6.9)**	**114**	**9.7**

Exhibit 5: Key performance indicators

Operating metrics	2QFY26	1QFY27	2QFY27	YoY	QoQ	2QFY27E	vs est.
India wireless							
Wireless ARPU	**256**	**264**	**271**	**5.9**	**2.7**	**269**	**0.7**
EoP reported subs (m)	**364.2**	**376.5**	**377.2**	**3.6**	**0.2**	**379.5**	**(0.6)**
Net adds (m)	1.4	3.3	0.7			3.0	
EoP prepaid subs	336.7	346.5	346.0	2.8	(0.1)	348.7	(0.8)
EoP postpaid subs	27.5	30.0	31.2	13.5	4.1	30.9	1.2
EoP data subs (m)	**289.4**	**303.2**	**305.4**	**5.5**	**0.7**	**306.7**	**(0.4)**
Data net adds (m)	4.7	4.1	2.3			3.5	
Data subs proportion (%)	79.5	80.5	81.0	150.1	44.5	80.8	15.9
EoP 4G subs (m)	**285.8**	**301.8**	**304.6**	**6.6**	**0.9**	**305.8**	**(0.4)**
4G net adds (m)	5.1	5.0	2.9			4.0	
Data volume (b MBs)	25,033	31,807	34,159	36.5	7.4	32,542	5.0
Data usage per data sub (GB/month)	**28.3**	**34.4**	**36.5**	**28.8**	**6.2**	**34.7**	**5.1**
Average data realization (INR/GB)	11.4	9.6	9.2	(19.4)	(3.8)	9.6	(4.2)
Voice usage on network (b mins)	1,249	1,276	1,280	2.5	0.3	1,293	(1.0)
Minute of usage per sub (min/month)	**1,145**	**1,135**	**1,131**	**(1.3)**	**(0.4)**	**1,140**	**(0.8)**
Network towers ('000)	342.3	347.5	348.0	1.7	0.1	349.5	(0.4)
MBB sites ('000)	1,154.8	1,202.4	1,214.1	5.1	1.0	1,208.4	0.5
Revenue per tower (INR/month)	2,72,510	2,85,253	2,93,933	7.9	3.0	2,91,736	0.8
Homes							
Cities covered (#)	1,551	1,653	1,669	7.6	1.0		
Reported ARPU (INR/month)	**534**	**523**	**509**	**(4.6)**	**(2.6)**	**521**	**(2.2)**
Calculated ARPU (INR/month)	543	527	518	(4.6)	(1.8)	525	(1.3)
EoP reported subs (m)	**11.9**	**14.7**	**15.4**	**28.9**	**4.6**	**15.4**	**(0.5)**
Net adds ('000)	951	473	676			750	
DTH*							
ARPU (Rs/month)	**163**	**160**	**163**	**(0.2)**	**1.5**	**163**	**0.1**
EoP active DTH subs (m)	**15.4**	**16.0**	**15.6**	**1.3**	**(2.8)**	**15.9**	**(1.8)**
Net adds ('000)	(341.1)	5.8	(443.0)			(150.0)	
Airtel Business							
M2M subs (m)	**56.3**	**82.8**	**88.6**	**57.3**	**7.0**		
Net adds ('000)	26,229	26,444	5,813				
Airtel Africa							
Reported ARPU (US$)	**2.6**	**2.9**	**3.1**	**18.5**	**6.9**	**3.3**	**(8.4)**
EoP subscriber base (m)	**173.8**	**189.0**	**193.9**	**11.6**	**2.6**	**192.5**	**0.7**
Net adds (m)	10.7	15.2	4.9			3.5	
EoP data subscriber base (m)	78.1	87.3	89.9	15.0	2.9		
Net adds (m)	6.7	9.2	2.6				
Data subs proportion (%)	45.0	46.2	46.4	140 bps	15 bps		
EoP mobile money subs base (m)	49.8	56.5	60.9	22.4	7.8		
Net adds (m)	5.4	6.7	4.4				

ONGC

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR230 — Buy

Beat driven by higher-than-estimated realization

- In 2QFY27, ONGC's standalone revenue came in line with our est. at INR439b.
  - Reported oil realization was USD92.3/bbl (est: USD90/bbl).
  - Crude oil production was down 1%/5% QoQ/YoY, while natural gas production declined 2% YoY (up 2% QoQ).
    - The YoY moderation was driven by reservoir complexities at KG-98/2 (Eastern Offshore) and by monsoon-related operational issues that delayed PRP-8 and PRP-9. Onshore gas was also hit by lower offtake after disruptions at some major consumer facilities.
    - ONGC has extended bp's Technical Service Provider role to the entire Western Offshore (TSP-1 and TSP-2) to arrest decline in mature fields and speed up development. bp mobilized its TSP-2 team (all of Western Offshore except the MH field) in Aug'26.
- Standalone EBITDAX stood 6% above our est. at INR263b.
  - Other expenses stood above est., while statutory levies stood below est.
- Standalone PAT stood 10% above our estimate at INR155b.
  - Depreciation, dry well write-offs, and other income came above our estimate.
- **New** Western **Offshore projects:** ONGC awarded two offshore development projects, MBOSN-2005-1/SD-4/BS-17 and the additional development of Ratna-1/NLM-14. Combined capex is ~INR118b, and the projects are expected to unlock ~22mmtoe of hydrocarbons. It also awarded PRP-X (>INR43b) for new subsea pipelines and replacement of aging pipeline infrastructure, aimed at asset integrity, operational reliability, and sustaining long-term production.
- **Other** exploration **highlights:** Under Samudra Manthan, ONGC's first exploratory well, Mahanadi deepwater, was proved gas-bearing. **In 2QFY27,** ONGC notified two onland discoveries: 1) Amraghat-1 flowed gas and was notified as a new prospect discovery; 2) Vadatal-48, Cambay encountered new sand below the Chhatral Pay. The find creates new exploration opportunities below active Chhatral Pay and is notified as new pool discovery.
- **CB-OS/2 takeover:** As GoI's nominee, ONGC took control and possession of all assets, data, facilities, infrastructure, and operations of the CB-OS/2 block w.e.f. 22nd Jul'26.
- The Board declared an interim dividend of INR8/sh (160%).

Analyst Meet Details



Date: 6 Nov'26
Time: 1530 hours IST
Call details:
086 34168832
086 45367270

Standalone - Quarterly Earning Model

(INR b)

Y/E March	FY26				FY27		FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q			2QE	(%)
Net Sales	**320**	**330**	**315**	**359**	**465**	**439**	**1,325**	**1,723**	**428**	**3%**
YoY Change (%)	*-9*	*-3*	*-6*	*3*	*45*	*33*	*-4*	*30*	*34*	
Total Expenditure	133	153	142	182	170	176	611	701	180	-2%
EBITDAX	**187**	**177**	**173**	**178**	**295**	**263**	**715**	**1,022**	**248**	**6%**
Margin (%)	*58*	*54*	*55*	*49*	*63*	*60*	*54*	*59*	*58*	*2*
Depreciation	65	64	66	56	63	85	251	264	67	
Exploration cost written off	15	11	21	51	11	15	97	97	12	
Interest	11	11	12	11	11	11	45	46	11	
Other Income	12	34	31	26	19	45	104	90	30	
PBT	**107**	**125**	**106**	**85**	**228**	**198**	**424**	**704**	**187**	**6%**
Tax	27	27	22	19	58	43	95	169	46	
Rate (%)	*25*	*21*	*21*	*22*	*25*	*22*	*22*	*24*	*25*	
Reported PAT	**80**	**98**	**84**	**66**	**170**	**155**	**329**	**535**	**141**	**10%**
YoY Change (%)	*-10*	*-18*	*2*	*3*	*112*	*57*	*-8*	*63*	*43*	
Margin (%)	*25*	*30*	*27*	*19*	*37*	*35*	*25*	*31*	*33*	
Key Assumptions (USD/bbl)										
Oil Realization (pre windfall tax)	66.1	67.3	61.6	78.3	99.5	92.3	68.4	89.7	90.0	3%
Crude Oil Sold (mmt)	4.7	4.8	4.7	4.6	4.4	4.4	18.8	18.1	4.6	-4%
Gas Sold (bcm)	3.9	3.9	3.9	3.8	3.7	3.8	15.5	15.4	3.9	-4%
VAP Sold (tmt)	616	592	662	595	471	623	2,465	2,292	482	29%

Hindalco

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR938 — Buy

Novelis 2QFY27 – Result Summary: In-line earnings

- Revenue stood at USD5.9b, up 25% YoY and 3% QoQ, driven primarily by higher average aluminum prices. It was 15% above our estimate due to better-than-expected NSR, while shipments were largely in line during 2QFY27.
- Shipments stood at 919kt, down 2% YoY and flat QoQ, while NSR increased 28% YoY and 2% QoQ to USD6,466/t during the quarter. Higher beverage packaging and aerospace shipments offset the muted shipments of automotive and specialty products.
- Adj. EBITDA came in line at USD508m, up 20% YoY and flat QoQ during the quarter. The improvement in adjusted EBITDA was mainly due to USD39m in business interruption insurance recoveries related to Oswego and favorable metal benefits (incl. both higher scrap consumption and lower aluminum scrap prices).
- Adjusted EBITDA/t stood in line at USD553, up 23% YoY and flat QoQ during the quarter.
- Adj. PAT stood largely in line at USD191m, rising 31% YoY but declining 12% QoQ during the quarter.

Quarterly Performance (Novelis) - USD m

Y/E March	FY26				FY27		FY26	FY27	FY27 2QE	Vs Est (%)
	1Q	2Q	3Q	4Q	1Q	2Q				
Sales (000 tons)	**963**	**941**	**809**	**844**	**916**	**919**	**3,557**	**3,685**	**930**	**-1.2**
Change (YoY %)	1.3	(0.4)	(10.5)	(11.8)	(4.9)	(2.3)	(5.3)	3.6		
Change (QoQ %)	0.6	(2.3)	(14.0)	4.3	8.5	0.3	-	-		
Net Sales	**4,717**	**4,744**	**4,186**	**4,787**	**5,793**	**5,942**	**18,434**	**20,827**	**5,132**	**15.8**
Change (YoY %)	12.7	10.5	2.6	4.4	21.0	25.3	7.5	13.0		
Change (QoQ %)	2.8	0.6	(11.8)	14.4	21.0	2.6	-	-		
EBITDA (adjusted)	**416**	**422**	**348**	**459**	**516**	**508**	**1,645**	**2,030**	**512**	**-0.7**
Change (YoY %)	(16.8)	(8.7)	(5.2)	(3.0)	24.0	20.4	(8.7)	23.4		
Change (QoQ %)	(12.1)	1.4	(17.5)	31.9	12.4	(1.6)	-	-		
EBITDA per ton (USD)	**432**	**448**	**430**	**544**	**563**	**553**	**462**	**551**	**550**	**0.5**
Interest	62	63	62	58	64	74	245	272		
Depreciation	148	152	155	161	150	150	616	680		
PBT (before EO item)	**206**	**207**	**131**	**240**	**302**	**284**	**784**	**1,078**		
Extra-ordinary Income	(60)	17	(286)	(439)	(74)	26	(768)	-		
PBT (after EO item)	**146**	**224**	**(155)**	**(199)**	**228**	**310**	**16**	**1,078**	**274**	**13.3**
Total Tax	50	61	4	(114)	64	100	1	269		
% Tax	34.2	27.2	(2.6)	57.3	28.1	32.3	6.3	25.0		
Reported PAT (after MI)	**96**	**163**	**(160)**	**(84)**	**164**	**210**	**15**	**808**		
Change (YoY %)	(36.4)	27.3	(245.5)	(128.6)	70.8	28.8	(97.8)	5,289.9		
Adjusted PAT	**156**	**146**	**69**	**179**	**217**	**191**	**550**	**833**	**205**	**-6.8**
Change (YoY %)	(34.2)	(27.7)	(45.0)	(28.8)	39.3	31.0	(32.6)	51.4		
Change (QoQ %)	(38.1)	(6.4)	(52.9)	160.8	21.1	(12.0)				

Key highlights from the management commentary

Performance Guidance and Outlook

- Oswego hot mill operations have normalized following the fires in 2025, although some customers continue to consume alter-inventory sourced during the outage. Management expects these residual supply chain effects to gradually normalize over the coming quarters.
- Management remains confident of achieving long-term EBITDA of ~USD1,000/t from Bay Minette, despite initial ramp-up costs and fixed-cost under-absorption.
- The Yeongju can facility, which supplies North America and Asia, witnessed a production halt following a union strike in early Sep'26. An agreement was reached in early Nov'26 and production has resumed currently. The strike impacted 2Q EBITDA by ~USD20m, with a directionally similar impact expected in 3QFY27 due to one month of lost production in Oct'26.
- The net negative tariff impact increased to USD78m in 2QFY27, primarily due to higher imports from Kingston (Canada) to maintain customer supplies following the Oswego outage. The portion of tariffs that cannot be contractually passed through to customers is recognized as a direct hit to profitability.
- Tariff costs are expected to reduce from 3Q/4QFY27 as production at Kingston is progressively reduced, with a greater share of production shifting to US-based facilities.
- Scrap market conditions and spreads remain favorable, although some moderation is expected as Oswego's supply chain normalizes and increases scrap purchases.
- The Structural Cost Reduction initiative has delivered more than USD240m of annualized run-rate savings over the past 18 months. Management remains on track to achieve ~USD300m of run-rate savings by FY27-end and its ultimate target of USD350–400m by FY28-end.
- Management expects cumulative insurance recoveries to reach ~USD900m by FY27-end, with the remaining ~USD400m expected to be received in FY28, taking total expected recoveries to ~USD1.3b. Recovery progress is ahead of earlier expectations.

Capital Allocation and Capacity Update

- FY27 capex is expected to be around USD2.1-2.4b. Moreover, spending is expected to taper as commissioning progresses and the project moves toward commercial operations.
- Bay Minette commissioning is progressing well, with the first cold mill coil produced in Sep'26. Commissioning of key assets is underway, with additional production capabilities expected to come online over the coming weeks and commercial shipments targeted in 1QFY28.
- Management's initial focus is on can body stock before gradually introducing automotive and other high-value products.
- The company expects Bay Minette ramp-up within ~2 years, supported by existing customer relationships, technical expertise, and operating capabilities across its global network.

- North American beverage packaging contracts for Bay Minette have already been secured till decade end. Management is also progressing automotive contracts and remains confident of placing the facility's entire output.
- Bay Minette recorded ~USD23m of start-up costs in 2QFY27 and USD21m in 1QFY27. These costs are related to operational readiness, employee training, and equipment testing.
- Management indicated that the Bay Minette facility will address output constraints in the North American aluminum market, improve supply chain flexibility, and reduce dependence on imports subject to Section 232 tariffs.

Other Highlights

- Management expects to return to positive free cash flow in 4QFY27, supported by seasonal cash-flow strength, ~USD300m of working capital release from inventory reduction, further insurance recoveries, and lower Bay Minette spending as commissioning progresses.
- Working capital normalization is expected across 2HFY27 as customer supply chains recover and Yeongju production resumes.
- Liquidity stood at ~USD2b, while net leverage was 4.7x at Q2FY27-end. Management believes leverage is at or near its peak and expects it to decline to ~4.0x by FY27-end, supported by stronger cash generation and lower capex.

LG Electronics India

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 06th November 2026
Time: 16:00 pm
Dial-in details:
+91 22 6280 1384
+91 22 7115 8285
Link for the call

Consol. Financials Snapshot (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	246.0	281.3	318.1
EBITDA	24.2	33.5	40.0
Adj. PAT	17.1	24.2	29.0
EBITDA Margin (%)	9.8	11.9	12.6
Adj. EPS (INR)	25.2	35.7	42.8
EPS Gr. (%)	(22.3)	41.5	19.9
BV/Sh. (INR)	112.9	136.1	163.9
Ratios			
Net D:E	(0.6)	(0.6)	(0.5)
RoE (%)	25.1	28.7	28.5
RoCE (%)	26.1	29.8	29.4
Payout (%)	0.0	35.0	35.0
Valuations			
P/E (x)	68.2	48.2	40.2
P/BV (x)	15.2	12.6	10.5
EV/EBITDA(x)	46.4	33.3	27.7
Div. Yield (%)	-	0.7	0.9
FCF Yield (%)	0.5	1.0	1.1

CMP: INR1,778 — Buy

EBITDA in line; announces diversification through a new business

- LGEIL's 2QFY27 revenue grew 20% YoY to INR73.8b led by 21% and 17% growth in the Home Appliance and Home Entertainment segments, respectively. EBITDA grew 28% YoY to INR7.0b (in line) with OPM up 65bp YoY at 9.5% (in-line). Its PAT was up 26% YoY to INR4.9b (in line).
- LGEIL plans to enter the Vehicle Solutions business, focusing on manufacturing, supplying and servicing automotive electronics and technology solutions, including infotainment systems, digital cockpits, telematics, ADAS and automotive software. Manufacturing will be undertaken at its third plant in Sri City, Andhra Pradesh.
- The entry will enable it to diversify beyond its existing product portfolio and capitalize on growing opportunities in connected vehicles, automotive electronics and intelligent mobility solutions. Investments will be undertaken in a phased manner, depending on operational scale, technology requirements and market conditions, with the business expected to create incremental revenue streams and support long-term growth.
- **We have a BUY rating on the stock.** However, we will review our assumptions after the conference call on 06th Nov'26.

Revenue up ~20% YoY; OPM up 65bp to 9.5% (est. 9.5%)

- LGEIL's consol. revenue/EBITDA/adj. PAT stood at INR73.8b/INR7.0b/ INR4.9b (+20%/+28%/+26% YoY; in line). OPM increased 65bp YoY to 9.5% (vs. est. 9.5%). Depreciation rose 31% YoY, and interest costs remained flat YoY. Other income increased ~7% YoY.
- Segmental highlights: **a) Home Appliances & Air Solutions** (**H&A)** revenue increased ~21% YoY to INR47.7b (~8% beat), EBIT grew ~28% YoY to INR4.2b (in line), and margin increased 50bp YoY at 8.7% (vs. est. 9.0%). **b) Home Entertainment (HE)** revenue grew ~17% YoY to INR26.1b (in line), EBIT increased ~20% YoY to INR3.4b (in line), and margin expanded 30bp YoY at 12.9% (vs. est. 13.0%).
- In 1HFY27, revenue/EBITDA/PAT grew 17%/27%/27% YoY to INR146.1b/INR16.1b/INR11.4b. OPM expanded 80bp YoY to ~11.0%. OCF stood at INR16.3b vs. INR10.3b in 1HFY26. Capex stood at INR11.6b vs. INR5.9b in 1HFY26. FCF stood at INR4.7b vs. INR4.4b in 1HFY26.

Management commentary

- H&A segment showed robust growth across key categories, with washing machines, refrigerators and RAC leading the momentum, while dishwashers delivered breakout growth. The two-track strategy drove growth across mass and premium segments, with the LG Essential range and launch of chest freezers further strengthening market positioning. EBIT margin improved and was supported by operating leverage and premium mix, partially offset by elevated commodity costs.

- HE segment grew on a high base, marking the segment's third consecutive quarter of double-digit growth. Television growth was driven by consumer upgrades to larger screens and record-high offline market share, while the B2B Information Display business continued to strengthen as an additional growth and profit engine. EBIT margin increased and was supported by operating leverage and improved B2B profitability, despite commodity inflation, FX headwinds and festive-season GTM investments.
- Margins were driven by operating leverage and premium mix, despite elevated commodity prices, rupee depreciation and GTM investments. Management reaffirmed FY27 targets of mid-teen revenue growth and early double-digit EBITDA margin, supported by festive-season demand, premiumization and exports. The Sri City plant is expected to commence operations in 3QFY27 with compressor manufacturing, enhancing localization and catering to domestic and export demand.

Valuation and view

- LGEIL reported a strong performance across both H&A and HE segments, driven by broad-based volume and value growth across key categories. Margin expansion was supported by operating leverage, a richer premium mix and improved profitability in the B2B business, despite commodity inflation, currency headwinds and higher GTM investments.
- **We have a BUY rating on the stock.** However, we will review our assumptions following the conference call on 06th Nov'26 (Concall Link).

Quarterly Performance (Consolidated)

	FY26				FY27E				MOFSL	Var.	YoY	QoQ
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	2QE			
Sales	**62,629**	**61,740**	**41,144**	**80,536**	**72,334**	**73,800**	**48,556**	**86,596**	**71,181**	4%	20%	2%
Change (%)	-2.3	1.0	-6.4	8.1	15.5	19.5	18.0	7.5	**15**			
Adj EBITDA	**7,163**	**5,476**	**2,085**	**9,454**	**9,043**	**7,009**	**5,673**	**11,783**	**6,795**	3%	28%	-22%
Change (%)	-25.2	-27.7	-38.7	-10.4	26.2	28.0	172.0	24.6	**24**			
Adj EBITDA margin (%)	11.4	8.9	5.1	11.7	12.5	9.5	11.7	13.6	**9.5**	(5)	63	(300)
Depreciation	902	935	1,107	1,016	1,118	1,227	1,252	775	**1,060**	16%	31%	10%
Interest	85	90	93	138	91	90	110	143	**110**	-18%	0%	-1%
Other Income	744	798	757	1,011	947	856	868	1,188	**962**	-11%	7%	-10%
PBT	**6,920**	**5,249**	**1,641**	**9,310**	**8,781**	**6,547**	**5,179**	**12,054**	**6,587**	-1%	25%	-25%
Tax	1,787	1,354	620	2,383	2,252	1,653	1,326	3,104	**1,686**			
Effective Tax Rate (%)	25.8	25.8	37.8	25.6	25.6	25.3	25.6	25.8	**26**			
Extra-ordinary items	-	-	(125)	-	-	-	-	-	**0**			
Reported PAT	**5,133**	**3,894**	**897**	**6,927**	**6,529**	**4,893**	**3,853**	**8,950**	**4,900**	0%	26%	-25%
Change (%)	(24.5)	(27.3)	(61.6)	(8.2)	27.2	25.7	329.7	29.2	**26**			
Adj PAT	**5,133**	**3,894**	**1,161**	**6,927**	**6,529**	**4,893**	**3,853**	**8,950**	**4,900**	0%	26%	-25%
Change (%)	(24.5)	(27.3)	(50.3)	(8.2)	27.2	25.7	232.0	29.2	**26**			


Segmental Performance (INR m)

Y/E March	FY26				FY27E				2QE	Var	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Sales												
Home Appliance and Air Solution division	49,086	39,481	27,885	65,165	55,814	47,717	32,904	68,475	44,021	8%	21%	-15%
Home entertainment division	13,547	22,262	13,264	15,374	16,575	26,084	15,652	18,121	27,159	-4%	17%	57%
EBIT												
Home Appliance and Air Solution division	5,643	3,245	1,108	7,748	6,467	4,164	3,784	9,764	3,962	5%	28%	-36%
Home entertainment division	2,125	2,810	1,273	2,066	3,163	3,370	2,348	3,196	3,531	-5%	20%	7%
EBIT Margin (%)												
Home Appliance and Air Solution division	11.5	8.2	4.0	11.9	11.6	8.7	11.5	14.3	9.0	(27)	51	(286)
Home entertainment division	15.7	12.6	9.6	13.4	19.1	12.9	15.0	17.6	13.0	(8)	30	(617)

Britannia Industries

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 06th Nov 2026
Time: 9:00 AM
Dial-in details:
+91 22 6280 1313 /
+91 22 7115 8214

Diamond Pass Registration

Financials & Valuations (INR b)

Y/E March	2027E	2028E	2029E
Sales	213.9	235.3	259.3
Sales Gr. (%)	11.7	10.0	10.2
EBITDA	39.8	45.2	51.2
EBITDA mrg. (%)	18.6	19.2	19.8
Adj. PAT	28.3	32.5	37.0
Adj. EPS (INR)	117.4	134.7	153.7
EPS Gr. (%)	12.2	14.8	14.1
BV/Sh.(INR)	235.6	274.6	330.6
Ratios			
RoE (%)	52.5	52.8	50.8
RoCE (%)	40.7	42.5	42.6
Payout (%)	78.8	70.1	62.8
Valuation			
P/E (x)	42.6	37.1	32.5
P/BV (x)	21.2	18.2	15.1
EV/EBITDA (x)	29.5	25.8	22.5
Div. Yield (%)	1.9	1.9	1.9

CMP: INR5,000

Beat in revenue with 13% volume growth; In-line EBITDA

- BRIT's consolidated net revenue up by 17% YoY to INR55.4b (est. INR54b).
- The volume growth stood at 13% YoY (est.10%, 2QFY26: -3%, 1QFY27: 9%)
- The company indicated that the growth was broad-based across channels and key states.
- Its Bakery and adjacency portfolio, alongside the International business, registered strong acceleration complementing the Biscuit growth.
- Moreover, the brand investments remained focused on driving consumer relevance through cultural and digital-first campaigns.
- Consolidated gross margin contracted by 200bp YoY and 190bp QoQ to 39.6% (est. 40.8%). BRIT remains watchful of the inflationary pressures.
- Employee expenses was up 11% YoY while Other expenses up by ~15% YoY.
- EBITDA margin contracted by 150bp YoY while expanded 150bp QoQ to 18.3% (est. of 19%).
- EBITDA up 7% YoY to INR10.2b (est. INR10.3b).
- PBT was up 11% to INR9.8b (est. INR9.7b).
- APAT was up 11% to INR7.3b (est. INR7.2b).

Consol. Quarterly Performance (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Base business volume gr. (%)	**2.0**	**-3.0**	**6.0**	**5.0**	**9.0**	**13.0**	**8.5**	**1.5**	**2.5**	**8.0**	**10.0**	
Net Revenue	**45,349**	**47,522**	**48,852**	**46,860**	**49,644**	**55,416**	**55,692**	**51,679**	**1,88,582**	**2,12,430**	**53,937**	2.7
YoY change (%)	9.8	4.1	9.5	7.1	9.5	16.6	14.0	10.3	7.5	12.6	13.5	
Other operating income	874	885	846	330	356	562	375	216	2,934	1,509	375	
YoY change (%)	-27.4	-12.7	-34.6	-41.8	-59.2	-36.4	-55.7	-34.5	-28.0	-48.6	-57.6	
Total Revenue	**46,222**	**48,406**	**49,698**	**47,189**	**50,000**	**55,978**	**56,067**	**51,895**	**1,91,516**	**2,13,939**	**54,312**	3.1
YoY change (%)	8.8	3.7	8.2	6.5	8.2	15.6	12.8	10.0	6.7	11.7	12.2	
Gross Profit	**18,631**	**20,177**	**21,500**	**19,879**	**20,750**	**22,195**	**23,548**	**22,334**	**80,187**	**88,827**	**22,159**	0.2
Margins (%)	40.3	41.7	43.3	42.1	41.5	39.6	42.0	43.0	41.9	41.5	40.8	
EBITDA	**7,571**	**9,545**	**10,286**	**8,529**	**8,401**	**10,217**	**11,550**	**9,667**	**35,930**	**39,835**	**10,319**	(1.0)
Margins (%)	16.4	19.7	20.7	18.1	16.8	18.3	20.6	18.6	18.8	18.6	19.0	
YoY growth (%)	0.4	21.8	21.7	5.9	11.0	7.0	12.3	13.3	12.7	10.9	8.1	
Depreciation	820	851	845	852	795	786	850	972	3,368	3,402	850	
Interest	262	347	333	187	229	358	300	294	1,128	1,181	350	
Other Income	570	521	595	555	614	735	650	543	2,240	2,543	600	
PBT	**7,059**	**8,869**	**9,703**	**8,044**	**7,991**	**9,808**	**11,050**	**8,945**	**33,675**	**37,794**	**9,719**	0.9
Tax	1,809	2,286	2,369	2,008	2,040	2,514	2,785	2,175	8,472	9,513	2,449	
Rate (%)	25.6	25.8	24.4	25.0	25.5	25.6	25.2	24.3	25.2	25.2	25.2	
Adjusted PAT	**5,201**	**6,551**	**7,182**	**6,056**	**5,934**	**7,260**	**8,228**	**6,559**	**24,990**	**27,981**	**7,224**	0.5
YoY change (%)	-0.6	23.2	23.3	8.3	14.1	10.8	14.6	8.3	13.8	12.0	10.3	

E: MOFSL Estimates

Bharti Hexacom

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th November 2026

Time: 12:00 hours IST

Financial Valuations (INR b)

INRb	FY27E	FY28E	FY29E
Net Sales	104.5	122.1	134.2
EBITDA	56.1	69.5	78.5
Adj. PAT	22.2	31.3	37.0
Adj. EPS (INR)	44.4	62.5	73.9
EPS Gr. (%)	29.9%	40.7%	18.2%
BV/Sh. (INR)	169.7	205.3	243.2
Ratios			
RoE (%)	28.4	33.3	33.0
RoCE (%)	19.1	25.9	30.1
Valuations			
P/E (x)	35.6	25.3	21.4
P/BV (x)	9.3	7.7	6.5
EV/EBITDA (x)	14.9	11.8	10.2

CMP: INR1,693 — Buy

In-line 2Q; slightly weaker than Airtel India

- Overall 2QFY27 reported revenue at INR25.8b (+11% YoY, in line) grew 3% QoQ. Excluding ICR revenue from in-roamers, customer revenue grew 2.6% QoQ to ~INR24.2b (vs. our est. INR24.4b).
- Overall 2Q reported EBITDA grew ~4% QoQ to INR13.8b (+14% YoY, in line).
- Reported EBITDA margin expanded ~65bp QoQ to 53.3% (+120bp YoY, in line) but remained significantly below 59.2% (up 10bp QoQ) for Bharti's India operations (ex-Indus).
- Reported EBITDAaL grew ~3.5% QoQ to INR12.5b, with pre-IND AS EBITDA margin rising ~40bp QoQ to 48.6%. Incremental pre-IND AS EBITDA margin stood at ~60% (vs. ~58% in 1QFY27).
- Depreciation and amortization rose ~1% QoQ to INR6b, while net finance cost declined ~1% QoQ (-16% YoY, ~10% higher than est.), resulting in PBT of INR7b (+7% QoQ, +24% YoY, in line).
- Reported PAT grew ~17% QoQ to INR5.7b (+34% YoY, 7% ahead of our est. of INR5.3b), mainly due to a lower tax rate.

Higher cash capex and cash tax outgo lead to moderation in FCF generation; dividend payments drive net debt higher

- BHL's reported segmental capex moderated ~9% YoY to INR3.4b (down ~12% QoQ, 17% below estimate); however, cash capex surged ~62% YoY to INR6.9b.
- Due to high capex and higher cash tax, free cash flow (after leases and interest payments) generation moderated to INR2.2b (vs. INR4.4b YoY). For 1HFY27, FCF stood at INR12.7b (vs. INR13.4b YoY).
- Overall net debt (ex-leases) increased INR6b QoQ to INR15.8b. Including the impact of leases, Hexacom's consolidated net debt rose ~INR5.6b QoQ to INR49.5b, likely due to dividend payments (INR9b).
- Net debt (ex-leases)-to-EBITDAaL increased to 0.31x (vs. 0.2x QoQ, vs. 0.79x for Bharti's India SA business).

Wireless: Steady 2Q, though slightly weaker than Bharti's India wireless business

- Wireless ARPU grew ~2.2% QoQ (vs. +1.5%/2.7% QoQ for RJio/Bharti India) to INR264 (+5% YoY, in line), due to one additional day QoQ and rationalization of INR299 plan.
- Paying subscriber base declined by ~16k (vs. 210k net adds QoQ and lower than our est. ~165k net adds). Comparatively, Bharti reported ~0.7m net adds.
- However, the subscriber mix continued to improve with ~48k smartphone net adds QoQ. BHL's share of Bharti's 4G/5G net adds moderated to modest ~1.7% (vs. ~6.9% QoQ and ~7.6% share of Airtel's 4G/5G subscriber base).

- The share of data subs in BHL's mix improved ~20bp QoQ to 80% but remained below Airtel India's at 81% (+45bp QoQ).
- Reported wireless revenue grew 2.7% QoQ to INR24.6b (+10% YoY, ~1% above our est. INR24.4b).
- Customer revenue grew ~2.5% QoQ (vs. ~3.2%/3.4% QoQ for R-Jio, including FTTH and Airtel's India wireless) to INR23b (+9% YoY, in line).
- Wireless EBITDA at INR13.6b (+11% YoY, in line) was up 2.9% QoQ (vs. ~5.2% QoQ R-Jio, including FTTH), and slightly below ~3.8% QoQ growth for Airtel's India wireless business.
- Wireless EBITDA margins expanded ~10bp QoQ to 55.4% (+60bp YoY, vs. +100bp QoQ to 55.7% for R-Jio, including FTTH), and was slightly weaker than 20bp QoQ improvement for Airtel's India wireless business to 61%.
- Incremental margins stood at ~59% (vs. 88%/68% for RJio/Bharti). On a YoY basis, incremental margin came in at ~62%
- Wireless capex moderated ~23% YoY to INR1.87b (-16% QoQ, 24% below estimate).

Homes and Offices: Weaker than our estimates, but growth remains ahead of Airtel India

- Homes BB subs base reached ~0.99m (+76% YoY) as net adds came in at 71k (vs. 75k QoQ and our est. of 90k). BHL accounted for ~10.5% of Airtel's Homes BB net adds (vs. ~6.4% share in Airtel's Homes BB subscriber base).
- Reported Homes ARPU declined ~1.4% QoQ to INR475/month (-2% YoY, vs. ~3.5% QoQ dip for Airtel to INR509/month).
- Homes and Offices revenue grew ~4% QoQ to INR1.31b (+49% YoY, 9% below), but remained better than ~2% QoQ growth for Airtel India.
- Homes and Offices EBITDA at INR0.53b (18% miss) rose ~6% QoQ (+79% YoY, vs. 1.4% QoQ growth for Airtel), as margins expanded ~80bp QoQ to 40.5% (+675bp YoY). Comparatively, Airtel's Home BB margins contracted ~35bp QoQ to 48.8%.
- Capex in Homes Business moderated ~6% QoQ to INR1.5b (up +19% YoY, 8% below).

Other highlights: Data engagement remains ahead of Airtel's India wireless business

- Data volume grew 5% QoQ (vs. 8% QoQ in 1QFY27, +3%/7% QoQ R-Jio, including FTTH/Airtel India).
- Data usage per sub improved to 38.1GB/month (vs. 36.2GB QoQ, 44.2GB reported by R-Jio including FTTH and higher than 36.5GB for Airtel on pan-India basis).
- Voice usage on network was stable QoQ (+1% QoQ in 1QFY27, flat QoQ for R-Jio and Airtel India), with minute of usage (MoU) per subscriber moderating to 1,105mins/month (vs. 1,114 mins QoQ, ~942 mins for R-Jio) though slightly lower vs. 1,131 mins for Airtel on pan-India basis).
- Tower count increased by 51 QoQ (vs. increase of 147 QoQ in 1QFY27) to reach ~26.94k towers. Revenue per site grew ~2% QoQ to INR304k/month (+8% YoY, vs. 3% QoQ to INR294k for Airtel).

Exhibit 6: Consolidated results

	2QFY26	1QFY27	2QFY27	YoY	QoQ	2QFY27E	vs est.
Bharti Hexacom							
Revenues	**23,173**	**25,099**	**25,818**	**11.4**	**2.9**	**25,743**	**0.3**
Access charges	1,675	2,041	2,077	24.0	1.8	1,841	12.8
License and spectrum fee	2,138	2,303	2,336	9.3	1.4	2,368	(1.4)
Network operating costs	5,303	5,376	5,618	5.9	4.5	5,537	1.5
Employee costs	320	268	325	1.6	21.3	342	(5.1)
SG&A expenses	1,656	1,889	1,691	2.1	(10.5)	1,931	(12.4)
Total costs	11,092	11,877	12,047	8.6	1.4	12,020	0.2
EBITDA	**12,081**	**13,222**	**13,771**	**14.0**	**4.2**	**13,723**	**0.3**
EBITDA margin (%)	52.1	52.7	53.3	120 bps	66 bps	53.3	3 bps
Depreciation and amortization	5,543	5,925	6,003	8.3	1.3	5,984	0.3
EBIT	**6,538**	**7,297**	**7,768**	**18.8**	**6.5**	**7,739**	**0.4**
EBIT margin (%)	28.2	29.1	30.1	187 bps	101 bps	30.1	3 bps
Net finance cost	897	767	757	(15.6)	(1.3)	689	9.8
PBT	**5,641**	**6,530**	**7,011**	**24.3**	**7.4**	**7,050**	**(0.6)**
Tax provision	1,429	1,706	1,350	(5.5)	(20.9)	1,774	(23.9)
Extraordinary items	-	-	-			-	
Reported net income	**4,212**	**4,824**	**5,661**	**34.4**	**17.4**	**5,275**	**7.3**
Adjusted net income	**4,212**	**4,824**	**5,661**	**34.4**	**17.4**	**5,275**	**7.3**
Reported EPS (INR)	8.4	9.6	11.3	34.4	17.4	10.6	7.3
Adjusted EPS (INR)	8.4	9.6	11.3	34.4	17.4	10.6	7.3
Costs as % of revenue							
Access charges	(7.2)	(8.1)	(8.0)	(82)bps	9 bps	(7.2)	(89)bps
License and spectrum fee	(9.2)	(9.2)	(9.0)	18 bps	13 bps	(9.2)	15 bps
Network operating costs	(22.9)	(21.4)	(21.8)	112 bps	(34)bps	(21.5)	(25)bps
Employee costs	(1.4)	(1.1)	(1.3)	12 bps	(19)bps	(1.3)	7 bps
SG&A expenses	(7.1)	(7.5)	(6.5)	60 bps	98 bps	(7.5)	95 bps
Total costs	(47.9)	(47.3)	(46.7)	120 bps	66 bps	(46.7)	3 bps

Exhibit 7: Net debt trends

Debt and cash trends	Mar-23	Sep-23	Mar-24	Sep-24	Mar-25	Sep-25	Mar-26	Jun-26	Sep-26
Reported gross debt	**62,693**	**62,353**	**48,347**	**48,901**	**37,800**	**31,264**	**26,943**	**26,943**	**26,521**
ST debt (inc. current maturities)	15,001	35,013	20,001	11,907	8,746	2,522	0	0	5
Deferred payment liabilities	27,693	27,340	28,346	36,994	29,054	28,742	26,943	26,943	26,516
Cash and Cash Equivalents	**11,015**	**15,775**	**2,774**	**340**	**910**	**3,081**	**6,642**	**17,338**	**10,767**
Cash and Cash Equivalents	555	463	398	334	171	212	330	100	75
Investments & Receivables	10,460	15,312	2,376	6	739	2,869	6,312	17,238	10,692
Net Debt excluding Lease Obligations	**51,678**	**46,578**	**45,573**	**48,561**	**36,890**	**28,183**	**20,300**	**9,604**	**15,755**
Lease Obligation	29,343	30,968	32,700	36,229	35,729	34,806	34,430	34,321	33,749
Net Debt including Lease Obligations	**81,021**	**77,546**	**78,273**	**84,790**	**72,619**	**62,989**	**54,730**	**43,925**	**49,504**
Net debt (including leases) to EBITDA	**2.63**	**2.35**	**2.23**	**2.12**	**1.55**	**1.30**	**1.08**	**0.83**	**0.90**
Net debt (excluding leases) to EBITDAaL			**1.46**	**1.35**	**0.87**	**0.64**	**0.44**	**0.20**	**0.31**

Exhibit 8: FCF (post-interest and leases)

FCF, after lease and interest payment	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27	FY25	FY26
CF before WC changes	**8,610**	**8,569**	**10,207**	**9,577**	**10,963**	**10,338**	**10,813**	**11,475**	**13,818**	**11,412**	**36,963**	**43,589**
WC changes	4,475	1,826	631	1,932	2,474	937	1,388	(3,748)	1,807	203	8,864	1,051
Cashflow from operations	**13,085**	**10,395**	**10,838**	**11,509**	**13,437**	**11,275**	**12,201**	**7,727**	**15,625**	**11,615**	**45,827**	**44,640**
Lease payments	(755)	(750)	(1,004)	(953)	(914)	(966)	(929)	(807)	(919)	(1,039)	(3,462)	(3,616)
Cash capex	**(4,728)**	**(5,252)**	**(4,025)**	**(11,167)**	**(2,956)**	**(4,220)**	**(4,119)**	**(3,533)**	**(3,629)**	**(6,853)**	**(25,172)**	**(14,829)**
Paid finance cost	(1,728)	(1,661)	(671)	(1,335)	(625)	(1,647)	(599)	(1,940)	(605)	(1,520)	(5,395)	(4,811)
FCF, after lease and interest payment	**5,874**	**2,732**	**5,138**	**(1,946)**	**8,942**	**4,442**	**6,554**	**1,447**	**10,472**	**2,203**	**11,798**	**21,384**
Spectrum prepayments				8,576							8,576	0
Adjusted FCF after leases and interest	**5,874**	**2,732**	**5,138**	**6,630**	**8,942**	**4,442**	**6,554**	**1,447**	**10,472**	**2,203**	**20,374**	**21,384**

Exhibit 9: Segment Result

	2QFY26	1QFY27	2QFY27	YoY	QoQ	2QFY27E	vs est
Segmental revenue (INR b)							
Wireless	**22,385**	**23,953**	**24,610**	**9.9**	**2.7**	**24,422**	**0.8**
Homes	880	1,265	1,312	49.0	3.7	1,443	(9.1)
Overall	**23,173**	**25,099**	**25,818**	**11.4**	**2.9**	**25,743**	**0.3**
Eliminations	(92)	(119)	(104)			(122)	
Segmental EBITDA (INR b)							
Wireless	**12,266**	**13,247**	**13,635**	**11.2**	**2.9**	**13,578**	**0.4**
Homes	297	502	531	78.8	5.8	645	(17.7)
Overall	**12,081**	**13,222**	**13,771**	**14.0**	**4.2**	**13,723**	**0.3**
Eliminations	(482)	(527)	(395)			(500)	
Segmental EBITDA margin (%)							
Wireless	**54.8**	**55.3**	**55.4**	**61 bps**	**10 bps**	**55.6**	**(19)bps**
Homes	33.7	39.7	40.5	674 bps	79 bps	44.7	(426)bps
Overall	**52.1**	**52.7**	**53.3**	**120 bps**	**66 bps**	**53.3**	**3 bps**
Segmental Capex (INR b)							
Wireless	**2,422**	**2,223**	**1,865**	**(23)**	**(16)**	**2,442**	**(24)**
Homes	1,254	1,599	1,498	19	(6)	1,620	(8)
Overall	**3,676**	**3,822**	**3,363**	**(8.5)**	**(12.0)**	**4062**	**(17.2)**

Exhibit 10: Key performance indicators

	2QFY26	1QFY27	2QFY27	YoY	QoQ	2QFY27E	vs. est
Operating metrics							
India wireless							
Wireless ARPU	**251**	**259**	**264**	**5.4**	**2.2**	**264**	**0.1**
EoP reported subs (m)	**28.0**	**29.0**	**29.0**	**3.3**	**(0.1)**	**29.2**	**(0.6)**
Net adds ('000)	(110)	210	(16)			166	(109.9)
EoP data subs (m)	**22.0**	**23.1**	**23.2**	**5.2**	**0.2**	**23.4**	**(0.8)**
Data net adds ('000)	184	342	49			230	(79)
Data subs proportion (%)	78.6	79.8	80.0	143 bps	21 bps	80.1	(12)bps
EoP 4G subs (m)	**22.0**	**23.1**	**23.1**	**5.2**	**0.2**	**23.3**	**(0.9)**
4G net adds ('000)	193	344	48			269	(82)
Data volume (b MBs)	2,077	2,556	2,713	30.6	6.1	2,604	4.2
Data usage per data sub (GB/month)	**30.7**	**36.2**	**38.1**	**23.9**	**5.0**	**36.5**	**4.4**
Average data realization (INR/GB)	11.0	9.6	9.3	(15.7)	(3.1)	9.6	(3.2)
Voice usage on network (b mins)	93.7	96.6	96.1	2.6	(0.5)	97.7	(1.7)
Minute of usage per sub (min/month)	**1,111**	**1,114**	**1,105**	**(0.5)**	**(0.8)**	**1,120**	**(1.3)**
Network towers ('000)	26,529	26,889	26,940	1.5	0.2	27,039	(0.4)
MBB sites ('000)	92,455	96,012	97,176	5.1	1.2	-	
Revenue per tower (INR/month)	2,80,610	2,96,923	3,04,148	8.4	2.4	-	
Homes							
Cities covered (#)	117	121	122	4.3	0.8	-	
Reported ARPU (INR/month)	**484**	**482**	**475**	**(1.9)**	**(1.4)**	**481**	**(1.1)**
Calculated ARPU (INR/month)	**552**	**479**	**459**	**(16.9)**	**(4.2)**	**500**	**(8.2)**
EoP reported subs (k)	**561**	**918**	**989**	**76.1**	**7.8**	**1,008**	**(1.9)**
Net adds ('000)	60	75	71			90	
Implied other revenue (INR m)	108	(8)	(48)	(144.2)	481.3	54	(188.4)

Prestige Estates Projects

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 06 November 2026
Time: 15:30 IST
Dial-in details:
+91-22 6280 1145 / +91 22 7115 8046

Financials & Valuations (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	126.9	143.2	176.5
EBITDA	37.1	43.1	54.0
EBITDA Margin (%)	29.2	30.1	30.6
PAT	12.0	15.8	24.0
EPS (INR)	27.8	36.7	55.7
EPS Gr. (%)	133.0	361.6	278.4
BV/Sh. (INR)	377.8	413.0	467.2
Ratios			
RoE (%)	7.5	9.3	12.7
RoCE (%)	8.8	9.9	11.5
Payout (%)	7.2	4.1	2.7
Valuations			
P/E (x)	59.2	44.8	29.5
P/BV (x)	4.3	4.0	3.5
EV/EBITDA (x)	22.5	19.5	15.5
Div yld (%)	0.1	0.1	0.1

CMP: INR1,643 — Buy

Strong operational performance

Operations

- In 2QFY27, PEPL reported residential presales increased 20% YoY to INR72.3b (8% beat on estimates), with sales volume of 5.84msf across 3,910 units.
- Bengaluru remained the largest contributor to 2QFY27 residential sales, accounting for 54% of sales, followed by Hyderabad at 15%, Mumbai at 12%, Chennai at 11% and other markets at 8%. Average realisation stood at INR12,375/sq. ft, down 16% YoY
- It launched three residential projects aggregating 5.91msf with a combined GDV of INR41.8b during Q2FY27 — Prestige Palm Court in Chennai (1.99msf, INR13.3b), Garden Breeze @ TPC in Bengaluru (1.23msf, INR11.0b) and Prestige Parklane in Bengaluru (2.69msf, , INR17.5b).
- Residential collections stood at INR52.9b in Q2FY27, up 26% YoY (7% beat on our estimates). taking H1FY27 collections to INR101.0b, reflecting healthy customer demand and execution across projects.
- During the quarter, the company has added 17 acres with a GDV potential of INR56b in Sector 109, Gurugram. The company has lined up a launch pipeline of over INR466b GDV for H2FY27 across Bengaluru, Mumbai, NCR, Chennai and Hyderabad.
- Across 2QFY27, it launched or commenced construction on nine projects spanning 10.09msf across business verticals and has completed construction across 5.07msf. Post the quarter end, the company also acquired a ~0.94msf retail asset in South Bengaluru, with an estimated annual rental potential of over INR1.35b. It is expected to become operational in FY28.
- The company Strengthened its hospitality business through a strategic investment of INR30.0b by CPP Investments in Prestige Hospitality Ventures for an approximately 27% stake.
- Retail malls achieved 10% YoY growth in quarterly gross turnover to INR7.21b, with occupancy at 99%.

Financials

- In 2QFY27, revenue declined 15% YoY to INR20.6b (32% miss on our estimate).
- EBITDA remained flattish YoY at INR9.3b, broadly in-line. EBITDA margins stood at a record high of 45.0%.
- It reported PAT declined 48% YoY to INR2.2b (19% miss on our estimate). PAT margin stood at 10.9%.
- Net debt increased INR2.1b QoQ to INR121b. The cost of debt reduced by 21bps to 9.09%.

Quarterly Performance

Y/E March	FY26				FY27E				FY26	FY27	FY27 2Q Est.	2QE Var. (%/bp)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
Net Sales	**23,073**	**24,317**	**38,726**	**40,738**	**26,751**	**20,602**	**39,892**	**55,979**	**1,26,854**	**1,43,224**	**30,491**	**-32**
YoY Change (%)	23.9	5.5	134.1	166.5	15.9	-15.3	3.0	37.4	72.6	12.9	25.4	
Total Expenditure	14,135	15,219	30,126	30,283	18,155	11,341	28,178	42,440	89,763	1,00,113	21,617	
EBITDA	**8,938**	**9,098**	**8,600**	**10,455**	**8,596**	**9,261**	**11,714**	**13,539**	**37,091**	**43,110**	**8,874**	**4**
Margins (%)	38.7	37.4	22.2	25.7	32.1	45.0	29.4	24.2	29.2	30.1	29.1	1,584.8
Depreciation	2,162	2,186	2,335	2,378	2,257	2,434	2,799	3,557	9,061	11,047	2,596	
Interest	3,839	3,851	3,838	4,296	4,184	4,822	5,063	5,413	15,824	19,482	4,393	
Other Income	1,614	2,661	129	697	1,605	1,620	2,673	3,698	5,101	9,596	2,043	
PBT before EO expense	**4,551**	**5,722**	**2,556**	**4,478**	**3,760**	**3,625**	**6,525**	**8,267**	**17,307**	**22,177**	**3,928**	**-8**
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	**4,551**	**5,722**	**2,556**	**4,478**	**3,760**	**3,625**	**6,525**	**8,267**	**17,307**	**22,177**	**3,928**	**-8**
Tax	1,271	1,266	336	1,209	943	1,080	1,539	1,669	4,082	5,231	927	
Rate (%)	27.9	22.1	13.1	27.0	25.1	29.8	23.6	20.2	23.6	23.6	23.6	
MI & P/L of Asso. Cos.	355	153	-6	768	458	304	321	71	1,270	1,154	246	
Reported PAT	**2,925**	**4,303**	**2,226**	**2,501**	**2,359**	**2,241**	**4,665**	**6,528**	**11,955**	**15,793**	**2,756**	
Adj PAT	**2,925**	**4,303**	**2,226**	**2,501**	**2,359**	**2,241**	**4,665**	**6,528**	**11,955**	**15,793**	**2,756**	**-19**
YoY Change (%)	25.8	123.9	1,157.6	900.4	-19.4	-47.9	109.5	161.0	155.7	32.1	-35.9	
Margins (%)	12.7	17.7	5.7	6.1	8.8	10.9	11.7	11.7	9.4	11.0	9.0	

Source: Company, MOFSL. **We may revisit our estimates after the conference call**

Fortis Healthcare

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR820

Revenue in-line; EBITDA/PAT – better-than-expected

- Fortis 2QFY27 revenues grew 17.3% YoY to INR27.3b (in-line).
  - Hospital segment revenue grew 18.6% YoY to INR23.4b, driven by 6.8% YoY growth in ARPP and remaining by volumes.
  - Diagnostics segment revenue grew 12.2% YoY to INR4.5b. The YoY growth is driven by both better realization and higher volumes.
- EBITDA margin contracted by 110bp YoY to 22.8%. This was due to increase in employee expense and other expenses (up 140bps/80bp as % of sales).
- EBITDA grew 12% YoY to INR6.2b (beat by 5%).
- Adj. PAT was largely stable YoY to INR3.1b (beat by 5%).
- For 1HFY27, Revenue/EBITDA/PAT grew by 17.4%/10.8%/2.6% to INR52.8b/11.6b/5.7b.

Other key highlights

- **Hospital segment:**
  - Hospital EBITDA grew 21% YoY to INR5.5b for 2QFY27.
  - Occupancy for 2QFY27 is 72%.
  - ARPP grew by 6.8% YoY to INR210k in 2QFY27. This implies volume growth of ~14% YoY
  - CONGO mix for the quarter was 52.8% (down 160bp YoY).
- **Diagnostic segment:**
  - Diagnostic EBITDA grew 13% YoY to INR1.2b for 2QFY27
  - During 2QFY27, Agilus conducted 11.39m tests, vs 10.62m in 2QFY26.
  - ARPT in 2QFY27 grew 5% YoY to INR393 per test.
  - ARPP in 2QFY27 grew 6% YoY to INR958 per patient.
  - Agilus added 300+ customer touchpoints to its network in 2QFY27.
  - Agilus B2C: B2B revenue mix stood at 54:46 in 2QFY27 compared to 52:48 in 2QFY26.

Conference Call Details



Date: 6th Nov 2026
Time: 11:00 am IST
Dial-in details:
Zoom: Link

Financials & Valuations (INRb)

Y/E MARCH	FY26	FY27E	FY28E
Sales	91.2	106.6	118.2
EBITDA	20.8	24.6	29.1
Adj. PAT	10.5	12.5	15.7
EBIT Margin (%)	22.8	23.0	24.6
Cons. Adj. EPS (INR)	13.9	16.5	20.8
EPS Gr. (%)	24.4	18.4	26.4
BV/Sh. (INR)	131.1	146.4	166.0
Ratios			
Net D:E	0.3	0.2	0.1
RoE (%)	11.2	11.9	13.3
RoCE (%)	10.5	10.8	12.0
Payout (%)	8.5	7.1	5.6
Valuations			
P/E (x)	58.8	49.7	39.3
EV/EBITDA (x)	31.2	26.3	22.0
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	1.1	1.0	1.6
EV/Sales (x)	7.1	6.1	5.4

Consolidated - Quarterly Earning Model

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	vs Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Gross Sales	**21,667**	**23,314**	**22,650**	**23,557**	**25,450**	**27,348**	**26,470**	**27,365**	**91,188**	**1,06,634**	**27,012**	1%
YoY Change (%)	16.6	17.3	17.5	17.4	17.5	17.3	16.9	16.2	17.2	16.9	15.9	
Total Expenditure	16,761	17,751	17,594	18,323	20,079	21,116	20,150	20,732	70,429	82,078	21,079	
EBITDA	**4,907**	**5,563**	**5,057**	**5,233**	**5,371**	**6,232**	**6,320**	**6,633**	**20,760**	**24,556**	**5,933**	5%
Margins (%)	22.6	23.9	22.3	22.2	21.1	22.8	23.9	24.2	22.8	23.0	22.0	
Depreciation	1,015	1,058	1,201	1,220	1,219	1,283	1,223	1,265	4,494	4,990	1,255	
Interest	696	749	857	843	804	783	881	881	3,145	3,350	881	
Other Income	154	226	83	44	145	67	106	109	507	427	108	
PBT before EO expense	**3,350**	**3,982**	**3,081**	**3,215**	**3,493**	**4,233**	**4,321**	**4,597**	**13,627**	**16,643**	**3,904**	
Extra-Ord expense	-126	-235	459	35	-95	0	0	0	132	-125	0	
PBT	**3,477**	**4,217**	**2,622**	**3,180**	**3,588**	**4,233**	**4,321**	**4,597**	**13,495**	**16,768**	**3,904**	
Tax	838	966	683	530	904	1,118	1,037	1,103	3,017	4,163	937	
Rate (%)	24.1	22.9	26.0	16.7	25.2	26.4	24.0	24.0	22.4	24.8	24.0	
MI & P/L of Asso	36	32	1	-9	20	20	10	10	61	61	10	
Reported PAT	**2,603**	**3,219**	**1,937**	**2,659**	**2,664**	**3,094**	**3,274**	**3,484**	**10,418**	**12,545**	**2,957**	
Adj PAT	**2,507**	**3,038**	**2,277**	**2,688**	**2,593**	**3,094**	**3,274**	**3,484**	**10,509**	**12,451**	**2,957**	5%
YoY Change (%)	51.2	37.8	0.6	18.8	3.4	1.9	43.8	29.6	24.2	18.5	-2.7	
Margins (%)	11.6	13.0	10.1	11.4	10.2	11.3	12.4	12.7	11.5	11.7	10.9	

Aditya Infotech

BSE SENSEX	S&P CNX
79,310	24,573

Conference Call Details



Date: 5thOct, 2026
Time: **12:30 pm** IST
Concall link:
Click here

CMP: INR4,170 — Buy

Strong earnings beat driven by better-than-expected operating leverage

- Consol. revenue grew 90% YoY/grew 25% QoQ to INR17.5b (est. INR16.6b).
- EBITDA grew 2.8x YoY/49% QoQ to INR3b (est. INR2.3b)
- EBITDA margin came in at 17.4% vs 11.8%/14.5% in 2QFY26/1QFY27. EBITDA margin expansion of 560bp was led by operating leverage (employee expense/other expense reduced 190bp/350bp YoY).
- Adj. PAT grew 3x YoY/47% QoQ to INR2.1b. (est. INR1.6b).
- In 1HFY27, Revenue/EBITDA/APAT grew 90%/3x/3.4x YoY to INR31.5b/INR5.1b/INR3.5b.
- In 1HFY27, CFO grew 2.9x YoY to INR5.2b. Gross debt stood at INR3.6b as of Sep'26 vs INR1.1b as of Mar'26
- Note: PAT is adjusted for losses of INR343.73m arising from a fire at wholly-owned subsidiary, AIL Dixon Technologies, which resulted in loss of inventory and impacted PPE. The insurance claim remains under assessment, with no recovery recognized.
- Aditya Infotech raised its FY27 revenue guidance to INR65-68b (+54-61% YoY) from INR60-65b following a strong 1H performance.
- The company also increased its PAT margin guidance to 9-10% (vs 8.5-9.5% previous guidance) as QIP proceeds help lower finance costs.
- Additionally, the company acquired a 30% stake in KGraph AI Solutions for INR454m to integrate AI video analytics into its hardware.

Quarterly performance

Y/E March	FY26				FY27				FY26	FY27E	FY27	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var
Gross Sales	**7,400**	**9,196**	**11,391**	**14,220**	**14,024**	**17,460**	**17,077**	**18,770**	**42,208**	**66,425**	**16,553**	**5%**
YoY Change (%)	16.4	37.5	37.3	45.5	89.5	89.9	49.9	32.0	35.6	57.4	80.0	
Total Expenditure	6,791	8,111	9,992	11,653	11,987	14,425	14,451	15,787	36,547	56,461	14,236	
EBITDA	**609**	**1,085**	**1,399**	**2,567**	**2,037**	**3,034**	**2,626**	**2,983**	**5,661**	**9,964**	**2,317**	**31%**
Margins (%)	8.2	11.8	12.3	18.1	14.5	17.4	15.4	15.9	13.4	15.0	14.0	
Depreciation	104	106	123	227	129	148	260	334	560	853	130	
Interest	105	69	51	77	43	60	25	27	302	136	40	
Other Income	40	26	47	16	41	39	55	66	128	202	40	
PBT before EO expense	**441**	**935**	**1,272**	**2,279**	**1,906**	**2,866**	**2,396**	**2,688**	**4,927**	**9,178**	**2,187**	
Extra-Ord expense	0	0	0	0	0	-344	0	280	0	0	-280	
PBT	**441**	**935**	**1,272**	**2,279**	**1,906**	**2,522**	**2,396**	**2,408**	**4,927**	**9,178**	**1,907**	
Tax	112	236	313	588	484	664	602	754	1,248	2,324	485	
Rate (%)	25.4	25.2	24.6	25.8	25.4	26.3	25.1	25.4	25.3	25.3	25.4	
MI & Profit/Loss of Asso. Cos.	-2	5	3	10	10	-4	0	0	0	0	0	
Reported PAT	**327**	**705**	**963**	**1,701**	**1,432**	**1,855**	**1,794**	**1,654**	**3,680**	**6,854**	**1,423**	
Adj PAT	**327**	**705**	**963**	**1,701**	**1,432**	**2,108**	**1,794**	**2,005**	**3,680**	**6,854**	**1,632**	**29%**
YoY Change (%)	46.1	199.7	140.4	209.6	338.5	199.3	86.4	17.9	145.1	86.3	131.6	
Margins (%)	4.4	7.7	8.5	12.0	10.2	12.1	10.5	10.7	8.7	10.3	9.9	

Tube Investments

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th Nov 2026
Time: 10am IST
Dial-in details: {Link}

Financials & Valuations (INR b)

INR b	FY26	FY27E	FY28E
Sales	85.6	91.9	99.4
EBITDA	10.8	10.4	12.3
Adj. PAT	8.4	7.8	9.2
EPS (INR)	43.4	40.2	47.7
EPS Gr. (%)	12.4	-7.3	18.7
BV/Sh. (INR)	309.4	345.6	388.4
Ratios			
RoE (%)	15.0	12.3	13.0
RoCE (%)	19.4	16.2	17.1
Payout (%)	8.2	9.9	10.5
Valuations			
P/E (x)	-0.2	-0.2	-0.2
P/BV (x)	0.0	0.0	0.0
Div. Yield (%)	1.5	0.7	1.1
FCF Yield (%)	85.6	91.9	99.4

CMP: INR2,299 — Buy

Earnings beat led by strong revenue growth

- TI's 2QFY27 standalone revenue grew 28% YoY to INR27.1b (17% above our est.).
- EBITDA margins contracted ~300bp YoY to 10.1% (vs. our est. of 10.8%).
- As a result, EBITDA declined 1% YoY to INR2.7b (9% above est).
- Segmental result
  - Mobility business revenue grew 28% YoY to INR2.5b, while EBIT margin improved 100bp YoY at 3.2%.
  - Engineering business revenue grew 32% YoY to INR18.2b, while EBIT margins contracted 250bp YoY to 9.4%.
  - MFB revenue grew 16% YoY to INR4.7b, while EBIT margins contracted 40bp YoY to 10.4%.
  - Other business revenue grew 15% YoY to INR2.6b, while EBIT margins were largely flat YoY at 7.8%.
- Adj. PAT was largely flat YoY at INR1.8b (10% above est).
- **Valuation and view:** Adjusted for its stake in CG Power and Shanti Gears, the standalone entity is valued at -0.2x/-0.2x FY27E/FY28E EPS.

Quarterly performance (S/A) (INR M)

Y/E March	FY26				FY27E				FY26	FY27E		VAV.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net Sales	**20,066**	**21,190**	**21,522**	**22,786**	**23,662**	**27,105**	**22,868**	**18,307**	**85,564**	**91,942**	**23,137**	17.2
YoY Change (%)	2.4	2.6	12.7	16.4	17.9	27.9	6.3	-19.7	8.4	7.5	9.2	
EBITDA	**2,474**	**2,765**	**3,094**	**2,511**	**2,459**	**2,732**	**2,743**	**2,459**	**10,844**	**10,393**	**2,507**	9.0
YoY Change (%)	3.1	12.4	27.3	10.1	-0.6	-1.2	-11.3	-2.1	12.9	-4.2	-9.3	
Margins (%)	12.3	13.1	14.4	11.0	10.4	10.1	12.0	13.4	12.7	11.3	10.8	-80bp
Depreciation	450	474	477	487	494	494	555	641	1,888	2,185	535	
Interest	37	16	14	11	11	12	30	87	78	140	38	
Other Income	234	229	78	1,593	174	306	120	1,504	2,110	2,104	240	
PBT before EO expense	**2,221**	**2,504**	**2,681**	**3,606**	**2,127**	**2,532**	**2,278**	**3,235**	**10,988**	**10,172**	**2,174**	
Tax	540	637	641	737	541	650	535	664	2,553	2,391	511	
Tax Rate (%)	24.3	25.4	25.3	24.0	25.4	25.7	23.5	20.5	23.2	23.5	23.5	
Adj PAT	**1,681**	**1,868**	**2,005**	**2,861**	**1,586**	**1,882**	**1,743**	**2,571**	**8,472**	**7,782**	**1,663**	13.1
YoY Change (%)	8.8	11.3	24.7	9.9	-5.6	0.8	-13.1	-10.1	13.4	-8.1	-10.9	

E: MOFSL Estimates

Segmental Mix (INR m) **(INR M)**

	FY26				FY27E				FY26	FY27E		VAV.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Mobilty business	1,984	1,938	1,831	2,076	2,504	2,470	1,977	1,582	7,828	8,534	2,131	15.9
Growth (%)	9.8	15.7	29.1	14.8	26.2	27.5	8.0	(23.8)	16.7	9.0	10.0	
PBIT margin (%)	3.5	2.2	2.2	2.0	3.6	3.2	-	5.0	2.5	2.9	-	
Contribution (%)	9.9	9.1	8.5	9.1	10.6	9.1	8.6	8.6	9.1	9.3	9.2	
Engineering business	12,982	13,816	14,375	14,949	15,663	18,281	15,238	11,380	56,208	60,561	15,198	20.3
Growth (%)	2.6	4.4	18.6	21.7	20.6	32.3	6.0	(23.9)	12.4	7.7	10.0	
PBIT margin (%)	11.8	11.9	13.6	11.8	9.8	9.4	-	27.9	12.3	10.6	-	
Contribution (%)	64.7	65.2	66.8	65.6	66.2	67.4	66.6	62.2	65.7	65.9	65.7	
Metal formed business	3,658	4,079	4,084	4,209	4,078	4,728	4,370	4,007	16,058	17,183	4,364	8.3
Growth (%)	2.3	0.9	2.2	4.4	11.5	15.9	7.0	(4.8)	0.8	7.0	7.0	
PBIT margin (%)	10.0	10.9	11.3	8.4	6.8	10.4	-	14.7	10.1	7.9	-	
Contribution (%)	18.2	19.2	19.0	18.5	17.2	17.4	19.1	21.9	18.8	18.7	18.9	
Other business	2,363	2,269	2,137	2,460	2,561	2,598	2,287	2,244	9,229	9,690	2,450	6.0
Growth (%)	(4.3)	(6.7)	(15.3)	0.8	8.4	14.5	7.0	(8.8)	(6.5)	5.0	8.0	
PBIT margin (%)	7.2	8.1	8.9	6.4	8.1	7.8	-	10.0	7.6	6.6	-	
Contribution (%)	11.8	10.7	9.9	10.8	10.8	9.6	10.0	12.3	10.8	10.5	10.6	
Total Revenue (post inter segment)	**20,066**	**21,190**	**21,522**	**22,786**	**23,662**	**27,105**	**22,868**	**18,307**	**85,564**	**91,942**	**23,137**	
Growth (%)	2.4	2.6	12.7	16.4	17.9	27.9	6.3	(19.7)	8.4	7.5	9.2	

E: MOFSL Estimates

Thermax

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th November 2026
Time: 11:00 am IST
Dial-in details:
Diamond pass

Financials & Valuations (INR b)

Y/E March	2027E	2028E	2029E
Sales	127.9	154.0	178.7
EBITDA	10.6	15.8	18.7
Adj. PAT	6.1	9.7	11.7
Adj. EPS (INR)	54.5	86.4	104.2
EPS Gr. (%)	-9.3	58.5	20.6
BV/Sh.(INR)	532.4	603.8	693.0
Ratios			
RoE (%)	10.6	15.2	16.1
RoCE (%)	9.2	12.6	13.4
Valuations			
P/E (x)	61.0	38.5	31.9
P/BV (x)	6.2	5.5	4.8
EV/EBITDA (x)	36.5	24.2	20.2
Div. Yield (%)	0.5	0.5	0.5

CMP:INR4,251 — Sell

Results below our estimates

- Thermax reported a weak set of results, with a miss on revenue, EBITDA, and PAT.
- Revenue increased 11% YoY to INR27.6b in 2QFY27 vs. our estimate of INR29b. YoY growth was supported by growth seen in all segments.
- Gross margin contracted ~130bp YoY to 45.8% (vs. our estimate of 45.5%).
- Absolute EBITDA rose 13% YoY to INR1.9b, vs. our estimate of INR2.3b.
- While gross margin was broadly in-line with our estimate, EBITDA margin 7% came below our est. of 8%, mainly due to higher-than-expected employee cost as % of sales. Quarterly profitability was affected in the Industrial Product Segment due to product mix and higher input costs. It was further affected by a INR150m impairment provision in one of the hybrid renewable energy projects in the Green Solutions segment.
- These factors led to a 5% YoY dip in PAT to INR1.1b (vs. our est. of INR1.3b)
- The company has done some level of reclassification within segments. Segment-wise, EBIT margin in the Industrial Product segment declined YoY to 6.1% in 2QFY27 (vs 9.9% in 2QFY26 and vs. our est. of 8.0%). Industrial Infra segment 2QFY27 EBIT margin recovered to 5.6% after a loss in 1Q on account of higher revenue, additional PSI income. Chemical segment EBIT margin contracted to 6.5% vs. 9.8% last year and our est. of 9.0% due to higher input costs and change in product mix. Green Solutions EBIT stood at 1.1% vs. our est. of ~7%.
- Order inflow for the quarter declined 8% YoY to INR32.6b, taking the total order book as on Sep'26-end to INR143b (+16% YoY).
- For 1HFY27, revenue increased 9% YoY to INR51b, while EBITDA/PAT declined 34%/50% YoY to INR2.6b/INR1.3, and margin contracted 340bp YoY to 5.2%.
- For 1HFY27, OCF increased 400% to INR3.6b supported by increase in other liabilities. It reported a free cash outflow of INR1.6b in 1HFY27 (vs. an outflow of INR3.1b last year).

Consolidated - Quarterly Earnings Model

(INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E 2QE	Est Var (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Net Sales	**21,575**	**24,739**	**26,347**	**34,280**	**23,027**	**27,559**	**32,863**	**44,446**	**1,06,942**	**1,27,895**	**28,982**	**-5**
YoY Change (%)	-1.2	-5.3	5.1	11.1	6.7	11.4	24.7	29.7	2.9	19.6	17.2	
Total Expenditure	**19,324**	**23,019**	**23,799**	**30,537**	**22,341**	**25,617**	**29,733**	**39,650**	**96,679**	**1,17,341**	**26,665**	
EBITDA	**2,251**	**1,720**	**2,548**	**3,743**	**686**	**1,941**	**3,130**	**4,796**	**10,263**	**10,553**	**2,317**	**-16**
YoY Change (%)	59.5	-38.1	34.8	24.9	-69.5	12.9	22.8	28.1	13.0	2.8	34.7	
Margins (%)	10.4	7.0	9.7	10.9	3.0	7.0	9.5	10.8	9.6	8.3	8.0	-100 bp
Depreciation	489	515	533	540	595	702	577	436	2,076	2,310	577	21
Interest	302	322	342	424	352	369	516	673	1,390	1,910	466	-21
Other Income	656	854	627	537	682	818	577	172	2,675	2,249	548	49
PBT before EO expense	**2,117**	**1,738**	**2,300**	**3,317**	**421**	**1,689**	**2,613**	**3,859**	**9,471**	**8,582**	**1,822**	**-7**
Extra-Ord expense	0	0	588	25	0	0	0	0	612	0	0	
PBT	**2,117**	**1,738**	**2,888**	**3,341**	**421**	**1,689**	**2,613**	**3,859**	**10,084**	**8,582**	**1,822**	**-7**
Tax	600	543	837	897	204	558	745	940	2,877	2,446	519	
Rate (%)	28.4	31.2	29.0	26.9	48.3	33.0	28.5	24.4	28.5	28.5	28.5	
MI & P/L of Asso. Cos.	2	1	1	-0	0	0	0	0	4	0	0	
Reported PAT	**1,515**	**1,194**	**2,050**	**2,444**	**218**	**1,131**	**1,868**	**2,919**	**7,203**	**6,136**	**1,303**	**-13**
Adj PAT	**1,515**	**1,194**	**1,633**	**2,424**	**218**	**1,131**	**1,868**	**2,919**	**6,765**	**6,136**	**1,303**	**-13**
YoY Change (%)	38.4	-39.7	43.6	17.9	-85.6	-5.3	14.4	20.4	14.9	-14.8	9.1	
Margins (%)	7.0	4.8	6.2	7.1	0.9	4.1	5.7	6.6	6.3	4.8	4.5	

INR m	FY26				FY27E				FY26	FY27E	FY26E 2QE	Est Var (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Segmental revenue												
Industrial Products	9,547	11,888	12,898	16,628	10,582	13,037	15,607	20,839	50,961	60,064	14,265	-9
YoY Change (%)	*-0.6*	*12.4*	*19.4*	*16.2*	*10.8*	*9.7*	*21.0*	*25.3*	*12.5*	*17.9*	*20*	
Industrial Infra	8,975	9,487	10,326	14,693	8,142	10,062	13,424	20,900	43,481	52,528	10,910	-8
YoY Change (%)	*-3.0*	*-23.7*	*-8.8*	*3.8*	*-9.3*	*6.1*	*30.0*	*42.2*	*-7.8*	*20.8*	*15*	
Green Solutions	1,732	1,917	1,636	2,037	2,447	2,880	2,208	1,733	7,322	9,268	2,224	29
YoY Change (%)	*-0.3*	*9.5*	*-13.5*	*34.2*	*41.3*	*50.2*	*35.0*	*-15.0*	*6.1*	*26.6*	*16*	
Chemical	1,732	1,910	2,002	1,932	2,295	2,255	2,363	1,977	7,576	8,891	2,235	1
YoY Change (%)	*1.4*	*0.4*	*4.5*	*-8.1*	*32.5*	*18.1*	*18.0*	*2.4*	*-0.7*	*17.4*	*17*	
Less: Intersegmental	-410	-463	-516	-1,010	-438	-675	-739	-1,003	-2,398	-2,856	-652	4
Total revenues	**21,575**	**24,739**	**26,347**	**34,280**	**23,027**	**27,559**	**32,863**	**44,446**	**1,06,942**	**1,27,895**	**28,982**	**-5**
YoY Change (%)	*-1.6*	*-5.5*	*4.7*	*10.9*	*6.7*	*11.4*	*24.7*	*29.7*	*2.9*	*19.6*	*17*	
Segmental EBIT												
Industrial Products	777	1,173	1,194	2,256	642	794	1,717	2,854	5,400	6,006	1,141	-30
Margin (%)	*8.1*	*9.9*	*9.3*	*13.6*	*6.1*	*6.1*	*11.0*	*13.7*	*10.6*	*10.0*	*8.0*	
Industrial Infra	710	-148	655	959	-707	560	537	660	2,175	1,051	327	71
Margin (%)	*7.9*	*-1.6*	*6.3*	*6.5*	*-8.7*	*5.6*	*4.0*	*3.2*	*5.0*	*2.0*	*3.0*	
Green Solutions	332	362	321	20	106	31	177	335	1,034	649	156	-80
Margin (%)	*19.2*	*18.9*	*19.6*	*1.0*	*4.3*	*1.1*	*8.0*	*19.4*	*14.1*	*7.0*	*7.0*	
Chemical	161	187	92	95	256	147	224	262	536	889	201	-27
Margin (%)	*9.3*	*9.8*	*4.6*	*4.9*	*11.2*	*6.5*	*9.5*	*13.2*	*7.1*	*10.0*	*9.0*	

Kalpataru Projects

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th November 2026
Time: 09:00am IST
Dial-in details:
Diamond Pass

Financials & Valuations (INR b)

Y/E March	2027E	2028E	2029E
Sales	265.3	303.1	345.7
EBITDA	23.3	26.7	30.4
Adj. PAT	11.9	13.8	16.3
Adj. EPS (INR)	69.6	81.0	95.5
EPS Gr. (%)	18.7	16.5	17.8
BV/Sh.(INR)	541.5	613.6	700.1
Ratios			
RoE (%)	13.6	14.0	14.5
RoCE (%)	12.3	12.9	13.5
Valuations			
P/E (x)	20.1	17.3	14.7
P/BV (x)	2.5	2.2	2.0
EV/EBITDA (x)	10.4	9.0	7.8
Div. Yield (%)	0.7	0.7	0.7

CMP: INR1,373 — Buy

In-line revenue and EBITDA; PAT above our est.

- KPIL's 2QFY27 revenue stood at INR62b (+15% YoY). Growth was driven by strong execution across key segments barring water and railways. T&D/B&F revenue rose 7%/20% YoY, while O&G saw strong revenue growth of 58% YoY. The water/infrastructure segment declined 4%/11% YoY. In railways, the company is focusing on project closure.
- Gross margin remained flat YoY at 24.1%.
- Absolute EBITDA grew 17% YoY to INR5.2b, while EBITDA margin expanded 10bp YoY to 8.4%.
- PAT increased 35% YoY to INR2.7b, vs. our est. of INR2.5b. A lower-than-expected tax rate led to PAT beating our estimate by 7%.
- YTD order inflows for FY27 stood at INR239b, indicating order inflows of ~INR163b in 2QFY27 bringing the order book to INR719b at the end of Sep'26.
- OCF for 1HFY27 was positive at INR10b vs. a negative OCF of INR4.4b in 1HFY26. FCF for 1HFY27 was positive at INR5.1b vs a negative INR8b in 1HFY26.


Standalone - Quarterly earnings (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Net Sales	**50,397**	**54,188**	**57,876**	**69,640**	**54,819**	**62,127**	**66,328**	**82,040**	**2,32,101**	**2,65,314**	**59,696**	**4**
YoY Change (%)	35.4	31.0	19.9	12.2	8.8	14.7	14.6	17.8	22.9	14.3	10.2	
Total Expenditure	46,114	49,716	53,063	62,921	49,940	56,893	60,558	74,575	2,11,814	2,41,966	54,442	
EBITDA	**4,284**	**4,472**	**4,813**	**6,719**	**4,879**	**5,234**	**5,771**	**7,465**	**20,287**	**23,348**	**5,253**	**-0**
YoY Change (%)	36.7	28.3	19.8	28.4	13.9	17.0	19.9	11.1	27.8	15.1	17.5	
Margins (%)	8.5	8.3	8.3	9.6	8.9	8.4	8.7	9.1	8.7	8.8	8.8	
Depreciation	936	966	1,005	1,041	1,117	1,111	1,276	1,404	3,948	4,907	1,184	-6
Interest	840	1,025	926	890	677	805	730	803	3,680	3,014	730	10
Other Income	234	242	255	369	524	354	67	74	1,101	1,018	154	129
PBT before EO expense	**2,742**	**2,723**	**3,138**	**5,157**	**3,610**	**3,672**	**3,832**	**5,332**	**13,759**	**16,445**	**3,493**	**5**
Extra-Ord expense	-	-	295	2,033	-	-	-	-	2,328	-	-	
PBT	**2,742**	**2,723**	**2,843**	**3,124**	**3,610**	**3,672**	**3,832**	**5,332**	**11,431**	**16,445**	**3,493**	**5**
Tax	734	724	730	926	956	981	1,073	1,551	3,114	4,561	969	
Rate (%)	26.8	26.6	25.7	29.6	26.5	26.7	28.0	29.1	27.2	27.7	27.7	
Reported PAT	**2,008**	**1,999**	**2,112**	**2,198**	**2,654**	**2,690**	**2,759**	**3,781**	**8,317**	**11,884**	**2,524**	**7**
Adj PAT	**2,008**	**1,999**	**2,331**	**3,673**	**2,654**	**2,690**	**2,759**	**3,781**	**10,011**	**11,884**	**2,524**	**7**
YoY Change (%)	72.1	51.1	48.2	38.2	32.2	34.6	18.3	3.0	49.0	18.7	26.3	
Margins (%)	4.0	3.7	4.0	5.3	4.8	4.3	4.2	4.6	4.3	4.5	4.2	

Gujarat Energy

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th Nov'26
Time: 1600 hrs IST
Dial-in details:
+91 22 6280 1354
+91 22 7115 8233

CMP: INR225 — Buy

In-line performance

- The standalone revenue stood 29% above our est. at INR96b (+61% YoY, +2% QoQ).
- The EBITDA came in line at INR8b (+24% YoY, -38% QoQ). EBITDA margin stood at 8.3% (vs 13.7%/10.8% in 1QFY27/2QFY26).
  - Assuming similar YoY depreciation for CGD business, 2QFY27 EBITDA/scm for CGD business stood at INR4.6/scm (INR5.2/scm in 1QFY27; INR5.6/scm in 2QFY26)
- The APAT also came in line at INR6.3b (+22% YoY,-36% QoQ).
- **Standalone segmental performance:**
  - Gas trading EBIT stood at INR3.3b, up 89% YoY, down 55% QoQ.
  - CGD segment EBIT stood 5%/28% down YoY/QoQ at INR3.2b.
- **CGD volume growth:**
  - During the quarter, **overall CGD volumes** stood 12% above our estimate at 10.7mmscmd (+24% YoY/ -13% QoQ).
    - In 1HFY27, volumes came in at 11.5mmscmd (+31% YoY), driven by industrial demand and CNG penetration.
  - **CNG volumes** came in line at 3.7mmscmd in 2QFY27 (+11% YoY/ -2%QoQ)
    - In 1HFY27, CNG volumes came in at 3.7mmscmd (+12% YoY).
- **PNG volumes** (D-PNG and I&C-PNG) came in 19% above our est. at 7mmscmd.
- **Strategic and corporate developments:**
  - The board has approved long-term LNG sourcing agreements aggregating ~0.8mmtpa for up to 10 years, linked to Henry Hub, with reputed international suppliers to secure reliable gas supplies.
  - The Board has further approved a firm Regasification Agreement for LNG cargo slots at GSPC LNG Ltd.'s Mundra terminal.
- **Operational updates:**
  - **Capex**: The company has incurred capex of INR1.8b in 2Q, taking 1HFY27 capex to INR3.1b
    - FY27 guidance reiterated at INR10b.
  - **CNG:** Added 13 stations in 2Q, taking the total network to 857 stations as of 1HFY27.
  - **PNG:** Added ~49,000 domestic customers in 2Q and ~0.11m in 1HFY27.
  - **Gas sourcing:** Imported 14 LNG cargoes (including partial cargoes) in 2Q, taking 1HFY27 imports to 24 cargoes (vs. 12 in 1HFY26).
- GSPC (JPDA) Ltd. commenced voluntary liquidation in Feb'26, against which the holding company had already provided 100% impairment on its investment. Gujarat Energy received final liquidation proceeds of ~INR20.4m in Aug'26 and derecognised its investment as of Sep'26, while the Liquidator has filed an application before the NCLT seeking dissolution.

- Jubilant Offshore Drilling Pvt Ltd. (JODPL) defaulted on cash calls in the KG block, requiring Gujarat Gas (being the non-defaulting partner) to fund its share, resulting in a ~INR5.3b receivable. The entire amount has been provided for as an impairment through FY26 due to uncertain recovery, while Gujarat Gas pursues forfeiture and assignment of JODPL's participating interest as recovery, subject to NCLAT proceedings and Government approval. No additional impairment was required in 2QFY27.

Standalone - Quarterly Earnings Model (INR m)

Y/E March	FY26				FY27		FY26	FY27E	FY27 2QE	Var (%)	YoY (%)	QoQ (%)
	1Q	2Q	3Q	4Q	1Q	2Q						
Net Sales	**57,298**	**59,663**	**59,265**	**57,651**	**94,439**	**95,900**	**2,33,877**	**3,45,587**	**74,323**	**29%**	**61%**	**2%**
YoY Change (%)	28.8	57.8	42.7	-9.5	64.8	60.7	-13.4	47.8	24.6			
EBITDA	**7,704**	**6,428**	**9,555**	**7,825**	**12,954**	**7,972**	**31,512**	**13,650**	**8,330**	**-4%**	**24%**	**-38%**
Margin (%)	13.4	10.8	16.1	13.6	13.7	8.3	13.5	3.9	11.2			
Depreciation	1,412	1,458	1,476	1,444	1,421	1,459	5,790	6,093	1,528			
Interest	88	100	99	95	90	100	382	371	91			
Other Income	1,252	2,103	1,249	1,605	1,868	2,222	6,209	6,085	2,250			
PBT before EO expense	**7,455**	**6,973**	**9,230**	**7,891**	**13,311**	**8,635**	**31,549**	**13,271**	**8,961**	**-4%**	**24%**	**-35%**
Extra-Ord expense	0	0	32	630	0	0	662	0	0			
PBT	**7,455**	**6,973**	**9,198**	**7,261**	**13,311**	**8,635**	**30,887**	**13,271**	**8,961**	**-4%**	**24%**	**-35%**
Tax	1,845	1,726	2,276	2,055	3,331	2,242	7,901	3,390	2,255			
Rate (%)	24.7%	24.7%	24.7%	28.3%	25.0%	26.0%	25.6%	25.5%	0.3			
Reported PAT	**5,611**	**5,247**	**6,922**	**5,206**	**9,980**	**6,393**	**22,986**	**9,881**	**6,705**	**-5%**	**22%**	**-36%**
Adj. PAT	**5,611**	**5,247**	**6,946**	**5,674**	**9,980**	**6,393**	**23,478**	**9,881**	**6,705**	**-5%**	**22%**	**-36%**
YoY Change (%)	70.1	71.0	213.4	15.3	77.9	21.8	-42.3	-57.9	27.8			

IRB Infra

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 06 Nov 2026
Time: 11:30 am IST
Conference call details: Link

Financials & Valuations (INR b)

Y/E March	2026	2027E	2028E
Sales	76.5	86.3	108.2
EBITDA	39.8	45.7	58.0
Adj. PAT	8.8	12.2	19.4
EBITDA Margin (%)	52.1	53.0	53.6
Adj. EPS (INR)	0.7	1.0	1.6
EPS Gr. (%)	30.4	38.8	58.4
BV/Sh. (INR)	17.3	18.2	19.6
Ratios			
Net D:E	0.9	0.8	0.7
RoE (%)	4.3	5.7	8.5
RoCE (%)	6.0	6.7	8.7
Payout (%)	14.9	17.8	11.2
Valuations			
P/E (x)	23.5	17.3	10.7
P/BV (x)	1.0	0.9	0.9
EV/EBITDA(x)	9.8	8.2	6.3
Div. Yield (%)	0.4	0.9	0.9
FCF Yield (%)	13.7	20.0	11.2

CMP: INR17 — Buy

In-line operating performance; low interest outgo drives a beat on APAT

- Revenue grew ~8% YoY to INR18.9b during 2Q FY27 (in line). Revenue includes 1) gain on InvITs & Related Assets as per fair value measurement and 2) Dividend / Interest income from InvITs & Related Assets.
- EBITDA margin came in at 55.6% (vs. our estimate of 53%) in 2QFY27 (+280bp YoY and +165bp QoQ). EBITDA grew ~14% YoY to INR10.5b (in line).
- APAT grew 85% to INR2.6b (31% above estimate), led by low interest cost.
- Construction revenues stood at INR ~8.2b (flat YoY); BOT revenue stood at INR 7.2b (+15% YoY); and InvIT & related assets revenue stood at INR3.5b.
- The Board declared an interim dividend of INR 0.05 per equity share.
- Order book stood at ~INR433b (excl. GST) as at the end of Sept'26.
- During 1HFY27, the revenue/EBITDA/APAT grew by 5%/18%/65%.

Quarterly Performance (INR m)

Y/E March	FY26				FY27E		FY26	FY27E	FY27	Var
	1Q	2Q	3Q	4Q	1Q	2Q			2QE	%
Net Sales	**20,990**	**17,510**	**18,712**	**19,270**	**21,373**	**18,971**	**76,482**	**82,120**	**19,295**	**(2)**
YoY Change (%)	13.3	10.4	(7.6)	(10.3)	1.8	8.3	0.5	7.4	10.2	
EBITDA	**9,520**	**9,246**	**10,224**	**10,828**	**11,526**	**10,546**	**39,818**	**44,674**	**10,227**	**3**
Margins (%)	45.4	52.8	54.6	56.2	53.9	55.6	52.1	54.4	53.0	
Depreciation	2,692	2,621	2,894	3,213	3,334	3,290	11,420	13,353	3,200	
Interest	4,620	4,510	4,364	4,058	4,380	3,877	17,551	16,182	4,680	
Other Income	656	493	411	499	354	474	2,058	2,079	500	
PBT before EO expense	**2,864**	**2,608**	**3,377**	**4,056**	**4,166**	**3,853**	**12,905**	**17,218**	**2,847**	
Extra-Ord expense	-	-	(427)	-	-	-	(427)	-	-	
PBT	**2,864**	**2,608**	**2,950**	**4,056**	**4,166**	**3,853**	**12,478**	**17,218**	**2,847**	
Tax	839	1,200	842	1,094	1,103	1,250	3,975	5,217	854	
Rate (%)	29.3	46.0	28.5	27.0	26.5	32.4	31.9	30.3	30.0	
Share of profit in Associates	-	-	-	-	-	-	-	-	-	
Reported PAT	**2,025**	**1,408**	**2,108**	**2,963**	**3,063**	**2,603**	**8,504**	**12,001**	**1,993**	
Adj PAT	**2,025**	**1,408**	**2,428**	**2,963**	**3,063**	**2,603**	**8,823**	**12,001**	**1,993**	**31**
YoY Change (%)	44.6	41.0	9.4	38.0	51.3	84.9	30.4	36.0	41.5	
Margins (%)	9.6	8.0	13.0	15.4	14.3	13.7	11.5	14.6	10.3	

RESULTS FLASH

Happy Forgings

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 06th November 2026
Time: 11:00 AM
Concall registration [Link]
+91 22 6280 1309

Financials & Valuations (INR b)

Y/E MARCH	FY27E	FY28E	FY29E
Sales	19.8	25.1	30.0
EBITDA	6.3	8.2	9.8
Adj. PAT	4.0	5.5	6.6
EPS (INR)	42.6	57.9	70.4
EPS growth %	33.4	35.7	21.7
BV/Sh. (INR)	263	313	372
Ratios			
RoE (%)	17.5	20.1	20.6
RoCE (%)	15.2	17.4	18.6
Payout (%)	12.9	13.8	15.0
Valuations			
P/E (x)	43.9	32.3	26.6
P/BV (x)	7.1	6.0	5.0
EV/EBITDA (x)	28.4	21.7	17.8
Div. Yield (%)	0.3	0.4	0.6

CMP:INR1,871 — Buy

In-line performance

- Standalone revenue grew 33% YoY in 2QFY27 to INR5b (in line), driven by volume growth of 25% to 18,754MT. Realization/kg improved QoQ to INR267.
- Revenue mix in 1HFY27 (vs. 1HFY26):
- CV at 33% (37%), Farm Equipment at 31% (34%), Off-highway at 12% (10%), Industrials at 16% (13%), and PV at 9% (5%).
- Domestic – 72% (73%), Deemed exports – 12% (12%), direct exports – 16% (16%).
- EBITDA margins contracted 80bp QoQ to 30.6% (110bp below est.) due to cost headwinds. EBITDA also grew 32% YoY to INR1.5b (in line).
- PAT grew 33% YoY to INR975m (in line).
- The board approved an additional capex of INR5b for additional forging and machining capacities to support anticipated growth in business volumes across the existing and target end markets. This capex would target PV, Industrials and CV (exports) markets and the capex would be incurred in phases in FY28 and FY29 and would be funded via a mix of internal accruals and debt.
- Valuation view: The stock trades at 44x/32x FY27E/FY28E EPS.

Quarterly (Standalone) (INR M)

	FY26				FY27E				FY26	FY27E		Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net operating income	**3,538**	**3,774**	**3,913**	**4,238**	**4,494**	**5,007**	**5,087**	**5,238**	**15,463**	**19,826**	**4,831**	**3.7**
Change (%)	3.6	4.5	10.4	20.4	27.0	32.7	30.0	23.6	9.8	28.2	28.0	
RM/Sales (%)	42.1	39.7	41.1	40.6	39.3	39.2	40.7	42.2	40.9	40.4	40.7	
Staff Cost (%)	9.1	8.9	8.8	8.6	8.6	8.2	8.4	8.5	8.8	8.4	8.4	
Other Exp. (%)	20.3	20.7	19.3	19.3	20.7	22.1	19.3	16.2	19.9	19.5	19.3	
EBITDA	**1,012**	**1,158**	**1,204**	**1,333**	**1,409**	**1,531**	**1,610**	**1,734**	**4,707**	**6,284**	**1,529**	**0.2**
EBITDA Margins (%)	28.6	30.7	30.8	31.5	31.3	30.6	31.7	33.1	30.4	31.7	31.7	-110bp
Change (%)	3.6	9.9	18.7	30.4	39.3	32.2	33.7	30.1	15.7	33.5	32.0	
Non-Operating Income	104	63	82	60	111	83	85	51	308	330	65	
Interest	23	19	25	38	31	30	30	31	105	121	28	
Depreciation	206	216	224	245	262	279	280	307	890	1128	270	
PBT after EO items	**886**	**986**	**1,037**	**1,111**	**1,226**	**1,306**	**1,385**	**1,447**	**4,020**	**5,365**	**1,296**	
Tax	230	252	247	275	312	331	346	352	1004	1341	324	
Eff. Tax Rate (%)	25.9	25.5	23.9	24.8	25.4	25.3	25.0	24.3	25.0	25.0	25.0	
Rep. PAT	**657**	**734**	**789**	**836**	**915**	**975**	**1,039**	**1,095**	**3,016**	**4,024**	**972**	
Change (%)	2.9	2.8	22.4	23.3	39.2	32.8	31.6	31.1	12.7	33.4	32.3	
Adj. PAT	**657**	**734**	**789**	**836**	**915**	**975**	**1,039**	**1,095**	**3,016**	**4,024**	**972**	**0.3**
Change (%)	2.9	10.2	22.4	23.3	39.2	32.8	31.6	31.1	12.7	33.4	32.3	

E: MOFSL Estimates

Pearl Global

BSE Sensex	S&P CNX
79,310	24,537

CMP: INR1,339 **BUY**

Conference Call Details



Date: 06 November 2026
Time: 16:30 IST
Diamond pass link

Revenue up 37% YoY; gross margin improves 340bp

For the quarter

- Consolidated revenues grew 37.2% YoY to INR18b (~14% above MO estimates)
- Volumes grew by 14.6% YoY to 22.8m pieces, while realizations grew 19.8% YoY to INR790 per piece
- Gross margin improved by 340bp YoY to 48.2%
- EBITDA came in at INR1.7b (in-line) (41% YoY), with EBITDA margin at 9.5% (24bp YoY; EBITDA adjusted for one-time net tariff adjustment gain and the marginal contribution from the value-added services amounting ~INR115m)
- Employee expenses and other expenses grew 22% and 72% YoY, respectively
- APAT grew 58% to INR1.2b (7% ahead of MO estimates), with an APAT margin of 6.4%
- For India business, revenue grew at 17% YoY to INR3b
- WC cycle increased from 43 days as of Mar'26, to 56 days as of Sep'26, on account of an increase in receivable days.
- The Board declared an interim dividend of INR5 per equity share.

We will provide further updates after the conference call on 6th Nov'26.

Consolidated - Qtrly performance **(INR m)**

Y/E March	FY26				FY27				FY26	FY27E	FY27E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Net Sales	**12,279**	**13,129**	**11,702**	**13,136**	**15,283**	**18,015**	**12,111**	**13,613**	**50,246**	**59,022**	*15,755*	*14.3*
YoY Change (%)	*16.6*	*9.2*	*14.4*	*6.9*	*24.5*	*37.2*	*3.5*	*3.6*	*11.5*	*17.5*	*20.0*	
Gross Profit	**5,654**	**5,881**	**5,953**	**6,418**	**7,877**	**8,686**	**5,813**	**6,545**	**23,906**	**28,921**	*7,720*	*12.5*
Total Expenditure	11,158	11,919	10,742	11,791	13,644	16,312	10,768	11,924	45,607	52,648	*14,054*	*16.1*
EBITDA	**1,121**	**1,210**	**960**	**1,345**	**1,638**	**1,703**	**1,343**	**1,689**	**4,639**	**6,374**	*1,701*	*0.2*
Margin (%)	*9.1*	*9.2*	*8.2*	*10.2*	*10.7*	*9.5*	*11.1*	*12.4*	*9.2*	*10.8*	*10.8*	
Depreciation	197	224	224	228	257	263	270	262	873	1,052	*262*	*0.4*
Interest	274	274	221	263	266	288	275	273	1,032	1,101	*270*	*6.6*
Other Income	113	82	75	102	107	98	97	110	371	412	*110*	*-10.5*
PBT before EO items	**763**	**794**	**590**	**956**	**1,223**	**1,251**	**895**	**1,264**	**3,105**	**4,633**	*1,279*	*-2.2*
Extraordinary Inc / (Exp)	-3	0	-4	-5	-27	-18	0	0	-12	-46	*0*	
PBT	**761**	**794**	**586**	**950**	**1,196**	**1,233**	**895**	**1,264**	**3,093**	**4,588**	*1,279*	*-3.6*
Tax	108	74	70	141	203	90	170	225	393	688	*192*	*-53.0*
Rate (%)	*14.2*	*9.3*	*12.0*	*14.8*	*17.0*	*7.3*	*19.0*	*17.8*	*12.7*	*15.0*	*15.0*	
JV and Associates	-23	-13	-17	-23	-13	0	0	0	-76	-13	*0*	
Reported PAT	**676**	**733**	**533**	**833**	**1,005**	**1,143**	**725**	**1,039**	**2,777**	**3,913**	*1,087*	*5.1*
Adj PAT	**678**	**733**	**537**	**838**	**1,032**	**1,161**	**725**	**1,039**	**2,789**	**3,958**	*1,087*	*6.8*
YoY Change (%)	*9.5*	*31.8*	*11.2*	*29.0*	*52.2*	*58.4*	*35.2*	*24.0*	*23.3*	*41.9*	*48.3*	
Margin (%)	*5.5*	*5.6*	*4.6*	*6.4*	*6.8*	*6.4*	*6.0*	*7.6*	*5.6*	*6.7*	*6.9*	

Vedant Fashions

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th Nov 2026

Time: 3:30pm IST

Financials & Valuations (INR b)

Y/E March	FY27E	FY28E	FY29E
Sales	15.0	16.0	17.0
EBITDA	6.5	7.1	7.6
Adj. PAT	3.9	4.4	4.7
EBITDA Margin (%)	43.5	44.2	44.7
Adj. EPS (INR)	16.1	17.9	19.4
EPS Gr. (%)	3.7	11.4	8.4
BV/Sh. (INR)	86.5	96.1	106.2
Ratios			
Net D:E	(0.5)	(0.6)	(0.6)
RoE (%)	18.0	18.1	17.7
RoCE (%)	17.3	17.6	17.4
Payout (%)	50.0	50.0	50.0
Valuations			
P/E (x)	31.5	28.3	26.1
EV/EBITDA (x)	19.2	17.3	15.7
EV/Sales (X)	8.3	7.6	7.0

CMP: INR506 — Neutral

Muted quarter

- Customer sales were flat YoY (+0.6%) at INR3.5b, as SSS declined ~5.8% in 2Q.
- Its 2QFY27 revenue **grew ~2% YoY** to INR2.7b (vs. our estimate of flat YoY).
- Gross profit grew ~2% YoY to INR1.91b (vs. our est. INR1.86b), as gross margin contracted ~60bp YoY to 71.1% (~55bp beat).
- Employee expenses increased ~5% YoY (4% above our est.), while other expenses rose ~13% YoY (14% above estimates), reflecting elevated operating costs amid subdued revenue growth.
- Reported EBITDA **declined ~5% YoY** to INR1.05b (3% below our est.), as EBITDA margin **contracted ~310bp YoY** to 39.0% (~215bp miss), due to weaker gross margin and operating deleverage.
- Depreciation and amortization declined ~1% YoY and finance costs dipped ~14% YoY, while other income rose ~17% YoY, partially offsetting the decline in operating profitability.
- PAT remained flat YoY at INR562m (in line), despite the ~5% decline in EBITDA, supported by lower finance costs and higher other income.
- Domestic EBO count declined to 497 in 2QFY27 (vs. 501 in 1QFY27), while EBO area remained broadly flat QoQ at 1.67m sq ft.

1HFY27: Tepid performance; notable WC build-up ahead of festive season

- Customer sales inched up ~2% YoY to INR7.7b, with SSS declining 0.3% YoY in 1H.
- Revenue grew ~5% YoY to INR5.7b.
- Reported EBITDA grew ~2% YoY to INR2.4b as margin contracted ~115bp YoY to 41.4%, largely due to ~120bp contraction in gross margin.
- Pre-IND AS EBITDA stood at INR1.4b (flat YoY), with margins at 24.3% (-80bp YoY).
- Reported PAT grew ~8% YoY to INR1.4b, supported by ~16% higher other income and ~11% YoY decline in finance costs.
- Working capital days increased sharply to 199 (vs. 153 YoY), driven by sharp surge in receivables (180 days vs. 121 YoY, likely indicating channel stuffing). Inventory days moderated to 36 (vs. 48 YoY), while payables increased to 77 days (vs. 72 YoY). Consequently, net working capital increased to INR8.0b (up 33% YoY, vs. ~2% YoY growth in sales).
- Operating cash flow (post-interest and leases) declined to INR109m in 1HFY27 (vs. INR186m YoY), largely due to working capital build-up (INR700m vs. INR580m YoY). However, lower capex of INR9m (vs. INR112m) supported FCF improvement to INR100m (vs. INR74m in 1HFY26).

Consol P&L (INR m)	2QFY26	1QFY27	2QFY27	YoY%	QoQ%	2QFY27E	v/s Est (%)
Total Revenue	**2,632**	**3,014**	**2,694**	**2**	**-11**	**2,638**	**2**
Raw Material cost	746	886	779	4	-12	778	0
Gross Profit	**1,885**	**2,128**	**1,914**	**2**	**-10**	**1,860**	**3**
Gross margin (%)	**71.6**	**70.6**	**71.1**	**-57.5**	**46.4**	**70.5**	**56.9**
Employee Costs	165	152	174	5	15	168	4
Other expenses	613	666	690	13	4	607	14
EBITDA	**1,108**	**1,310**	**1,051**	**-5**	**-20**	**1,086**	**-3**
EBITDA margin (%)	**42.1**	**43.5**	**39.0**	**-310.0**	**-446.5**	**41.2**	**-215.0**
Depreciation and amortization	417	422	414	-1	-2	435	-5
EBIT	691	888	636	-8	-28	651	-2
EBIT margin (%)	26.3	29.5	23.6	-263.0	-583.6	24.7	-104.6
Finance Costs	150	130	128	-14	-1	132	-3
Other income	199	297	233	17	-22	229	2
Exceptional item			0	NM	NM	0	NM
Profit before Tax	**740**	**1,055**	**741**	**0**	**-30**	**748**	**-1**
Tax	180	249	179	0	-28	188	-5
Tax rate (%)	24.3	23.6	24.2			25.2	-4.0
Profit after Tax	**561**	**806**	**562**	**0**	**-30**	**560**	**0**
Adj Profit after Tax	**561**	**806**	**562**	**0**	**-30**	**560**	**0**
Operating metrics	**2QFY26**	**1QFY27**	**2QFY27**	**YoY%**	**QoQ%**	**2QFY27E**	**vs. Est (%)**
Gross Profit (incl-Job Charges)	**1,716**	**1,979**	**1,747**	**2**	**-12**	**1,682**	**4**
Gross margin (%)	**65.2**	**65.7**	**64.9**	**-35.4**	**-81.2**	**63.8**	**109.5**
Other expenses	443	517	523	18	1	429	22
Operating metrics	**2QFY26**	**1QFY27**	**2QFY27**	**YoY%**	**QoQ%**		
SSSG (%)	**-2.0%**	**3.8%**	**-5.8%**				
Domestic EBOs	508	501	497	-2	-1		

Fujiyama Power Systems

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR388 — Buy

Strong beat on earnings

- Consol. revenue grew 2.3x YoY to INR13.1b (est. INR10b).
- Gross margin contracted 200bp YoY to 25%.
- EBITDA grew 2.2x YoY to INR2.2b (est. INR1.9b). EBITDA margin contracted 100bp YoY to 17.1% (est. 19.0%).
- Adj. PAT grew 2.1x YoY to INR1.3b (est. INR1.1b).
- For 1HFY27, Revenue/EBITDA/Adj. PAT grew 2.3x/2.3x/2.3x YoY to INR27b/INR5b/INR3b.
- Gross debt stood at INR8.5b vs INR4.6b as of Mar'26. The company had a net cash outflow of INR2.6b vs INR1.5b as of Sep'25.

Conference Call Details



Date: 10th Nov, 2026
Time: 12:00pm IST
Dial-in details:
Click Here

Consolidated - Quarterly Earning Model (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2QE	%
Gross Sales	**5,973**	**5,679**	**5,885**	**9,008**	**13,457**	**13,068**	**10,000**	**13,512**	**26,545**	**50,037**	**10,000**	**31**
YoY Change (%)	52.1	72.6	73.8	87.5	125.3	130.1	69.9	50	*72*	*88*	76.1	
Total Expenditure	4,915	4,649	4,780	7,293	10,909	10,839	8,100	10,944	21,636	40,792	8,100	
EBITDA	**1,059**	**1,030**	**1,105**	**1,715**	**2,548**	**2,229**	**1,900**	**2,567**	**4,909**	**9,244**	**1,900**	**17**
Margins (%)	17.7	18.1	18.8	19	18.9	17.1	19	19	*18.5*	*18.5*	*19*	
Depreciation	70	78	87	206	250	275	270	300	442	1,096	250	
Interest	94	124	122	96	109	173	150	236	436	668	125	
Other Income	4	19	4	28	24	21	20	20	55	85	10	
PBT before EO expense	**899**	**846**	**899**	**1,441**	**2,212**	**1,801**	**1,500**	**2,051**	**4,086**	**7,565**	**1,535**	
Extra-Ord expense	0	0	6	0	1,436	0	0	0	6	1,436	0	
PBT	**899**	**846**	**894**	**1,441**	**777**	**1,801**	**1,500**	**2,051**	**4,080**	**6,129**	**1,535**	
Tax	223	217	220	378	199	473	378	516	1,039	1,565	386	
Rate (%)	24.8	25.7	24.7	26.2	25.6	26.2	25.2	25.2	25.5	25.5	25	
MI & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	**676**	**629**	**673**	**1,063**	**578**	**1,329**	**1,122**	**1,535**	**3,041**	**4,564**	**1,149**	
Adj PAT	**676**	**629**	**678**	**1,063**	**1,655**	**1,329**	**1,122**	**1,535**	**3,479**	**5,641**	**1,149**	**16**
YoY Change (%)	56.4	97.4	125.7	107.6	144.8	111.2	65.7	44.4	122.5	62.2	*82.6*	
Margins (%)	11.3	11.1	11.5	11.8	12.3	10.2	11.2	11.4	13.1	11.3	*11.5*	

Bikaji Foods International

BSE Sensex	S&P CNX
79,310	24,537

Conference Call Details



Date: 06 November 2026

Time: 12:00 IST

Diamond pass link

CMP: INR492 BUY

Revenue up 13% YoY; EBITDA margin contracts as costs rise

- Consolidated revenue grew 13.0% YoY to INR9.4b (~2% beat), backed by 5.0% volume growth (46,075 tonnes) and ~7.7% realization growth. Revenue was up 27.8% QoQ, led by festive seasonality.
- Western Snacks (+44.2% YoY to INR815m) was the fastest-growing category, followed by Ethnic Snacks (+19.7% to INR5,751m, now ~61% of revenue). Packaged Sweets (-11.3%) and Papad (-6.3%) declined.
- Core Markets grew 17.5% YoY and Exports 9.6%, while Focus Markets slowed to 7.6% and others fell 13.2%. Impulse packs (+21.2%) outgrew Family packs (+6.4%).
- Gross margin contracted 60bp YoY to 34.4% due to commodity inflation.
- Employee costs rose 18.7% YoY and other expenses 29.3% (higher marketing spend and fuel costs).
- EBITDA came at INR1,187m (~9% beat, -7.4% YoY), with EBITDA margin at 12.6% (-280bp YoY). Ex-PLI EBITDA margin was 11.0% (-280bp YoY). Other income fell 29% YoY, finance costs rose 37%, and depreciation rose 16%.
- APAT declined 15.9% YoY to INR690m (~2% beat), with APAT margin at 7.3% (vs 9.9% in 2QFY26). Reported PAT after minority interest was INR708m. The Q2FY26 base included an exceptional loss of INR44m.
- 1HFY27: Revenue grew 12.8% to INR16.7b, EBITDA margin stood at 13.0% (-210bp YoY), and PAT was INR1,284m (-6% YoY).
- Inventory nearly doubled to INR2.2b (from INR1.2b) and receivables rose to INR1.9b (from INR1.1b), reflecting a festive-season stock build.
- Net working capital rose to INR2.9b from INR1.6b, equivalent to ~29 days on annualized 2Q revenue vs. ~20 days as of Mar'26.
- Capex surged to INR1.4b (from INR0.8b in 1HFY26), leaving free cash flow at -INR0.5b (vs +INR0.2b in 1HFY26).


Consolidated Qtrly performance (INR m)

Y/E March	FY26E				FY27E				FY26	FY27E	2Q FY27E	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Net Sales	**6,527**	**8,303**	**7,900**	**7,209**	**7,343**	**9,385**	**9,243**	**8,198**	**29,939**	**34,169**	*9,216*	*1.8*
YoY Change (%)	*14.1*	*15.1*	*10.5*	*17.5*	*12.5*	*13.0*	*17.0*	*13.7*	*14.4*	*14.1*	*11.0*	
Gross Profit	**2,282**	**2,906**	**2,740**	**2,565**	**2,621**	**3,231**	**3,318**	**2,895**	**10,494**	**12,066**	*3,023*	*6.9*
Total Expenditure	5,564	7,021	6,917	6,331	6,352	8,198	8,018	7,158	25,833	29,726	*8,127*	*0.9*
EBITDA	**963**	**1,282**	**984**	**877**	**990**	**1,187**	**1,225**	**1,040**	**4,106**	**4,443**	*1,089*	*9.0*
Margin (%)	*14.8*	*15.4*	*12.5*	*12.2*	*13.5*	*12.6*	*13.3*	*12.7*	*13.7*	*13.0*	*11.8*	
Depreciation	230	237	240	243	262	275	269	251	950	1,058	*270*	*2.0*
Interest	47	51	41	39	52	70	45	33	178	201	*56*	*24.9*
Other Income	100	123	113	178	131	87	159	270	514	648	*135*	*-35.2*
PBT before EO items	**786**	**1,117**	**816**	**773**	**807**	**929**	**1,070**	**1,026**	**3,491**	**3,833**	*898*	
PBT	**786**	**1,117**	**816**	**773**	**807**	**929**	**1,070**	**1,026**	**3,448**	**3,833**	*898*	*3.4*
Tax	200	296	194	213	213	239	265	241	904	958	*224*	*6.6*
Rate (%)	*25.5*	*26.5*	*23.8*	*27.5*	*26.3*	*25.8*	*24.8*	*23.5*	*26.2*	*25.0*	*25.0*	
Reported PAT	**585**	**820**	**622**	**560**	**595**	**690**	**805**	**786**	**2,544**	**2,874**	*673*	*2.4*
Adj PAT	**585**	**820**	**622**	**560**	**595**	**690**	**805**	**786**	**2,197**	**2,499**	*673*	*2.4*
YoY Change (%)	*0.8*	*19.6*	*123.8*	*40.4*	*1.6*	*-15.9*	*29.4*	*40.2*	*46.1*	*13.8*	*-17.9*	
Margin (%)	*9.0*	*9.9*	*7.9*	*7.8*	*8.1*	*7.3*	*8.7*	*9.6*	*7.3*	*7.3*	*7.3*	

VA Tech Wabag

BSE Sensex	S&P CNX
79,310	24,537

Conference Call Details



Date: 06 November 2026

Time: 16:00 IST

Diamond pass link

CMP: INR1,866 — Buy

Healthy operating results and cash flows; robust order book

2QFY27 result highlights

- Consolidated revenue/adjusted EBITDA/APAT surged 20%/20%/23% YoY.
- Adj. EBITDA margin stood high at 14.4%.
- Performance driven by the ROW markets, with 26% YoY revenue growth and 31.6% EBIT margin.
- 2Q order intake of INR52b.
- Robust order book of over INR202b, providing robust revenue visibility.
- Strong cash flow generation leading to gross-cash level of INR12.2b and net-cash level of INR10b.
- The company will stay selective, focusing on securing more "Large" and "Mega", technology-led projects.

Quarterly performance

(INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Net Sales	**7,340**	**8,345**	**9,613**	**14,144**	**8,868**	**10,002**	**11,403**	**16,853**	**39,442**	**47,057**	**9,933**	**1**
YoY Change (%)	17.2	19.2	18.5	22.3	20.8	19.9	18.6	19.2	19.7	19.3	19.0	
Total Expenditure	6,384	7,452	8,398	12,570	8,073	8,759	9,871	14,513	34,668	41,216	8,703	
EBITDA - reported	**956**	**893**	**1,215**	**1,574**	**795**	**1,243**	**1,532**	**2,340**	**4,774**	**5,841**	**1,230**	**1**
Margins (%)	13.0	10.7	12.6	11.1	9.0	12.4	13.4	13.9	12.1	12.4	12.4	
EBITDA – adj. to forex gain	**956**	**1,205**	**1,310**	**1,771**	**1,163**	**1,445**	**1,582**	**2,390**	**5,242**	**10,866**	**1,280**	**13**
Margins (%)	13.0	14.4	13.6	12.5	13.1	14.4	13.9	14.2	13.3	23.1	12.9	
Depreciation	14	17	16	15	16	17	15	15	62	63	15	
Interest	188	196	179	166	172	177	170	170	729	689	170	
Other Income	113	416	232	319	520	311	130	130	943	1,091	130	
PBT before EO expense	**867**	**1,096**	**1,252**	**1,712**	**1,127**	**1,360**	**1,477**	**2,285**	**4,926**	**6,180**	**1,175**	
Extra-Ord expense	0	0	-47	0	0	0	0	0	-47	0	0	
PBT	**867**	**1,096**	**1,299**	**1,712**	**1,127**	**1,360**	**1,477**	**2,285**	**4,973**	**6,180**	**1,175**	
Tax	209	260	300	419	281	315	347	537	1,188	1,480	276	
Rate (%)	24.1	23.7	23.1	24.5	24.9	23.2	23.5	23.5	24.3	23.9	23.5	
Minority Interest	0	0	-4	-3	0	-1	-2	-2	-7	-5	-2	
Profit/Loss of Asso. Cos.	0	12	8	-13	55	0	0	0	7	55	20	
Reported PAT	**658**	**848**	**1,011**	**1,283**	**901**	**1,046**	**1,132**	**1,750**	**3,799**	**4,760**	**921**	**14**
Adj PAT	**658**	**848**	**964**	**1,283**	**901**	**1,046**	**1,132**	**1,750**	**3,752**	**4,760**	**921**	**14**
YoY Change (%)	19.6	20.1	37.3	28.9	36.9	23.3	17.4	36.4	27.1	26.9	8.6	
Margins (%)	9.0	10.2	10.0	9.1	10.2	10.5	9.9	10.4	9.5	10.1	9.3	

E: MOSL Estimates

Operating Metrics

Y/E March	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27	% YoY	% QoQ
Geography-wise revenue break-up (INR m)							
India	4,044	4,196	6,218	4,228	4,545	12	7
RoW	4,313	5,521	7,924	4,660	5,444	26	17
EBIT margin (%)						**YoY (bp)**	**QoQ (bp)**
India	17.3	20.2	9.7	24.4	23.3	601	(111)
RoW	26.2	26.6	29.4	23.9	31.6	533	769

Signature Global

BSE Sensex	S&P CNX
79,301	24,537

Conference Call Details



Date: 06th November 2026
Time: 08:00 IST
Dial-in details:
+91 22 6280 1144 /
+91 22 7115 8045

Financials & Valuations (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	26.0	40.1	52.6
EBITDA	-0.5	2.0	3.2
EBITDA (%)	-1.8	5.0	6.0
Adj. PAT	-1.7	2.3	3.6
EPS (INR)	-12.3	16.5	25.3
EPS Gr. (%)	NM	NM	53.5
BV/Sh. (INR)	131.6	148.1	173.4
Ratios			
Net D/E	0.1	0.2	0.2
RoE (%)	-13.4	11.8	15.7
RoCE (%)	2.2	6.4	8.2
Payout (%)	0.0	0.0	0.0
Valuations			
P/E (x)	-59.7	44.5	29.0
P/BV (x)	5.6	4.9	4.2
EV/EBITDA (x)	-220.1	53.1	33.9
Div Yield (%)	0.0	0.0	0.0

CMP: INR733 **Buy**

Pre-sales lower than expected; BD outlay sharply increases

Operational performance

- Pre-sales declined 9% YoY to INR18.3b (16% miss on our estimate), with sales volume of 0.88msf across 454 units.
- As of 1HFY27, pre-sales declined 18% YoY to INR38.0b, with sales volume of 1.60msf across 680 units.
- Average sales realization increased 12.3% to INR17,122/sq. ft. in 2QFY27, driven by the successful launch and strong response to the premium residential project Tonino Lamborghini Residences on Southern Peripheral Road (SPR), Sector 71, Gurugram.
- Collections grew 9% YoY to INR10.1b in 2QFY27 (7% miss on our estimate). Post-tax, net OCF increased 20% YoY to INR4.8b in 1HFY27.
- The company's land advance/acquisition outflows increased 190% YoY to INR5.5b in 1H.
- Construction expenses declined 9% YoY to INR4.2b during the quarter.
- In 2QFY27, the company expanded its land bank by 194.2 acres in Farrukhnagar, Gurugram, with an estimated development potential of 6.77msf and a GDV of INR55-60b. Additionally, it acquired 0.38msf at SG Sarvam, DXP Estate, Sector 37D, and 2.7msf of land in Sohna. Following 2QFY27, the company further added 0.1msf of development potential in Sector 71.

Financial performance

- In 2QFY27, revenue increased 141% YoY to INR8.2b (11% miss on our estimate).
- EBITDA profit stood at INR756m (30% beat on our estimate) vs EBITDA loss of INR743m YoY. EBITDA margin stood at 9.2%
- It reported PAT profit worth INR669m (11% beat on our estimate) vs PAT loss of INR469m YoY.
- Net debt increased INR600m QoQ to INR4.5b in 2QFY27.

Quarterly Performance

Y/E March	FY26				FY27E				FY26	FY27	FY27 2Q Est.	2QE Var. (%/bp)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
Net Sales	**8,657**	**3,385**	**2,844**	**11,073**	**5,520**	**8,174**	**11,326**	**15,120**	**25,959**	**40,140**	**9,232**	**-11%**
YoY Change (%)	116.1	-54.8	-65.6	112.8	-36.2	141.5	298.2	36.6	3.9	54.6	172.7	
Total Expenditure	8,324	4,128	3,477	10,509	5,965	7,418	10,372	14,378	26,437	38,133	8,652	
EBITDA	**332**	**-743**	**-632**	**564**	**-445**	**756**	**954**	**743**	**-479**	**2,007**	**580**	**30%**
Margins (%)	3.8	-21.9	-22.2	5.1	-8.1	9.2	8.4	4.9	-1.8	5.0	6.3	
Depreciation	76	78	79	85	69	86	89	122	318	366	71	
Interest	126	135	169	173	291	297	300	180	603	1,069	294	
Other Income	327	340	283	880	597	533	620	446	1,830	2,196	505	
PBT before EO expense	**458**	**-615**	**-598**	**1,185**	**-208**	**905**	**1,184**	**887**	**431**	**2,768**	**720**	
Extra-Ord expense	1	1	0	-12,673	0	0	0	0	-12,671	0	0	
PBT	**457**	**-616**	**-598**	**13,858**	**-208**	**905**	**1,184**	**887**	**13,102**	**2,768**	**720**	
Tax	113	-147	-144	2,334	-45	234	195	72	2,155	455	118	
Rate (%)	24.7	23.9	24.1	16.8	21.6	25.8	16.4	8.1	-0.9	-5.2	16.4	
MI & P/L of Asso. Cos.	0	0	0	0	2	2	0	-4	0	0	0	
Reported PAT	**344**	**-469**	**-453**	**11,524**	**-165**	**669**	**989**	**820**	**10,947**	**2,313**	**601**	**11%**
Adj PAT	**345**	**-467**	**-453**	**-1,149**	**-165**	**669**	**989**	**820**	**-1,725**	**2,313**	**601**	**11%**
YoY Change (%)	393.5	-1,227.9	-255.7	-287.1	-148.0	-243.1	-318.2	-171.3	-269.7	-234.1	-228.6	
Margins (%)	4.0	-13.8	-15.9	-10.4	-3.0	8.2	8.7	5.4	-6.6	5.8	6.5	

Source: Company, MOFSL. **We may revisit our estimates after the conference call**

Lemon Tree Hotel

BSE SENSEX	S&P CNX
79,310	24,537

CMP: INR118 — Buy

Operating performance above our estimate

- Revenue grew ~18% YoY to INR3.6b (in line)
- EBITDA grew 22% YoY to INR1.6b (est. INR1.5b).
- EBITDA margin expanded 152bp YoY to ~44.2% (est. 43.9%)
- Adj. PAT grew ~16% YoY to INR401m (est. INR496m)
- For 1HFY27, the company's revenue/EBITDA/Adj PAT grew 13%/14%/18% to INR7.1b/ INR3.1b/INR861m
- Gross debt stood at INR14.3b vs. INR15b as of Mar'26. CFO stood at INR3.1b vs INR2.3b as of Sept'25
- Exceptional items stood at INR220.9m in 2QFY27, including property tax provision (INR158.3m), impairment of investment in an associate (INR334.7m), and acquisition-related expenses (INR36.6m), partly offset by a lease termination gain of INR416.4m.

Conference Call Details



Date: 11th November'26
Time: 4:00pm IST
Dial-in details:
Click here

Consolidated Quarterly Performance (INRm)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2Q	(%)
Gross Sales	**3,158**	**3,063**	**4,061**	**4,164**	**3,446**	**3,614**	**4,496**	**4,687**	**14,445**	**16,242**	**3,471**	**4**
YoY Change (%)	17.8	7.7	14.3	10.0	9.1	18.0	10.7	12.6	12.3	12.4	-8.3	
Total Expenditure	1,753	1,756	2,014	2,012	1,949	2,017	2,151	2,217	7,533	8,334	1,947	
EBITDA	**1,405**	**1,307**	**2,047**	**2,152**	**1,497**	**1,597**	**2,344**	**2,469**	**6,912**	**7,908**	**1,524**	**5**
Margins (%)	44.5	42.7	50.4	51.7	43.4	44.2	52.1	52.7	47.8	48.7	43.9	
Depreciation	342	343	348	355	361	366	363	370	1,388	1,460	362	
Interest	447	423	414	388	364	364	350	328	1,672	1,406	360	
Other Income	16	17	17	31	21	24	22	30	82	98	22	
PBT before EO expense	**633**	**558**	**1,302**	**1,441**	**794**	**891**	**1,653**	**1,802**	**3,933**	**5,141**	**824**	
Extra-Ord expense	0	0	313	19	0	-221	0	0	333	-221	0	
PBT	**633**	**558**	**988**	**1,422**	**794**	**1,112**	**1,653**	**1,802**	**3,601**	**5,362**	**824**	
Tax	148	139	170	251	218	311	416	453	708	1,399	207	
Rate (%)	23.3	24.9	17.2	17.7	27.4	28.0	25.2	25.2	19.7	26.1	25.2	
MI & P/L of Asso. Cos.	102	73	191	255	116	235	222	284	622	857	121	
Reported PAT	**383**	**346**	**627**	**915**	**460**	**566**	**1,015**	**1,064**	**2,271**	**3,106**	**496**	
Adj PAT	**383**	**346**	**862**	**929**	**460**	**401**	**1,015**	**1,064**	**2,520**	**2,940**	**496**	**-19**
YoY Change (%)	93.5	16.7	37.9	9.8	20.1	15.8	17.8	14.5	28.2	16.7	-41.4	
Margins (%)	12.1	11.3	21.2	22.3	13.4	11.1	22.6	22.7	17.4	18.1	14.3	

Time Technoplast

BSE Sensex	S&P CNX
79,310	24,537

Conference Call Details



Date: 6 Nov 2026
Time: 16:00 IST
Diamond pass link

CMP: INR174 **BUY**

Strong quarter; earnings beat by 6%

- Consolidated revenue/EBITDA/PAT grew 32%/18%/27% YoY and were 4-12% ahead of our expectations.
- Strong revenue growth of 32% was driven by 13.8% volume growth and better realization to combat RMC inflation.
- TIME achieved EBITDA growth of 18% YoY and PAT growth of 27%, compared with volume growth of 14%.
- The higher EBITDA growth relative to volume growth demonstrates the company's ability to improve profitability through effective pricing, product mix, and operational efficiencies, rather than relying solely on volume expansion.
- India and overseas, both reported a heathy YoY volume growth of ~14% each.
- **Established Product:** Revenue up 32% YoY, EBITDA margin 11% (contracted in % term due price-led growth).
- **VAP:** Revenue up 32% YoY, EBITDA margin 18.5% (remained healthy).
- **Strong order book:** Packaging products INR3.75b, Composite CNG cascades INR2.1b, PE Pipes INR1.95b.
- Capex plans across product lines are progressing well.

Quarterly performance (INR m)

Y/E March	FY26				FY27				FY26	FY27E	FY27	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Net Sales	**13,527**	**15,111**	**15,648**	**16,767**	**16,927**	**19,942**	**18,346**	**19,651**	**61,052**	**74,895**	**17,850**	**12**
YoY Change (%)	10.0	10.3	12.8	14.2	25.1	32.0	17.2	17.2	11.9	22.7	18.1	
Total Expenditure	11,578	12,884	13,313	14,357	14,684	17,311	15,679	16,803	52,131	64,477	15,313	
EBITDA	**1,949**	**2,228**	**2,335**	**2,410**	**2,244**	**2,631**	**2,667**	**2,848**	**8,921**	**10,418**	**2,537**	**4**
Margins (%)	14.4	14.7	14.9	14.4	13.3	13.2	14.5	14.5	14.6	13.9	14.2	
Depreciation	446	457	460	470	510	523	528	533	1,833	2,094	515	
Interest	218	215	188	176	169	150	150	150	798	619	150	
Other Income	9	11	23	49	11	19	15	15	92	60	15	
PBT before EO expense	**1,293**	**1,566**	**1,710**	**1,813**	**1,576**	**1,977**	**2,004**	**2,180**	**6,382**	**7,765**	**1,888**	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	**1,293**	**1,566**	**1,710**	**1,813**	**1,576**	**1,977**	**2,004**	**2,180**	**6,382**	**7,765**	**1,888**	**5**
Tax	328	394	425	470	397	494	521	567	1,616	1,979	491	
Rate (%)	25.4	25.1	24.8	25.9	25.2	25.0	26.0	26.0	25.3	25.5	26.0	
MI & JV share	15	18	22	25	16	22	20	20	79	78	20	
Reported PAT	**951**	**1,155**	**1,263**	**1,318**	**1,162**	**1,461**	**1,463**	**1,593**	**4,687**	**5,709**	**1,377**	
Adj PAT	**951**	**1,155**	**1,263**	**1,318**	**1,162**	**1,461**	**1,463**	**1,593**	**4,687**	**5,709**	**1,377**	**6**
YoY Change (%)	19.9	17.4	25.4	20.4	22.2	26.6	15.8	20.9	20.8	21.8	19.3	
Margins (%)	7.0	7.6	8.1	7.9	6.9	7.3	8.0	8.1	7.7	7.6	7.7	

E: MOFSL Estimates

Operational data

Y/E March	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27	% YoY	% QoQ
Volume Growth (% YoY)								
India	12	13	15	14	10	14		
Overseas	17	16	17	11	14	13		
Total	14	14	16	13	11	14		
Revenue Mix (%)								
Established Products	74	70	70	73	74	70		
Value-Added Products	26	30	30	27	26	30		
Established Products								
Revenue	10,031	10,522	10,897	12,281	12,543	13,897	32	11
EBITDA Margin (%)	13.2	13.1	13.4	13.1	11.7	11.0		
Value-Added Products								
Revenue	3,505	4,600	4,773	4,535	4,395	6,064	32	38
EBITDA Margin (%)	18.0	18.7	18.8	18.9	17.9	18.5		

Cello World

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 5th Nov, 2026
Time: **10:00am** IST
Concall link:
Click here

CMP: INR372 — Buy

Earnings in line with estimates

- Consol. revenue grew 8% YoY/20% QoQ to INR6.3b, in line with our estimate.
- EBITDA declined 5% YoY but grew 23% QoQ to INR1.3b, in line with our estimate.
- EBITDA margin stood at 19.2% vs 21.7%/18.8% in 2QFY26/1QFY27 (est. 18.5%).
- Adj. PAT declined 10% YoY to INR819m, in line with our estimate.
- In 1HFY27, revenue grew 4% YoY to INR11.6b, while EBITDA/PAT declined 7%/10% YoY to INR2.2b/INR1.6b.
- CFO grew 33% YoY to INR1.7b in 1HFY27. Gross debt declined to INR217m as of Sep'26 from INR346m as of Mar'26.

Consolidated - Quarterly Earning Model (INRm)

Y/E March	FY26				FY27				FY26	FY27E	FY27	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	
Gross Sales	**5,290**	**5,874**	**5,537**	**6,536**	**5,267**	**6,332**	**6,398**	**7,386**	**23,237**	**25,384**	**6,285**	**1%**
YoY Change (%)	5.7	19.9	-0.6	11.0	-0.4	7.8	15.6	13.0	8.8	9.2	18.8	
Total Expenditure	4,200	4,598	4,480	5,247	4,277	5,114	5,068	5,839	18,524	20,297	5,123	
EBITDA	**1,091**	**1,277**	**1,057**	**1,289**	**991**	**1,218**	**1,331**	**1,547**	**4,713**	**5,087**	**1,163**	**5%**
Margins (%)	20.6	21.7	19.1	19.7	18.8	19.2	20.8	20.9	20.3	20.0	18.5	
Depreciation	186	195	199	197	218	241	235	245	777	939	225	
Interest	1	5	6	4	6	5	5	4	15	20	5	
Other Income	173	136	166	76	181	132	100	152	551	565	150	
PBT before EO expense	**1,076**	**1,213**	**1,018**	**1,165**	**947**	**1,104**	**1,191**	**1,450**	**4,472**	**4,692**	**1,083**	
Extra-Ord expense	0	0	74	0	0	0	0	0	74	0	0	
PBT	**1,076**	**1,213**	**944**	**1,165**	**947**	**1,104**	**1,191**	**1,450**	**4,397**	**4,692**	**1,083**	
Tax	269	299	250	264	213	285	302	385	1,082	1,186	275	
Rate (%)	25.0	24.7	26.5	22.6	22.5	25.8	25.4	26.6	24.6	25.3	25.4	
Adj PAT	**807**	**913**	**750**	**901**	**734**	**819**	**888**	**1,065**	**3,371**	**3,506**	**808**	**1%**
YoY Change (%)	-9.8	5.2	-18.9	-6.3	-9.0	-10.3	18.5	18.1	-7.6	4.0	0.1	
Margins (%)	15.2	15.5	13.5	13.8	13.9	12.9	13.9	14.4	14.5	13.8	12.9	

Symbiotec Pharmalab

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6rd Nov 2026

Time: 9:30 AM IST

Dial-in details: Link

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	8.7	11.4	14.5
EBITDA	2.4	3.0	3.8
Adjusted PAT	1.2	1.3	1.8
EBIT Margin (%)	21.2	17.6	18.3
Cons. Adj EPS (INR)	18.5	21.3	28.0
EPS Growth (%)	20.1	14.8	31.6
BV/Share (INR)	183.3	227.3	254.0
Ratios			
Net D-E	0.3	0.2	0.2
RoE (%)	11.8	9.5	11.9
RoCE (%)	9.3	8.4	10.7
Payout (%)	0.0	6.1	4.5
Valuations			
P/E (x)	68.7	65.8	44.7
EV/EBITDA (x)	35.2	28.5	21.8
Div. Yield (%)	0.0	0.1	0.1
FCF Yield (%)	NA	NA	NA
EV/Sales (x)	9.6	7.2	5.7

CMP: INR1,275

Revenue up 43% YoY; PAT surges 169% YoY

- Symbiotec's sales grew 43.2% YoY to INR2.8b.
- API grew 16% YoY to INR2.3b (36% of revenue), driven by healthy volume and favorable product mix.
- Gross margin expanded 750bp YoY to 71.6%.
- EBITDA margin expanded 700bp YoY to 32.7%, mainly due to a reduction in employee expenses (down 250bp YoY) as % of sales.
- EBITDA increased 81.9% YoY to INR915m.
- PAT stood at INR517m, up 169% YoY.
- In 1HFY27, consolidated revenue/EBITDA/PAT grew by 25%/26%/34% YoY to INR5b/INR1.4b/INR658m.
- New businesses contributed INR530m to 2QFY27 revenue.
- Net debt stood at INR3.1b as on Sep'26.
- Company did gross capex of INR15b as of Sep'26, expected to increase to INR16b by end of FY27.

Other updates

- Successfully completed four major regulatory audits, including EU-GMP audits at Rau and Pithampur in Mar'26, with approval certifications received for both plants; USFDA audits were also completed in 1HFY27, with EIRs received for both facilities.
- The first ANDA for a DCV molecule was successfully filed and accepted by the USFDA, while filing of the second ANDA is scheduled for 4QFY27; pre-submission facility correspondence was submitted, qualifying for expedited Priority Review.
- Commercial supplies of the two DCV products are expected to commence in FY28, with the majority of the existing DCV capacity already reserved with a strategic partner.
- The 10-year take-or-pay term sheet with a Europe-based alternative protein player is at an advanced stage, with initial manufacturing expected to commence in 4Q.

Quarterly Result Snapshot (INR m)

Y/E March	FY26			FY27E				FY26	FY27E
	1Q	2Q	4Q	1Q	2QE	3QE	4QE		
Gross Sales	**2,032**	**1,955**	**2,453**	**2,182**	**2,799**	**2,788**	**3,850**	**8,691**	**11,618**
YoY Change (%)				7.4	43.2	NA	57.0	15.6	33.7
EBITDA	**580**	**503**	**621**	**452**	**915**	**638**	**1,290**	**2,379**	**3,295**
YoY Change (%)				-22.0	81.9	NA	107.7	**17.8**	38.5
Margins (%)	28.5	25.7	25.3	20.7	32.7	22.9	33.5	27.4	28.4
Depreciation	105	106	198	218	219	242	267	533	946
EBIT	**475**	**397**	**423**	**234**	**696**	**396**	**1,022**	1,846	**2,348**
YoY Change (%)				-50.8	75.4	NA	141.4	NA	NA
Margins (%)	23.4	20.3	17.3	10.7	24.9	14.2	26.6	21	20.2
Interest	53	64	73	62	57	68	68	253	255
Other Income	26	2	2	3	1	4	5	31	14
PBT before EO expense	**448**	**335**	**352**	**175**	**640**	**332**	**959**	**1,624**	**2,107**
Extra-Ord expense	0	0	0	0	0	0	0	0	0
PBT	**448**	**335**	**352**	**175**	**640**	**332**	**959**	**1,624**	**2,107**
Tax	149	143	77	35	123	83	240	435	481
Rate (%)	33.2	42.6	21.9	19.8	19.3	25.0	25.0	26.8	22.8
Minority Interest & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0
Reported PAT	**299**	**192**	**275**	**141**	**517**	**249**	**719**	**1,189**	**1,626**
Adj PAT	**299**	**192**	**275**	**141**	**517**	**249**	**719**	**1,189**	**1,626**
YoY Change (%)				-53.0	169.0	NA	161.3	20.1	36.8
Margins (%)	14.7	9.8	11.2	6.4	18.5	8.9	18.7	13.7	14.0

Gokaldas Export

BSE Sensex	S&P CNX
79,310	24,537

CMP: INR737 — Buy

Conference Call Details



Date: 6 November 2026

Time: 12:30 IST

Diamond pass link

In-line performance; gross margin improves 600bp YoY

Consolidated

- Revenue grew 13% YoY to INR11b (in-line with MO estimates)
- Gross margin improved 600bp YoY to 53.8%
- EBITDA came in at INR1b (~3% below our estimate; +62% YoY), with an EBITDA margin of 9.4% (290bp YoY)
- APAT grew 410% to INR412m (in line), with an APAT margin of 3.7%.

Standalone

- Revenues grew at 8.6% YoY to INR7.4b
- Gross margins expanded 240bp YoY to 50.3%
- EBITDA grew 4% YoY to INR690m, EBITDA margin dipped 40bp to 9.2%.

We will provide further updates after the conference call on 6th Nov'26.

Consolidated - Quarterly Earning (INR m)

Y/E March	FY26							FY26	FY26	FY27E	2QFY27E	v/s Est (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Net Sales	**9,558**	**9,844**	**9,787**	**10,688**	**11,535**	**11,128**	**12,429**	**12,837**	**39,876**	**47,929**	**11,123**	***0%***
YoY Change (%)	2.5	6.0	-0.9	5.3	20.7	13.0	27.0	20.1	3.2	20.2	13.0	
RM Cost	4,424	5,134	4,480	5,209	5,491	5,140	5,966	6,408	19,247	23,006	5,373	*-4%*
Gross Profit	**5,134**	**4,710**	**5,306**	**5,480**	**6,044**	**5,988**	**6,463**	**6,428**	**20,630**	**24,923**	**5,751**	*4%*
Margins (%)	53.7	47.8	54.2	51.3	52.4	53.8	52.0	50.1	51.7	52.0	51.7	
Total Expenditure	8,585	9,197	9,017	9,523	10,410	10,080	11,122	11,380	36,313	42,992	10,043	*0%*
EBITDA	**973**	**646**	**769**	**1,165**	**1,125**	**1,048**	**1,307**	**1,456**	**3,564**	**4,937**	**1,080**	***-3%***
Margins (%)	10.2	6.6	7.9	10.9	9.8	9.4	10.5	11.3	8.9	10.3	9.7	
Depreciation	394	426	463	386	458	481	480	431	1,669	1,850	475	*1%*
Interest	225	223	240	264	305	295	240	152	952	992	308	*-4%*
Other Income	214	190	195	185	267	222	210	132	773	831	250	*-11%*
PBT before EO expense	**568**	**187**	**261**	**700**	**628**	**495**	**797**	**1,005**	**1,716**	**2,926**	**547**	***-10%***
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	**568**	**187**	**261**	**700**	**628**	**495**	**797**	**1,005**	**1,716**	**2,926**	**547**	***-10%***
Tax	153	106	115	340	185	83	199	264	715	731	137	
Rate (%)	27.0	56.8	44.1	48.6	29.5	16.7	25.0	26.3	41.7	25.0	25.0	
MI & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	**415**	**81**	**146**	**360**	**443**	**412**	**598**	**741**	**1,001**	**2,194**	**410**	***0%***
Adj PAT	**415**	**81**	**146**	**360**	**443**	**412**	**598**	**741**	**1,001**	**2,194**	**410**	***0%***
YoY Change (%)	52.6	-71.3	-71.0	-31.9	6.8	410.0	309.0	105.9	-36.8	119.1	407.6	
Margins (%)	4.3	0.8	1.5	3.4	3.8	3.7	4.8	5.8	2.5	4.6	3.7	

Aditya Birla Fashion & Retail

BSE SENSEX	S&P CNX
79,310	24,537

Conference Call Details



Date: 6th Nov 2026
Time: 04:00Pm IST

Financials & Valuations (INR b)

INR million	FY27E	FY28E	FY29E
Sales	89.0	97.0	105.2
EBITDA	7.4	9.4	10.9
NP	(8.2)	(9.5)	(11.0)
EBITDA Margin (%)	8.3	9.7	10.4
Adj. EPS (INR)	(6.7)	(7.7)	(9.1)
BV/Sh. (INR)	53.6	44.3	33.4
Ratios			
Net D:E	0.4	0.5	0.7
RoE (%)	(14.0)	(19.0)	(28.0)
RoCE (%)	(4.0)	(4.8)	(5.6)
Valuations			
P/E (x)	NM	NM	NM
EV/EBITDA (x)	11.2	9.2	8.2
EV/Sales (x)	0.9	0.9	0.8

CMP: INR48 — Neutral

Washout quarter, losses widen; net debt jumps INR12b in 1H

- Revenue **grew 2% YoY** to INR20.3b (in-line) as the shift in the festive period to 3Q weighed across segments.
  - Pantaloons revenue remained flat YoY due to the shift in Pujo to 3Q (vs. partly in 2Q in FY26).
  - Ethnics revenue growth was also subdued at ~2% YoY, reflecting the festive shift and subdued wedding calendar, although growth excluding TCNS stood at ~12% YoY.
  - Store network: Pantaloons 387 (-12), OWND 90 (+2), TCNS ~460 (-14), TMRW 150+ (+15) and TCMB 49 (-2).
- Gross profit declined ~0.5% YoY (~3% miss) as gross margin **contracted ~170bp** YoY to 56.2%, (~130bp below our estimate), amid rising input and logistics costs.
- Employee/other expenses inched up ~5% YoY each, while reported rental costs declined ~4% YoY.
- **Reported EBITDA** stood at ~INR133m, **down ~81% YoY** as EBITDA **margin contracted ~280bp YoY** to **0.7%** (in-line), owing to operating deleverage on account of festive shift, higher one-off expenses in Sabyasachi and the losses in newer businesses such as OWND and Galeries Lafayette, partly offset by narrowing losses in TMRW.
- Adj. net loss widened 30% YoY to INR3.4b (~7% higher than est.) on higher D&A (+14% YoY) and finance costs (+22% YoY).

Segmental performance

Pantaloons and OWND!

- Revenue was flat YoY at INR11.4b (in-line) due to the shift in Pujo to 3Q, while OWND continued to scale, with revenue rising 58% YoY led by store additions.
  - Adjusted for the festive shift and store closures, the Pantaloons format grew ~6% YoY.
  - The format delivered -7% LTL (vs. +4% LTL in 1QFY27), while non-East markets delivered +2% LTL.
  - E-commerce revenue grew 19% YoY, with contribution of ~4% of segment revenue.
  - Pantaloons' store count fell to 387 from 399 QoQ (4 additions, 16 closures). Store area declined 1% YoY to 5.68m sqft.
  - OWND added two stores during the quarter, taking its network to 90 stores.
- EBITDA at INR1.2b declined 24% YoY as margin contracted ~330bp YoY to 10.4% (~30bp miss), primarily due to operating deleverage and losses in OWND.

Ethnic

- Revenue grew modest ~2% YoY to INR5.2b (inline), while growth excluding TCNS stood at ~12% YoY.
  - **Sabyasachi** delivered strong double-digit growth and opened a 25,000+ sqft flagship in New Delhi.
  - **Tarun Tahiliani** grew in double digits, led by bridal and couture menswear.
  - **Tasva** sustained double-digit growth in 1HFY27.

- **Jaypore** continued to narrow losses, with online share at ~20%.
- **TCNS** revenue moderated due to the festive shift and store rationalization, as it continued to focus on profitable growth.

- **Reported operating loss widened to INR171m** (vs. INR10m loss YoY), with loss margin at -3.3% vs. -0.2% YoY (~220bp better than our estimate), due to the festive shift and brand investments in designer labels.

TMRW

- The 2Q revenue grew modest ~10% YoY to INR2.4b (~6% miss), while growth including WROGN stood at 19% YoY.
- Losses continued to narrow, with **operating loss declining 34% YoY to INR410m**.
- Loss margin narrowed ~11.1pp YoY (~240bp QoQ) to 16.8% (~170bp better than our est.), marking the fourth straight quarter of YoY improvement.
- The portfolio **added 15+ stores** (including WROGN) and now spans 150+ exclusive brand stores (84 excluding WROGN).

Others (Luxury Retail)

- Other segment **revenue grew 11% YoY** to INR1.6b (in line), led by the Galeries Lafayette ramp-up, while TCMB's online contribution exceeded 15%.
- Reported **EBITDA declined 66% YoY to INR120m,** with margin contracting to 7.6% from 24.5% YoY, due to losses in Galeries Lafayette and YoY lower treasury income.

Balance Sheet and Cashflows

- ABFRL's **Inventory rose 15% YoY to INR31.7b**, taking inventory days to 137 (vs. 130 YoY), likely due to pre-festive stocking. Payable days fell to 113 (vs. 125 YoY), leading to increase in core working capital days to 43 (vs. 27 YoY). Core working capital rose 72% YoY to INR10.0b.
- 1HFY27 **OCF** (after interest and leases) outflow stood at **INR7.5b (vs. INR6.3b YoY),** due to 18% YoY decline in cashflow from operations, 26% YoY increase in lease rentals. Capex moderated to INR2b (-23% YoY), which resulted in **FCF outflow (after leases and interest) of INR9.5b (vs. INR8.8b YoY).**
- Gross borrowings jumped INR6.6b in 1HFY27 to INR23.5b, while cash declined by INR5.3b to INR10.2b, **taking net debt up by INR11.8b in 1HFY27 to INR13.3b (vs. INR1.5b in FY26).**

ABFRL (INR m)	2QFY26	1QFY27	2QFY27	YoY%	QoQ%	2QFY27E	vs. est
Revenue	**19,817**	**20,256**	**20,300**	***2.4***	***0.2***	**20,352**	***-0.3***
Raw Material cost	8,347	8,790	8,892	*6.5*	*1.2*	8,650	*2.8*
Gross Profit	**11,470**	**11,466**	**11,408**	***-0.5***	***-0.5***	**11,702**	***-2.5***
Gross margin (%)	**57.9**	**56.6**	**56.2**	***-168bps***	***-41bps***	**57.5**	***-130bps***
Employee Costs	3,305	3,459	3,453	*4.5*	*-0.2*	3,521	*-1.9*
Rent	620	623	596	*-3.9*	*-4.3*	661	*-9.8*
SGA Expenses	6,857	6,215	7,226	*5.4*	*16.3*	7,378	*-2.1*
Total	**10,782**	**10,297**	**11,275**	***4.6***	***9.5***	**11,561**	***-2.5***
EBITDA	**688**	**1,169**	**133**	***-80.7***	***-88.6***	**142**	***-6.3***
EBITDA margin (%)	***3.5***	***5.8***	***0.7***	*-282bps*	*-512bps*	***0.7***	*-4bps*
Depreciation and amortization	3,252	3,497	3,694	*13.6*	*5.6*	3,567	*3.5*
EBIT	-2,564	-2,328	-3,561	*38.9*	*53.0*	-3,425	*4.0*
EBIT margin (%)	*-12.9*	*-11.5*	*-17.5*	*-460bps*	*-605bps*	*-16.8*	*-71bps*
Finance Costs	1,242	1,371	1,517	*22.1*	*10.7*	1,405	*8.0*
Other income	545	560	598	*9.6*	*6.7*	327	*82.6*
Exceptional item	*0*	-	-			-	
Profit before Tax	**-3,260**	**-3,139**	**-4,480**	***37.4***	***42.7***	**-4,503**	***-0.5***
Tax	-380	-715	-781	***105.6***		-1,135	***-31.2***
Tax rate (%)	*11.6*	*22.8*	*17.4*			*25.2*	
Share in JV	247.3	271.0	271.1			150.0	
Profit after Tax	**-2,633**	**-2,152**	**-3,428**	***30.2***	***59.3***	**-3,219**	***6.5***
Adj Profit after Tax	**-2,633**	**-2,152**	**-3,428**	***30.2***	***59.3***	**-3,219**	***6.5***

Segments	2QFY26	1QFY27	2QFY27	YoY%	QoQ%	2QFY27E	vs. est
Pantaloons							
Revenue	**11,417**	**12,044**	**11,400**	***-0.2***	***-5.4***	**11,303**	***0.9***
EBITDA	1,570	1,920	1,190	*-24.2*	*-38.0*	1,215	*-2.1*
% Margin	*13.8*	*15.9*	*10.4*	*-331bps*	*-550bps*	*10.8*	*-31bps*
Ethnic							
Revenue	**5,050**	**4,540**	**5,170**	***2.4***	***13.9***	**5,050**	***2.4***
EBITDA	-10	5	-171	*1606.1*	*-3857.9*	-278	*-38.6*
% Margin	*-0.2*	*0.1*	*-3.3*	*-310bps*	*-340bps*	*-5.5*	*220bps*
TMRW							
Revenue	**2,220**	**2,200**	**2,440**	***9.9***	***10.9***	**2,597**	***-6.1***
EBITDA	-620	-422	-410	*33.9*	*3.0*	-481	*14.7*
% Margin	*-27.9*	*-19.2*	*-16.8*	*1113bps*	*240bps*	*-18.5*	*170bps*
Others							
Revenue	**1,430**	**1,570**	**1,580**	***10.5***	***0.6***	**1,602**	***-1.3***
EBITDA	350	157	120	*-65.7*	*-23.5*	112	*7.1*
% Margin	*24.5*	*10.0*	*7.6*	*-1688bps*	*-240bps*	*7.0*	*60bps*

Repco Home Finance

BSE Sensex	S&P CNX
79,310	24,537

Conference Call Details



Date: 06th Nov'26
Time: 15:30 HRS IST
Dial-in details:
Link

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
NII	7.7	8.4	9.3
PPP	5.5	6.3	7.1
PAT	4.5	4.6	5.0
EPS (INR)	72.4	74.2	80.3
EPS Gr. (%)	1	3	8
BV/Sh. (INR)	624	694	769
Ratios			
NIM (%)	5.1	5.1	5.0
C/I ratio (%)	31.8	29.3	28.4
RoAA (%)	2.9	2.7	2.6
RoE (%)	12.2	11.3	11.0
Payout (%)	4.1	6.2	6.2
Valuation			
P/E (x)	4.6	4.5	4.2
P/BV (x)	0.5	0.5	0.4
P/ABV (x)	0.5	0.5	0.5
Div. Yield (%)	0.9	1.4	1.5

CMP: INR327 — Neutral

Disbursements pickup but loan growth muted; NIM stable QoQ

Asset quality improves and credit costs benign despite sharp improvement in S3 PCR

- Repco (REPCO)'s 2QFY27 PAT grew 8% YoY to INR1.2b (inline). NII in 2QFY27 grew ~9% YoY to ~INR2.1b (in line). Other income grew ~16% YoY to INR143m (vs est. of INR130m; ~10% beat). Opex rose ~18% YoY to INR709m (~13% higher than est.).
- PPOP grew ~6% YoY to INR1.5b (~5% miss). Provisions stood at ~INR4m, translating into annualized credit costs of ~1bp (PY: -4bp and PQ: 24bp)
- The Board declared an interim dividend of INR5/share.

Loan book rises ~9% YoY; disbursements healthy

- Disbursements grew ~13% YoY and ~43% QoQ to INR12.1b in 2QFY27. Loan book grew ~9% YoY/ 2.7% QoQ to ~INR164b. Repayment rates declined ~50bp YoY to ~19.3% (PY: ~19.8% and PQ: 18.5%).
- As of Sep'26, loans to the non-salaried segment accounted for 53.6% of the outstanding loan book and loans for salaried segment accounts for 46.4%. Housing loans accounted for 71% of the loans while Home Equity accounted for 29% of loan book.

Reported yields and margins stable sequentially

- Reported yields in 2QFY27 were stable QoQ at ~11.7% and the CoB was also stable QoQ at ~8.3%. This lead to spreads remaining stable QoQ at ~3.4%. Reported NIM was stable QoQ at 5.4%.
- Capital adequacy ratio stood at ~37% as of Sep'26.

Asset quality improves; PCR jumps ~12pp QoQ

- GS3 declined ~30bp QoQ to ~2.4% while NS3 declined ~40bp QoQ to ~0.8%. PCR on S3 loans spiked ~12pp QoQ to ~66%. Stage 2 assets declined ~20bp QoQ to ~7% as of Sep'26.
- For the book originated from Apr'22 onwards, GS2 stood at 4.3% (v/s 7% for the overall book) and GS3 stood at 1.1% (vs 2.4% for the overall book).

Valuation and view

- REPCO delivered mixed quarter where earnings were inline driven by lower credit costs however loan growth was impacted driven by higher repayments despite healthy disbursements growth. Asset quality improved sequentially driven by decline in GS2 and GS3 resulting in benign credit costs. Yields and margins remained stable during the quarter. With the stock currently trading at ~0.4x FY28E P/BV, our key focus will remain on the demand environment, disbursement outlook going forward, and margin trajectory.
- We will closely monitor management's outlook on FY27 loan growth and margins and may revisit our estimates following further clarity from the earnings call scheduled on 06th Nov'26 at 3:30PM.

Quarterly performance (INR M)

Y/E March	FY26				FY27E				FY26	FY27E	2QFY27E	Act v/s est(%)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
Interest Income	4,257	4,334	4,453	4,441	4,569	4,673	4,825	4,886	17,501	18,953	4,633	1
Interest Expenses	2,441	2,444	2,489	2,468	2,513	2,610	2,727	2,702	9,842	10,552	2,561	2
Net Income	**1,816**	**1,890**	**1,964**	**1,974**	**2,056**	**2,063**	**2,098**	**2,185**	**7,660**	**8,401**	**2,073**	**0**
YoY Growth (%)	8.3	14.2	10.2	15.5	13.2	9.1	6.8	10.7	9.0	9.7	9.7	
Other income	150	123	118	100	110	143	135	135	476	523	130	10
Total Income	**1,966**	**2,013**	**2,082**	**2,074**	**2,166**	**2,205**	**2,233**	**2,320**	**8,135**	**8,924**	**2,203**	**0**
YoY Growth (%)	7.3	6.8	5.3	9.6	10.2	9.6	7.2	11.9	8.6	9.7	9.4	
Operating Expenses	530	603	748	704	592	709	752	558	2,585	2,611	627	13
YoY Growth (%)	17.2	16.7	39.9	20.6	11.7	17.6	0.5	-20.8	23.8	1.0	4.0	
Operating Profits	**1,436**	**1,410**	**1,334**	**1,370**	**1,574**	**1,496**	**1,481**	**1,762**	**5,550**	**6,314**	**1,575**	**-5**
YoY Growth (%)	4.1	3.1	-7.6	4.7	9.6	6.1	11.0	28.7	2.7	13.8	11.7	
Provisions	-27	-15	-156	-114	97	4	20	-14	-311	107	30	-87
Profit before Tax	**1,463**	**1,424**	**1,490**	**1,483**	**1,477**	**1,492**	**1,461**	**1,777**	**5,860**	**6,207**	**1,545**	**-3**
Tax Provisions	384	355	402	192	336	334	368	527	1,333	1,564	389	-14
Profit after tax	**1,080**	**1,069**	**1,088**	**1,291**	**1,142**	**1,159**	**1,093**	**1,250**	**4,528**	**4,643**	**1,156**	**0**
YoY Growth (%)	2.4	-5.0	2.1	12.3	5.7	8.3	0.5	-3.2	0.8	2.5	8.1	
Loan growth (%)	7.2	7.7	8.8	9.6	8.9	9.3	9.7	10.3	10.6	10.9	9.3	
Cost to Income Ratio (%)	26.9	30.0	35.9	34.0	27.3	32.2	33.7	24.0	31.8	29.3	28.5	
Tax Rate (%)	26.2	24.9	27.0	12.9	22.7	22.4	25.2	29.6	22.7	25.2	25.2	
Key Parameters (%)						1.2						
Yield on loans (Cal)	11.7	11.7	11.7	11.4	11.5	11.5	11.6	11.4	11.8	11.5		
Cost of funds (Cal)	8.8	8.7	8.6	8.2	8.3	8.4	8.5	8.2	8.4	8.2		
Spreads (Cal)	2.9	3.0	3.1	3.1	3.2	3.1	3.1	3.2	3.4	3.3		
NIMs (Reported)	5.4	5.5	5.6	5.5	5.4	5.4	0.0	0.0	5.1	5.1		
Credit Cost	-0.07	-0.04	-0.41	-0.29	0.24	0.01	0.02	-0.03	-0.2	0.1		
Cost to Income Ratio	26.9	30.0	35.9	34.0	27.3	32.2	33.7	24.0	31.8	29.3		
Tax Rate	26.2	24.9	27.0	12.9	22.7	22.4	25.2	29.6	22.7	25.2		
Balance Sheet												
AUM (INR B)	146.9	150.3	153.9	158.8	159.9	164.3	168.8	175.1	158.8	175.1		
Change YoY (%)	7.2	7.7	8.8	9.6	8.9	9.3	9.7	10.3	9.6	10.3		
AUM Mix (%)												
Non-Salaried	52.3	53.0	53.0	53.0	53.5	53.6			51.3	51.4		
Salaried	47.7	47.0	47.0	47.0	46.5	46.4			48.7	48.6		
AUM Mix (%)												
Home loans	72.4	71.0	71.0	71.0	70.8	71.0			71.0	70.0		
LAP	27.6	29.0	29.0	29.0	29.2	29.2			29.0	30.0		
Disbursements (INR B)	8.3	10.7	10.6	11.9	8.4	12.1			41.5	46.0		
Change YoY (%)	21.8	23.3	39.8	21.6	1.7	12.7			26.3	11.0		
Borrowings (INR B)	110.7	115.0	117.7	122.2	120.8	128.1			122.1	135.1		
Change YoY (%)	1.5	0.3	6.2	9.6	9.1	11.4			9.6	10.7		
Loans/Borrowings (%)	132.6	130.8	130.8	130.0	132.4	128.2			130.1	129.6		
Borrowings Mix (%)												
Banks	82.1	84.8	84.1	85.5	86.7	85.6			77.7	79.2		
NHB	8.4	7.0	7.0	6.2	6.2	7.2			12.0	10.8		
Repco Bank	8.2	7.0	6.9	5.4	4.8	4.5			10.3	10.0		
NCD	0.0	0.0	0.0	1.0	1.0	1.0			0.0	0.0		
CP	1.3	1.2	1.2	1.2	0.6	0.6			0.0	0.0		
Asset Quality												
GS 3 (INR B)	4.9	4.8	4.5	4.1	4.3	4.0			4.1	3.9		
Gross Stage 3 (% on Assets)	3.30	3.16	2.92	2.55	2.67	2.42			2.6	2.2		
NS 3 (INR B)	1.72	2.25	2.13	1.82	1.94	1.35			1.8	1.8		
Net Stage 3 (% on Assets)	1.20	1.5	1.42	1.17	1.24	0.8			1.2	1.0		
PCR (%)	64.7	52.5	52.7	55.1	54.6	66.1			55.1	54.0		
Return Ratios (%)												
ROA (Rep)	2.9	2.9	2.9	3.4	2.9	2.9			2.9	2.7		
ROE (Rep)	14.0	13.5	13.3	14.9	12.7	12.6			12.2	11.3		

E: MOFSL Estimates



Apollo Hospitals: New Bed Additions To Start Contributing To EBITDA By 2027
Suneeta Reddy, Managing Director

- Commissioned 520 beds with another 500 opening by December, targeting full EBITDA contribution within 12 months.
- Minimal impact anticipated from oncology drug margin caps due to full-service integrated care delivery.
- Pharmacy and diagnostic segments posted strong operating leverage, maintaining a 20% growth trajectory.

Read More

Endurance Tech: Aviation, Defence To Be Key Target Markets Going Ahead
Aditya Jhawar, Head of Growth & Business Transformation

- Margins set to improve with price hikes and softening raw material costs.
- Four greenfield facilities (₹1,100 crore capex) ramp up, targeting ₹2,700–3,000 crore peak revenue.
- Maxwell Electronics broke even, driving embedded electronics and targeting medium-term double-digit margins.
- Diversifying beyond automotive into defense, aviation, robotics, and railway components.

Read More

EPL: Indorama Merger on Track & Capex Front-Loaded
Hemant Bakshi, Global CEO

- See strong growth runway in beauty and cosmetics
- Indovida merger on track for completion by April 2027, argeting accelerated synergies of $35–50 million.
- IVL's stake in EPL to rise to 52% post reverse merger

Read More

Sanathan Textiles: Entering Uganda, Nigeria & Zambia
Samir Dattani), Executive Director

- Revenue doubled in Q2 led by Punjab plant operations, with FY27 revenue targeted to exceed ₹6,000 crore.
- Full-year EBITDA guided conservatively at ₹550+ crore, supported by strong festive demand and better fixed-cost absorption.
- Technical textiles capacity doubled to 18,000 tonnes, commanding higher margins of ₹19–20/kg.
- Peak debt capped at ~₹1,200 crore; Phase 2 expansions will be fully funded through internal accruals.

Read More

Index and MOFSL Universe stock performance

Index	1 Day (%)	1M (%)	12M (%)
Sensex	**2.6**	**9.6**	**-5.0**
Nifty-50	**2.4**	**8.8**	**-4.1**
Nifty Next 50	**1.4**	**3.7**	**2.3**
Nifty 100	**2.2**	**7.8**	**-3.0**
Nifty 200	**2.1**	**6.8**	**-2.3**
Company	**1 Day (%)**	**1M (%)**	**12M (%)**
Automobiles	**4.1**	**8.6**	**3.7**
Amara Raja Ener.	1.0	-0.7	-25.6
Apollo Tyres	4.1	4.3	-19.8
Ashok Leyland	10.5	11.5	21.2
Bajaj Auto	1.4	7.3	22.9
Balkrishna Inds	7.1	16.2	1.6
Bharat Forge	-3.3	-4.4	32.3
Bosch	3.0	16.7	38.6
CEAT	1.6	5.7	-13.3
CIE Automotive	3.3	-4.3	-16.3
Craftsman Auto	0.1	4.4	56.7
Eicher Motors	3.9	9.8	11.3
Endurance Tech.	0.3	-0.5	-13.4
Escorts Kubota	-0.3	-12.8	-35.6
Exide Inds.	-1.6	-10.5	-4.5
Gabriel India	1.0	7.9	11.1
Happy Forgings	2.2	-6.1	86.6
Hero Motocorp	2.1	8.3	3.9
Hyundai Motor I	2.8	6.1	-11.4
M & M	5.6	9.4	-12.7
Maruti Suzuki	5.5	9.7	-17.7
Motherson Wiring	0.5	19.9	-16.1
MRF	6.7	2.1	-20.3
Samvardh. Mothe.	5.3	7.3	60.8
Sona BLW Precis.	2.4	14.8	89.2
SPR Auto Tech.	1.1	-2.2	59.4
Tata Motors	6.5	0.5	
Tata Motors PVeh	5.5	1.7	-27.7
Tenneco Clean	0.7	-4.0	
Tube Investments	2.2	-0.9	-23.1
TVS Motor Co.	2.7	10.4	28.1
Uno Minda	11.5	21.3	6.6
Banks-Private	**3.4**	**7.0**	**2.2**
AU Small Finance	4.1	-8.6	6.9
Axis Bank	3.9	4.7	4.4
Bandhan Bank	2.5	-3.9	3.6
DCB Bank	4.8	0.6	22.2
Equitas Sma. Fin	-1.2	-19.8	-9.4
Federal Bank	1.0	3.4	42.3
HDFC Bank	3.2	7.8	-22.9
ICICI Bank	5.3	12.6	12.2
IDFC First Bank	4.1	-5.4	-4.1
IndusInd Bank	5.4	2.8	15.3
Kotak Mah. Bank	1.7	12.3	11.4
RBL Bank	2.1	-10.6	15.0

Index	1 Day (%)	1M (%)	12M (%)
Nifty 500	**2.0**	**5.7**	**-1.9**
Nifty Midcap 100	**1.9**	**2.5**	**1.0**
Nifty Smallcap 100	**0.6**	**-0.1**	**4.2**
Nifty Midcap 150	**1.9**	**2.5**	**0.7**
Nifty Smallcap 250	**0.8**	**-0.7**	**1.2**
Banks-PSU	**3.1**	**6.8**	**2.8**
Bank of Baroda	1.8	7.2	-13.3
Canara Bank	3.9	3.7	-12.0
Indian Bank	4.5	10.1	2.3
Punjab Natl.Bank	3.0	12.2	2.3
SBI	2.8	5.1	5.1
Union Bank (I)	2.2	11.9	24.1
Building Materials			
Astral	-2.5	1.9	-5.4
Century Plyboard	-1.2	-4.4	-14.3
Cera Sanitary.	0.5	-5.0	-23.7
Kajaria Ceramics	4.0	-0.7	3.3
Prince Pipes	6.9	28.6	-1.7
Supreme Inds.	-1.9	-3.2	-15.4
NBFCs	**4.0**	**7.9**	**-2.2**
AAVAS Financiers	0.3	-7.4	-31.2
Aditya Birla Cap	4.3	5.0	19.5
Bajaj Finance	7.6	10.3	1.2
Bajaj Finserv	4.5	4.8	-11.5
Bajaj Housing	2.1	0.4	-24.1
Can Fin Homes	2.7	2.8	-13.5
Cholaman.Inv.&Fn	6.2	9.6	0.8
CreditAcc. Gram.	2.6	-12.0	-20.1
Five-Star Bus.Fi	8.2	-17.2	-33.8
Fusion Finance	3.3	-5.4	-11.2
HDB FINANC SER	5.1	-14.6	-27.3
Home First Finan	1.6	0.3	-8.0
IIFL Finance	4.5	0.6	12.1
Indostar Capital	3.8	-3.1	-26.3
Jio Financial	3.3	8.3	-23.9
L&T Finance Ltd	5.6	5.6	-0.5
LIC Housing Fin.	1.7	4.8	-7.8
M & M Fin. Serv.	5.5	-12.6	-10.5
Manappuram Fin.	3.8	4.9	22.3
MAS FINANC SER	7.6	1.6	-13.0
Muthoot Finance	4.8	4.5	-11.0
Northern Arc	1.4	-2.9	2.3
Piramal Finance.	8.9	5.8	
PNB Housing	1.7	-0.5	18.1
Poonawalla Fin	1.2	5.1	0.5
Power Fin.Corpn.	2.1	2.3	-16.9
REC Ltd	3.0	0.0	-20.2
Repco Home Fin	-0.5	-0.9	-27.5
Shriram Finance	6.1	-0.8	21.0
Spandana Sphoort	1.9	-12.9	-23.4
Tata Capital	3.0	9.5	5.6

Company	1 Day (%)	1M (%)	12M (%)
Capital Markets			
360 ONE	6.8	8.7	5.7
Aditya AMC	4.5	-13.1	14.6
Anand Rathi Wea.	3.2	11.2	51.9
Angel One	4.5	14.4	29.5
Billionbrains	8.0	19.7	
BSE	5.2	19.2	51.8
C D S L	0.8	6.7	-13.3
Cams Services	2.9	4.6	-5.9
HDFC AMC	5.4	12.5	-2.3
ICICI AMC	3.4	-2.7	
KFin Technolog.	3.3	6.8	-13.4
Multi Comm. Exc.	1.5	5.8	80.5
N S D L	3.4	3.2	-29.9
Nippon Life Ind.	6.9	0.8	21.3
Nuvama Wealth	1.5	2.9	31.0
Prudent Corp.	2.6	-4.5	15.8
SBI Funds Mgt.	1.6	2.2	
UTI AMC	1.9	-6.1	-31.1
Insurance			
Canara HSBC	1.1	-12.7	4.9
HDFC Life Insur.	2.1	2.4	-26.8
ICICI Lombard	1.5	1.3	-20.6
ICICI Life Insurance	1.1	-6.0	-29.6
Life Insurance	0.0	5.0	-9.9
Max Financial	2.3	-5.5	-20.0
Niva Bupa Health	-0.3	1.4	0.6
SBI Life Insuran	1.5	1.5	-12.0
Star Health Insu	2.2	1.3	11.0
Chemicals			
Alkyl Amines	-1.4	-9.4	-14.4
Atul	2.0	-10.2	-10.8
Clean Science	3.4	-15.1	-31.0
Deepak Nitrite	-2.2	3.1	-11.9
Ellen.Indl.Gas	-10.0	-5.9	-31.7
Fine Organic	0.2	-1.2	16.8
Galaxy Surfact.	-4.6	-7.4	-4.7
Himadri Special	1.2	-13.8	22.9
Navin Fluo.Intl.	0.7	6.9	46.1
P I Industries	-19.1	-20.3	-51.9
Privi Speci.	-0.6	-5.4	9.1
SRF	1.0	1.0	-15.6
Tata Chemicals	2.1	-0.3	-31.0
Vinati Organics	1.1	-14.2	-39.2
Capital Goods	**-2.1**	**-4.0**	**1.5**
A B B	-1.8	-3.9	26.4
Atlanta Electric	-2.7	-21.7	46.9
CG Power & Ind	-3.9	-8.3	8.2
Cummins India	-14.1	-16.0	-6.0
GE Vernova T&D	-2.8	-2.4	31.7
Hitachi Energy	-3.1	-10.5	37.9

Company	1 Day (%)	1M (%)	12M (%)
Kalpataru Proj.	0.6	-0.3	4.5
KEC Internationa	2.5	-11.0	-59.3
Kirloskar Oil	-11.6	-29.0	56.9
Larsen & Toubro	2.7	8.0	3.2
MTAR Technologie	-5.0	-25.1	127.0
Siemens	-2.2	-7.3	10.0
Siemens Ener.Ind	-3.5	-13.8	-11.9
Thermax	1.1	2.8	1.5
Triveni Turbine	3.2	-2.1	-3.9
Cement			
ACC	3.5	3.6	-33.1
Ambuja Cements	3.2	5.9	-31.6
Birla Corpn.	3.2	2.9	-30.3
Dalmia BharatLtd	4.2	-12.4	-28.5
Grasim Inds	2.9	8.6	12.0
India Cements	4.3	15.9	-13.0
J K Cements	3.7	5.7	-8.9
JK Lakshmi Cem.	-1.5	1.3	-44.5
JSW Cement	0.6	10.3	-9.2
Shree Cement	3.0	13.2	-9.8
The Ramco Cement	5.3	-3.0	-21.0
UltraTech Cem.	3.7	12.9	3.6
Consumer	**0.4**	**4.2**	**-16.7**
Asian Paints	4.4	6.7	1.5
Bikaji Foods	4.1	1.1	-32.6
Britannia Inds.	0.7	4.4	-15.5
Colgate-Palmoliv	1.6	-4.9	-23.0
Dabur India	-2.5	1.7	-25.5
Emami	1.8	2.7	-27.8
Godrej Consumer	1.6	3.1	-25.8
Gopal Snacks	0.3	-2.4	-29.2
Hind. Unilever	0.2	7.8	-17.7
Indigo Paints	4.7	-13.4	-9.5
ITC	-0.4	3.7	-31.8
Jyothy Labs	5.9	10.1	-36.9
L T Foods	1.4	2.4	3.0
Marico	-0.3	12.4	23.8
Mrs Bectors	0.6	-0.6	-20.8
Nestle India	0.8	-3.0	-0.5
P & G Hygiene	1.0	3.8	-47.6
Page Industries	-0.6	-5.2	-11.5
Pidilite Inds.	2.9	4.4	6.8
Prataap Snacks	0.5	-0.4	-5.1
Radico Khaitan	2.9	5.5	41.4
Tata Consumer	0.9	13.0	-8.6
United Breweries	-0.6	1.1	-34.0
United Spirits	-1.7	1.9	-3.9
Varun Beverages	3.1	-1.4	-8.0
Zydus Wellness	-2.9	-1.9	2.5
Consumer Durables	**2.7**	**4.1**	**0.3**
Blue Star	1.1	4.1	-18.0

Company	1 Day (%)	1M (%)	12M (%)
Crompton Gr. Con	1.3	-2.3	-27.1
Havells India	-0.2	2.0	-28.1
KEI Industries	1.6	-12.4	1.8
LG Electronics	5.1	0.4	8.9
Polycab India	-1.0	-2.9	3.8
R R Kabel	-0.2	-23.9	41.7
Voltas	4.8	5.1	-17.9
Defense			
Astra Microwave	-1.4	-5.7	47.1
Bharat Dynamics	0.0	-1.9	-27.4
Bharat Electron	-0.7	2.7	-4.8
Data Pattern	-2.9	-6.3	46.6
Hind.Aeronautics	-0.7	7.8	7.6
Solar Industries	-4.5	-5.2	35.9
Unimech Aero.	2.0	-2.1	81.3
Zen Technologies	-0.3	7.8	22.6
EMS			
Aditya Infotech	4.3	4.5	215.4
Amber Enterp.	1.9	0.0	-15.5
Avalon Tech	2.9	-6.9	82.6
Cyient DLM	8.0	-14.1	79.1
Dixon Technolog.	2.7	-1.0	-17.3
Kaynes Tech	-1.1	-3.0	-50.6
Syrma SGS Tech.	0.2	-10.9	93.2
Healthcare	**1.0**	**5.7**	**23.6**
Ajanta Pharma	-0.8	-5.7	26.0
Alembic Pharma	-1.5	7.5	-7.0
Alkem Lab	-0.5	0.0	-8.4
Apollo Hospitals	-2.7	4.8	7.2
Aster DM Quality	0.0	4.1	4.5
Aurobindo Pharma	4.7	6.6	55.3
Biocon	5.1	-2.1	-4.9
Blue Jet Health	8.4	8.4	-5.0
Cipla	0.1	5.1	-6.6
Divi's Lab.	1.0	10.3	49.0
Dr Agarwal's Hea	-2.2	5.7	-0.6
Dr Reddy's Labs	-0.6	13.5	13.8
Emcure Pharma	3.9	15.9	69.5
ERIS Lifescience	1.6	3.9	-22.9
Fortis Health.	3.7	7.3	-19.6
Gland Pharma	-0.4	8.0	64.5
Glaxosmi. Pharma	-1.2	-8.5	-6.0
Glenmark Pharma.	-0.9	8.1	34.5
Global Health	-0.6	4.5	11.5
Granules India	0.0	-2.8	39.9
Ipca Labs.	-1.1	-0.1	50.6
Laurus Labs	1.0	19.0	138.6
Laxmi Dental	4.2	3.2	-37.9
Lupin	-1.0	-1.1	-0.5
Mankind Pharma	-0.8	1.6	6.3
Max Healthcare	0.5	1.6	-18.1

Company	1 Day (%)	1M (%)	12M (%)
Piramal Pharma	0.4	22.4	19.1
Molbio Diagnosti	1.6	-6.6	
Rubicon Research	1.4	8.2	166.7
Sun Pharma.Inds.	3.1	2.8	8.2
Symbiotec Pharma	3.1	8.7	
Torrent Pharma.	-0.6	-1.3	31.7
Zydus Lifesci.	0.4	4.7	22.8
Healthcare BPO			
Indegene	-0.3	2.8	14.1
Inventurus Knowl	0.3	-0.7	5.3
Sagility	0.5	2.9	-15.1
Infrastructure	**0.6**	**7.8**	**-1.9**
Adani Enterp.	0.9	-4.6	13.0
G R Infraproject	2.5	-0.2	-31.5
IRB Infra.Devl.	2.3	1.8	-23.1
KNR Construct.	2.2	-4.2	-40.3
Internet & New-Age Tech			
Eternal	4.0	11.7	14.3
FSN E-Commerce	-1.5	3.2	39.7
Indiamart Inter.	-0.9	-1.0	-36.1
Info Edg.(India)	4.0	1.3	-9.1
Lenskart Solut.	4.2	3.7	
Meesho	4.0	3.1	
One 97	2.8	5.8	40.5
PB Fintech.	0.7	-0.4	-46.7
Physicswallah	3.8	0.8	
Pine Labs	2.4	-3.3	
Swiggy	5.9	-20.6	-54.2
Turtlemint Fintech	3.0	-13.9	
Urban Company	2.2	-0.7	6.4
Logistics			
Adani Ports	-1.3	6.2	30.5
Blue Dart Expres	3.1	1.4	-28.2
Container Corpn.	3.7	-0.1	-18.7
Delhivery	2.9	7.4	-11.3
JSW Infrast	0.3	-3.6	19.5
Mahindra Logis.	0.8	3.3	22.0
TCI Express	0.7	2.2	-26.9
Transport Corp.	1.6	-0.1	-25.7
VRL Logistics	-5.6	9.7	15.5
Oil & Gas	**0.8**	**7.0**	**-8.4**
Aegis Logistics	-3.2	-12.8	55.4
B P C L	4.1	6.8	-15.0
Castrol India	-0.4	-2.7	0.3
GAIL (India)	-0.1	11.0	2.4
Gujarat Energy	1.6	-3.2	-35.5
H P C L	3.7	11.0	-21.6
I O C L	1.7	10.7	-14.6
Indraprastha Gas	2.9	-0.9	-34.5
Mahanagar Gas	4.4	6.0	-12.5
O N G C	-2.1	2.3	-8.9

Company	1 Day (%)	1M (%)	12M (%)
Oil India	-4.0	-1.5	1.9
Petronet LNG	1.9	9.3	13.0
Reliance Industries	0.2	10.7	-10.8
Media	**-0.8**	**8.7**	**10.7**
PVR Inox	0.3	28.4	36.1
Sun TV Network	-0.8	-4.8	6.3
Zee Entertainmen	-0.7	-8.4	-33.9
Metals	**0.9**	**0.8**	**20.0**
Coal India	-1.3	-7.2	4.4
Hindalco Inds.	0.2	-0.1	12.8
Hindustan Zinc	3.7	1.7	20.6
Jindal Stain.	-0.4	-7.6	-7.1
Jindal Steel	0.1	4.8	6.4
JSW Steel	0.9	9.7	14.7
Midwest	2.0	10.0	-10.0
Natl. Aluminium	1.5	-2.6	41.9
NMDC	0.7	-4.5	-5.2
S A I L	1.1	-2.6	24.7
Tata Steel	1.2	2.2	1.5
Vedanta	2.5	3.4	38.7
Vedanta Aluminium Metal	0.6	-4.4	
Real Estate	**3.5**	**6.7**	**-6.8**
A B Real Estate	2.7	0.7	-41.3
Anant Raj	1.2	-20.7	-27.8
Brigade Enterpr.	4.1	-1.5	-26.2
DLF	3.5	10.7	-3.8
Godrej Propert.	4.4	13.4	-20.9
Kolte Patil Dev.	-0.2	9.0	8.4
Lodha Developers	4.8	3.8	-3.9
Mahindra Life.	-1.0	-11.4	-23.9
Oberoi Realty	1.8	-0.6	-2.2
Phoenix Mills	2.2	9.9	20.3
Prestige Estates	4.0	13.7	-5.9
SignatureGlobal	3.6	-0.8	-32.0
Sobha	8.7	7.8	-20.2
Sri Lotus	1.3	-1.6	31.7
Sunteck Realty	1.5	7.2	-35.2
Retail			
Kalyan Jewellers	5.9	0.6	7.2
P N Gadgil Jewe.	3.3	4.8	-9.7
Senco Gold	2.3	0.5	-4.7
Titan Company	1.7	5.6	26.8
A B Lifestyle	5.1	5.6	-43.5
Aditya Bir. Fas.	2.8	-5.8	-50.3
Arvind Fashions.	0.7	-7.8	-35.3
Avenue Super.	0.2	-4.1	-18.2
Bata India	0.7	4.4	-40.2
Campus Activewe.	0.1	-2.0	-27.5
Go Fashion (I)	-0.6	-9.7	-59.0
Metro Brands	-0.8	4.3	-25.0
Raymond Lifestyl	5.5	-14.3	-54.1

Company	1 Day (%)	1M (%)	12M (%)
Relaxo Footwear	0.8	3.4	-32.7
Shoppers Stop	0.6	-8.9	-25.6
Trent	-0.2	18.4	-1.7
V2 Retail	8.2	-4.7	-34.2
Vedant Fashions	1.8	-3.0	-21.6
Vishal Mega Mart	3.4	-4.4	-34.6
V-Mart Retail	4.9	-0.2	-7.5
Devyani Intl.	8.9	-0.6	-18.9
Jubilant Food.	5.0	2.4	-23.1
Restaurant Brand	5.2	0.3	39.9
Sapphire Foods	8.6	-1.2	-26.3
United Foodbrands	-5.0	-21.6	159.6
Westlife Food	1.9	8.9	9.9
Staffing			
Quess Corp	0.4	-4.0	42.8
SIS	0.3	-6.4	17.3
Team Lease Serv.	-0.8	-4.8	-36.0
Updater Services	1.1	-2.6	-11.2
Technology	**2.4**	**16.0**	**-6.9**
Coforge	0.9	12.3	17.7
Cyient	1.4	-1.0	-2.4
HCL Technologies	1.8	19.0	-6.4
Hexaware Tech.	0.4	1.6	-27.6
Infosys	3.5	14.4	-20.5
KPIT Technologi.	3.8	10.3	-53.3
L&T Technology	2.3	31.4	3.4
LTM	4.5	9.6	-21.8
Mphasis	1.7	9.3	-9.3
Persistent Systems	0.7	10.5	4.3
Redington	-2.8	-13.7	42.4
Tata Elxsi	4.4	26.2	-27.2
Tata Technolog.	3.0	-3.6	-2.1
TCS	2.5	18.0	-16.5
Tech Mahindra	2.2	18.7	29.3
Wipro	2.0	22.4	-16.6
Zensar Tech.	6.1	25.3	-23.1
Telecom	-0.9	2.3	20.9
Bharti Airtel	-0.5	15.6	-2.7
Bharti Hexacom	-1.5	22.4	-9.6
Indus Towers	-1.0	0.8	-2.4
Jio Platforms	-0.3		
Tata Comm	-2.3	2.2	-10.1
Vodafone Idea	2.7	1.2	37.0
Textiles			
Arvind Ltd	-0.4	-6.2	57.3
Gokaldas Exports	1.7	10.7	-13.6
Indo Count Inds.	-4.6	12.3	78.7
K P R Mill Ltd	-0.6	8.8	10.5
Kitex Garments	3.8	18.3	-31.9
Pearl Global Ind	2.1	6.4	107.2
Trident	-0.1	9.2	-16.6

Company	1 Day (%)	1M (%)	12M (%)
Vardhman Textile	0.6	0.6	21.7
Welspun Living	-4.2	10.0	96.2
Travel & Leisure			
Le Travenues	13.2	1.7	-37.2
TBO Tek	3.2	-4.9	-0.9
Yatra Online	1.1	-23.3	-46.3
Utilities	-0.5	-0.7	4.0
ACME Solar Hold.	-3.0	-4.5	49.1
Adani Power	1.1	1.5	28.8
Indian Energy Ex	0.8	7.6	-18.5
Inox Wind	3.5	-3.1	-57.6
JSW Energy	2.4	6.4	-0.9
NTPC	-1.6	-1.6	-4.2
Power Grid Corpn	-0.3	1.6	-6.4
Premier Energies	-2.4	-1.1	-15.3
Saatvik Green	-2.7	-10.6	-32.1
Suzlon Energy	3.0	-0.8	-35.7
Tata Power Co.	1.3	3.7	-9.0
Torrent Power	2.5	2.5	-3.0
Waaree Energies	1.7	4.4	-27.3
Others			
APL Apollo Tubes	-0.3	4.5	23.3
Cello World	5.9	9.5	-41.6
Coromandel Inter	3.4	5.5	-12.4
EPL Ltd	2.0	-3.4	12.8
Fujiyama Power	-1.6	-6.0	
GNG Electronics	0.1	4.9	110.5
Godrej Agrovet	-0.1	-7.3	-8.4
Gravita India	1.4	5.0	-15.4
Indian Hotels Co	3.1	20.7	17.7
Interglobe Aviat	5.4	9.8	-3.8
Jain Resource	-0.1	-3.7	-25.8
Lemon Tree Hotel	1.7	9.0	-30.0
Safari Inds.	3.4	-4.4	-40.6
SBI Cards	5.8	3.4	-33.6
Shaily Engineer.	-0.4	-1.3	25.3
Time Technoplast	1.6	-2.6	-17.5
UPL	-0.5	4.8	-28.0
V I P Inds.	-0.4	-11.9	-38.4
Va Tech Wabag	0.6	-6.7	33.2
Ventive Hospital	0.9	-3.3	-28.2

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:
The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:
received any compensation/other benefits from the subject company of this report
managed or co-managed public offering of securities from subject company of this research report,
received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
Research Analyst may have served as director/officer/employee in the subject company.
MOFSL and research analyst may engage in market making activity for the subject company.
MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:
a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.
To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:
This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.
Analyst Certification
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement
Analyst ownership of the stock No
A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:
This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.
MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and

under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore
In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .
In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.
Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Disclaimer:
This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be` suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.